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Abstract
Elucidation of molecular mechanisms underlying metastasis is the final frontier
in cancer biology research. Identifying individual pathways in the metastatic cas-
cade could lead to development of metastasis-specific therapeutics; however, cur-
rent in vivo metastasis model systems are not efficient tools for isolating a single
molecular event from the network of complex biological pathways. In response
to these needs, we have developed a 3D in vitro co-culture system that isolates
molecular and physical interactions between metastatic cells and the endothelium,
which are prerequisite for invasive spread. We have used this model to iden-
tify key mediators of epithelial-endothelial cell interactions, to screen metastasis
specific therapeutics, and most significantly, to elucidate a novel form of intercel-
lular communication through thin cytoskeletal projections called nanoChannels
(nCs) that is involved in pathological angiogenesis and that may prime metastatic
spread. Metastatic cells preferentially form nCs with the endothelium, enabling
rapid and directed transfer of intracellular contents. Proteins, small cytoplasmic
dyes, nanoparticles, and most interestingly, functional microRNAs (miRNAs) are
transported through these structures. Communication of miRNAs through nCs
presents a novel mechanism of pathological angiogenesis and the angiogenic switch.
NanoChannel-mediated communication introduces a new paradigm of cancer pro-
gression in which tumor cells can directly transform surrounding cell populations
in order to facilitate cancer pathogenesis.
Thesis Supervisor: Shiladitya Sengupta, Ph.D.
Title: Assistant Professor
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the planar architecture present in 2D. In traditional 2D cultures there
are limited differences in morphology between non-malignant and
malignant breast epithelial cells. However, in 3D malignant cells
adopt an architecture that is very different from the phenotype of
non-malignant cells. Primary epithelial cells form organized spheroid
structures with characteristics resembling mammary acini in vivo.
Contrast this phenotype with the disorganized mammosphere struc-
tures formed by malignant cells, which lack a central lumen and or-
ganized morphology consistent with normal cellular morphology.
(B) The difference between 2D and 3D cultures also extends to ex-
pression of oncogenic pathways. There is up-regulation of p-AKT
(S473), p-ERK1/2 (T202/Y204), and p-FAK (Y925) expression in 3D
cultures compared to 2D cultures (inset). Cells were immunostained
with the aformentioned antibodies (Red) and counterstained with
D A PI (Blue). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
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3-8 3D model systems capture cell-cell interactions in tumorigenesis.
Analogous to results seen with breast epithelial cell monocultures,
our data highlights the advantages of 3D organotypic co-cultures to
study epithelial-endothelial (ENDO/EPI) cell-cell interactions. The
2D co-culture is characterized by a segregation phenotype where
the epithelial cells sit upon a bed of endothelial cells (dashed arrow)
clustered in epithelial islands (circle). However, in 3D co-cultures
there is a high degree of interaction between the cell types (solid
arrow). All cultures were incubated for 24-hours followed by im-
munostaining with rhodamine phalloidin (Red) and counterstain-
ing with DAPI (Blue). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
3-9 Activation of oncogenic pathways in co-culture model system. Co-
culture model systems with GFP labeled metastatic breast epithe-
lial cells (green) were immunostained with (A) p-AKT (S473), (B)
p-ERK1/2 (T202/Y204), and (C) p-FAK (Y925) (Red) and counter-
stained with DAPI to identify nuclei. Activation was observed in ar-
eas of epithelial-endothelial interactions (solid arrows) versus areas
with limited cell-cell interactions (dotted arrows). This data high-
lights the unique features that can be captured in model systems,
combining multiple cell types that are not present when either cell
type is cultured alone. A platform modeling cell-cell interactions is
particularly important for complex, multicellular disease pathways
such as m etastasis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
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3-10 Co-cultured MDA-MB-231 cells show increased Ki67 expression.
(A) Immunostaining with a Ki67 antibody in GFP+ve MDA-MB-
231 epithelial cell and HUVEC endothelial cell co-culture shows en-
hancement of Ki67 expression in co-cultured epithelial cells. (B)
This phenotype is confirmed via flow cytometry. In these studies,
GFP+ve MDA-MB-231 cells are added to DiL-Ac-LDL labeled en-
dothelial cells. After 24hrs, the cultures are fixed and stained with
PECAM-1 and Ki67. PECAM-1 is used to stain the endothelial cells
to allow for sufficient separation of the two populations. The MDA-
MB-231 cells are gated (pink) and the Ki67 expression is measured.
Co-cultured MDA-MB-231 cells have higher expression of Ki67 than
cells in separate monocultures. The increased Ki67 expression may
be a response to soluble factors released by the endothelium. . . . . . 149
3-11 Schematic overview of proliferation assay protocol. Three treat-
ment protocols were used to assess the role of soluble factors on
proliferation of MDA-MB-231 and MCF-7 cells. . . . . . . . . . . . . . 151
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3-12 Effects of secreted growth factors on proliferation of MDA-MB-
231 cells. (A) Bright field image showing MDA-MB-231 cells in
conditioned+ve and conditioned-ve from each cell type. The ef-
fects of secreted growth factors isolated from HUVEC endothelial
cells, mesenchymal stem cells, embryonic stem cells, fibroblasts, and
smooth muscle cells were measured using a commercially available
viability assay. The following three protocols were used: (B) con-
ditioning: metastatic cells are pre-conditioned for 4 days and then
transferred to DMEM; (C) no pre-conditioning: metastatic cells are
not pre-conditioned and then transferred to conditioned media; (D)
conditioned media throughout: metastatic cells are incubatd in condi-
tioned media for 4 days and remain in conditioned media for the du-
ration of the study. Measurements were taken at 36hrs, 60hrs, 84hrs,
and 5days. Conditioned media collected from endothelial cells, and
no other tumor stromal cells increased proliferation of MDA-MB-
231 breast epithelial cells. . . . . . . . . . . . . . . . . . . . . . . . . . 152
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3-13 Effects of secreted growth factors on proliferation of MCF7. (A)
Bright field image showing MCF7 cells in conditioned+ve and conditioned-
ve from each cell type. The effects of secreted growth factors iso-
lated from HUVEC endothelial cells, mesenchymal stem cells, em-
bryonic stem cells, fibroblasts, and smooth muscle cells were mea-
sured using a commercially available viability assay. The following
three protocols were used: (B) conditioning: tumorigenic cells are
pre-conditioned for 4 days and then transferred to DMEM; (C) no
pre-conditioning: tumorigenic cells are not pre-conditioned and then
transferred to conditioned media; (D) conditioned media throughout:
tumorigenic cells are conditioned for 4 days and remain in condi-
tioned media for the duration of the study. Measurements were
taken at 36hrs, 60hrs, 84hrs, and 5days. In contrast to results with
MDA-MB-231 cells, soluble factors from endothelial cells suppress
growth of MCF7 cells. These results suggest that tumorigenic cells
respond differently to soluble factors secreted by endothelial cells
than metastatic cells of the same tissue type. . . . . . . . . . . . . . . 154
3-14 Endothelial cells increase migration of metastatic cells. (A) Schematic
of Boyden chamber study design. Metastatic cells are seeded in
the top chamber in matrix, while endothelial cells are plated on a
layer of fibronectin in the bottom chamber. Metastatic cells can be
seen migrating through the membrane pore. (B) Image of HUVEC
monolayer on the bottom of each well. (C) Representative images
of migrated cells through growth factor enriched and growth fac-
tor reduced matrix in HUVEC±ve groups. (D) Quantification of
the number of migrated cells. In both growth factor reduced and
growth factor enriched matrix groups, the presence of endothelial
cells enhanced cellular migration. . . . . . . . . . . . . . . . . . . . . . 157
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3-15 Endothelial cells increase migration of breast epithelial cells. The
presence of endothelial cells enhance migration of fibrocystic MCF-
10A, tumorigenic non-metastatic MCF-7, and metastatic MDA-MB-
231 cells. (A) Representative images of migrated cells and (B) graph
of quantification results illustrate the enhanced migration of cells
due to the presence of the endothelium. . . . . . . . . . . . . . . . . . 158
3-16 Growth factors secreted from HUVEC endothelial cells increase
migration of MDA-MB-231 in a matrix invasion assay. (A) Illus-
tration of criss-crossed pattern of matrix enriched with conditioned
media from HUVEC endothelial cells and mouse ESCs. (B/C) MDA-
MB-231 cells were stained with phallodin and counterstained with
DAPI. (C) MDA-MB-231 cell can be seen migrating toward the growth
factor enriched matrix. (D) Scoring examples used in quantifying
the matrix invasion assay. (E) Graph summarizing results of the
matrix invasion assay. Conditioned media increases migration of
m etastatic cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
3-17 Metastatic cells align along the matrix. MDA-MB-231 cells can be
seen aligning along the matrix analogous to alignment along en-
dothelial vessels. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
3-18 Representative 2D and 3D monoculture and co-culture images for
a panel of breast epithelial cells. HUVEC endothelial cell co-cultures
with breast epithelial cells of varying grades of tumorigenicity. Ep-
ithelial cells are labeled with CFSE prior to addition to unstained en-
dothelial tubes. Samples are fixed after 24 hour co-culture and coun-
terstained with phallodin and DAPI. Three-dimensional co-cultures
reveal striking differences between EEC interaction phenotypes that
correspond to tumorigenicity of the cell types. . . . . . . . . . . . . . 163
3-19 Kinetics of formation of co-culture phenotypes. HUVEC endothe-
lial co-cultures with MCF-10A, MCF-7, MDA-MB-231, and 4T1 cells
were monitored over a 24hr period . . . . . . . . . . . . . . . . . . . . 165
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3-20 SEM images of epithelial-endothelial co-cultures. SEM micrographs
show EEC interaction phenotypes in HUVEC endothelial co-cultures
with (A) primary, (B) tumorigenic non-metastatic, and (C) metastatic
cells lines. Epithelial cells are indicated by EPI and endothelial cells
are given by the abbreviation ENDO. Vessel structures are outlined
with dotted lines. Monoculture and co-culture images for each class
of cells are given on the left and right of each panel, respectively. . . 167
3-21 Cryosectioning of co-culture model with metastatic epithelial cells.
(A) Cryosectioning of vessel structures in co-culture show an open
vessel lumen. The vessel is surrounding by metastatic cells (green).
(B) Metastatic cells can be seen penetrating the endothelial cell bound-
ary. Endothelial cells are labeled with DiL-Ac-LDL (red) and metastatic
cells are labeled with CFSE (green). The cultures are fixed and coun-
terstained with DAPI . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
3-22 Bright field images of co-culture model systems with primary, tu-
morigenic, and metastatic cells. Angiogenic and interaction param-
eters were quantified using bright field images. Primary cells, tu-
morigenic non-metastatic cells, and metastatic cells are outlined in
pink, green, and purple, respectively. . . . . . . . . . . . . . . . . . . . 170
3-23 Example of quantification parameters. Images demonstrating how
the quantification of angiogenic and interaction parameters were
performed. The angiogenic parameters quantified were length, width,
and nodal area and the interaction parameters quantified are EEDI
and the elongation index. . . . . . . . . . . . . . . . . . . . . . . . . . 171
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3-24 Summary of results of quantification of angiogenic parameters.
Quantification of (A) vessel length, (B) vessel width, and (C) nodal
radius area show that metastatic cells increase angiogenic parame-
ters. Primary cells are indicated with pink, tumorigenic non-metastatic
cells are indicated with green, and metastatic cells are indicated
in purple. Results are normalized to HUVEC monoculture cells
(black bar graph). Cell lines of non-human origin are indicated with
stripped bars. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
3-25 Summary of quantification results of interaction parameters. (A)
Quantification results of the EEDI. Metastatic cells exhibit increased
interaction with the endothelium compared to other cell types. (B)
Elongation ratio on the vessel, (C) elongation ratio off the vessel,
and (D) elongation index are presented. Metastatic cells undergo
a large deformation when in contact with the endothelium as indi-
cated by the elongation index > >1. Primary cells, tumorigenic non-
metastatic cells, and metastatic cells are indicated by pink, green,
and purple, respectively. Cell lines of non-human origin are indi-
cated with stripped bars. . . . . . . . . . . . . . . . . . . . . . . . . . . 175
3-26 2-parameter metastatic index. (A) Summary of quantification re-
sults of angiogenic and interaction parameters. (B) The 2-parameter
index may be a predictive model for identifying metastatic capacity
based on the behaviors of cells in co-culture. . . . . . . . . . . . . . . 179
3-27 Co-culture model with primary epithelial cells. Co-cultures with
MDA-MB-231 cells established with primary blood and lymph en-
dothelial cells. (A) lIx bright field images show formation of the
co-culture phenotype with primary endothelial cells that support
observations with HUVECs. (B) lIx and (C) 40x fluorescence im-
ages of co-cultures. Endothelial cells are stained with LDL (green),
MDA-MB-231 cells are labeled with Calcein Red-Orange (red), and
samples are counterstained with DAPI. . . . . . . . . . . . . . . . . . 181
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3-28 Quantification of metastatic cell co-cultures with primary blood
and lymph endothelial cells. (A) Vessel length, (B) nodal area, (C)
vessel width, and (D) EEDI were quantified in co-cultures with pri-
mary blood and lymph endothelial cells and compared to quantifi-
cation results in HUVEC co-culture. Co-cultures with SMCs were
used as a negative control to identify if interactions with endothe-
lial cells were unique compared to other stromal cells. . . . . . . . . . 182
3-29 Schematic of the cancer types included in the co-culture model
system. The co-culture model was established with epithelial cells
from a wide range of tissue types to determine if the phenotypes ob-
served with breast epithelial cells were translatable to other tumor
types.............................................183
3-30 Schematic of the cancer types included in the co-culture model
system. Quantification results from (A) prostate cancer epithelial
cell lines and (B) epithelial cells from other tissue types. Primary,
tumorigenic non-metastatic epithelial cells are indicated with pink,
green, and purple bars, respectively. Cell lines of non-human ori-
gin are indicated with stripped bars. Quantification results in other
tissue types are similar to results observed with breast epithelial cells. 184
3-31 Co-culture model can be used to examine molecular mediators of
EEC interaction phenotypes. (A) Adhesion to the endothelium is
a critical precursor to metastatic dissemination. (B) The role of the
FAK-integrin signaling axis in mediating the metastatic co-culture
phenotype was probed at three points along the pathway . . . . . . . 186
3-32 3-1 integrins are implicated in cancer metastasis. (A) Immunos-
taining with 3-1 integrin antibody (Red) showed increased expres-
sion of the protein in metastatic cells. (B) Areas of EEC interac-
tion show a punctate /-1 signature in co-cultures with GFP-labeled
metastatic breast cancer cells (green). Cultures were counterstained
w ith DAPI (blue). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
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3-33 SiRNA knockdown of 3-1 integrins led to disruption of the co-
culture phenotype. (A) SiRNA knockdown of 3-1 integrins dis-
rupted the ability of metastatic cells to interact with the endothe-
lium. (B) Western blots show knockdown results. (C) Calculation
of EEDI metric quantified the increased dissociation resulting from
inhibition of /-1 integrins. . . . . . . . . . . . . . . . . . . . . . . . . . 188
3-34 Inhibiting /-1 integrins with a neutralizing antibody disrupts the
metastatic co-culture phenotype. /-1 integrins are important for
(A) endothelial vessel formation and (B) adhesion between metastatic
cells and the endothelium in co-culture. These interactions can be
blocked with a neutralizing antibody. . . . . . . . . . . . . . . . . . . 190
3-35 FAK knockdown disrupts the co-culture phenotype. (A) FAK can
be phosphorylated at several sites, affecting signaling to several im-
portant regulator pathways. (B) FAK phosphorylation is increased
in areas of high EEC interactions (C) that can be disrupted by siRNA
knockdown of FAK. (D) Quantification results show an increase in
EEDI after FAK knockdown consistent with the observed decline
in epithelial-endothelial interactions. (E) Knockdown of FAK de-
creases signaling in several downstream pathways. . . . . . . . . . . 191
3-36 FAK KD decreases migration of metastatic breast cancer cells. Knock-
down of FAK expression leads to defects in cell migration. (A) Im-
ages and (B) quantification results showing a decline in cell migra-
tion. The decrease in migration likely contributes to the disrupted
EEC interaction phenotype seen in co-culture. . . . . . . . . . . . . . 192
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3-37 P13K pathway is critical for endothelial cell biology. (A) Recruit-
ment of angiogenic vessels by tumor spheroids is dependent on
P13K. Vessel recruitment assay shows recruitment of endothelial ves-
sels by tumor spheroids. (B) Endothelial vessels can be disrupted
by the P13K inhibitor LY294002. (C) Treatment with the PI3Ki led to
a decrease pAKT expression and an increase in apoptotic markers
(e.g. caspase-9 and pARP). Interestingly, there was also inhibition
of p-FAK after treatment with PI3Ki. This may be due to a feedback
loop. ....... ..................................... 193
3-38 Inhibiting the P13K and MAPK pathways affects migration and
proliferation of MDA-MB-231 cells. (A) Dose titration was per-
formed to determine appropriate drug concentrations. Combination
of PI3Ki and MAPKi leads to defects in (B) proliferation and (C) mi-
gration of MDA-MB-231 cells. These defects likely both contribute
to reduced EEC interactions. . . . . . . . . . . . . . . . . . . . . . . . . 195
3-39 Combination of PI3Ki and MAPKi reduce EEC interaction phen-
toypes. (A) Images and (B) quantification of co-cultures following
treatment with a combination of inhibitors targeting the P13K and
MAPK pathways. (C) Drug treatment results in increased apoptosis
m arkers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
3-40 Inhibition of EGFR signaling disrupts the co-culture phenotype.
(A) EGFR pathways acts through P13K and MAPK pathways. (B/C)
Dose titration using increasing concentrations of EGFRi leads to path-
way inhibition. Inhibition of EGFR signaling results in decreased
cellular (D/E) migration, (F) proliferation, and EEC interactions. . . . 197
3-41 Overview schematic of steps captured by the co-culture model.
CFSE (green) labeled metastatic breast epithelial cells are added to
the matrix containing DiL-Ac-LDL (red) labeled endothelial tubes.
The figure depicts the distinct stages captured in the co-culture model.200
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4-1 Three-dimensional co-cultures provide a physiologically relevant
platform to study interactions between metastatic cancer cells and
the endothlium. Epifluorescence imaging of 2D and 3D monocul-
tures and co-cultures of metastatic cancer cells (EPI) and the en-
dothelium (ENDO). CFSE (green) loaded MDA-MB-231 tumor cells
were incubated with pre-formed HUVEC endothelial tubes in a 3D
matrigel@ matrix followed by immunostaining with rhodamine phal-
loidin and counterstaining with DAPI. In the 3D platform, the metastatic
breast cancer cells interact directly with the endothelium, elongating
and aligning along the endothelial vessels (solid arrow). This phe-
notype contrasts with the mammospheres observed in traditional
3D monotypic cultures. In 2D co-cultures, there is segregation of
cell types where epithelial cells cluster together in epithelial islands
(circle) atop a bed of endothelial cells (dashed arrows). . . . . . . . . 205
4-2 SEM images of co-cultures model reveal intimate interactions be-
tween metastatic cells and the endothelium. (Al/A2) Metastatic
breast epithelial cells MDA-MB-231 (EPI) align along endothelial
tubes (ENDO). Metastatic cells preferentially interact with the en-
dothelium compared to normal and tumorigenic, non-metastatic cell
lines. (A2) Higher magnification view of the intimate interactions
between the cell types. (B) NanoChannels (nCs) form connections
between metastatic breast epithelial cells and endothelial tubes (ar-
row). NanoChannel structures project from the surface of the metastatic
epithelial cell to the surface of the endothelium. Inset shows lower
m agnification view. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
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4-3 NanoChannels contain both actin and tubulin cytoskeletal com-
ponents. Unlike TNTs, which are typically formed from actin fibers2' 3 ,
the nanostructures observed in this study included both F-actin and
a/3-tubulin cytoskeletal components. (A) Representative epifluo-
rescence images reveal F-Actin and a/3-tubulin cytoskeletal com-
ponents within nC structures. Co-cultures were stained with a//-
tubulin antibody (green) and phalloidin (purple) and counterstained
with DAPI (nuclear) + WGA (plasma membrane) (blue). Endothe-
lial cells were labeled with DiL-Ac-LDL (red). (B) Immunocyto-
chemistry revealed the presence of myosin V (green) within the nCs.
The presence of myosin V motor proteins suggests a possible active
transport mechanism in intercellular transfer of cargo within nCs.
Samples were counterstained with phalloidin (red) and DAPI (blue). 207
4-4 Schematic of nCs versus other cytoskeletal projections. (A) Filopo-
dia are composed of parallel actin bundles, while lamellipodia con-
tain a meshwork of actin filaments supported by a zone of micro-
tubules. (B) nCs are structurally unique. They are approximately
the same physical dimensions as filopodia but contain both actin
and tubulin cytoskeletal components. (C) Images illustrating other
projections versus nC structures. NanoChannels are thinner struc-
tures, while many of the other projections quantified in the culture
are typically much wider. (C4-6) nCs are very structurally diverse,
ranging from linear projections to structures with large curvatures. . 210
4-5 Rules for defining nC structures. (A) Schematic illustration of nC
growth. A structure must extend from a donor cell, an epithelial cell,
to a recipient cell, typically an endothelial cell, in order to be consid-
ered an nC. SEM images show examples of (B) small protrusions,
(C) nascent nCs, or (D) broken nCs. . . . . . . . . . . . . . . . . . . . . 211
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4-6 Demonstration of nanoChannel length and width measurements.
This schematic provides an illustration of how length (long axis)
and width (short axis) measurements were performed. The long
axis (length) of the structures were considered from the point of ori-
gin (donor cell) to the point of termination (recipient cell). Due to
size variabilities along the length of the structures, measurements of
the short axis were taken at three distinct positions along the length
of the structure and then averaged together to obtain an average
width measurement. Non-linear nC structures were quantified by
summing the lengths of shorter linear segments. . . . . . . . . . . . . 213
4-7 Physical dimensions of nanoChannel projections. (A) Length and
width of nanoChannels (nCs) and larger cytoskeletal projections,
such as lamellipodia and filopodia were quantified using SEM. NanoChan-
nels have unique physical properties. They are much thinner and
longer then other cytoskeletal projections found in co-cultures (p <
0.0001). (B) Length and width of cytoskeletal projections in 2D ver-
sus 3D cultures. nCs have the same width dimension in both 2D and
3D. However, nCs are slightly longer in 2D likely due to the spatial
separation of the cells. SEM captures smaller projections that are not
easily visible with fluorescence microscopy. . . . . . . . . . . . . . . . 215
4-8 nC structures can span hundreds of microns of distance. . . . . . . 217
4-9 NanoChannel characteristic size descriptor (A) Length and width
dimensions of nCs and other projections were plotted, demonstrat-
ing unique length scales of nCs. (B) A characteristic length scale was
defined by taking a ratio of the width:length of the projections. This
parameter was plotted against width. nCs tightly cluster at W/L
ratio less than 0.3036. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
29
4-10 Comparison of nanoChannel structures in monoculture versus co-
culture. (A) Length and width measurements of nCs in monoculture
and co-culture. The physical dimensions of the structures are the
same in both mono and co-culture indicating that the structures in
both culture platforms are the same. (B) Percentage of nC+ve cells
in monoculture versus co-culture. (C/D) Average number of nCs
per cell excluding nC-ve cells (C) and including nC-ve cells (D). . . . 220
4-11 Cytoskeletal arrangement inside nCs. (A) Unlike filopodial cellu-
lar projections, nanoChannels are composed of both actin and tubu-
lin cytoskeletal fibers. Filopodia contain parallel actin fibers and
few microtubules. Interactions between actin and tubulin may be
critical in achieving the unique length scales seen in nCs. Models
used to describe mechanical properties of filopodia are not appro-
priate to use in describing nCs. These models may fail to define
structural characteristics of nCs because they do not consider actin
tubulin interactions. Microtubules are roughly two orders of magni-
tude more rigid than microfilament bundles. The presence of micro-
tubules may be critical in providing the structural support required
to achieve the length scales observed in nC structures. (B) Schematic
of idealized cytoskeletal arrangement inside nCs represents the two
extremes: hollow cylinder and solid pipe. The reality may likely ex-
ist somewhere in between. (C) 3D cross-section of an nC projection
with labeled a/3-Tubulin and F-Actin cytoskeletal proteins. nCs
seem to be formed from an actin core supported by a punctate 7-
tubulin signature. Tubulin may provide structural support as the
nC elongates, potentially serving as a protein cap for the elongating
actin filaments (solid arrow). . . . . . . . . . . . . . . . . . . . . . . . 222
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4-12 Kinetics of formation of nC structures over 24hrs. (A) SEM mi-
crographs show representative nC structures at a selected subset of
time points (0.5hr, 1.5hr, 2.Ohrs, 3.Ohrs, 5.Ohrs, and 24hrs). NanoChan-
nel formation appears to be a directed process with structures form-
ing with directional polarity toward endothelial cells. (B) Growth of
nC projections was quantified over time. Lengthening of nC struc-
tures begins slowly, followed by a burst of nC growth from 2-16hrs
with a plateau of length after 16hrs. These results correlate with
studies examining intercellular transport through nC structures over
tim e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
4-13 Quantification of nascent versus mature nCs over time. (A) NanoChan-
nel projections were quantified over time. NanoChannels were quan-
tified as complete nCs (green) or nascent nCs (pink). Total projec-
tions (black) is the sum of complete nCs and nascent nCs. At early
time points the majority of projections are nascent nCs, while at later
time points mature nCs dominate. (B) The percentage of nascent
nC+ve cells, complete nC+ve cells, and both nascent and complete
nC+ve cells was quantified over time. (C) Schematic illustration of
nC growth over time. At early time points, small projections emerge
on the cell surface. A fraction of these nascent nCs go on to form
complete nCs, while the remaining nCs regress. At 5hrs, the num-
ber of complete nCs peaks, quickly declining by 6hrs and staying
fairly constant up to 24hrs. . . . . . . . . . . . . . . . . . . . . . . . . . 226
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4-14 Percentage of nC+ve cells over time. (A) The nC+ve population
was further subdivided into cells with epithelial-epithelial connec-
tions (EPI-EPI) (grey), epithelial-endothelial connections (EPI-ENDO)
(maroon), and both connections (light blue). A majority of metastatic
cells form connections with the endothelium. (B) Average number
of nCs per cell were quantified and classified according to the type
of nC projection (mature vs. nascent) and the recipient (EPI, ENDO,
or Both). Cells which form EPI-ENDO connections also express a
higher number of nC structures per cell. . . . . . . . . . . . . . . . . . 227
4-15 NanoChannel structures in primary, tumorigenic, and metastatic
cells (A) SEM images show nanoChannels formed by primary breast
epithelial cells (HMEC), tumorigenic breast epithelial cell lines (SkBr3,
MCF-7), and metastatic breast epithelial cell lines (MDA-MB-468,
MDA-MB-435). (B) Graphs show the percentage of nC+ve cells and
(C) average number of nCs per cell quantified in each culture. (D)
Average number of nCs per cell including nC-ve cells. (E) Maximum
and mean number of nCs (per cell) for each analyzed epithelial cell
line. Averages are indicated by the black band on each bar. (F) nC
structures formed by different cell lines have similar length scales.
Quantification was performed on >300 cells of each cell type. . . . . 229
4-16 Optimization of flow cytometry experiments to detect intercellu-
lar transfer. (A/B) Optimization of CFSE concentration for loading
MDA-MB-231 cells. (C-F) Optimization of endothelial cell labeling.
Endothelial cells are dual labeled with Dil-Ac-LDL and PECAM-1. . 233
4-17 Experimental overview of studies examining nC-mediated inter-
cellular transport of cytoplasmic contents. . . . . . . . . . . . . . . . 234
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4-18 NanoChannels provide intercellular connectivity between cells.
(A) TEM micrograph shows intercellular connectivity between an
MDA-MB-231 epithelial cell (EPI) and a HUVEC endothelial cell
(ENDO). (B) Cytonemes versus nanoChannels. (C) Confocal mi-
croscopy images capture nanoChannel-mediated transfer of cyto-
plasmic contents. CFSE loaded MDA-MB-231 (EPI) cells (green)
were co-cultured with HUVEC endothelium (ENDO). Transfer of
the CFSE dye was observed after 24-hr co-culture through nCs (solid
white arrow). CFSE dye can be seen within the DiL-Ac-LDL (red) la-
beled HUVEC cells (yellow arrowheads). Metastatic breast epithe-
lial cells can be seen invading endothelial vessels (white dashed ar-
row ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237
4-19 Quantification of transport of intercellular contents through nanoChan-
nels. (A) Schematic and (B) graph summarize flow cytometry re-
sults examining intercellular transfer of CFSE from metastatic cells
into the endothelium through nCs. Dual cultures control for endocytosis/exocytosis-
mediated intercellular transfer. Separate cultures control for back-
ground autofluorescence of endothelial cells. (C) Images illustrate
bottom chamber of 0.4pm and 3pm dual chamber assay. Both pore
sizes allow for transport of extracellular vesicles. (D) The percent in-
tercellular transfer in both chambers was equivalent to background,
illustrating that extracellular vesicles are not mediating the observed
intercellular transfer in co-culture. . . . . . . . . . . . . . . . . . . . . 238
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of how quantification of intercellular transfer was performed in co-
culture. (B) Intercellular transport was quantified over time. Plot of
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Percent difference of intercellular CFSE concentration in MDA-MB-
231 cells in separate cultures and co-culture. There is less than <
10% difference between groups indicating that MDA-MB-231 cells
act as an infinite source of CFSE and the concentration of CFSE does
not change significantly in co-culture. (D) A concentration versus
time curve was plotted for separate and co-cultures based on fluo-
rescence intensity values. However, to obtain the actual concentra-
tion plot requires correcting for background autofluorescence. . . . . 243
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cells containing transferred nanoparticles. (B/C) Intercellular trans-
fer of Q-dots was confirmed via flow cytometry. In co-cultures,
48.10±7.200% of the endothelial cell population was positive for
quantum dots compared to 9.570±0.4300% in separate cultures (p<0.05).251
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labeled with LysoTracker Red and then co-cultured with MDA-MB-
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lial cells to metastatic breast epithelial cells. Only a small percentage
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tures. Dose titrations with cytoskeletal polymerization inhibitors
(A) latrunculin A, (B) docetaxel, and (C) cytochalasin D were per-
formed in a MDA-MB-231 monoculture system. (D) Combination of
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decreased intercellular communication compared to each drug alone. 257
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tochalasin D) and microtubules (docetaxel) were used to disrupt
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in MDA-MB-231. (D-E) Viability studies using combination of F-
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brane matrix. (C) Schematic illustration of Boyden Chambers. Cells
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primary human blood and lymph endothelial vessels. (A) SEM
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pared to monoculture. The lymph endothelial cells formed disorga-
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cular endothelial vessels, correlating with physiological difference
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cells and primary endothelial cells (dotted white arrows). (B) As
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cells. (A) nC-mediated intercellular transfer occurs between metastatic
cells and primary endothelial cells through nanoChannel structures
(yellow arrow heads). (B) Intercellular transfer was quantified us-
ing flow cytometry to determine the percentage of CFSE+ve cells in
dual-labeled endothelial cell populations. Vascular endothelial cells
were identified with immunostaining for PECAM-1/DiL-Ac-LDL,
Thrombomodulin/DiL-Ac-LDL, or PECAM-1 /Thrombomodulin. Lymph
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mary endothelial cell population and 12.29%±2.075% of the primary
lymph endothelial cell population were CFSE+ve. Statistical analy-
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Chapter 1
Introduction
Cancer cell metastasis is the highest cause of cancer-related mortality, responsi-
ble for 90% of all cancer-associated death7 -9. More than 1 in 3 individuals will
be diagnosed with cancer over their lifetime, resulting in greater than 500,000 US
deaths annually10 . Decades of research in cancer biology have brought the field
tremendous understanding of the disease; however metastasis remains the most
poorly understood aspect of cancer progression7 ' 9,11. Limited treatment options
exist for patients with metastatic cancer, and surgical interventions are rarely suc-
cessful 7,8,1 2 . Despite aggressive treatment, only 20% of patients who receive a diag-
nosis of metastatic cancer will survive more than 5 years8,10,12 compared to a nearly
70% survival rate upon early diagnosis10 . Limited understanding of the mechanis-
tic steps that underlie metastasis imposes the rate-limiting step in the development
of future generations of successful cancer therapies8' 9. Metastasis is a complex cas-
cade involving genetic, environmental, and physical forces that transform a single
tumor-initiating cell into wildly invasive disease7 9 ,1 2 1 . One of the major limiting
factors in the study of cancer metastasis is development of appropriate in vivo and
in vitro model systems that allow for the isolation and probing of discrete steps of
the metastatic cascade. An understanding of the individual steps that underlie
metastatic progression will allow for the development of therapeutic interventions
7directly targeting invasion .
Much of the insight into cancer metastasis has been gained through the de-
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velopment of in vivo model systems or retrospective analysis of metastatic tis-
sues removed from human patients8 16. However, these approaches suffer from
unique weaknesses. The greatest limitation of animal model systems is their in-
ability to decouple individual stages of metastasis. Retrospective analyses of hu-
man metastatic tumors also suffer from a similar weakness due to difficulty in
determining de novo site-specific roles that a genetic anomaly may have served16 .
Appropriate in vitro model systems would create a platform for the direct obser-
vation and manipulation of cellular processes involved in metastasis not easily
allowed by the currently available tools 16 17.
Each stage in the metastatic cascade presents unique therapeutic opportunities.
Beginning with formation of the primary tumor, the steps of metastatic invasion
can be summarized into breakdown of the basement membrane and local tissue
invasion, systemic dissemination through the vasculature, and finally seeding of
a secondary tumor site. Each of these stages presents an opportunity for inter-
vention1 2 . However, current insight into the mechanisms that control colonization
are less well developed than our understanding of the initial stages of metastasis
which are formation of the primary tumor and interactions with the endothelium.
While the majority of current drug therapies target the biology of the primary tu-
mor, arguably one of the most promising, yet untapped, opportunities for thera-
peutic intervention within the metastatic cascade is disruption of interactions be-
tween metastatic cells and the endothelium that are prerequisite for formation of
secondary tumor sites. Disruption of the events underlying these interactions may
introduce new therapeutic strategies for both early and late stages in metastasis.
The complexity of cancer underlies the need to develop physiologically rel-
evant platforms that mimic tumor development in vivo. Previous studies have
shown that 3D culture systems provide a more structurally appropriate context to
study cancer progression, offering superior recapitulation of the tumor environ-
ment compared to traditional 2D systems. The advantage of 3D systems is best
epitomized in breast cancer research. Standard two-dimensional model systems
are limited in their ability to accurately capture the molecular mediators underly-
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ing breast cancer and cannot be used to study interactions between multiple cell
types18 . The utility of 3D cultures to better capture cancer physiology has been
well demonstrated18 ; 3D cultures allow for the recapitulation of native cellular
morphology and architecture, which affect cellular gene expression, behavior, and
response to external environment16 . The use of 3D mammosphere cultures for
the study of breast cancer has been widely adopted by the research community16 .
However, a limitation of these current systems is their exclusive focus on the de-
velopment of the primary tumor: the model systems do not capture the molecular
events underlying more advance stages of cancer, specifically the interactions with
the endothelium that precede invasive spread throughout the body.
In an attempt to address these needs, this thesis describes the engineering of
a 3D in vitro co-culture system which captures molecular and physical interac-
tions between metastatic cells and the endothelium that allow for the discovery
of metastasis-promoting pathways. I begin the thesis with a review of literature
in Chapter 2 which discusses biological mechanisms involved in formation of a
primary tumor with specific emphasis on the role of the endothelium and tumor
microenvironment in cancer progression. I end with a perspective into mecha-
nisms of cell-cell communication, emphasizing modes of intercellular communica-
tion that enable to spread of genetic material.
The review of literature is followed in Chapter 3 by a deep characterization
and discussion of the model system. Interactions between metastatic cells and
the endothelium are pre-requisite for the development of metastatic disease, pre-
senting a key point of therapeutic intervention motivating the development of
our co-culture system. This powerful model has enabled discovery of important
mediators of epithelial-endothelial cell (EEC) interactions by providing a high-
throughput platform to study interaction phenotypes and screen anti-angiogenic
and anti-tumorigenic therapies. Characterization of EEC interaction phenotypes
reveals stark differences between primary, tumorigenic non-metastatic, and metastatic
cells. Interestingly, metastatic cells derived from several tissue types preferentially
align and incorporate within vessels, while primary and tumorigenic cells have
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low to moderate interaction with the endothelium, respectively. From our analy-
sis of these cultures arose a two-parameter interaction index that can differentiate
metastatic capacity of breast epithelial cells by examining EEC interaction phe-
notype. We have used this model to identify key mediators of EEC interactions,
such as FAK and 31 integrins. RNAi inhibition of FAK and /1 integrins resulted
in the disruption of the architecture, leading to 3.4 (p<0.001) and 8.6 (p<0.001)
fold change in cell interactions, respectively. Small molecule inhibitors of the FAK-
31 signaling pathway were used to perturb this architecture, resulting in a 68%
(p<0.05) decrease in invasive capacity while enhancing the susceptibility to the
metastatic cells to the cytotoxic agent doxorubicin.
The co-culture model enabled drug screening of metastatic specific therapeu-
tics. However, the most interesting finding from characterization of the model
system was the discovery of a novel form of intercellular communication between
metastatic cells and the endothelium through thin cytoskeletal projections called
nanoChannels (nCs). The remainder of this thesis focusses on describing this com-
munication in order to understand its functional significance in cancer.
Chapter 4 introduces communication through nCs. Unlike classical modes of
cell-cell communication (i.e. paracrine, endocrine, and autocrine signaling), nCs
allow for both rapid and directed transfer of intracellular contents from metastatic
breast cancer cells to the endothelium. We have found that metastatic cells, un-
like primary and tumorgenic cells, preferentially form nCs with the endothelium.
nCs form quickly (- 1.Ohrs) mediating transfer of intercellular contents to 20-60%
(p<0.0001) of the endothelial cell population. Functional nCs have been identified
in both in vitro cultures and in vivo metastatic mouse models. Proteins, small cyto-
plasmic dyes, nanoparticles, and most interestingly, functional microRNAs (miR-
NAs) are transported into the endothelium through these structures. Transport of
microRNAs through nCs is the subject of focus in Chapter 5. Metastatic cell com-
munication of miRNAs presents a new mechanism for pathological angiogenesis
and the angiogenic switch as presented in Chapter 6. nC-mediated communica-
tion leads to a 26x and 2x increase in pathological angiogenesis markers CD137
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(p<0.001) and CD276 (p<0.001), respectively. nCs are composed of cytoskeletal
proteins and can be disrupted by low-dose actin-tubulin small molecule inhibitors,
presenting potential drug candidates for metastasis specific therapies. Combina-
tion of 500pM Docetaxel with 30nM Latrunculin A or 50nM Cytoclasin D resulted
in a 3x (p<0.01) disruption of TNT structures, reducing TNT-mediated communi-
cation by 42% (p<0.0001) and 56.6% (p<0.0001), respectively.
NanoChannel-mediated communication introduces a new paradigm of cancer
progression where tumor cells can directly manipulate surrounding cell popula-
tions to facilitate cancer pathology. Chapter 7 discusses the potential role of nCs in
metastasis and the future work required to further our understanding of the role
these structures may play in cancer progression. We have shown that nCs function
in both early and late stages of cancer. Therefore, we propose that in the future,
nCs may be a therapeutic target for the treatment of invasive disease.
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Chapter 2
Review of Literature
2.1 Cancer: A Historical Perspective
Cancer has plagued the human body Suicide
throughout history and remains the
second leading cause of death in the
United States, exceeded only by cardio-
vascular disease (Figure 2-1). Approxi-
mately, 50% of men and 33% of women
will develop cancer over their life-
times. Earliest descriptions of cancer
can be found in the Edwin Smith Pa-
pyrus a selection from an ancient Egyp-
tian trauma surgery textbook dating
back to 3000 BCE19. Over the centuries Figure 2-1: Leading causes of death.
development of the scientific method Cancer is the 2nd leading cause of death
in the US after cardiovascular disease.
and advances in technology have trans-
formed our understanding of cancer as an imbalance of the four humors to a ge-
netically based disease with heritable and environmental (e.g. chemical, radiation
and viral exposures) causes. Figure 2-2 provides a timeline of milestones occurring
throughout the history of cancer.
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Figure 2-2: Milestones throughout the history of cancer.
2.2 Cancer Metastasis
Although decades of research in cancer biology have brought the field tremen-
dous progress and understanding about this disease, metastasis remains the most
poorly understood aspect of cancer progression. Limited understanding of the
mechanistic steps underlying metastasis imposes the rate-limiting step in devel-
opment of future generations of successful cancer therapies. The path from a sin-
gle cell the acquires sufficient genetic hits for tumorigenesis, to the development
of wildly invasive disease involving many secondary sites, has yet to be clearly
paved. Although critical pieces of the puzzle have been discovered, and viable
therapies developed, there remains much to be understood.
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2.2.1 Stages of Metastatic Progression
Metastasis is a hidden process that occurs deep within the body, making each of
the individual stages difficult to observe. Furthermore, cancer metastasis is diffi-
cult to study due to dynamic and reciprocal system-wide interactions that define
advanced stages of cancer 20. Cancer metastasis can be broken down into three dis-
tinct stages outlined in Figure 2-3. The first is tumor initiation and development
into an invasive lesion. This is followed by metastatic cell migration and inter-
action with lymph and endothelial vessels; this stage is defined by intravasation,
survival and migration through the vasculature, and finally extravasation into sur-
rounding tissue. The final stage is seeding of secondary sites and the development
of micrometastases 9 ,1 2
2.2.1.1 Development of the Primary Tumor
Over the centuries, there have been several theories developed to explain the com-
plex origins of cancer. For example, Otto Warburg in his manuscript On ihe Origin
of Cancer Cells proposed that cancer is a metabolic disease 21, while others have
attributed the origins of cancer to a failure of organogenesis 22-26 . However, the dis-
covery of the double-helix structure of DNA in 1953 by Watson and Crick and the
subsequent identification of the first oncogenes and tumor suppressors in the 1970s
concluded many of these debates, replacing these theories with a general consen-
sus that cancer is primarily a genetic disease?, 27,28 . Nevertheless, proponents of
other theories remain active today2 2 -25 .
It is widely accepted that cancer results from successive genetic mutations that
lead to disruption of proliferation pathways and other elements of normal cel-
lular physiology. These principles form the foundation of the somatic mutation
theory 4 . Tumorigenesis is a multistep process that occurs once a sufficient num-
ber of genetic alterations have occurred. These genetic alterations result in un-
controlled cell growth and other hallmark characteristics of cancer pathology14 .
Generally, cancer is an age-dependent disease requiring four-to-seven indepen-
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Figure 2-3: Overview of the metastatic cascade. Cancer metastasis can be broken down into three general phases, (i)
development of the primary tumor and acquisition of an invasive phenotype, (ii) interactions with the endothelium, and
(iii) formation of a secondary tumor site.
. ....... ....  ... ...... .
dent, stochastic, and rate-limiting events to incite tumorigenesis13 . The confluence
of characteristics may provide insight into why cancer is relatively rare over the
human lifetime. Early analysis of tumor pathology samples showed that cancer
evolves through a series of states beginning with normal tissue morphology and
ending with highly invasive disease29 . In a hallmark paper in 2000, Hanahan and
Weinberg outline six characteristic features underlying cancer formation and pro-
gression: (1) unlimited replication potential, (2) self-sufficiency in growth signals,
(3) insensitivity to antigrowth signals, (4) escape of apoptosis signals, (5) angio-
genesis, and (6) tissue invasion and metastasis (Figure 2-4).
Unlimited replication potential Cancer cells are uniquely capable of sustaining
unlimited replicative capability. A tumor is able to accomplish this through defects
in regulatory pathways that normally control cellular proliferation and homeosta-
sis. Contrast this to most cells in the body which exhibit limited replicative capac-
ity.
There are two natural barriers to cellular proliferation in healthy cells. The
first is senescence which refers to a shift from a proliferative to nonproliferative
state, maintaining cellular viability14 . The second state is crisis which ends in cell
death. In normal cells continued cellular proliferation induces senescence and in
some cell populations cellular crisis and apoptosis.
Induction of senescence and cellular crisis is regulated by telomeres. Telomeres
are repetitive hexanucleotide sequences present at the ends of each chromatid .
They function in protecting the chromosome during cellular replication by pre-
venting shortening, deterioration, or fusion with neighboring chromosomes1 4 . The
length of telomeres controls the number of replicative cycles that a cell can undergo
before entering cellular crisis. In normal cells continuous proliferation results in
shortening of telomeres, which leads to chromosomal instability30 . However, im-
mortalized cells and cancer cells are able to escape this process, partly with the
aid of telomerase. Telomerase is a specialized DNA polymerase that functions in
lengthening telomere repeat units. Telomerase is expressed in many human can-
57
Sustained
Proliferation
Resistance to Evading Growth
Cell Death Surpressors
Invasion andInflammation Metastasis
Sk
Unlimited Extracellular
Replication Environment
Disruption
Metabolism iof Cel ular Induction ofMt s Angiogenesis
Figure 2-4: Hallmarks of Cancer. Cancer results from perturbations in normal
physiological pathways.
cers and in 90% of immortalized cells. Its activity has been shown to prevent
senescence and crisis, the hard-wired cellular defenses against cancer 4 '.
Regulation of telomeres in tumor cells is complex. Tumor cells are able to
maintain telomeric DNA at significant lengths to prevent initiation of senescence
or apoptosis. However, early in tumor progression in certain cancers a transient
telomerase deficiency occurs1 4 . For example, early breast cancers experience telom-
ere shortening undergoing telomere crisis due to loss of telomerase function. Telom-
ere crisis in turn leads to genomic instability that promotes the acquisition of tumor-
promoting mutations32. In late tumors, telomerase function is restored stabilizing
the genome leading to frank tumor growth resulting form the genetic mutations
gained during telomere crisis32 .
Senescence can also be triggered by excessive growth signaling. Studies exam-
ining Ras, Myc, and Raf overexpression demonstrated that prolonged upregula-
tion of growth promoting pathways can trigger senescence in cells. Cancer cells
are able to successfully regulate expression of oncogenes in order to achieve high
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levels of growth while still avoiding induction of anti-proliferative mechanisms".
Self-sufficiency in growth signals Proliferation in normal cells is tightly reg-
ulated and directly linked to appropriate biological stimuli 3 ,". A key charac-
teristic of cancer cells is the decoupling of cellular proliferation from appropri-
ate growth signals. Growth signals typically come from growth factors which
initiate normal cellular proliferation through binding of intracellular tyrosine ki-
nase domains 13,. However, growth signals can also come from components of
the extracellular matrix (ECM) or cellular adhesion molecules. These signals are
transmitted into the cell through transmembrane receptors, which regulate cellu-
lar pathways controlling growth, survival and energy metabolism. Determining
the exact source of these growth signals is difficult due to tightly regulated tempo-
ral and spatial paracrine signaling which are difficult to probe experimentally13 14 .
The complexity is further heightened because regulation of growth promoting sig-
naling is superimposed on chaotic mechanisms controlling the bioavailability of
growth factors, such as unpredictable enzymatic liberation of soluble factors se-
questered in the extracellular matrix (ECM) or pericellular spaces by proteases and
sulfatases.
Cancer cells develop self-sufficiency of growth signals through a variety of dif-
ferent mechanisms. Normal cells require mitogenic growth signals before they can
move from a quiescent to an active proliferative state. However, cancer cells can
avoid this requirement by creating their own growth signals. Tumors characteris-
tically show a reduced requirement for exogenous growth signals because they are
able to generate their own growth cues.
Roughly five general mechanisms enable tumors to maintain self-sufficiency of
growth. The first is autocrine proliferative stimulation. Tumor cells themselves
produce growth factors that support their continued proliferation. One example is
platelet-derived growth factor (PDGF) autocrine signaling implicated in sarcomas
and glial-derived neoplasms. Another example of tumor autocrine signaling is
basic fibroblast growth factor (bFGF) signaling in melanoma33
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The second mechanism used to maintain self-sufficiency of growth in cancer
is release of growth activating signals by the stroma. For example, fibroblast, a
significant component of the tumor microenvironment, commonly secreting ECM
proteins, growth factors, and angiogenic factors, have been shown to enhance in-
vasive disease34 . For example, in breast tumors, conditional deletion of type II
transforming growth factor-3 (TGF-3) receptor in fibroblast led to increased hepa-
tocyte growth factor signaling which enhanced the invasive behavior of the mam-
mary carcinoma cells34.
The third mechanism utilized by cancer cells to achieve self-sufficiency of growth
signals is increasing the number of receptor proteins on cancer cells. Therefore,
even in the setting of normal growth factor signaling, the tumor cells elicit a hyper-
responsive effect. Common examples of this mechanism are EGF-R/erbB overex-
pression in stomach, brain, and breast tumors or HER2/neu receptor overexpres-
sion in stomach and mammary carcinomas13 . In the extreme, high levels of growth
factor receptor expression can results in ligand independent signaling, such as
ERB-2 overexpression in mammary tumor cells35 .
The fourth mechanism underlying unregulated tumor growth are structural
mutations in receptors that enable ligand-independent signaling. In many tumors,
deletions of the epidermal growth factor receptor (EGFR) external domain leads
to constitutive signal activation independent of ligand binding. Similar ligand in-
dependent signal have been observed for RET, Trk, and Met receptors33. Alterna-
tively, cancers can also express growth stimulating ECM integrin receptors13 .
Lastly, growth independent signaling can be achieved by completely bypassing
the receptor by activating downstream targets. For example, approximately 40%
of human melanomas exhibit B-Raf activating mutations that lead to constitutive
signaling from Raf to the mitogen activated protein kinase (MAPK) pathway.
Furthermore activating mutations in the phosphoinositide 3-kinase (P13K) path-
way have been identified in several tumor types14 .
Negative regulators of proliferation signaling also play critical roles in cancer.
For example, RAS mutations result in uncontrolled growth due to defects in RAS
60
GTPase activity that disable its ability to turn off G-protein signaling1 4 . Another
example is, phosphatase and tensin homolog (PTEN) protein negative regulation
of P13K function through the degradation of phosphatidylinositol (3,4,5) trispho-
sphate (PIP3). Therefore mutations in PTEN function result in unchecked P13K
signaling". The presence of these negative feedback loops can also play unin-
tentional roles in drug therapy. For example, through a negative feedback loop
pharmacological inhibition of mammalian target of rapamycin (mTOR) leads to
up-regulation of the P13K pathway counteracting the growth inhibitory effects of
mTOR inhibition 4 .
Insensitivity to antigrowth signals The ability to regulate cellular proliferation
is essential to maintaining normal cellular homeostasis. Therefore, cells have adapted
many anti-proliferative signaling pathways. These pathways are typically under
the control of tumor suppressor genes. Common examples are PT53 and RB tu-
mor suppressor proteins. These proteins function as gateways of cellular division.
In order for cancer cells to thrive they must develop mechanisms for circumvent-
ing these negative proliferation signals. For example, almost all human cancers
have defects in the p53 pathway. P53 is commonly known as the "guardian of the
genome." It's activated in response to a variety of cellular stresses including DNA
damage, hypoxia, and expression of oncogenes 36. In response, it triggers changes
in cellular proliferation cues leading to apoptosis, cell cycle arrest, or senescence36 .
P53 has diverse cellular functions including repair and recombination, chromatin
modification, participation in genome stabilizing protein complexes, or acting di-
rectly as a transcription factor 37 . As a result of its diverse roles, p53 functions in
varied biological functions including, but not limited to, cellular metabolism, cell-
cycle regulation, immune response, angiogenesis, cellular differentiation, cell-cell
communication, and cellular motility. Due to its diversity of roles disruption of
p53 function leads to devastating and widespread cellular consequences37 . Not
surprisingly, p53 mutations are present in most human cancers. Approximately
50% of cancer p53 mutations alter transcriptional activity. In the remainder of
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cases, p53 mutational defects lead to reduction in nuclear p5337 .
Escape of apoptosis signals In addition to overexpression of pro-growth stim-
uli, tumor cells have also adapted mechanisms for circumventing cellular death
signals. Apoptotic pathways are initiated by physiological stresses such as DNA
damage or deregulation of oncogene signaling. There are two distinct apoptotic
pathways for extracellular and intracellular stresses. The intrinsic pathway, or mi-
tochondrial pathway, is activated by intracellular stresses acting through caspase-
938. Extracellular stresses are received via binding of tumor necrosis factor (TNF)
family of ligands to cell surface 'death receptors' which activate the extrinsic path-
way through caspase-838 . Activation of caspases initiates apoptotic machinery di-
recting cells toward cell death.
The intrinsic pathway regulated by the B-cell lymphoma 2 (Bcl-2) family of
proteins is the primary apoptotic pathway implicated in cancer pathogenesis14 ,38.
Apoptosis via the intrinsic pathway is regulated by pro- (i.e. Bax, Bak) and anti-
apoptotic (i.e. Bcl-2 family) signals". The Bcl-2 family of proteins are inhibitors
of apoptosis. By binding to Bax and Bak, the two pro-apoptotic regulators, Bcl-
2 proteins prevent them from disrupting the outer mitochondrial membrane and
releasing pro-apoptotic signaling proteins such as cytochrome C". Cytochrome
C release in turn activates proteolytic caspases that lead to cellular destruction.
Bcl-2 disregulation has been implicated in human cancers, primarily human lym-
phomas38
Tumor cells have adapted several mechanisms in order to avoid cell death
through apoptosis. The most common is loss of TP53, circumventing its role as
a sensor of damaged DNA 4 . In normal cellular physiology in response to DNA
breaks and chromosomal abnormalities, p53 increases expression of Noxa and
Puma BH3-only proteins1 4 . BH3-only proteins inhibit apoptosis by directly inhibit-
ing Bcl-2 proteins or increasing pro-apoptotic proteins1 4 . BH3 mimetics may act as
potential cancer therapeutics 38 . Tumor cells also avoid cell death by directly up-
regulating anti-apoptotic regulators like Bcl-2, increasing growth factor survival
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signals, or decreasing pro-apoptotic regulators4 .
Similar to apoptosis, cancer cells also exhibit defects in autophagic programs.
Autophagy refers to the breakdown of cellular components such as organelles that
allows for the recycling of the components in a resource limited setting1 4 . The role
of autophagy in cancer is complex and paradoxical. Autophagy can increase tumor
cell survival by allowing cancer cells to better withstand metabolic stress like hy-
poxia39 . Similarly, in response to drug therapies an increase in autophagy seems to
protect cancer cells". Paradoxically however, cancer cells also up-regulate growth
promoting pathways which inhibit autophagic signaling pathways.
Autophagy is regulated through similar mechanisms as apoptosis. For exam-
ple, BH3 regulatory proteins such as Beclin-1 can trigger autophagy. In mice inhibi-
tion of Beclin-1 increases susceptibility to cancer". Tumor cells with defects in both
apoptotic and autophagic pathways may trigger necrotic cell death which through
a pro-inflammatory environment can promote tumor growth and survival39 .
In contrast to apoptosis and autophagy, necrosis cell death is tumor promoting.
Necrosis is unregulated cell death characterized by increased membrane blebs,
cell membrane rupture, and release of intracellular contents. Necrosis creates a
pro-inflammatory state that leads to endothelial cell recruitment and angiogene-
sis, increased tumor cell invasiveness, and growth stimulation 4 . Necrotic cells can
also directly secrete growth signals such as IL-la directly stimulating neighboring
tumor cell proliferation.
Angiogenesis Angiogenesis, the process of forming new blood vessels from pre-
existing vasculature, is critical for cancer progression. The growth of both the pri-
mary tumor and secondary metastatic lesion requires the recruitment of an ad-
equate blood supply to support the metabolic demands of the growing cancer.
These vessels also serve a dual role functioning as conduits of escape for metastatic
cells from the primary tumor.
The pioneering work of Juda Folkman introduced the concept that angiogen-
esis is critical for tumor development. An "angiogenic switch" occurs in cancers
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where tumor cells constitutively activate angiogenesis". This contrasts the tran-
sient activation seen in normal physiology for example in wound healing or in the
female reproductive cycle". Folkman established the requirement that angiogene-
sis is necessary to support tumor expansion beyond 2-3mm 4 1 . This was supported
by work showing that early lesions in the breast and cervix display characteristics
of the angiogenic switch.
Physiological angiogenesis is regulated through a delicate balance of pro-and
anti-angiogenic signals44 . The first discovered angiogenesis factor was a chondrosarcoma-
derived growth factor 45 later identified as basic fibroblast growth factor (bFGF or
FGF-1) 4 . BFGF was described as a growth factor derived from chondrosarco-
mas that stimulates proliferation of endothelial cells, which was purified due to
its strong affinity for heparin45 . However, the most potent and ubiquitous pro-
angiogenic factor is vascular endothelial growth factor-A (VEGF-A) 4'4 .
VEGF-A functions in both physiological and pathological angiogenesis, regu-
lating growth of new blood vessels during embryogenesis and the maintenance of
endothelial cells homeostasis in the adult14 . VEGF-A was initially discovered as
a vascular permeability factor released from hepatocarcinoma cells 46 ,4 7 . VEGF-A
belongs to the vascular permeability factor (VPF)/VEGF family which regulates
angiogenesis along with other growth factors such as TGF-3, PDGF, ephrins, and
angiopoietins48. There are several types of growth factors in the VPF/VEGF family
including VEGF-B, VEGF-C, VEGF-D, placenta growth factor (PIGF), and VEGF-
E. VEGF-B functions in coronary artery development, VEGF-C and D are primar-
ily implicated in lymphangiogenesis, but they can also induce angiogenesis and
demonstrated to increase vascular permeability 48. PIGF is highly expressed in the
placenta, but not in normal embryonic or adult tissues. Tumors, however, have
high expression of PIGF, which is believed to aid VEGF-A in inducing pathologi-
cal angiogenesis 48.
Development of normal healthy endothelium requires the complex interplay of
many of these growth factors. However, formation of tumor endothelium is much
more simplistic, dependent on a limited subset of cytokines. Tumor endothelium
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can be induced by VEGF-A alone48 .
The VPF/VEGF family exert their biological effects by binding three high affin-
ity tyrosine kinase receptors, VEGFR-1, VEGFR-2, and VEGFR-3. VEGFR-1 and
VEGFR-2 are normally expressed on endothelial cells in vivo and in vitro. VEGFR-1
functions in monocyte and macrophage migration and negatively regulates VEGFR-
2 function through a soluble variant that binds to VEGF preventing its binding to
VEGFR-2 4 9. VEGFR3 primarily functions in lymphatic endothelial cell biology 49.
VEGF receptors are also present on non-endothelial cell types including both nor-
mal and tumor epithelial cells indicating the possibility that autocrine stimulation
pathways are involved in VEGFR signaling.
Angiogenesis is critical for all stages of tumor growth, initiation48 , devel-
opment, invasion and metastasis44 . Angiogenesis is a multistep process requir-
ing integration of many biological phenomena such as endothelial cell prolifera-
tion, migration, organization, recruitment of pericytes, etc.; therefore to effectively
study pathological angiogenesis requires an in vivo system. The development of
pathological angiogenesis models have been primarily elucidated in an in vivo
mouse ear model using adenoviral vectors to overexpress an isoform of VEGF-A,
VEGFA 164 / 5 that can singly induce pathological angiogenesis 48 .
Tumor endothelium is poorly organized with little basement membrane and
decreased intercellular junctional complexes, presenting convenient opportunities
for tumor cells to exit from the primary site into the bloodstream4 4 . As many as
2 * 106 mammary carcinoma cells can be found in the circulation of a breast cancer
patient, although few of these cells will become tumors44 . Angiogenesis is strongly
correlated with metastasis and tumor progression. Decreasing angiogenesis results
in decreased metastatic lesion4 4 . There are also correlations between angiogenic
factors and relapse and prognosis of invasive cancers44 . For example, high levels
of bFGF in renal cancer leads to poor survival rates4 4 . In breast cancer, VEGF has
been linked to early relapse4 4 . Furthermore in several cancers (e.g. breast, prostate,
lung, stomach, cervix, ovary, and squamous cell carcinoma of the head and neck)
density of the vasculature is correlated with disease outcomes, highlighting the
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44role of angiogenesis in tumor progression
There is diversity among tumors regarding the requirement for angiogene-
sis14 -44 . Some tumors are highly vascular, such as human renal and pancreatic
neuroendocrine carcinomas, while others have little vasculature, such as pancre-
atic ductal adenocarcinomas14 . Differences in neovascularization patterns may be
partly regulated by tissue-dependent induction of angiogenesis by tumor stro-
mal microenvironments50 . Angiogenesis signals may also be regulated directly
by oncogenes like Ras and Myc or indirectly by stromal cells or immune inflam-
matory cells.
Due to the high dependence of tumor cells on angiogenesis, not surprisingly,
treatment of tumor cells with angiogenesis inhibitors has shown great efficacy in
cancer4 4 . Anti-angiogenesis drugs work against the tumor through a variety of
mechanisms. Several studies have demonstrated that pro-apoptotic, anti-angiogenesis
drugs, can overcome the growth advantages conferred to tumor cells by oncogenes
and loss of tumor suppressors51 . Furthermore, anti-angiogenesis drugs have been
shown to normalize tumor vasculature, which makes delivery of chemotherapeu-
tic drugs more efficient52 .
There are a variety of natural and synthetic angiogenesis inhibitors, which have
been tested as possible therapeutic agents in cancer. The best characterized en-
dogenous inhibitor of angiogenesis is thrombospondin-1 (TSP-1)4 4 . Another ex-
ample is interferon. Interferon is a potent inhibitor of angiogenesis through the
inhibition of capillary endothelial cell migration". Metallic proteinase inhibitors
exhibit anti-angiogenic properties. Naturally occurring matrix metallic proteinase
inhibitors referred to as TIMPS (tissue inhibitors of metallic proteinases) inhibit an-
giogenesis by preventing successful migration of endothelial cells when forming
new vasculature".
Anti-angiogenesis inhibitors have also effectively been used in the clinic. The
first approved anti-angiogenesis drug was Avastin5 3 . Avastin is an anti-VEGF
antibody commonly used in the treatment of breast cancer5 3 . Following the ap-
proval of Avastin there has been an explosion in the development of additional
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anti-angiogenesis agents. Tarceva is an epidermal growth factor tyrosine kinase
inhibitor that can block VEGF-B, FGF, and TGF-a signaling that is used for treat-
ment of lung cancer 3 . Linomide has been shown to inhibit angiogenesis induc-
tion through various pro-angiogenic factors, such as VEGF, FGF, and TNF-alpha13
Celecoxib is an inhibitor of the inducible prostaglandin G/H synthase COX23 . Is
used in treatment of familial adenomatous polyposis (FAP) and has been shown
to reduce the number of colorectal polyps in patients with familial FAP. COX2 in-
hibitors function as anti-angiogenesis agents by decreasing FGF and VEGF signal-
ing, which are both pro-angiogenic factors. Their use for the treatment of prostate
and cervical cancer is currently being explored 3.
Combinations of anti-angiogenesis drugs and chemotherapy are commonly used
in the clinic for the treatment of cancer and have demonstrated enhanced therapeu-
tic efficacy. These improvements have lead to the development of anti-angiogenic
chemotherapy 3 . Anti-angiogenesis chemotherapy optimizes the dose and sched-
ule of chemotherapy in order to optimally to target endothelial cells, and not cancer
cells. Surprisingly, these treatment strategy has shown increased efficacy 3. In ad-
dition, combination of multiple anti-angiogenesis drugs may also improve treat-
ment outcomes. For example, combination of Tarceva and Avastin led to better
53clinical outcomes than either drug alone
Tissue invasion and metastasis The development of an invasive phenotype can-
not be modeled as a simple linear set of sequential, discrete steps. Instead it is
better represented as a complex algorithm with many inputs of overlapping and
parallel steps (Figure 2-5). This algorithm is dictated by the confluence of numer-
ous chaotic genetic alterations, angiogenic contributions, and influences from the
microenvironment. An invasive phenotype can generally be characterized by al-
terations in tumor cell adherence to both neighboring cells and the ECM, increased
migratory capacity, and change in cellular morphology. These changes are medi-
ated by the inappropriate activation of a developmental regulatory program re-
ferred to as epithelial-mesenchymal transition. Its unclear if cancer cells slowly
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A. Simple linear system
Step 1 Step 2 Step 3
B. Complex system
Step 1 --- Step 2 Step 3
Step 1 Step 1
Figure 2-5: Development of an invasive phenotype is complex. Development of
an invasive phenotype is a complex algorithm with many inputs of overlapping
and parallel steps.
develop an invasive phenotype or if some cancers are invasive from their initia-
tion. There is likely a combination of both factors. However, one thing that remains
clear is that the transition of cancer from a localized proliferative disease into an
invasive migratory disease represents an important and disease outcome altering
change. To address all of the elements of development of an invasive phenotype
would be overly exhaustive, however, I will highlight the most critical elements:
loss of contact inhibition, epithelial-mesenchymal transitions (EMT), and cellular
migration.
Loss of contact inhibition: Adhesion molecules are critical regulators of nor-
mal cell physiology. Integrins function primarily as mediators of cellular adhesion
to the ECM. They are heterodimeric cell surface proteins composed of a combina-
tion of a and # subunits 4 . There are 24 distinct heterodimers formed from 18 a and
8 / subunits 54. The extracellular domains of integrins bind to specific sequences in
EMC proteins such as fibronectin and collagen. Binding of integrins to the ECM
results in conformational changes which promote linkage of their cytoplasmic tails
with the actin cytoskeleton 5 . Integrins exert their cellular functions by recruiting
scaffolding and signaling proteins like paxillin and focal adhesion kinase (FAK)
(Figure 2-6). There are two models of initiation of adhesion complexes55. The first
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Figure 2-6: Schematic of FAK-Ingrin signaling axis. Integrins mediate cell-ECM
adhesion by forming adhesion complexes typically through focal adhesion kinase
(FAK). The FAK-integrin signaling axis signals through critical survival and prolif-
eration pathway such as P13K and MAPK pathways. Not surprisingly aberrations
in FAK-integrin signaling is implicated in cancer pathogenesis and invasion.
is binding of integrins to the ECM leading to assembly of adhesion complexes. The
second is initiated by actin polymerization. In this model, dendritic actin is use as
the template for the formation of adhesion complexes 55. Formation of adhesion
complexes is regulated by the Rho family of GTPases5 6. The best characterized
members, Rac, Rho, and Cdc42, have been implicated in cancer progression. They
function by regulating guanine nucleotid exchange factors (GEF) and GTPase ac-
tivation proteins (GAP) in adhesion complexes5 5.
The morphology of migrating tumor cells varies considerably from benign cells.
The most important factors regulating this is compliance of the substrate (i.e. the
ECM) and the intrinsic contractility of the cells55. For example, tumor cells with
weak adhesion are rounded, similar to the shape of lymphocytes 55. Contrast this
morphology with fibroblasts and endothelial cells which are highly spreading due
to tight adhesions 55 . The force balance between the ECM and the surface of the cell
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Figure 2-7: Force balance between cells and ECM. In normal tissues cells expe-
rience mechanical forces from neighboring cells and the ECM. The force balance
between the ECM and the surface of the cell are critical regulators of cellular mor-
phology.
are critical regulators of this dynamic55 (Figure 2-7).
Cadherins mediate cell-cell adhesions. E-cadherin is a calcium dependent cell-
cell adhesion molecule that is the primary mediator of adhesion in epithelial cells57 .
E-cadherin forms complexes with #-catenin, and a-E-catenin in order to estab-
lish connections at the junction between two neighboring cells 57 . The E-cadherin-
catenin complex (CCC) is linked to the cytoskeletal system 7. Cancer is character-
ized by aberrations in cell matrix adhesions and cell-cell adhesions. Proliferation
in normal cells is regulated by a phenomenon called contact inhibition. Contact
inhibition refers to the normal physiological response where formation of dense
populations of normal cells, suppress cell proliferation. This phenomenon leads
to confluent cell monolayers of cultured cells. Tumor cells, however, no longer
exhibit this phenotype.
NF2 pathway regulates contact inhibition through the actions of merlin 8 59.
Merlin functions in contact inhibition, by coupling cell surface adhesion molecules
to transmembrane receptor tyrosine kinase (e.g. E-cadehrin to EGFR receptor)58 5 9.
Through this mechanism, merlin strengthens the adhesiveness of cadherin medi-
ated cellular attachments. Loss or defects in merlin therefore may result in a reduc-
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tion of contact inhibition 859 . An alternative contact inhibition pathway is through
LKB1 protein60-62. LKB1 epithelial polarity protein is responsible for organization
of epithelial structures. Its important for the maintenance of tissue integrity. When
LKB1 function is disrupted, epithelial cells become susceptible to Myc transforma-
tion60 . Both LKB1 and merlin are tumor suppressorss- 62.
Epithelial-Mesenchymal Transition: Epithelial-mesenchymal transition de-
scribes a complex developmental program that epithelial cells undergo as they lose
their differentiated characteristics and acquire mesenchymal features, that results
in an invasive phenotype. It's characterized by loss of adhesion molecules, in-
creased motility, enhanced resistance to apoptosis, expression of matrix degrading
proteases, and alterations in cellular shape from a polygonal to a spindly fibrob-
lastic morphology 14 ,63 . For example, invasive cancers show a characteristic loss
of E-cadherin, the primary adhesion molecule responsible for cell-cell adhesion
in epithelial cells, accompanied by an up-regulation of N-cadherin". N-cadherin
is normally expressed on migrating neurons during development and is associ-
ated with embryogenesis and inflammation". The switch in cadherin expression
from E-cadherin, which promotes cell-cell adherence in the tumor, to N-cadherin,
expressed on migrating mesenchymal cells, facilitating tumor cell binding to the
stoma, is a hallmark feature of invasive tumors.
Mesenchymal-epithelial transitions (MET) refers to the reversal of EMT that
seems to occur following seeding of the secondary site. Both EMT and MET are
critical regulatory programs in normal embryonic development. However, inap-
propriate initiation of these programs underlies cancer pathology and other hu-
man diseases 63. There have been several studies that have linked expression of
EMT related proteins and the acquisition of an EMT phenotype with the develop-
ment of metastatic disease. For example, in patients with tumorigenic breast can-
cer expression of invasive gene signatures correlated with patient survival and the
occurrence of metastatic disease64 . In another study, the presence of a progenitor-
like phenotype in differentiated mammary epithelial cells correlated with invasive
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cell populations65'66.
EMT is orchestrated by a set of transcription factors functioning in migratory
processes during embryogenesis, such as Snail, Slug, Twist, and Zebi/24. These
transcription factors seems to regulate the entire metastatic cascade with the excep-
tion of colonization 63 . For example, Snaill in epithelial cells represses E-cadherin
expression by regulating Zeb2, a transcriptional repressor of E-cadherin that is up-
regulated in Snail-induced EMT67. There is dynamic interplay between these tran-
scription factors, therefore induction of one set of these factors commonly leads to
up-regulation of the others66.
There are many factors that contribute to initiation of the EMT program includ-
ing interactions between cancer cells and the tumor stroma, genetic and epigenetic
changes, aberrant growth factor and developmental pathway signaling, and en-
vironmental stimuli such as hypoxia. Not surprisingly, the inherent genetic and
epigenetic instability of cancer cells promotes EMT programming in cancer. Ge-
netic instability allows for the development of diverse heterogeneity in a tumor,
increasing the likelihood that one cell will have the genetic alterations necessary
to progress through EMT. For example, in mammary epithelial cells, induction of
EMT results in epigenetic changes which in turn lead to de novo methylation of
other gene promoters that maintained the EMT state68.
Interactions between tumor cells and the microenvironment also contribute to
EMT program initiation. For example, in colon cancer, there are spatial distinc-
tions between mesenchymal-like and non-mesenchymal like tumor cells that are
believed to be the result of differential interactions with the microenvironment. In
these tumors, mesenchymal-like cells were found at the invasive front, while cells
in central areas of the tumor and at secondary metastatic sites express features
characteristic of differentiated cells. These differences have been linked to changes
in localization of 0-catenin, the primary oncogene in colon cancer, from the nucleus
to the membrane/cytoplasm, which are associated with a mesenchymal-like and
epithelial-like phenotype, respectively 69 . This data is further supported by higher
expression of Snail in peripheral tumor cells versus central tumor cells in several
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epithelial cancers. The Snail gene is believed to function as a critical regulator of
EMT through repression of E-cadherin70 .
The microenvironment also seems to function in mediating MET, restoring an
epithelial phenotype in the secondary metastases. For example, co-culturing prostate
carcinoma cells with normal hepatocytes increased expression of E-cadherin, sim-
ilar to E-cadherin expression at the primary and secondary tumor sites, but higher
than E-cadherin expression in cells during the initial invasive phase71 .
Matrix degrading proteases such as MT1-matrix metalloptoteinase (MMP)/MMP-
14 are implicated in ECM remodeling 72. These proteases provide a mechanism of
escape for tumor cells by re-patterning of collagen fibers in the ECM to create tube-
like microtracks that allow for collective mass movement of cancer cells20
Signaling pathway such as transforming growth factor- (TGF-), Wnt, Notch,
and Hedgehog pathways have been implicated as critical regulators of EMT pro-
gram63 . The TGF-3 pathway is one of the best characterized regulators of EMT in
both normal physiology and tumor progression73 . The cytokine members of the
TGF-/3 pathway regulate EMT directly through ligand-receptor interactions or in-
directly through involvement with Notch, Wnt, and integrin signaling pathways6 3.
TGF-O exerts its function in EMT through Par6. Par6 is a regulator of epithelial cell
polarity and tight junction formation 38 , 74 . Par6 is a substrate for the type II TGF-3
receptor. Binding of Par6 to the TGF-3 receptor controls interaction with Smurf1
which targets RhoA for degradation, in turn leading to loss of tight junctions 74.
TGF3 also exerts its role in EMT through effects on the immune system. Through
systemic immune suppression it inhibits anti-tumor immune responses7 5. In ad-
dition, TGF3 indirectly regulates EMT by directing tumor stromal cells to initiate
invasion-promoting changes in the tumor 75 . Cancer stem cells are also key hall-
mark features of EMT. In human mammary epithelial cells, EMT promotes devel-
opment of stem-cell like properties 76-78. Interestingly the TGF-O pathway is also
highly active in these stem-cell like populations in mammary cancers79.
EMT is a developmental regulatory mechanism therefore it's not surprising that
initiation of EMT in cancer is associated with aberrant signaling of important de-
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velopmental pathways, such as Wnt, Notch, and Hedgehog 80 . Constitutive acti-
vation of the Wnt signaling pathways have long been linked to tumorgenesis in
colon cancer and has recently been linked to EMT63 . -catenin acts a transcription
factor leading to activation of EMT promoting genes63. There are studies suggest-
ing that therapeutic targeting of the Wnt signaling pathway with inhibitors may be
a potential strategy for modifying EMT in cancer8 1 . However, -catenin expression
alone cannot induce EMT, highlighting the complex regulator pathways required
to orchestrate this transition 3
A second developmental pathway, Notch, has also been implicated in EMT
pathways both in normal physiological development and tumorigenesis 63. In pan-
creatic cancer cells, Notch induces EMT by regulating the NF-tB (NF-KB) pathway,
VEGF signaling, and MMP release 82 . The Notch pathway can also directly alter
TGF-B activity.
Finally, although less frequently cited, the Hedgehog pathway also regulates
tumor metastasis and EMT progression 63 . The best characterized ligand of the
Hedgehog pathway, Sonic hedgehog, is known to be a mediator of angiogenesis.
Mutations in the SHH pathway are commonly linked to increased cellular prolif-
eration and tumorigenesis83 . In pancreatic cancer, high SHH expression has been
linked to initiation of EMT programming which can be reversed by the SHH in-
hibitor cyclopamines3
External stimuli such as hypoxia can also result in EMT initiation6 3 . Hypoxia
leads to EMT through induction of Hypoxia Inducible Factors (HIFs), regulating
a variety of EMT stimulating mechanisms including signaling pathways such as
Notch and NF-KB, induction of epigenetic modification, or direct up-regulation of
EMT transcription factors such as Snail and Twist 63 ,84 .
Lastly, miRNAs have been shown to be critical regulates of EMT63 .The miR-200
family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and miR-205 have
been shown by several group to be primary miRNA regulators EMT, acting on
E-cadherin respressor proteins zinc-finger E-box-binding homeobox factors ZEB1
and ZEB285 ,86. These miRNA also act through the TGF-3 pathway 87.
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Migration The cytoskeleton plays critical roles in basic cellular functions (e.g.
cell motility, cell division, wound healing, cellular integrity, and transport)88-90.
Understanding cytoskeletal dynamics provides insight into principles underlying
both normal and pathological disease states 8 ,8 9,91 ,92 . Through the use of molecular
biology, biochemistry, and engineering models, there has been significant progress
in understanding the principles that define dynamic morphogenesis: how the
cytoskeleton works to change cell shape, transport of intercellular contents, and
maintain cell integrity88 90 . Complex interactions between microtubules and actin
form the basic underpinnings of this dynamic system88 .
The cytoskeleton accomplishes complex cellular tasks using three basic con-
stituents: microfilaments (actin filaments), intermediate filaments, and microtubules 90.
Although each of these structures play varying roles, actin filaments generally are
more involved in motility and maintaining cellular integrity, while microtubules
play larger roles in cell division and transport of macromolecules90 . Intermediate
filaments are primarily responsible for mechanical support acting as cytoplasmic
and nuclear scaffolds93 . Cytoskeletal filaments combined with regulatory proteins,
such as capping proteins and severing proteins (e.g. actin depolymerizing factor
(ADF)/cofilin family), work through signaling pathways (e.g. Ras/Rho family of
small GTPases) to achieve varied cellular functions89 9 1.
Lamellipodia, filopodia, blebs, and invadopodia are four classically defined
plasma membrane protrusions88,92 . Lamellipodia function primarily in cellular
migration extending long distances to form attachments with the ECM that anchor
the cell and provide the traction required for movement through tissues92 . Filopo-
dia are important for guidance and sensing in the cellular environment. Membrane
blebs are important for regulating directional cell migration that may play a role
in development. Invadopodia are protrusions optimized for matrix degradation.
Vesicles carrying matrix-degrading proteases are targeted to these projections by
the exocyst complex92. Figure 2-8 provides a schematic of cellular cytoskeletal pro-
jections.
Each of these structures is composed of an actin cytoskeletal network; lamel-
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Figure 2-8: Cytoskeletal projections. Cells form diverse cytoskeletal projections
that perform many critical cellular tasks including migration, environmental sens-
ing, and cell-cell communication.
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lipodia are formed by dendritic actin networks and filopodia are made of parallel
actin bundles88 . Exact mechanisms explaining the interactions between actin and
microtubules to create diverse cytoskeletal projections are poorly defined and an
active area of research. In lamellipodia, the dominant hypothesis is that micro-
tubules are structurally linked to actin retrograde flow, which leads to net growth
of microtubules toward the leading edge8 . In filopodia, microtubule filaments
grow alongside the actin bundles through a process called dynamic instability94 .
Microtubule-actin interactions are critical for directed motility where projections
are targeted to specific locations. For example, recent studies on neuronal pathfind-
ing have shown that actin bundles guide microtubules toward the leading edge,
promoting extension of the projections toward the appropriate stimulus 88 94-97. Mem-
brane projections are initially devoid of actin and are formed at sites of local weak-
ening of the plasma membrane9, 92 . They form when the plasma membrane tran-
siently detaches at a focal position from the underlying actin cortex. This allows
for hydrostatic pressure of the cytoplasmic contents to push the membrane out9,92.
Invadopodia are actin-rich projections that also contain microtubules that likely
function in transport of the protease filled vesicles 92. The Rho family proteins are
the primary regulators of protrusion formation, controlling actin remodeling. Rac,
Cdc42, and RhoG are all required for lamellipodia and filopodia formation and
function91 .
Recently, new forms of cytoskeletal projections have been described that func-
tion primarily in cell-cell communication. Cytonemes, or filopodial bridges, and
tunneling nanotubes (TNTs) are thin cytoskeletal connections composed of actin
that connect neighboring cel198. Cytonemes are closed end cellular projections,
while tunneling nanotube are open-ended cellular projections. Cytonemes enable
intercellular transfer of cell-surface associated cargo, for example membrane re-
ceptors or even pathogens. Tunneling nanotubes in contrast are open cellular con-
nections that allow for the transport of both cell surface associated and intercellular
cargo 98. The dynamics of cytoskeletal formation of filopodial bridges and tunnel-
ing nanotubes is an active area of research.
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Figure 2-9: Cellular Migration. Cell migration can be described in three stages:
(1) morphological polarization plus membrane extension and formation of cell-
substratum attachments, (2) internal contraction, and (3) rear release.
Cell migration in 3D is complex involving interactions between chemical sig-
naling pathways and mechanical mechanisms. Chemokines, which are chemotatic
cytokines that bind G-protein coupled receptors, induce cell motility acting as po-
tent stimulators of cell migration. Chemokines also induce infiltration of tumors
by macrophages and lymphocytes, resulting in release of inflammatory stimuli
and proteases. Matrix breakdown by matrix metalloproteinases (MMPs) prote-
olyticly degrade the ECM, leading to liberation of embedded growth factors and
chemokines. These soluble factors act through signaling pathways such as P13K,
MAPK, FAK activating Rac and Rho signaling, which control actin polymerization.
Migration can be described in 3 distinct stages: (1) morphological polarization
plus membrane extension and formation of cell-substratum attachments, (2) inter-
nal contraction, and (3) rear release 99 100 (Figure 2-9). Dynamic interactions with
the membrane leads to formation of protrusions that in response to a gradient of
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soluble factors leads to directed growth of actin filaments and cytoskeletal struc-
tures99 .
Cells require polarization in order to migrate. This can be achieved through
concentration gradients or spatial/temporal stimulus gradients that result from
random fluctuations or microscopic non-uniformities in receptor-ligand binding99
. Microscopic non-uniformities result from molecular rearrangements such as re-
distribution of chemosensory signaling receptors, integrin adhesion receptors, and
integrin cytoskeletal linkages99 100. The consequence of polarization is extension of
active membrane processes primarily at the cell front, giving cell locomotion a per-
sistent random walk characteristic100 .
Membrane extension can be described using an elastic Brownian Ratchet model101
This model explains how polymerizing actin creates protrusive forces on the mem-
brane without motor proteins 01. Random thermal fluctuations in the membrane
produce gaps between the actin polymer tip and the membrane, allowing for in-
sertion of new monomers along the filament chain. Free energy released from the
polymerization reaction alters the random thermal fluctuation of the membrane to
create directed motion. An alternative mechanism called cortical expansion may
also describe the formation of actin cytoskeletal protrusion101 . In this mechanism,
filament severing or favorable entropic driving forces due to filament-water inter-
actions cause an increase in osmotic pressure. The increase in pressure triggers a
local influx of water that causes the actin-filament gel to swell 01 . The Brownian
Ratchet model may better describe filopodia formation while the cortical expan-
sion model may provide insight into lamellipodia formation101 .
Speed of protrusion formation is dependent on the response time to a stim-
ulus and the net polymerization of actin91 . The Rho GTPase family is the pri-
mary molecular mediator of actin cytoskeletal dynamics that mediate formation of
lamellipodia and filopodia protrusions 91 . In response to a stimulus, these molecules
lead to increase in the number of actin polymerization sites. A net increase in the
rate of addition of actin monomers results in a protrusion91 . Protrusion formation
is regulated by actin polymerization dynamics, which depend on ATP mediated
79
addition of actin monomers, depolymerization kinetics, and interactions of regu-
latory proteins. These proteins include profilin and ADF/cofilin, which function
in depolymerization, cortactin, which stabilizes branches, and filamin A and a-
actinin, which stabilizes the entire network by cross-linking filaments91 .
The net polymerization of actin is critical to the rate of protrusion formation;
even with a specific stimulus, polymerization of actin will occur in random di-
rections but only net growth in one specific direction will allow for cellular loco-
motion99' 100 . The speed of protrusion formation is primarily determined by actin
polymerization speed and not signaling pathway kinetics, since signal transduc-
tion occurs very quickly, on the order of milliseconds 99100 .
Formation and stabilization of attachments is the final phenomenon to con-
sider 99 . Evidence suggests that attachments to the substratum preferentially form
at the leading edge of cells. New adhesions appear as small aggregates that in-
crease in size as the cell migrates over them; these adhesions remained fixed un-
til they reach the rear or edge of the cel199. Molecular mediators initiating this
process are unknown. One potential hypothesis is that there may be pre-existing
cytoskeletal complexes to which adhesion molecules incorporate; however, FAK,
paxilin, tensin, and integrins are known constituents in adhesion complexes and
are believed to play a big role in attachment to the substratum9 9 . These adhesion
bonds are reversible; proteins are recycled back to the leading edge to replenish
those lost to existing adhesion complexes99 .
The second step of migration is internal contraction99 . There are two primary
forces that are generated by a moving cell: (1) protrusion force to extend mem-
brane processes and (2) contractile forces that move the cell body forward. Gener-
ation of contractile forces depends on active myosin based motors. Contraction of
filaments connecting cell-substratum adhesion complexes with intracellular struc-
tures results in relative motion of adhesion complexes across cortical actin filament
tracks 99 100. The substratum exerts an equal and opposite traction force on the cell
via adhesion complexes. The magnitude of contractile forces do not alone directly
explain migration speed; instead the ratio of contractile force to cell substratum
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adhesion correlates to the rate of migration in a biphasic manner. Maximal migra-
tion speed is associated with an intermediate ratio of adhesive forces. If the ratio
of adhesive forces becomes too large, the cells may be unable to move, however, if
the ratio is too small, the cells may not be able to attach.
The final step is rear release99 . The rate-limiting step is not formation of adhe-
sion but disruption of adhesions99 . The rate of disruption is proportional to the
adhesion force to the substratum. This process is accelerated by myosin-mediate
actin filaments pulling on adhesion complexes 99 . Rates of protrusion and rear re-
lease both contribute to overall migration speed but evidence suggests that rear
release kinetics dominate in many cells99 . Mechanisms of rear release combine
mechanical contributions, signaling pathways regulating adhesion receptors, and
ATP driven motor processes. Rear release results from optimal balance of adhesive
forces and traction; however, forward attachments remain, creating asymmetry be-
99tween the front and rear
Summary of Development of the Primary Tumor Cancer arises from a series of
genetic alterations that disrupt multiple physiological processes. In Section 2.2.1.1,
I discuss the six key characteristic features of cancer progression, (1) unlimited
replication potential, (2) self-sufficiency in growth signals, (3) insensitivity to anti-
growth signals, (4) escape of apoptosis signals, (5) angiogenesis, and (6) tissue in-
vasion summarized by Figure 2-10. Now I begin a discussion of the subsequent
step in the metastatic cascade, interactions with the endothelium. Once a tumor
cell develops an invasive phenotype, the endothelium provides a conduit of es-
cape to the systemic circulation, exposing the cells to foreign organs and tissues.
2.2.1.2 Interactions with the endothelium
Interactions with the endothelium are critical to tumor progression occurring dur-
ing multiple stages in the metastatic cascade and are pre-requisite for establishing
secondary metastatic lesions. In addition to the essential role endothelial cells play
in cancer progression through angiogenesis, it also provides the primary escape
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Figure 2-10: Schematic Summary of Primary Tumor Development. Tumor for-
mation starts with development of a tumorigenic phenotype in a single cell. De-
velopment of a tumor requires multiple genetic and physiological changes. These
changes lead to frank tumor formation characterized by the six hallmark features
of tumor cells: (1) unlimited replication potential, (2) self-sufficiency in growth
signals, (3) insensitivity to antigrowth signals, (4) escape of apoptosis signals, (5)
angiogenesis, and (6) tissue invasion.
routes tumor cells must take to form secondary lesions'. Tumor cells can enter
the circulation directly or indirectly. Hematogenous dissemination represent the
direct entry of tumor cells in the circulation. Alternatively, tumor cells may also
enter the circulation through the lymphatic system. The lymphatic system empties
into the lymphatic ducts, which drain into the subclavian veins at the junction of
the subclavian and internal jugular veins (Figure 2-11).
Entry and exit of tumor cells from a blood or lymphatic vessel is referred to
as intravastion and extravasation, respectively. The mechanisms underlying these
physical interactions are not well-characterized, primarily due to the lack of mod-
els that allow for isolation of these interactions102 . Successful intravasation and
extravasation in metastasis requires coordination between mechanical and chemi-
cal signaling pathways that coordinate alterations in the cytoskeleton to allow for
transmigration in response to chemical stimuli that lead to migration. Much of the
insight gained on tumor cell intravasation and extravasation have come from an
understanding of leukocyte entry and exit from the vessel0 2 . Similar to leukocytes
during an inflammatory response, tumor cells undergo diapedesis to enter the en-
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Figure 2-11: Anatomical versus cellular view of metastasis. Tumor cells can enter
the circulation directly, referred to as hematogenous dissemination, or indirectly
through the lymphatic circulation.
dothelium. Diapedesis refers to the process of extending psudopodia projections
disrupting intercellular junctions in the endothelium. This process leads to remod-
eling of the cytoskeleton allowing the metastatic cells to penetrate the endothelial
layer'. Metastatic cells are 80% softer than benign cells. The decrease in cell stiff-
ness may enhance the ability of these cells to successfully cross the endothelial
cell barrier 0 3 10 4 Diapedesis is also facilitated by actin rearrangement in the en-
dothelial cell population. However, the mediators of this process have not been
elucidated, but it's clear that reciprocal interactions between the two cell types
is critical for invasion'0 2. For example, tumor cells lead to up-regulation of IL-8
and Gro-3 chemokines in the endothelium 0 5 . In response to increased secretion
of these chemokines tumor cells expressed higher levels of CXCR2, the receptor
for IL-8 and Gro-6. The combination of increased secretion of IL-8 and Gro-# in
endothelial cells and increased expression of CXCR2 in the metastatic cancer cells
resulted in enhanced tumor cell transmigration'05 . There has been work to suggest
that metastasis in lung cancer model were initiated predominantly by attachment
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Cellular View
to the endothelium rather than by extravasated tumor cells'06 . However, these
results remain controversial and have been contradicted by other reports107. Nev-
ertheless, emphasizing the dynamic role of endothelial cells in metastasis.
Tumor cells extravasate by inducing endothelial cell retraction. However, the
mechanism by which this occurs has not been elucidated. Cdc42, a member of the
Rho GTPases family of proteins has been linked to endothelial cell retraction and
in mediating interactions between metastatic cancer cells and the endothelium 08 .
Cdc42 was shown to be required for spreading, protrusion extension, and colo-
nization in an in vivo mouse lung model. However, the mechanism by which ex-
pression of a Rho GTPase protein in the metastatic epithelial cells results in changes
in an endothelial cell, remains to be elucidated.
Although cancer cells do not require adhesion to the endothelium to arrest,
transmigration is strongly dependent on the expression of adhesion molecules
such as integrins and other cell-surface glycoproteins. For example, in breast can-
cer, transmigration through endothelium was enhanced by CD44 and expression
of 1-integrins'0 2 . Similarly, 31 intgrins acting through cdc42 have been shown to
promote transendothelial migration of metastatic cancer cell'08 . In addition, en-
dothelial cell expression of certain adhesion molecules has been linked to organ-
specific metastasis. Lectins and selectins are two classes of cell adhesion molecules
involved in metastasis. Lectins are carbohydrate binding proteins and selectins are
glycoproteins that function as cell adhesion molecules. The mechanism of organ-
specific dissemination can in part be explained by adherence of tumor cells to tis-
sue specific endothelium, which has been demonstrated both in vivo and in vitro' 2
This may partly explain seeding difference for different metastatic cancers8,102 . For
example carbohydrates sLea and sLew have been shown to play a role in organ-
specific spreading in several tumors including colon, gastric, and breast cancers' 09.
Integrin associated ligands have been identified as key regulators of metastatic
progression in several tumor types, including colon, skin, and breast, linked di-
rectly to the roles integrins play in mediating interactions with the endothelium
during intravasation and extravasation 09. For example, in breast tumors, integrin-
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Figure 2-12: Interactions with the endothelium. Interactions with the endothe-
lium is an essential step in the metastatic cascade, beginning with attachment to
the vessel, local breakdown of endothelial cell tight junctions and intravasation,
travel through the circulation, and finally extravasation from the vessel.
#33 and 4 have been linked to lung cancer metastasis, while only integrin-33 is
linked to metastasis to the bone109. The steps underlying interactions with the en-
dothelium are given by Figure 2-12.
Survival in the Circulation Following intravasation, cells which have escaped
from the primary tumor must travel through blood circulation to reach secondary
sites. Unlike white blood cells which utilize adhesive interactions mediated by
selectins and integrins, arrest of cancer cells is due primarily to size restrictions
in small capillaries in the new organs" 0 . However, in certain circumstances can-
cer cells can undergo adhesive arrest. For example, in the liver activation of the
endothelium by interleukin (IL)-la leads to tumor cell adhesion" 0 . A similar phe-
notype has been seen in colon cancer metastases within the lung 1.
In order to metastasize, cancer cells must be able to withstand the harsh en-
vironment of blood'. While in the circulation, tumor cells are detached from the
substratum exposed to high shear forces and immune cells (Figure 2-13). In normal
cells, detachment from the substratum should lead to cell death through a process
called anoikis8 . Metastatic cells which cannot avoid anoikis die in the circulation,
possibly contributing to the high number of cell deaths in the circulation.
The trajectory taken by a tumor cell depends on several factors including the
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Figure 2-13: Survival in the Circulation. In order to metastasize, tumor cells must
be able to withstand the harsh environment within the bloodstream. (A) Tumor
cells that are detached still exchange mechanical forces with the environment. (B)
Shear forces from fluid flow activate cytoskeletal remodeling and cell-cell adhesion
genes. Diapedesis requires new mechanical interactions between tumor cells and
endothelial cells. (Adapted from Kumar et. al., 2009)1
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pattern of blood flow, the capillary diameter, and the balance between sheer forces
and adhesive forces with the endothelium 5 . Metastatic cancer cells must be able to
withstand shear forces in order to successfully form a secondary lesion. Deforma-
tion of the cells in the new organ system is dependent on blood pressure. Differ-
ence in deformation patterns can be seen in high-pressure (e.g. muscle) versus low-
pressure systems (e.g. liver)" 0 . Cells sense forces using mechanochemical systems
which includes adhesion receptors like integrins, focal adhesion complexes, cy-
toskeletal networks, and molecular motors1 . The shear forces experienced while in
the circulation activate the mechnobiological regulatory systems. These pathways
interact with signaling pathways that lead to reorganization of the cytoskeleton
1
and changes in adhesion molecule expression
Tumor cell arrest can occur through three mechanisms: adhesion to the en-
dothelium, size restriction in the capillaries, or by binding coagulation factors to
form a tumor embolus'. As mentioned previously, tumor cell arrest is not primar-
ily mediated by adhesive forces, instead physical constraints in the capillary play
a larger role 12. Formation of tumor emboli involve coagulation factors such as tis-
sue factor, fibrinogen, fibrin, and thrombin, but also involve adhesion molecules
present on the endothelium such as P-selectin1 3 .
There are two possible initial fates for cells in a secondary site, as solitary cells
or small pre-angiogenic micrometastases" 0 . The majority of these cell populations
are clinically undetectable and will remain as occult lesions falling into a state of
dormancy or undergoing apoptosis. Dormancy for a single cell refers to a state
where neither proliferation or apoptosis is occurring while a dormant micrometas-
tases refers to a cell population where both apoptosis and proliferation occur at the
same rate, resulting in no net increase in tumor mass"0.
Tumor cells interact with the endothelium in a variety of ways including re-
cruitment of angiogenic vessels and as a means of escape from the primary tu-
mor. Despite the important role that physical interactions between metastatic cells
and the endothelium play in cancer metastasis, it remains a poorly understood as-
pect of cancer progression, underlying the need to better understand endothelial-
87
epithelial interactions. The final stage of the metastatic cascade is colonization,
which is likely the most complex segments of metastasis and the next subject of
discussion.
2.2.1.3 Metastatic colonization
Understanding the organ-specific pattern underlying cancer metastasis may likely
present the most challenging aspect in unraveling the mysteries underlying cancer
metastasis1 0 . Many tumor types exhibit a predictable pattern of metastasis, for
example breast cancer metastasizes commonly to liver, brain, bones, and lungs,
prostate cancer preferentially metastasize to bone, while colorectal cancer com-
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monly leads to liver metastasis
Stephen Paget in an 1889 article in The Lancet explained the organ-specific pat-
tern of metastasis using the concept of the tumor cells as Seed and the host en-
vironment as the Soil" 4 . In this theory, the formation of secondary metastases is
dependent on complex interplay between the biology of the primary tumor and
the microenvironment. However, an opposing theory presented by James Ewing
in the 1920s postulates that formation of a secondary tumor site is not dependent
on tumor-stromal interplay, but instead is largely dependent on anatomical circu-
lation routes" 0 . Therefore the site of metastases is dictated by blood flow patterns.
There is scientific evidence to support both theories and it's likely that elements
of each theory are necessary to predict the tissues where a secondary tumor will
be formed. For example, in breast and prostate cancer, there are higher numbers
of bone metastases then would be predicted by blood flow patterns alone1 0 . A
similar trend is seen in stomach and testicular cancers where blood flow routes ex-
plain only approximately 66% of metastatic lesions" 0 . It's likely that once a tumor
cell has arrested in a particular organ, molecular interactions with the surrounding
stroma largely dictate whether a metastatic lesion will be formed" 0 .
Overall, the formation of a secondary metastatic lesion is an inefficient process.
Less than 0.1% of tumor cells are viable 24 hours post entry into the circulation
and only 0.01% of these cells will go on to form frank metastases" 5 . To further add
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to the complexity, metastases may occur years following treatment due to tumor
dormancy" 0 . Lastly, endothelium in tissues differs, explaining the inefficiencies in
seeding efficiency in different organs"O.
Commonly metastatic lesions occur in the bone, liver, brain, and lung. The bone
is common site of metastatic colonization for many tumor types including breast,
prostate, lung, kidney, thyroid, and Multiple Myeloma8 . There are two classes of
metastatic lesions found in bone, osteoblastic, or bone forming metastases, and
osteoclastic, or bone degrading metastases. Formation of these lesions involves
aberrations in BMP/IGF signaling8 . Osteoblastic bone metastases are commonly
found in prostate cancer, while osteoclastic metastases occur more frequently in
breast cancer and Multiple Myeloma8 and have been linked to PTHrp/RANKL
signaling8 . Colonization of the liver is commonly seen in colon cancer primarily
due to the circulatory pattern in the digestive system. Colon cancer cells enter the
hepatic-portal system and first encounter the capillary beds of the liver. Coloniza-
tion of the brain occurs frequently in lung, breast, and melanoma. Drug therapies
have also been linked to increased brain metastases. For example, treatment with
HER2 inhibitors in breast cancer, or EGFRi inhibiters in lung cancer, have been
linked to increased incidence of brain metastases 8. Finally, colonization of the lung
has been linked to signaling pathways involved in cell survival and resistance to
apoptosis regulated by the TGF-3, NF-rB, and apoptotic signaling pathways.
2.3 Genetics of cancer metastasis
There are genes that positively and negatively regulate metastasis but these are not
the same genes responsible for positive and negative regulation of primary tumor
growth116 . Metastasis suppressor genes work at multiple stages in the metastatic
process. However, several of them have been demonstrated to directly suppress
the colonization. Metastasis suppressor genes may act at several stages along the
metastatic cascade in cancer and studies have shown that restoring metastasis sup-
pressor functions may be a viable therapeutic strategy. Some metastasis suppres-
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sor genes regulate cytoskeletal rearrangement. For example, DLC1 and Rho GDI2
regulates Rho GTPase signaling 116. However, some metastatic suppressor proteins
function directly on receptor pathways. For example, KAL leads to inhibition of
EGFR signaling and the induction of senescence116 .
2.4 Tumor Microenvironment
A tumor is not composed of a singular cell type but instead is a complex tissue
of multiple, diverse and important cells types that participate in heterotypic in-
teractions to promote tumor progression 117-119 (Figure 2-14). An understanding
of tumor biology requires that cancer be studied in the context of physiologically
relevant cell-cell and cell-matrix interactions117" 18 . Stromal cells that were once
thought to be passive participants in cancer progression are now known to be vi-
tal contributors to the tumor niche117"19 . Studies have shown that tumor stroma,
particularly tumor endothelium, is genetically different than the stroma of normal
epithelial tissue 120-122 and that pathological stroma can encourage tumor progres-
sion 1 7 . An understanding of the role of the stroma in cancer progression presents
unique therapeutic opportunities.
In metastasis, understanding the role of tumor stroma requires additional con-
siderations because metastatic progression is affected by the microenvironment of
the primary tumor, in addition to the microenvironment of the secondary metastatic
site2 3 . In order for metastasis to successfully occur, a tumor cell must be able
to take residency in foreign, potentially inhospitable environment. Although tu-
mor cells can be present in multiple organs, metastatic lesions form in only a frac-
tion of these tissues; thousands of cancer cells enter the circulation, however, only
0.01%, produce clinically detectable metastasesus. Cancer cells can lie dormant
for years before clinically detectable metastases are formed. The inefficiency of
the metastatic process comes from the inability of cells to successfully navigate
each of the steps required for progression, with a significant number of cells lost
once they enter the circulation or undergo apoptosis due to inability to grow in a
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Figure 2-14: Tumor Microenvironment. The tumor microenvironment is a dy-
namic regulator of tumor biology. Tumor stroma has both cellular and acellular
components that together contribute to a tumor's invasive potential.
foreign microenvironment. Formation of a metastatic lesion is an intricate dance
between the biology of the metastasizing cell and its new stromal home. Successful
metastatic cells must demonstrate significant plasticity in adapting to the diverse
environments they will encounter during systemic invasion: primary tumor, blood
circulation, and secondary tumor sites.
2.4.1 Tumor Stroma
There are two distinct components to the stroma, a cellular component and a ma-
trix component. The non-cellular component is referred to as the ECM which pro-
vides the scaffolding on which tissues are built. The cellular stroma includes a
wide range of cell types, namely fibroblasts, endothelial cells, mesenchymal stem
cells, inflammatory cells, etc., each serving diverse and unique roles in normal
physiology and tumor pathogenesis.
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2.4.1.1 Extracellular Matrix
The ECM is a rich protein network composed of diverse macromolecules that cre-
ates a highly regulated structure on which cells attach to build complex tissue ar-
chitectures. The composition of the ECM depends on the tissue type and location
of the matrix. For example, interstitial ECM is rich in fibrillar collagens, glycopro-
teins, and proteoglycans, while basement membrane is a specialized ECM with a
defined matrix of laminin, fibronectin, and type IV collagen1 2 4 . The primary func-
tion of the ECM is to function as a physical scaffold on which cells attach and
organize. However, the ECM also provides critical growth and development sig-
nals. It acts as a reservoir for growth factors that can be released by proteolytic
cleavage 123. Aberrant release of these growth factors can lead to disease pathology,
for example, by metalloproteinases in cancer 4.
The extracellular matrix plays critical roles in regulating normal physiology
and disease pathology. Disruption of its highly regulated biomechanical and bio-
chemical behavior is strongly correlated to disease progression and potentially,
disease initiation. For example, increased stiffness properties of ECM can initiate
an oncogenic phenotype in normal mammary breast epithelial cells12 5 . The breast
epithelial cells lose their organized mammosphere morphology and instead adopt
a tumor-like phenotype characterized by loss of a defined central lumen and de-
creased cell-cell and cell-ECM adhesion proteins.
Abnormal ECM is a hallmark feature of cancer pathology characterized by per-
turbations in composition, density, stiffness, and topography. For example, in
breast tumors the ECM fibers are oriented in linear patterns, contrasting the criss-
crossed orientation of normal ECM fibers 4 . Matrix degrading enzymes, such as
heparanases and MMPs, play a large role in the abnormal features of the ECM in
cancer 4 .
The ECM acts as a natural barrier to cancer progression due to its role in sepa-
rating tissue structures from one another. Disruption of the basement membrane in
cancer by matrix digesting enzymes compromises its intrinsic barrier function, re-
92
ducing the ECM's ability to inhibit escape and migration from the tissue of origin.
The ECM can also indirectly affect cancer cells by regulating the behavior of other
stromal cells, such as endothelial cells or fibroblasts, to create a pro-tumorigenic
environment.
The ECM is filled with pro- and anti-angiogenic factors that are critical for an-
giogenesis regulation. It is also important for endothelial cell survival, prolifer-
ation, and migration during angiogenesis. The ECM forms a protective barrier
around endothelial cells that helps to prevent leakage of material from vessels.
However, in tumors, the basement membrane around endothelial cells is defective
and leaky allowing exudate, including metastatic cells, to easily exit the vessel.
The ECM has also been shown to regulate the stem cell niche124 . Matrix fibers
provide anchorage points for stem cells to remain in the stem cell niche, which is
essential for the maintenance of paracrine signals that regulate stem cell function.
The ECM can also directly regulate stem cell differentiation through mechanisms
being actively explored 124 . Due to its regulation of stem cell biology, it's no surprise
that the ECM may promote cancer by acting directly on stem cell populations.
Abnormal ECM has been linked to expansion of cancer stem cell populations124
2.4.1.2 Tumor Fibroblasts
Fibroblasts are the dominant cell type found in tumor stroma and have been shown
to be potent modulators of malignant progression in cancer. There are two types
of fibroblast commonly found in tumors: cancer-associated fibroblast analogous
to the fibroblasts found in normal tissue and myofibroblasts14 . Myofibroblasts are
not typically found in normal tissue; these cells are associated with chronic inflam-
mation and are linked to the development of pathological fibrosis in many tissue
types14.
Tumor associated fibroblasts enhance a wide range of tumor cell traits includ-
ing increased proliferation, angiogenesis, and invasion 14. They are activated by
inflammation associated growth factors such as IL-1, TGF-3, and PDGF. In con-
trast, normal healthy fibroblasts may be tumor protective. For example, in prostate
93
epithelial cells, normal fibroblasts were able to prevent, and even reverse, the de-
velopment of a malignant phenotype123
One of the primary mechanisms tumor fibroblasts contribute to cancer progres-
sion is through the secretion of aberrant ECM protein components. As previously
discussed, a displastic ECM is a potent mediator of cancer tumor invasiveness 20.
For example, in breast cancer, activated fibroblasts trigger a linear alignment of
collagen fibers that promote cancer migration20
2.4.1.3 Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are the precursor cells that form osteoblasts, con-
drocytes, and adipocytes. They are recruited to tumors and have been linked to in-
crease metastasis123 . For example, when co-cultured with metastatic breast cancer
cells with weak metastatic capability, MSCs increased dissemination of cancer cells
to the lung123 . The enhancement of metastasis by MSCs seems to be dependent on
the CCL5-CCR5 pathway. CCL5 has been known to simulate invasive behavior in
tumorigenic cells123 . Binding of CCL5 is linked to stimulation of this invasive be-
havior. However the effects of MSCs on development of metastatic lesions may be
transient. MSCs did increase the number of metastases, however, in the long term
there were no increases in metastatic cell outgrowth123 . The transient nature of this
effect illustrates the dynamic role of the microenvironment. Some cell populations
might affect tumorigenesis in a transient manner, while other cell populations af-
fect tumorigenesis more longitudinally. For example, endothelial cells regulate
both early and late stage cancer progression.
2.4.1.4 Cancer Stem Cells
Dysregulation of stem cell self-renewal is a likely requirement for the development
of cancer. Cancer may arise from a fully differentiated cell that has regained the
ability to self-renew or from a mutation in a cell already with self-renewing poten-
tial. The self-renewing nature of cancer suggests that tumors may be derived from
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mutations in cells that already exhibit a self-renewal mechanism. A cancer stem
cell (CSC) refers to a cancer cell that is able to self-renew giving rise to the devel-
opment of a tumor mass. These cells may have originated from mutations in the
quiescent stem cells or the highly proliferative progenitor cells. Cancer stem cells
are believe to play critical roles in cancer progression and may also be responsible
for drug resistance in tumors.
2.4.1.5 Inflammatory Cells
The role of chronic inflammation as a potent enhancer of cancer progression has re-
cently been recognized in the last decade. Described as wounds that never heal, 126
evidence of infiltration of immune cells can be found in almost all tumor tissue
types1 4 . Previously, immune cells were believed to be a natural defense mecha-
nism against cancer. However, paradoxically the same cells that are designed to
protect the body may at the same time be potent enhancers of cancer progression.
Inflammatory cells promote cancer primarily through the secretion of biological
macromolecules into the ECM 123 . For example, inflammatory cells secrete growth
factors that induce cellular proliferation (e.g. EGF, VEGF, FGF2) and matrix digest-
ing enzymes (e.g. MMPs, hepranases, cysteine cathepsin proteases) which pro-
mote angiogenesis and metastasis. Inflammatory cells also release reactive oxygen
species that cause genetic transformation in populations of cells that are inherently
unstable.
Cancer cells have developed sophisticated mechanisms for evading immune-
mediated rejection. For example, cancer cells can release TGF-, which inhibits
function of cytotoxic T cells and natural killer cells that target tumors123 . Cancer
cells also recruit immunosuppressive immune cells such as regulatory T cells or
myeloid derived suppressor cells that inhibit the function of cancer targeting im-
mune cells123 . Tumor cells also directly promote recruitment of immune cells that
are cancer promoting rather than cancer inhibiting. Bone marrow-derived cells
(BMDC), notably macrophages, neutrophils, mast cells, and myeloid progenitor
cells, gather at the margins of tumor lesions and initiate various cancer promoting
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processes including the angiogenic switch, tumor cell invasion, and protection of
the vasculature from drug therapies". "Vascular progenitor cells" derived from
the bone marrow have been found to incorporate within the neovasculature in
place of endothelial cells or pericytes". They have been linked to increased angio-
genesis and metastasis.
The role of inflammatory cells in cancer is both tissue and context dependent
with several cell types, CD4+ T cells, macrophages, and natural killer (NK) T cells,
having both pro- and anti-tumorigenic properties123 . For example, CD8+ T cells
and mature dendritic cells are correlated with improved prognosis in both head
and neck cancer and colorectal cancer 3 . In contrast, macrophage infiltration is
strongly associated with poor disease outcome in several tumor types, such as
breast, thyroid, and bladder cancer 3
Tumor Associated Macrophages (TAMs) Tumor associated macrophages (TAMs)
are the BMDCs with the most pro-tumorigenic characteristics, leading to increased
angiogenesis, invasion and metastasis1 2 3 . Activated by IL-4 producing cancer cells,
macrophages encourage local invasion through secretion of matrix degrading en-
zymes1 4 . Little is known about the overall mechanisms underlying the pro- and
anti-tumorigenic characteristics of TAMs14 ,1 23 . However, in breast cancer, TAMs ac-
tivate EGFR signaling through the secretion of its receptor ligand, EGF. The tumor
cells in return secrete CSF1, a chemoattractant for TAMS14 ,1 2 3. Immature myeloid
cells with poorly differentiated macrophage features facilitate the spread of col-
orectal cells through MMP2 and MMP9 secretion 3
An interesting theory has been developed to try to understand the role of macrophages
in creating an "invasive niche." 2 3 The combination of endothelium, macrophage
cells, and tumor cells seem to create an environment rich in metastasis promoting
factors that function through paracrine signaling loops to promote invasion. In
human breast cancer, the density of these three cell types together has been linked
to increased metastasis 3
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Myeloid cell-derived suppressor cells (MDSCs) Similar to tumor-associated macrophages,
myeloid cell-derived suppressor cells (MDSCs) have a primarily pro-tumorigenic
function2 . MDSCs are immature cells of the myeloid linage at different stages
of differentiation that suppress T-cell mediated tumor cell death. MDSCs block
CD4+ T cells and CD8+ T cells through three distinct mechanisms: secretion of
arginase and nitric oxide, increasing regulatory T cells, and inhibition of NK cell ac-
tivation1 2 3 . These MDSCs promote tumors by inhibiting immune cell surveillance
of tumor cells, creating a localized immunosuppressive state that favors metasta-
sis123.
2.4.1.6 Platelets
Although not normally considered part of the tumor microenvironment, platelets
function in protecting tumor cells in the circulation 2 . In a wide range of can-
cers including breast, colorectal and lung, high platelet counts are associated with
decreased survival1 2 3 . Tumor cells bind to platelets using them as a shield to in-
crease survival while in the circulation. Tumor cells express tissue factor which
is the receptor for coagulation factors VIIA and X,12 3 the main initiators of the co-
agulation pathway. This interaction allows for thrombomediated proteolysis, en-
abling the tumor cells to effectively form microthrombi and bind to the platelets.
Binding to platelets protects the tumor cells from cell mediated lysis by natural
killer cells, and also through an additional mechanism of utilizing circulating pro-
thrombin 127 . Formation of thrombi can also function to reduce shear forces in the
vessels that can damage the circulating tumor cells 3 . Platelets can also enhance
adhesion of cancer cells to blood vessels, encouraging subsequent extravasation at
the secondary sites1 2 3 . Furthermore, treatment with anticoagulants have shown to
decrease metastasis in experimental models 3.
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Figure 2-15: Endothelium in tumors is physiologically abnormal. Tumor en-
dothelium is abnormal with large, leaky distorted vessels, excessive branching,
disrupted basement membrane, and loss of support cells.
2.4.2 Tumor Endothelium
The endothelium can act as an enhancer of invasive phenotypes directly increas-
ing metastatic capacity of tumor cells 05"20 . The endothelium of a tumor is dra-
matically different than normal physiological endothelium. Tumor endothelium
is characterized by an abnormal morphology, with large distorted vessels, convo-
luted and excessive branching, precocious capillary sprouting, erratic blood flow,
microhemorraging, leakiness, and abnormal cell proliferation and apoptosis42,'
(Figure 2-15). In normal adult tissue, there are few examples of continuous physi-
ological angiogenesis in healthy adults, such as tissue injury or in the female repro-
ductive system 42. In healthy adults, endothelial cells are quiescent and are second
longest lived cells in the body second to neurons42.
Tumors have poorly defined venules, arterioles, and capillaries that are prone
to leakage and hemorrhage. Blood vessels in tumors, are very heterogeneous, there
are 6 distinct vessel types that are commonly found in tumors: mother vessels, cap-
illaries, glomeruloid microvascular proliferations, vascular malformations, feed-
ing arteries, and draining vessels 28 . Mother vessels are transient structures that
arise from pre-existing venules 48 . They are large, thin-walled vessel structures,
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with a serpentine architecture, characterized by loss of pericytes and high VEGFR
receptor expression 8. Blood flow through these vessels is disrupted, which in-
creases risk of thrombosis. Mother vessels are transient structures from which
different types of daughter vessel structures arise48. Glomeruloid microvascu-
lar proliferations are poorly organized structures that resemble renal glumeruli,
characterized by tiny lumens and serpentine microvessels48 . They have twice the
amount of basement membrane that is normally present in vessels and are highly
cellular due to increased replication of both endothelial cells and pericytes within
these vessels 48 . The capillaries found in tumors are characteristic of vessels found
in normal tissue48. In contrast, vascular malformations are characterized by asym-
metry48 . Smooth muscle cells initiate formation of vessel malformations 12 8. Mother
vessels which have acquired a coat of smooth muscle cells are apt to form vascular
malformation128 . You can distinguish vascular malformations from normal arteries
and veins due to their unusually large size, and their thin and asymmetric coating
of smooth muscle cells128. Vascular malformations are not permeable to macro-
molecules, and they can persist independent of VEGF-A signaling, unlike mother
vessels and glomeruloid proliferations described previously 128. This might be due
to the fact that the smooth muscle cells that are in close proximity to these vessel
structures actually secrete VEGF-A locally, which is able to maintain these struc-
tures4 8 ,1 2 8 . This has important implications in the fact that vascular malformations
will not be targeted by VEGFR inhibitors commonly used to treat cancer48 128
The last two types of vessels, feeding arteries and draining vessels are gen-
erated through arteriovenogenesis that occurs simultaneously with angiogenesis;
however the exact mechanism by which this occurs is unknown128 . Inhibition of
feeding arteries and draining veins could be interesting therapeutical targets be-
cause these vessels lie upstream and downstream of tumor structures 128, therefore
cutting off their blood supply would reduce the tumor blood supply both up-
stream and downstream, which may be more efficient than targeting the blood
supply within just the tumor structure the approach taken by traditional anti-
angiogenesis drugs12 8 . Feeding arteries and draining vessels are formed through
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Figure 2-16: Schematic of angiogenesis. Angiogenesis is a tightly regulated pro-
cess. However, in cancer, tight regulation is lost.
remodeling of existing vessel structures 128.
During embryonic vasculogenesis, vessels are formed de novo, from endothe-
lial precursor cells called angioblasts 42 . These cells organize to form primary cap-
illary plexus. The cells subsequently differentiate to form new blood sprouts that
branch from pre-existing vessels in a process called angiogenesis. In tumors this
process is altered.
Most tumor endothelium is formed through angiogenesis; however some tu-
mors utilize vasculogenesis in recruitment of endothelial cell precursor cells in
order to form the appropriate vasculature 42 . The steps of tumor angiogenesis or
pathological angiogenesis can roughly be defined as follows (Figure 2-16): The
first step is vessel dilation and increasing vascular permeability of pre existing cap-
illaries, or post capillary venules, in response to VEGF signaling42 . This leads to
extravasation, or flow out of the vessel, of plasma proteins. These plasma proteins
form the provisional matrix on which the vessels will form 42. The activated en-
dothelial cells use matrix to migrate and form the vessel structure. Cell-cell adhe-
sions between pericytes and endotheial cells are weakend in tumor endothehium.
Loosing of pericytes on endothelial vessels occurs through the binding of ANG-
2 to TiE-2, a tyrosine kinase receptor selectively expressed on endothelial cells 42.
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Endothelial cells migrate into the peri-vascular space undergoing proliferation to
form a migration column. Formation of the migration column signals for differ-
entiation, creating a differentiation zone where the endothelial cells change shape
and adhere to one another to form a lumen. The cells continue to proliferate along
the vascular wall increasing the diameter of the vessel structures, and finally, there
is recruitment of peri-vascular cells and formation of the vascular basal lamina".
There is speculation about the mechanism leading to pathological angiogene-
sis1 20 ,12 2 including the role of microRNAs1 06 ,12 ,1 3 0. However, the molecular details
on how this transformation occurs have yet to be elucidated.
Studies have shown that tumor associated endothelium is genetically abnor-
mal, showing upregulation of many tumor and cancer promoting genes, such as
the VEGFR receptors. Studies by Hida et. al. show that tumor endothelial cells
have genetically abnormal centrosomes and demonstrate aneuploidy13 1 . These
findings were seen in multiple human cancers, such as human renal cell carci-
noma, and also in mouse endothelial cells isolated from tumor xenografts of hu-
man melanoma and liposarcoma tumors 13 1 . The tumor endothelial cells are be-
lieved to acquire these genetic abnormalities from the tumor microenvironment,
however the mechanism as to how these genetic abnormalities occur is still yet to
be elucidated132' 1 3
2.4.2.1 Pericytes
Pericytes are specialized mesenchymal cells that are related to smooth muscle
cells". They provide both mechanical and physiological support to the endothe-
lium through projections that enclose endothelial tube blood vessels. Pericytes
typically communicate with the endothelium through paracrine signaling help-
ing to maintain quiescence in the endothelial cells though the ANG1-Tie2 receptor
pathways 4 . Pericytes aid endothelial cells in synthesis of the vascular basement
membrane that help to keep vessel structures intact, anchoring both pericytes and
endothelial cells and strengthening the vessel wall to withstand the hydrostatic
pressure of blood flow. Abnormalities in pericyte function are strongly correlated
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with the development of pathological angiogenic vessels. Loss of pericytes leads
to increased instability of the tumor endothelial cell vessels and also enhances the
ability of cancer cells to intravasation/extravasation into the circulatory system for
hematologic dissemination.
2.5 The role of intercellular communication in the de-
velopment of an invasive cancer phenotype
Cell-cell communication is an important part of maintaining cellular homeostasis,
playing dynamic roles in cellular, organ, and organism function, 134 -36 . Evolution
of multicellular organisms, embryonic development, adaptation to the external en-
vironment, and defense against pathogens would not be possible without local and
systemic delivery of signaling molecules 3,134-136. Despite the fundamental role of
cell-cell communication in normal cellular physiology, inappropriate or deranged
pathways of cell-cell communication play powerful roles in almost every human
disease 36. For example, in cardiovascular disease, derangements in growth factor,
cytokine, or hormone signaling leads to myocyte hypertrophy contributing to car-
diac dysfunction and eventually heart failure137 . In a similar way, in the immune
system, inappropriate intercellular communication is linked to immune dysfunc-
tion 138 and the spread of pathogens 136,139. Neurological disorders such as Parkin-
sons disease and Alzheimers disease have also been linked to aberrant modes of
intercellular communication 136. Lastly, there is overwhelming evidence showing
that disruption of classical modes of intercellular communication, such as cytokine
and growth factor signaling pathways4 , in addition to alternate modes of intercel-
lular communication, such as exosomes, play important roles in cancer pathology
regulating primary tumor biology and promoting a pro-metastatic microenviron-
ment 1- 4 4 . Interestingly, intercellular transport of RNAs has been recently eluci-
dated as a potent mediator of cellular transformation and disease progression in
cancer and other diseases 5 .
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2.5.1 How do cells communicate?
Cell-cell communication can be grouped into indirect and direct modes. Indi-
rect modes of communication are typically classified as receptor-ligand interac-
tions involved in paracrine and endocrine signaling,', 117, 146,14 7 while direct modes
of cell-cell communication involve physical interactions between cells that allow
for transfer of intercellular contents148 . Mechanisms of cell-cell communication are
complex and varied, with many overlapping characteristics, making strict adher-
ence to this classification system difficult. For example, under one classification,
extracellular vesicles can be considered as a form of carrier-mediated chemokine
signaling, activating receptor-ligand signaling pathways in a similar way to solu-
ble factors136 1 42 . However, extracellular vesicles also share similarities with modes
of direct cell-cell communication. For example, like gap junctions and membrane
bridges, exosomes allow for the transfer of genetic material such as functional mR-
NAs, miRNA, and DNA.
Roughly speaking, autocrine, paracrine and endocrine signaling fall into the
category of indirect modes of communication, along with more recently discov-
ered forms of indirect modes of cell-cell communication, such as exosomes, ecto-
somes, and apoptotic bodies. In contrast, direct modes of cell-cell communication
include membrane bridges, gap junctions, fungal septa, and plasmodesmata (Fig-
ure 2-17). Multicellular organisms have developed sophisticated machinery for
utilizing many if not all of these mechanisms 149 . The number of varied mecha-
nisms that exist underlies the evolutionary advantage provided to a cell which can
effectively communicate with itself, neighboring cells, or cells far away - in other
tissues, organs, or organ systems149'15O.
2.5.1.1 Modes of indirect cell-cell communication
The role of soluble factors Classical descriptions of cell-cell communication fo-
cused on the role of soluble factors in mediating biological functions. Cytokines,
chemokines, growth factors, hormones, and neurotransmitters are examples of me-
103
Autocrine
Paracrine
Endocrine
PhagoytIS
Ectosomes
Exosomes
Plasmodesmata Cyto. -W
Dsm~otubule
Gap Junctions
Membrane
Bridges
Figure 2-17: Modes of Intercellular Communication. Cells have adapted diverse
mechanisms to communicate with the external environment. Each of these mecha-
nisms have distinct and overlapping functions, but collectively function to regulate
many aspects of cellular physiology. Modes of intercellular communication can be
divided into direct and indirect modes of communication.
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diators of this class of communication. There are three classically defined mech-
anisms of extracellular communication: autocrine signaling, paracrine signaling,
and endocrine signaling. In autocrine signaling, cells secrete soluble factors that
they themselves respond to. For example, autocrine signaling has been shown to
allow for constitutive Wnt pathway activation in a significant number of human
breast and ovarian cancers"'.
The second mechanism, paracrine signaling, involves the release of signaling
molecules by a cell that unlike autocrine self-signaling, targets cells in close prox-
imity. For example, activation of epidermal growth factor receptor (EGFR) by its
ligands (e.g. epidermal growth factor and TGF-o) occurs through paracrine sig-
naling. Paracrine signaling has also been demonstrated to be a mechanism of
hedgehog pathway activation in cancer. Overexpression of Hh ligands in tumor
cells leads to pathway activation of Shh in neighboring stromal cells through a
paracrine signaling mechanism5 2 . Furthermore, it was found that inhibition of
the Hh pathway in the stromal microenvironment in turn results in suppression
of tumor growth. This interaction is an example of the complex interplay in cell
signaling, where changes in signal pathway activation in one cell type can affect
neighboring cell populations through a paracrine signaling mechanism1 2.
Endocrine signaling is the final classically defined mechanism of intercellular
communication. It involves the systemic delivery of signaling molecules. The sig-
naling molecules in endocrine signaling are usually referred to as hormones. Hor-
mones are carried throughout the body in the systemic circulation, playing criti-
cal roles in maintaining homeostasis and in regulating physiologically processes
in multi-cellular organisms. For example, hormones like angiotensin and aldos-
terone are critical for the regulation of cardiovascular function. Deregulation or
inappropriate expression of these hormones leads to hemostatic instabilities and
difficulties maintaining appropriate blood pressure both of which are large con-
tributors to the development of cardiovascular disease'.
To further add to the complexity several of these pathways act through many,
if not all, of these mechanisms. One example is the EGFR pathway. Acting as a
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hormone, EGF is secreted by the maternal mammary gland, regulating neonatal
development153 . However, EGFR activation can also occur through autocrine and
juxtacrine mechanisms1 3 . Juxtacrine signaling is unique because it combines as-
pects of traditional signaling by soluble factors with the requirement of physical
contact, analogous to direct modes of intercellular communication. Juxtacrine sig-
naling is a type of contact dependent signaling induced by cell-cell or cell-ECM
interactions. The best example of juxtacrine signaling is the canonical Notch sig-
naling pathway154 155. Notch is a transmembrane receptor protein that is activated
by its ligands which are typically members of the Delta and Jagged family of cell
membrane proteins154 155 . Notch signaling requires that cells be in close physical
contact as a consequence of its activation by cell membrane ligands. Contrast this
requirement of close contact to other forms of direct modes of communication like
membrane nanotubes that allow for directed cell-cell communication over long
distances of separation156 .
Extracellular vesicles: A form of carrier-mediated signaling Carrier-mediated
signaling provides an alternative mechanism for cells to communicate via autocrine157,
paracrine14 3 , endocrine signaling14 3 ,15 8 ,159, as well as providing a conduit for trans-
fer of biomolecules that until recently were less commonly associated as mediators
of intercellular communication, such as cytoplasmic RNAs135 ,136. Carrier-mediated
signaling is accomplished by cell-derived vesicles covered by membrane lipid bi-
layers'35 " 36 . Since the original description of extracellular vesicle release from rat
and sheep reticulocytes,160"161 membrane vesicles have been described in almost
every body fluid such as urine, blood, sweat, serum, and plasma162 . They have
been described in both eukaryotic and prokaryotic cell types and have been shown
to carry a wide array of cargo including proteins, lipids, and nucleic acids13 6.
There are three main extracellular vesicles involved in chemokine signaling,
exosomes, microvesicles, and apoptotic bodies. Exosomes are small intralumi-
nal vesicles (ILVs) (30-100nm) formed inside late endosomes called multivesicu-
lar bodies (MVBs) 35 ,163 . They are released from cells when multivesicular bodies
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fuse with the membrane. Exosomes have a distinct membrane composition that
reflects their endosomal origin 13 , 163 . There are characteristic proteins associated
with exosomes that have varied functions such as membrane fusion proteins, cy-
toskeletal proteins, signal transduction proteins, anti-apoptotic proteins, adhesion
molecules, and cell specific proteins163.
Ectosomes and apoptotic bodies represent the two other commonly studied ex-
tracellular vesicles. Ectosomes, are larger than exosomes (100nm-1pum), resulting
directly from membrane blebbing and are believed to serve similar functions as ex-
osomes 131. Apoptotic bodies are the largest extracellular vesicles at >1Pm 135 . They
are commonly released by tumor cells but not other cell types. They are charac-
terized by phosphatidylserine externalization and commonly contain fragmented
DNA13 .
2.5.1.2 Modes of direct cell-cell communication
Direct modes of cell-cell communication require physical contact between two
cell types. These modes of communication can range from short-range commu-
nication, for example via gap junctions, to long-range communication as is seen
with membrane bridges. These modes of communication are unique in contrast
to modes of indirect cell-cell communication because they allow for specificity in
targeting an individual cell or a particular cell population. Examples of this mode
of communication include membrane bridges, gap junctions, and plasmodesmata.
Plasmodesmata Plasmodesmata are plasma membrane lined channels within the
cell wall of plants that allow for regulated transport of cellular contents between
adjacent cells 164 . These structures can form between mature cells or during cellular
division from components of the endoplasmic reticulum. Transport of molecules
through plasmodesmata occurs between the plasma membrane and the endoplas-
mic reticulum central core called a desmotubule and is regulated by callose found
at both ends of the pore1 64 .
Plasmodesmata have long been identified as a mode of intercellular communi-
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cation in plants allowing for the transport of a wide range of biomacromolecules.
They are an important mechanism for regulating plant cellular physiology and
development and can also contribute to cellular pathology for example when ex-
ploited by pathogens164 . One very interesting feature of communication through
plasmodesmata is the ability to transport RNA silencing signals.
The discovery of mobile RNA sequences was first made in plant species. One
early study demonstrated that silencing signals inserted in the stalk resulted in si-
lencing of grafted scions derived from non-silenced plants. Silencing in this model
occurred at 100% efficiency and transport was determined to be unidirectional
from stalk to scion165 . Transport of these signals has the potential to affect im-
portant physiological processes such as host genome defense against pathogens
and response to external environmental stimuli. For example, transport of trans-
genes derived from sRNA and endogenous sRNA was shown to result in epige-
netic modifications in the genome of the recipient cells potentially altering host
responses to physiological stresses and insults166.
Gap Junctions Gap junctions are a form of short-range direct cellular communi-
cation. Gap junctions are formed by the connexin family of proteins 67 and similar
to previously described modes of cellular communication, gap junctions mediate
important physiological process, such as T cell activation in the immunological
synapse during antigen presentation by dendritic cells 168, and are involved in dis-
ease pathology. Gap junctions have a unique structure forming open channels be-
tween two adjacent cells that allow for intercellular connectivity and free diffusion
of macromolecules and ions.
A single gap junction does not allow for intercellular contact between distant
cells. However, gap junctional communication can still allow for intercellular com-
munication between a population of cells because similar to plasmodesmata, gap
junctions form a network of intercellular connectivity connecting each cell to its
adjacent neighbors. Therefore this mode of communication too can enable rapid
dissemination of intercellular signals within a population. Gap junctions can trans-
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port miRNA and small interfering RNA (siRNA) silencing signals16 170 that regu-
late gene expression for example in mammalian heart cells 17 0 . Furthermore, gap
junctional communication has been shown to enhance a metastatic phenotype in
breast cancer171.
Membrane connections The final class of direct cell-cell communication mech-
anisms are the membrane bridges, which include, fungal septa, cytonemes, and
tunneling nanotubes. Fungal septa are cross walls that divide individual fungal
cells. In some ways they resemble plasmodesmata, functioning as pores that trans-
port cytoplasm and organelles between neighboring cells'49 . Tunneling nanotubes
and cytonemes have similar structures and overlapping, yet distinct, functions.
Cytonemes and tunneling nanotubes are thin membrane bridges composed of cy-
toskeletal proteins, primarily F-actin. The primary distinction is that cytonemes are
non-tubular bridges with no cytoplasmic connectivity, while tunneling nanotubes
are open tubular structures that connect the cytoplasm of adjacent cells98 . As a con-
sequence, intercellular contents such as endolysosomal cargo can be transported
within TNT structures, while cytonemes can only transport membrane bound macro-
molecules or pathogens98 . Membrane projections have been implicated in a wide
range of disease pathologies including cancer172 , autoimmune diseases?, and in-
fectious diseases 173 . For the purposes of this discussion, I will focus on the modes
of communication relevant to mammalian cell biology giving specific emphasis to
tunneling nanotubes.
Original description of Tunneling Nanotubes Tunneling nanotubes are a re-
cently discovered, novel form of cellular communication wherein direct transfer
of intercellular contents occurs through thin, nanotubular projections2 . Since the
initial observation of TNTs in rat pheochromocytoma cells (PC12)2, TNT and TNT-
like structure have been observed in prokaryotic174 and diverse eukaryotic cell
types such as neuronal, immune, and epithelial cells 2,3 ,1 7 1 7 . These structures pro-
vide a conduit for a dynamic mode of cell-cell communication that allows for the
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exchange of cellular contents over hundreds of microns of physical separation 17 .
Across cell types, there is a fair degree of heterogeneity in TNT length (major axis),
width (minor axis), and cytoskeletal composition, so no single definition can be
used to classify all TNTs 17,156,175. The unifying feature among all TNTs is cyto-
plasmic continuity between cells; also unlike other cellular protrusions, such as
lamellipodia and filopodia, TNTs are found to hover above the substratum 2,117.
TNTs carry a diverse array of cargo including cytoplasmic fluorophores, proteins,
and organelles 17, 156, 175; they are also mediators of bacterial 176 177 and viral patho-
genesis 17717' and present novel routes of disease transmission. TNTs may serve
important roles in disease pathology, highlighting the motivation to understand
their physical properties and biological characteristics11 14 156 .
TNT projections found in PC12 cells had unique physical dimensions with a
average diameters ranging between 50 and 200nm and lengths greater than several
cell diameters2 . TNTs in this model system were fragile structures, rupturing from
exposure to light, mechanical stress, and chemical fixation. Interestingly, exposure
to trypsin-EDTA did not lead to disruption of structures 2. TNTs were also observed
in human embryonic kidney (HEK) and normal rat kidney (NRK) cells, implying
that these structures may be evolutionarily conserved and present in many tissue
types 2.
The authors speculate that TNTs were formed from growing filopodial protru-
sions that make contact with neighboring cells and emphasize that these struc-
tures are not remnants of incomplete cytokinesis. In this model system, TNTs ap-
peared as single structures, rarely displaying branching characteristics; however
occasionally existing as complex networks connecting many neighboring cells 2 .
TNTs formed by PC12 cell types were composed of F-actin cytoskeletal compo-
nents and not microtubules 2. Future studies, however, have shown that TNT and
TNT-like structures in other cell types contain microtubules, and the inclusion of
microtubules may be dependent on the dimensions of the minor axis of the projec-
tion176.
The primary reported function of TNTs has been intercellular communication.
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Live cell video microscopy was used to capture transport of intercellular cargo
within these projections. In PC12 cells, two hours post co-culture, TNTs allowed
for unidirectional and selective transport of organelles with 74% of TNT+ve cells
showing evidence of transfer. Furthermore, Myosin Va co-localized with the synap-
tophysin, the endosomal marker used to track the organelles, suggesting a pos-
sible actin-mediated active transport mechanism. TNT structures could be dis-
rupted with inhibitors of actin polymerization, emphasizing the role of the actin
cytoskeleton in formation of these structures. Only plasma membrane proteins
and not cytoplasmic molecules such as green fluorescent protein or calcein, a small
molecule dye, could be transported through these structures suggesting that pas-
sive diffusion of soluble cytoplasmic molecules did not occur through TNT struc-
tures observed in PC12 cells. However, subsequent studies have demonstrated
that cytoplasmic molecules can indeed be transported through TNT projections,
again emphasizing the variability of these structures among different cell types.
Tunneling Nanotubes in Normal Cell Physiology After the initial demon-
stration of TNTs in PC12, there has been a flurry of investigations into the role
of TNTs in other cell types, particularly in the immune system. TNTs have been
implicated in both normal and disease pathology of the immune system. Mem-
brane nanotube structures have been shown to connect a wide range of immune
cells such as Epstein-Barr virus transformed cells, primary macrophages, and NK
cells179 .
In the immune system, TNTs display varied functions ranging from intercellu-
lar calcium signaling to pathogen transmission. Chemically or mechanically stim-
ulated dendritic cells and monocytes quickly transmit calcium signals to neighbor-
ing cells through TNT structures180 . Transport of calcium signals through TNTs is
believed to be analogous to calcium signaling through gap junctions. Membrane
nanotubes transport a second messenger inositol 1,4,5-trisphosphate (IP3). This
second messenger induces calcium release from the endoplasmic reticulum. In ad-
dition, calcium may also be directly transferred within the TNTs, further enhancing
111
calcium signals in the second population180 . In dendritic cells, transport of calcium
signals within TNTs is believed to function in antigen recognition. In these cells,
calcium signals received via TNTs promoted changes in cellular morphology that
enhanced the ability of these immune cells to respond at an antigenic site. TNTs
have also been identified as a mechanism for exchange of MHC class I molecules,
potentially highlighting the role of these structures in antigen presentation181 . In
HeLa cells, membrane bound HLA-A2-EGFP was transported along the nanotube;
however, soluble HLA-G2-EGFP protein was not 181 . Overexpression of LST1, an
inducer of nanotube formation, could promote HLA molecule transfer 81. LST1
has been previously identified as an inducer of functional nanotube formation in
leukocytes 182 . LST1 is a transmembrane MHC class III protein, which functions
through interactions with the small GTPase RalA and the exocyst complex182.
Nanotubes function in both mechanisms of innate and adaptive immunity183'184*
For example, in the innate immune system, these structures regulate interactions
between NK cells and their target cells1 83 . Nanotubes promote the cytotoxic func-
tion of natural killer cells through two distinct mechanisms. First, nanotubes cre-
ate direct contact between the NK cell and its target, improving efficiency of cell
lysis. Second, nanotubes move target cells closer to NK cells for lysis via forma-
tion of a conventional immune synapse183 . Cytotoxic T cells also utilize membrane
nanotubes in order to enhance killing of their targets in a similar manner as NK
cells 184 . TNTs also enhance the antigen recognition in immune cells by creating
what is referred to as a submicron synapse. This allows the NK cells to stay in
contact with a previous target cell conferring antigens of interest that promote im-
proved identification of other infected cells to target for destruction183 . Similarly,
in B-cells, antigen receptors can be transported between activated and bystander B
cells leading to more efficient expansion of antigen binding B cells185 .
TNTs also play a protective role in the immune system by preventing develop-
ment of autoimmunity138 . In normal cellular physiology, healthy T cells destroy
autoreactive T cells through Fas-FasL binding. However, a new mechanism uti-
lizing TNTs has recently been identified, where transport of caspases between T
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cells also contributes to destruction of autoreactive cells138 . The TNT projections
are themselves directly induced by secretion of Fas by autoreactive T cells. This
mechanism, referred to as social apoptosis, appears to be critical in preventing
autoimmune disease138 . For example, defects in this pathway has been linked to
development of autoimmune lymphoproliferative syndrome, characterized by the
inability to completely eliminate autoreactive T cells138.
Beyond the immune system, tunneling nanotubes have been described in a
whole host of cell types including retinal pigment epithelial cells 18 6, vascular smooth
muscle cells1 87, cardiomyocytes and cardiofibroblasts 188, renal proximal tubular
epithelial cells 146, and astrocytes1 89 . There have been no unifying theories regard-
ing the role of TNTs in normal cellular physiology. However, these structures
seem to regulate a wide range of cellular activities and have been linked to dis-
ease pathogenesis.
2.5.2 Cell-cell communication in disease progression
Cell-cell communication plays critical roles in normal cellular physiology. There-
fore it's unsurprising that aberrations in cellular communication are implicated in
varied diseases including spread of pathogens136 , cardiovascular disease137, neu-
rodegeneration, 136 and cancer progression1 36. For example, gap junctional intercel-
lular communication between breast cancer cells and bone marrow stroma have
been implicated in cancer metastasis167, highlighting that aberrations in ligand-
receptor signaling is a fundamental element in cancer pathogenesis. In the car-
diovascular system, microvesicle transport of miR-150 from THP-1 monocytes to
microvascular endothelial cells promotes atherosclerosis through c-MYB190 . As a
final demonstration, exosomes released by diseased neurons may be linked to the
transport of pathogenic proteins through neuronal tissue1 91.
Membrane bridges and membrane vesicles are the two most recently discov-
ered mechanisms of cell-cell communication. Unique to these modes of com-
munication is the capability to transport genetic material, such as cytoplasmic
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RNAs, making them dynamic and powerful modes of cell-cell communication.
The unique nature of these communication mechanisms makes them interesting
candidates of disease progression. Indeed, these mechanisms may represent two
extremes of a single mode of communication where cargo is protected by the plasma
membrane. As such, exosomes enable a long-range, low specificity form of this
communication, and membrane bridges promote short range, high specificity com-
munication. Each of these mechanisms has been linked to a wide range of disease
pathologies; however, the largest body of evidence for the function of these modes
of intercellular communication are in the fields of infectious diseases and cancer
pathogenesis.
2.5.2.1 Infectious Diseases
There has been a great deal of interest in the role of TNTs in disease progression
due to the specificity and signal-amplifying quality of communication through
nanotube connections192 . Membrane nanotubes present a potent mechanism of
disease pathogenesis where one infected cell can simultaneously communicate
with multiple neighboring uninfected cells, making nanotubes an efficient tool
for exploitation by pathogens. There have been several studies demonstrating
exploitation of TNT structures by both bacterial and viral pathogens19 3. For ex-
ample, TNTs have been shown to be a mechanism of human immunodeficiency
virus (HIV)-1 transfer'7 1,4. HIV-1 can be transferred from infected T cells trough
membrane nanotubes in a receptor dependent fashion 178 . Transmission of HIV
through nanotubes was 100-1000 times more efficient than cell-free HIV transmis-
sion 178 . A similar study in macrophages showed that HIV-1 could directly induce
formation of TNT structures to increase efficiency of infection194 . In these studies,
the authors describe the ability of HIV to "hijack" TNT communication in order to
facilitate pathogenesis. The mechanism of HIV induced TNTs involves interactions
between the exocyst complex and HIV-1 Nef195 .
The ability of pathogens to induce formation of cytoskeletal projections is not
a new concept. Over a decade ago, Listeria monocytogenes was found to induce
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protrusion of finger like projections from infected macrophages allowing for bac-
teria transport to neighboring cells176 . Pathogens were able to induce formation of
projections by directly promoting actin polymerization. These viruses (e.g. alpha
herpes virus family and pseudo rabies virus family) utilized these projections to
facilitate immune silent spread through entire cell populations, avoiding immune
detection by reducing their exposure to the extracellular environment176 .
Microvesicles are also potent mediators of viral transmission139 . For example,
the chemokine receptor, CCR5, is transferred via membrane-derived microparti-
cles released from the surface of peripheral blood mononuclear cells. CCR5 is
a critical co-receptor used by macrophage tropic strains of HIV-1 to infect host
cells. Transfer of CCR5 confers sensitivity to HIV-1 infection in previously re-
sistant CCR5 deficient mononuclear cells. Furthermore, microvesicle transfer of
CCR5 to endothelial cells enabled HIV-1 infection of these cells, demonstrating
that exogenous CCR5 transported via microvesicles can make cells normally re-
sistant to HIV, susceptible to infection139 . There is also evidence to suggest that
mature DCs can also transfer HIV to neighboring CD8+ and CD4+ cells through
secreted exosomes196 .
Exploitation of these modes of communication to promote pathogen infectiv-
ity is not limited to viruses19 2. In macrophage cells, bacteria can utilize mem-
brane nanotubes to infect healthy cells 176 . Two different classes of TNT struc-
tures have been described in macrophage cells; large projections containing F-
actin and microtubules and smaller structures containing only F-actin. Bacteria can
only be transported along the thin nanotube projections, while the thicker projec-
tions transport intercellular vesicles such as endosomes and lysosomes. Transport
through both classes of projections was inhibited by azide treatment, suggesting
that TNT formation is an energy-intensive process. However, disruption of TNTs
with microtubule destabilizing agents, such as colchicine and nocodazole, resulted
in only inhibition of organelle transport and not disruption of bacteria transport.
These results emphasize the distinctly different role of the large and small TNT
connections in these cell types 176. TNTs formed from dendritic cells to primary
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neurons have also been demonstrated as a mechanism of prion spreading from the
peripheral nervous system to the central nervous system 173.
Pathogens have the unique ability to exploit normal cellular physiological pro-
cesses to achieve ever increasingly efficient mechanisms of transmission, which in
many ways characterizes the nature of malignant cells197 . Similar to HIV, other
pathogens are able to directly induce formation of disease-promoting membrane
projections. For example, Rice Dwarf Virus (RDV), through a viral protein called
PNS10 was able to induce formation of membrane projections between infected
insect cells and non-infected mammalian cells'98 . The intercellular virus exploited
these tubular structures to move into healthy neighboring animal cells'98 .
2.5.2.2 Cancer
Membrane bridges and vesicles present exciting mechanisms for tumorigenesis,
metastasis, and drug resistance136"99 . Using these modes of communication, a tu-
mor cell may be able to perturb, potentially even transform, surrounding epithelial
and stromal cell populations. These modes of communication serve three primary
roles: to promote tumorigenesis, to inhibit tumorigenesis, or as a means of com-
munication between tumor cells and the stroma 5 . One example of the role played
by membrane vesicles in cancer pathogenesis involves release of mRNA, miRNA,
and protein filled microvesicles by Glioblastma cells. These microvesicles were
taken up by surrounding tumor and microvascular endothelial cells, leading to
increased tumor proliferation and enhanced angiogenesis 200. The oncogenic re-
ceptor EGFRvIII was transferred between cells through microvesicles termed "on-
cosomes" that allowed for horizontal propagation of oncogenes and presented a
potential mechanism of cellular transformation20'. In another example, EMPPRIN,
a transmembrane glycoprotein, was also transported via microvesicles between tu-
mor cells and the surrounding microenvironement. EMPRINN is expressed at high
levels by tumor cells leading to stimulation of matrix metalloproteinase expression
in fibroblast to facilitate tumor invasion and metastasis 202. In pleural mesothelioma
cells, TNTs were demonstrated to transfer vesicles, proteins, and mitochondria be-
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tween malignant cells 2 3.
Exosomes secreted by cancer cells also have immune modulating activity. For
example, oral squamous cancer cells secrete microvesicles carrying Fas ligand that
induces apoptosis of activated T cells and Jurkat cells. Tumors also release exo-
somes which promote expansion of regulatory T-cell populations that target tumor
recognizing CD8+ T cells for destruction 204 . These mechanisms likely promote im-
mune evasion by cancer cells 2 05 . In contrast, tumor derived exosomes can also
enhance destruction of tumor cells by the immune system. For example, tumor-
derived exosomes have been shown to induce antigen sensitization in dendritic
cells 206.
Membrane bridges and vesicles may also be linked to drug resistance. For ex-
ample, trastuzumab resistant breast cancer cells secrete HER-2+ve exosomes. Se-
cretion of HER-2+ve exosomes has been previously linked to reduced drug toxicity.
One possible mechanism to explain the reduced drug toxicity is that in these cells,
internalized drug binds to exosome-bound Her-2 instead of intracellular Her-2.
Therefore the drug is expelled from the cells during exosome release207 . In MCF-7
breast epithelial cells, transfer of P-glycoprotein (pGp) resulted in a non-genetic
multi-drug resistant phenotype208 209.
These modes of communication may actually serve as the greatest roles in tu-
mor stromal interactions. For example, tumor exosomes have been implicated in
endothelial cell activation, angiogenesis210 , and metastasis21141. In melanomas,
tumor-derived exosomes promoted metastasis through transformation of bone mar-
row progenitor cells, consequently leading to activation of an MET signaling path-
way. Activation of the MET receptor created a pro-vascular phenotype that en-
hanced formation of a pre-metastatic niche141 . In another study, transfer of tumor
microvesicles containing oncogenic EGFR activated VEGF signaling in endothe-
lial cells, promoting pathological angiogenesis 15 7. Furthermore, transfer of mito-
chondria from tumor cells to endothelial cells through TNTs has been linked to
chemoresistance 21 2 . Lastly, TNT-mediated exchange of pGp may also induce stro-
mal cell transformation2
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2.5.3 Transport of RNAs as potent mechanism of cellular trans-
formation in cancer
Intercellular transfer of genetic material presents a powerful means of cellular
communication, playing critical roles in both normal and disease pathology. Al-
though transfer of genetic material in plants and other lower eukaryotic life forms
has been well demonstrated, exchange of genetic information in mammalian cells
is a relatively recent concept 135 ,136 . Horizontal transfer of DNA, mRNA, and small
RNA (sRNAs) from one cell to neighboring cell populations have been described
in many cell types including cancer cells, stem cells, and immune cells135 ,136,2 14 . The
nucleic acids can be encapsulated in extracellular vesicles, exist as free molecules,
or bound to carrier proteins214 .
Early research examining intercellular communication in animals cells described
the presence of mRNA and microRNAs in exosomes secreted from mouse and hu-
man mast cells 2 15 . The mRNA found in these vesicles was functional and expressed
in recipient cell populations. The authors coined this mechanism of cellular com-
munication as "exosomal shuttle RNA", a novel mechanism of cellular transfor-
mation 215 . The capability of genetic material to act as candidates for intercellular
communication introduces new and dynamic mechanisms by which cells maintain
homeostasis and interact with the surrounding environment. Horizontal transfer
of genetic materials allow cells to directly manipulate the behavior of neighbor-
ing populations. For example, horizontal transfer of DNA through phagocytosis
of apoptotic bodies has been implicated in viral pathogenesis and cancer progres-
sion. Co-culturing apoptotic bodies containing viral DNA derived from lymphoid
cells infected with Epstein-Barr virus (EBV) led to expression of EBV genes in re-
cipient cells 2 16 . Similarly, exosomes secreted by EBV positive B cells transferred
functional miRNAs to uninfected monocytes 217.
Similar to DNA, circulating RNAs have been implicated in both normal and
pathological disease states1 3 6,2 14 . Once believed to be too fragile and susceptible to
degradation by extracellular nucleases, RNAs have been detected in many body
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fluids including serum, plasma, saliva, urine, and milk214,218 . They have also been
linked to pathological disease states such as diabetes, cancer, immune dysfunction,
and tissue injury2 14 ,2 19. For example, antigen-dependent unidirectional transfer of
microRNA+ve CD63+ exosomes from T cells to antigen presenting cells (APCs)
functioned in immune synapse formation220 . In the cardiovascular system, extra-
cellular vesicles carrying miRNAs were found to be cardioprotective. Exosomes
released by Kruppel-like factor 2 (KLF2) expressing endothelial cells or shear stress
stimulated endothelial cells to transport miR-143/145 to smooth muscle cells lead-
ing to reduction of atherosclerosis in the aorta of ApoE-/- mice 22 1 . KLF2 is a regu-
lator of endothelial cell genes in atheroprotective flow.
2.5.3.1 Initial identification of mobile RNA signals
The spread of mobile RNA sequences was first uncovered in plant species. Gene
silencing signals were found to spread from cell-to-cell through specialized struc-
tures called plasmodesmata 34,135 . Although it would be several years until the
identity of the mobile silencing signals was definitively identified as RNA134 , sev-
eral studies demonstrated that the signals were found to spread over long dis-
tances and with high efficiency, lead to post-transcriptional silencing134' 135 . Local
and systemic silencing caused by administration of double-stranded RNA (dsRNA)
was also observed in Caenorhabditis elegans2 2 2 . In this model system, dsRNA was
more effective at signal interference than single-stranded RNA (ssRNA). Surpris-
ingly, the authors observed silencing affects in both somatic and germline cells ad-
ministration of dsRNA in the parent generation lead to silencing in the progeny222 .
The mobile systemic RNAi was believed to move through a transmembrane pro-
tein, Sid-1, possible acting like a channel for transport of dsRNA, siRNAs, or other
yet to be discovered RNAi signaling molecules223. Hamilton et. al. found that
RNA molecules could themselves be infectious agents producing symptoms anal-
ogous to viral infection in plants 224 . The viral RNAs were found to move between
plant cells conferring systemic mosaicism in leaves2 25 . However, the existence of
endogenous silencing signals was still unknown135
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In 2010 three groups described intercellular transfer of endogenous RNA species
in plants. Using inhibitors to blocking small RNA (sRNA) biogenesis, movement
of endogenous sRNA from donor shoots to recipient roots was demonstrated in
Arabidopsis thaliana. The study illustrated the role sRNAs may play in epigenetic
modifications providing resistance to pathogens and directing appropriate response
to external stimuli through a mechanism that persists much longer than traditional
soluble factors166 . The sRNAs sequences themselves, and not the precursor se-
quences, were the mobile elements2 26 . Movement of these mobile sequences were
found to be a critical element in regulating physiological processes such as tissue
pattern during organ development 227. Furthermore, through the function of RNA
polymerases IV (Pol IV) and RNA-dependent RNA polymerases (RDRs), the RNA
signal could be amplified, resulting in potent downstream effects in neighboring
recipient cells134 13 . Signal amplification is a unique feature of RNA signals in
plants and C. elegans
2.5.3.2 Circulating Nucleic Acids in Cancer
Intercellular communication of genetic materials may play important roles in can-
cer pathology. Transfer of mRNA and microRNAs have been implicated in many
different tumor types, but microRNA communication holds particular promise be-
cause it allows for long-term regulation of biological function. MicroRNas have
been implicated in almost every type of cancer 2 18 and are potent mechanisms of
biological regulation. A single miRNA can target several mRNA sequences giving
miRNA signals a unique amplification effect. Therefore, aberrant miRNA expres-
sion can have widespread and diverse consequences.
Circulating RNAs have the potential to act as biomarkers to predict disease
outcomes 2 1 8,2 2 8 . Specifically, circulating miRNA is a unique biomarker because un-
like other biological macromolecules it does not undergo transcriptional or transla-
tional modifications 218 . Furthermore, microRNAs are robust and stable molecules
compared to other RNAs, resistant to extreme pH and temperature conditions,
and repeated freeze thaw cycles 2 29 . There is significant interest in the development
120
of cancer diagnostics based on circulating miRNA 230, as well as in other diseases
and/or organ injury (e.g. brain, heart, kidney, and liver) 2 3 1 .
Circulating RNAs are commonly found within lipids carriers (i.e. apoptotic
bodies, microvesicles, or exosomes) that protect them from serum ribonucleases 131,214.
However, they can also exist as free molecules or bound to carrier proteins214. For
example, they can be encapsulated in cholesterol rich lipid vesicles 2 1 4 ,2 3 2 or bound
to carry proteins such as Argonute 2233 and NPM12 3 4 . In actuality, the majority of
circulating miRNAs are bound to proteins rather than vesicles 233.
Circulating microRNAs have been identified in almost every body fluid (e.g.
plasma, urine, cerebrospinal fluid, pleural fluid, tears, breast milk, seminal fluid,
amniotic fluid, saliva, peritoneal fluid, colostrum, and fluid from bronchial lavage) 231.
In cancer, many circulating RNAs have been linked to disease progression. One of
the initial studies correlating serum miRNAs and disease found that high levels of
miR-21 was linked to improved survival in B-cell lymphoma236 . In prostate cancer,
miR-141 serum levels distinguished healthy and diseased patients21 ,230 . The pres-
ence of miR-141 also distinguished xenografted mice from control mice in an in
vivo prostate cancer model 230. Upregulation of circulating RNAs have been linked
to several tumor types (e.g. breast cancer 23 7 , lung cancer 2 3 8,2 3 9, ovarian cancer 2 40 ,2 4 1 ,
pancreatic cancer 2 4 2 ,2 4 3 , tongue squamous cell carcinoma 2 4 4 , leukemia 2 45 ,2 4 6, colon 2 4 7 ,2 4 8
rhabdomyosarcoma 249, gastric250 , salivary cancer 2 1 ). However, the functional role,
if one exists, has yet to be elucidated.
The release of RNAs may be linked to cellular stresses. For example, following
serum deprivation, cell secrete more miRNAs in an energy dependent process 2 3 4 .
Therefore, not surprisingly, circulating RNAs are also associated with other dis-
eases or states of cellular stresses. For example, detection of fetal nucleic acids
circulating in the maternal plasma have the potential for non-invasive prenatal di-
agnosis, such as identification of chromosomal aneuploidies and single nucleotide
mutations25 2. MicroRNAs are also increased in pregnancy 25 2 or other altered phys-
iological conditions25 3 such as liver injury 242.
The potential of Nucleic acids as cancer diagnostic markers is not limited to
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RNA. Similar to observations with miRNA, soluble DNA can be found in the
blood of healthy and diseased individuals25 4 . The presence of circulating DNA
has been described in a variety of cancers such as lung cancer 25 ,256 , breast can-
cer 257, head and neck cancers 258 , colon cancer 25 9 , ovarian cancer 2 60 and prostate
cancer 261 . Furthermore, mutations in circulating DNA are commonly observed in
cancer patient 25 4, 2 62 ,2 63 . For example mutated KRAS sequences can be found in the
blood of patients with pancreatic cancer25 4 . In prostate cancer, circulating DNA
demonstrates loss of heterozygosity similar to tumor cells 25 7,2 62 and in melonoma
patients mutant BRAF is often observed in plasma263 . Mutant TP53 DNA is found
in several cancers, such as stomach, colon and rectal cancers 264 .
The amount of circulating DNA may provide insight into disease progression.
Higher levels of DNA were found in the serum of patients with metastatic dis-
ease compared to patients with less advanced cancers265 . Necrosis or apoptotic
cell death may explain the high levels of circulating DNA in these patients 261. Cir-
culating DNA levels may also provide insight into a patient response to treatment.
For example, radiation therapy led to decreased DNA levels in patient serum.
The decrease in serum DNA was in general correlated with improved clinical out-
comes 266 . Circulating DNA is also present in diseased states such as hepatitis and
rheumatoid arthritis267. However, there is still skepticism with regard to the utility
of extracellular DNA as diagnostic tool 2 68 .
The presence (correlation) of circulating nucleic acids with disease has long
been established. However, only recently have the functional roles of circulating
nucleic acids in cancer been identified. Intercellular transfer of mRNA, miRNA,
and DNA serve important biological functions in tumor progression at all stages
from primary tumor biology to interactions with the stroma, invasiveness, and
metastasis.
Intercellular transport of nucleic acids has been linked to cancer progression in
several tumor types, including glioblastoma, lung cancer 269 and heptocellular car-
cinoma270 . In glioblastoma, microvesicles containing mRNA, miRNA, and proteins
led to increased tumor proliferation and enhanced angiogenesis 200. Furthermore,
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serum from glioblastoma patients contained microvesicles with mutant mRNA se-
quences, reflecting mutations commonly found in gliomas 200. Tumor promoting
miRNA sequences can also be transported through gap junctions 271. For exam-
ple, miR-67 was transferred between glioma cells, regulating protein expression in
neighboring tumor cells 27 1.
Intercellular communication of miRNAs regulate tumor biology in complex,
sometimes, unpredictable ways. For example, transport of miRNAs have been
shown to directly promote tumor growth by enhancing expression of proliferative
pathways or indirectly by targeting tumor suppressors. For example, microvesi-
cles released by gastric cancer cells contained members of the Let-7 family of mi-
croRNAs. These miRNAs are commonly regarded as tumor suppressors. Expul-
sion of the Let-7 family of miRNAsvia exosomes reduced expression of these miR-
NAs within tumor cells, indirectly promoting tumorigenesis within these cells 272.
In prostate cancer, genetic exchange between tumor cells has been shown increase
the number of metastatic cells 2 73 .
Intercellular communication of nucleic acids may potentially explain, at least
in part, the genetic alterations commonly found in the tumor stroma. Genetic al-
terations found in tumor stromal cells may be critical regulators of cancer pro-
gression, and in some tumor types, such as mammary carcinoma, may even pre-
ceed frank tumor development2 . Mechanisms leading to transformation of tumor
stroma are likely multifactorial, with the transfer of genetic material playing a key
role.
One of the early demonstrations of transfer of genetic material from tumor cells
to stromal cells involved apoptotic bodies derived from rat fibrosarcoma cells. The
apoptotic bodies secreted by these tumor cells contained DNA and were endo-
cytosed by neighboring endothelial and fibroblast cells. Uptake of the vesicles re-
sulted in transformation of these stromal cells in both in vitro and in vivo model sys-
tems 2 75 ,2 7 6. Furthermore, stromal cells isolated from a fibrosarcoma murine in vivo
model also demonstrated evidence of cellular transformation exhibiting immortal-
ized cell growth when placed in culture. Horizontal transfer of mRNA containing
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microvesicles also induced angiogenesis through a PI3K/AKT signaling mecha-
nism 27 7 . Lastly, RNAs may themselves exert a pro-tumorigenic phenotype. For
example, extracellular RNAs have been shown to induce VEGF release by binding
directly to and activating the VEGFR receptor278 .
Intercellular transfer of nucleic acids not only regulates tumor endothelium,
but also functions in immune system regulation. For example, tumor derived
microvesicles can transfer mRNA and surface molecules to monocytes 279 . Exo-
somes released by lung cancer cells carry microRNAs (miR-16, miR-21, and miR-
29a) 280 . These microvesicles bind to intracellular endosomal bound toll-like recep-
tors (TLR8 in human and TLR7 in mice) in macrophages in the tumor microen-
vironment. These miRNA molecules act as paracrine agonists of TLRs; their re-
lease and subsequent binding to the TLRs causes a prometastatic inflammatory
response, leading to upregulation of NFrB, TNFa, IL6, and CD692 80 .
Inflammation is an important step in the formation of premetastatic niche280.
Macrophages recruited to tumor cells in response to an elevation of inflammatory
signals, play a significant role in tumor progression2 3 . For example, microvesicles
released by renal cancer stem cells that carry RNA that have been linked to an-
giogenesis and metastasis to lungs281 . In these studies lung endothelial cells was
found to overexpress markers of "pre-metastatic niche" such as MMP2, MMP9,
PECAM, CD146, CD45, VEGFR1 and a6-integrin2 8 1 . Studies show an extensive list
of several miRNAs up- and down-regulated in pathological angiogenesis possibly
secondary to microvesicle transport281. In pancreatic cancer, secretion of extracel-
lular DNA in plasma and serum has been associated with invasiveness and metas-
tasis28 2 . This effect may result for up-reglation CXCL9 and other inflammatory
chemokines in response to release of the extracellular DNA. Furthermore, treat-
ment with DNAse I was shown to reduce invasive and metastatic characteristics 282.
Lastly, intercellular transfer of nucleic acids has been linked to tumor dor-
mancy. In metastatic breast cancer, gap junctions enable intercellular transfer of
miRNAs from bone marrow stromal cells to metastatic cells. This communication
induces cell cycle arrest and quiescence in the tumor cells. However, these metas-
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tases can reoccur years later with no history of primary tumor283 .
The mechanisms by which intercellular transfer of nucleic acids occurs is a sub-
ject of several research efforts. The role of exosomes in transport of nucleic acids
has been well demonstrated199 . However, our recent work has demonstrated that
intercellular transfer of RNAs can also occur through membrane bridges and may
be mechanism leading to pathological angiogenesis. Exosomes derived from tu-
mors differ from exosomes released by normal cells; tumor exosomes are bigger
and carry unique microRNAs and receptors284 . Tumor derived vesicles also con-
tain proteins which modulate miRNA activity 285 . These proteins are involved in
assembly and breakdwon of RISC complexes that are believed to be important for
miRNA loading into vesicles and may be important of miRNA target recognition
in monocytes, HeLA cells, and dendritic cells 2 85 . Incorporation of miRNA in exo-
somes is believed to occur through a ceramide dependent pathway 145
2.5.4 Comparative Review: Conclusions and implications
Functional microRNA and mRNA sequences can be transported from tumor cell
to surrounding cellular populations, affecting each stage of the metastatic cascade
from growth of the primary tumor to development of metastases. Transport of
genetic material introduces a new role for cell-cell communication. Unlike the tra-
dition concepts of intercellular communication which only elicit transient changes
in cellular physiology, intercellular communication of genetic material may be a
mechanism by which one cell can exert long term effects the surrounding environ-
ment.
Although cells are capable of transferring DNA, miRNA, mRNA molecules,
transport of different classes of nucleic acids may not all be equivalent. For ex-
ample, DNA transfer occurs almost exclusively through apoptotic bodies and un-
bound sequences. Contrast this to RNA transfer which appears to be tightly reg-
ulated, commonly packed in exosomes?. The distinction between how these two
molecules are transported may provide insight into the physiological significance
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of each. Release of DNA is unregulated and may be a result of cellular catastrophe
occurring in cell death, and not a long term mechanism of cellular transformation.
There may also be distinctions between RNA molecules involved in intercellular
communication. MiRNAs may be better candidates for causing long-term changes
in the recipient cell population than other cellular RNAs. MiRNAs have a long
half-life and can exhibit profound effects on gene expression due to the ability of a
single miRNA molecule to regulate multiple pathways.
MiRNAs are released from cells via three overall mechanisms passive leakage
from cells, encapsulated within membrane vesicles, or bound to carrier proteins21 4.
MicroRNAs delivered by each of these mechanisms may serve distinct physiologi-
cal roles. For example, packaging of miRNAs within exosomes does not appear to
occur randomly. The selectivity of exosomal miRNA packaging may be dictated
by varying cellular responses to different stimuli2 1 4.
Although, intercellular miRNA transport holds fascinating possibility, impor-
tant questions remain to be addressed about its role in vivo. Currently, many stud-
ies have focussed only on phenomenological descriptions of RNA molecules in
body fluids without any understanding of the role, if any, these nucleic acids are
serving. There has been some promising work regarding understanding the role of
intercellular communication of miRNA molecules in the microenvironemnt. Inter-
cellular communication of miRNA may be a mechanism for local cell-cell commu-
nication and the function of these molecules may be found locally within the tumor
microenvironment and not systemically within the body. MicroRNAs found freely
in body fluids may just be by-products of cellular metabolism and only encapsu-
lated miRNAs exhibit long-term effects on cell biology.
Communication of genetic material significantly alters traditional paradigms
of cell-cell communication, introducing the possibility that intercellular communi-
cation can provide a mechanism of intercellular transformation. In other words,
communication through membrane vesicles and membrane bridges may enable a
single cell to genetically transform surrounding cellular populations. This prospect
holds particular intrigue in the field of cancer biology where it has previously been
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established that genetic mutations are present in both the tumor compartment as
well as the stromal microenvironment120 122 . Important similarities (i.e. mecha-
nism of formation and transported cargo) and differences (i.e. biological function
and specificity of transport) between these modes of communication exist, which
presents opportunities for therapeutic interventions.
2.6 Conclusion: Why is cancer metastasis so difficult
to treat?
Metastasis remains the number one cause of cancer deaths. Surgical interventions
are ineffective for treating metastasis, and there are few alternative therapeutic
options currently available. It is universally accepted that cancer, particularly ad-
vanced cancer, is a serious and sometimes life-threatening disease, however, its of-
ten unclear exactly how cancer leads to death. Approximately 50% of individuals
with advanced cancer dies from complications due to invasion and compression
of normal tissue by the malignant tumor. For example, invasion of tumor cells into
a large blood vessel can result in hemorrhage. Alternatively, invading cells can
compress healthy tissues, as is the case with cerebral metastases.
Organ dysfunction is also a common cause of death in cancer. Metastases
can often lead to respiratory or hepatic failure or anuria from ureteric compres-
sion. Tumor cells can directly invade endocrine organs (e.g. adrenal and pituitary
glands). Cancer may also compromises a patient's immune system either directly
by suppressing bone marrow function or indirectly, through immune-suppressing
chemotherapeutics. Patients with advance cancer often face severe recurrent in-
fections commonly succumbing to disease such as pneumonia. Similarly, cancer
patients experience cachexia (i.e. the progressive loss of body fat and lean body
mass) and anorexia (i.e. reduced appetite), resulting in prolonged negative nitro-
gen balances. Paraneoplastic syndromes caused by secretion of humoral factors
(e.g. hormones or cytokines) by tumor cells commonly lead to life-threatening
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physiological disturbances. Finally, many cancer patients succumb to the adverse
effects associated with treatment complications.
Most metastatic disease is not treated with surgery instead treatment typically
involves a combination of chemotherapy, hormonal therapy, and radiation therapy.
However, therapeutic options remain limited. The complexity of the metastatic
cascade, coupled with the limited understanding of tumor pathogenesis, contributes
to the lack of metastatic specific therapeutics. There is a diversity of mechanisms
by which cancer kills; however, optimistically, there are also diverse untapped
therapeutic opportunities in cancer metastasis treatment. For example, the de-
velopment of more efficacious anti-angiogenesis therapies that specifically target
the biology of tumor endothelium may function to prevent metastatic spread. Al-
ternatively, metastasis suppressing therapies targeting genes or modes of cell-cell
communication that promote metastasis may be effective. Treatment strategies tar-
geting early metastases may focus on disrupting interactions with the endothelium
that occur early in invasive spread, while therapies targeting late metastases may
inhibit mechanisms controlling metastatic colonization. Nevertheless, despite the
diversity of opportunities for intervention, one commonality among them all is
that development of new therapies requires a better understanding of the mech-
anisms underlying cancer metastasis. To this end, the development of reliable,
low-cost, and reproducible model systems of metastasis may be the first step in
gaining the knowledge required for development of novel therapeutic approaches
to address these unmet needs.
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Chapter 3
Establishing an epithelial-endothelial
co-culture model system
3.1 Introduction
As discussed extensively in Chapter 2 the initiation, growth, and spread of a tumor
is a complex and intricate process involving many separate, yet interconnected
stages that together result in the multi-dimensional disease we refer to as cancer.
Although each stage in cancer presents unique therapeutic opportunities, mecha-
nisms underlying cancer metastasis remain the most underexplored, yet arguably,
the most ripe for development of new therapeutic strategies. Beginning with for-
mation of a primary tumor, the steps of metastatic invasion can be summarized
into breakdown of the basement membrane and local tissue invasion, systemic dis-
semination through the vasculature, and finally seeding of a secondary tumor site.
These steps are reviewed in Figure 3-1. Each of these stages presents an oppor-
tunity for intervention". However, as described in Chapter 2 our current insight
into the mechanisms that control colonization are less well developed than our un-
derstanding of the initial stages of metastasis: formation of the primary tumor and
interactions with the endothelium.
The majority of current drug therapies target the biology of the primary tumor.
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Figure 3-1: Overview of cancer progression. Cartoon schematic of the steps of
metastatic progression. Interaction with the endothelium is prerequisite for the
development of metastatic disease (dashed boxes). An invasive tumor cell can di-
rectly enter the systemic circulation in a process referred to as hematogenous dis-
semination. Alternatively, metastatic cells can invade neighboring lymph nodes.
The lymphatic system in turn empties directly into the systemic circulation. Once
in the systemic circulation a metastatic cell has access to surrounding tissues and
organ systems.
However, arguably one of the most promising yet untapped opportunities for ther-
apeutic intervention within the metastatic cascade is disruption of interactions be-
tween metastatic cells and the endothelium that are prerequisite for formation of
secondary tumor sites (Figure 3-1). Disruption of the events underlying these in-
teractions may introduce new therapeutic strategies for both early and late stages
of metastasis.
There is a diversity of biological mechanisms that enable metastatic cells to
successfully interact with the endothelium (Figure 3-2). These interactions can be
classified in three categories: (1) biomechanical interactions, (2) chemokine me-
diated interactions, and (3) tumor-endothelial intercellular communication. One
example of biomechanical interactions between tumor cells and the endothelium
involves mechanisms underlying endothelial cell retraction. Metastatic breast ep-
ithelial cells change the biomechanical properties of the endothelium in order to
promote metastatic invasion 2 0 . Previous studies have demonstrated a decrease
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Figure 3-2: Epithelial-endothelial cell (EEC) interactions. There are diverse
mechanisms of interaction between endothelial cells and epithelial cells, includ-
ing biomechanical, chemokine, and physical connections.
in endothelial cell stiffness when the two cell types are co-cultured together. This
decreased stiffness is believed to enhance epithelial cell transmigration120 .
The second mechanism of epithelial-endothelial cell (EEC) interactions utilizes
chemokine signaling pathways. Secreted factors have long been established to be
mediators of metastatic progression through recruitment of angiogenic vessels. For
example, VEGF-A, the primary growth factor involved in pathological angiogene-
sis28 6, has been extensively demonstrated to be a critical initiator of the "angiogenic
switch". The development of a pathological angiogenic phenotype is required for
invasive disease. In another example of chemokine-mediated EEC interactions,
miR-126, a suppressor of metastatic cell invasion that inhibits endothelial cell re-
cruitment, is regulated by the IGF signaling pathway287 . Lastly, chemokine sig-
naling can also regulate biomechanical interactions between metastatic cells and
the endothelium. For example, secretion of IL-8 and Gro-3 by endothelial cells
increases transmigration of metastatic epithelial cells through the actions of the
CXCR2 receptor105 .
The third, and final mechanism involves EEC interactions mediated by intercel-
lular communication. In recent years, intercellular communication between cancer
cells and the endothelium has gained research interest. For example, transfer of mi-
tochondria from endothelial cells to cancer cells has been linked to development of
chemoresistance in breast cancer212 . In another example, microvesicles released by
glioblastoma tumor cells were demonstrated to encourage a pro-angiogenic phe-
notype that enhances the invasive phenotype of the tumor200.
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The metastatic cascade is a chaotic, multi-system process underscoring the need
to develop model systems that decouple the stages of metastasis into discrete seg-
ments. This chapter discusses the engineering of a 3D co-culture model system that
combines epithelial cells and the endothelium in order to study EEC interactions
essential for metastatic progression. It introduces evidence that demonstrates the
utility of the model system in elucidating novel EEC interactions involving biome-
chanical, chemokine, and cell-cell communication mechanisms. This chapter illus-
trates the use of this model system to enable the discovery of important mediators
of EEC interactions, providing a high-throughput platform for screening molecu-
lar targets and therapeutics. In addition, the model system enables the discovery
of novel phenotypes by providing an observable platform that may be used as a
first-order approach to shed light into the occult processes that underly metastasis.
3.1.1 Motivation
Due to the complexity of cancer pathology, one of the greatest obstacles in cancer
research remains the development of physiologically relevant model systems that
allow for accurate mimicry of tumor development in vivo and are also efficient, re-
producible, and cost effective 18 . This need is even more pronounced for the devel-
opment of model systems capturing elements of metastasis. In vivo model systems
are the gold standard and an invaluable resource of biomedical research. However,
these systems are complex, inefficient, and expensive. Cost-effective drug devel-
opment ideally utilizes animal model systems predominately in the later stages of
pre-clinical drug screening once a druggable target has been identified and can-
didate drugs have been optimized in more high-throughput platforms. Probing
the role of pro- and anti-metastatic pathways utilizing only in vivo model systems
often leads to confounding and uninterpretable results. For example, a protein tar-
get can be identified as a regulator of metastasis, but it's often difficult to isolate
exactly where in the cascade this target is acting.
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3.1.1.1 Metastatic cancer model systems
Much of the insight into cancer metastasis has been gained through the develop-
ment of in vivo model systems or retrospective analysis of metastatic tissues re-
moved from human patients8 16 . Each of these approaches suffers from unique
weaknesses. Xenograft studies in mice have become the mainstay of model sys-
tems used to probe the molecular players of metastasis', 130 288 . Spontaneous assays
are commonly used. These model systems require that the tumor be injected into
a site, preferably the site of greatest physiological relevance (i.e. orthotopic loca-
tion), and then to wait for the formation of metastatic lesions130 . Such studies are
often long, inconclusive, and difficult to quantify8, 130 . As a time saving alterna-
tive, tail vein injections are performed to directly inoculate metastatic cells into
the systemic circulation, yielding higher numbers of metastatic lesions 130 . Al-
though this method allows for reliable and consistent results in shorter times, it
does not capture the pre-intravasation stages of metastasis8 . Transgenic metastatic
model systems have been created but these mouse models are expensive and time-
consuming. The greatest limitation of all of the animal model systems is their
inability to decouple the individual stages of metastasis.
Retrospective analyses of human metastatic tumors also suffer from a similar
weakness due to the difficulty of determining de novo the site-specific role that the
genetic anomaly may have served16 . Appropriate in vitro model systems would
create a platform for the direct observation and manipulation of cellular processes
involved in metastasis that the other previous approaches would not allow (Fig-
ure 3-3)16.17. Current in vitro model systems for metastatic cancer generally only
examine migratory or invasive phenotypes through chemoinvasion boyden cham-
ber assays2 88 ,2 89 . However, these approaches do not allow for the examination
of cell-cell interactions, specifically epithelial-endothelial cell interactions that are
pre-requisite for metastatic invasion.
The use of videomicroscopy studies have gained recent interest in the study
of cancer metastasis and have elucidated roles of metastatic mediators previously
133
Limited experimental opportunities,
3Maximum clinical relevance focus on retrospective analysis
SHih pExpensive, time
-- High physiological relevance consuming , cannot easily
decouple complex systems
Better recapitulation of in vivo
setting, allows for Unable to capture whole body
deconstruction of physiological processes
complex in vivo processes
Fast, efficient, and cost effective Questionabe physiological
Figure 3-3: Model systems. Three-dimensional model systems may address un-
met experimental needs not conveniently solved using current in vivo models and
traditional 2D cultures.
unidentified" 0. For example, videomicroscopy has been used in elucidating the
roles of MMPs in metastasis. Originally believed to function only in early stages of
metastasis, videomicroscopy studies have shown that MMPs have many functions
in metastasis including metastatic colonization" 0 .
Deconstruction of the critical events that lead to an invasive phenotype may en-
able the development of metastasis specific therapies. However, development of
novel pharmacological interventions requires that individual metastasis promot-
ing mechanisms and signaling pathways be identified and isolated to allow for
experimental intervention. Without the capacity to probe the effects of drug ther-
apies on a singular druggable target, development of metastasis preventing drugs
will be stymied due to difficulty in determining how to effectively assess drug
efficacy. For metastasis-specific therapeutics, this screening becomes increasingly
cumbersome due to limitations of current model systems and the lack of reliable
study endpoints and measurements of efficacy. Furthermore, since metastasis is a
multi-cellular disease the ability to characterize cell-cell interactions is an essential
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characteristic of an effective screening platform.
3.1.2 Three-dimensional model systems
The development of cancer is a complex process that involves genetic, mechanochem-
ical, and environmental changes, which initially lead to amplification, and even-
tually to a complete disruption of normal physiological processes 290. As a result
of the complexity of this disease, a major obstacle in cancer research is the de-
velopment of physiologically relevant platforms that allow for accurate mimicry
of tumor development in vivo18 ,2 91 . Appropriate model systems would serve two
primary purposes: to allow for recapitulation of both the tissue architecture and
physiological condition and to provide opportunities for experimental modifica-
tions to gain insight into development and pathogenesis'8 29 1.
Over the last several decades, the development of three-dimensional (3D) in
vitro systems have been emphasized, based on the recognition that the 3D organi-
zation of a tumor underlies an important component of tumor progression18,
1 1 8
,119,292-295
A tumors interaction with neighboring cells and the extracellular matrix (ECM),
response to growth factors, and activation of signaling pathways are dependent
on the 3D context 16, 18 ,2 90,2 91 . Monotypic 3D cell culture systems, established for
a variety of cell types including liver, lung, skin, kidney and mammary epithe-
lium1 8 have been used to elucidate important pathways for cell adhesions such as
integrins and focal adhesion kinase (FAK) pathways7 ,296,297 ; to probe oncogenic
pathways such as P13K and ERK/MAPK pathways16, 2 97 ,2 98 ; and also as platforms
for drug screening298. Organotypic co-cultures of various cell types have also been
developed in order to capture cell-cell interactions, in addition to cell-ECM inter-
actions18 .
3.1.2.1 Three-Dimensional Mammosphere Cultures
Much of the work on 3D in vitro culture systems has focused on the study of breast
cancer pathogenesis. To establish these cultures, laminin-rich Matrigel@ is used as
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a substitute for ECM18, 297- 299. Physiologically, epithelial cells create a laminin-rich
basement membrane, making Matrigel@ an appropriate substitute for the ECM.
However, it should be noted that Matrigel@ is not a perfect representation of the
ECM because it is composed of a poorly characterized mixture of ECM proteins
derived from mouse sarcoma tumor cells17,18, 2 99,30 0 .
3D mammosphere cultures have provided valuable insight into: (1) the devel-
opment and maintenance of glandular lumens and disruption of these structures
in cancer18, (2) the role of cell-cell and cell-matrix adhesion pathways in mammary
epithelial tumorigenesis296,297 , (3) regulation of mammary polarity and its disrup-
tion in cancer, and (4) the importance of adhesion forces in maintaining tissue ar-
chitecture and promoting pathogenesis17, 2 96,2 97 . Three-dimensional model systems
were used to demonstrate that cellular behavior of mammary epithelial cells is de-
pendent on both the genetic and architectural phenotype. Furthermore, in breast
cancer it has been shown that disruption of normal mammosphere architecture
leads to the development of an oncogenic phenotype independent of the existence
of genetic anomalies29 7.
Current 3D mammosphere cultures provide a platform to study the develop-
ment of normal and tumorigenic mammary structures, however they do not cap-
ture the interactions between tumor cells and the angiogenic component, an es-
sential step in tumor progression10 6. The ability to closely examine epithelial cells
interactions with endothelial vessels would provide an opportunity to elucidate
mechanisms for metastatic cell invasion into the vasculature'06 . An understanding
of this process may result in generation of possible metastasis specific therapies106 .
3.2 Development of an epithelial-endothelial co-culture
model system
The development of a model system that can mimic features of EEC interactions
in metastasis could potentially provide a valuable tool for identification of novel
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druggable targets and for high-throughput screening. An appropriate model sys-
tem must exhibit the following elements:
1. Decouple EEC interactions from other stages within the metastatic cascade
2. Allow for single point experimental interventions to probe the effects of in-
dividual molecular pathways
3. Be highly modular, enabling quick modifications in order to create model
systems that range from simple to complex
4. Allow for multiple cell types to interact in a physiological and architecturally
appropriate context
5. Reproducible
6. High-throughput
7. Quantifiable
To tackle this challenge, based on the criteria outlined above, we have engineered
a 3D co-culture system that combines epithelial cells and the endothelium to study
EEC interactions that are essential for metastatic progression. In engineering our
model, we hypothesized that interactions between metastatic epithelial cells and
the endothelium would be distinct from interactions of non-metastatic epithelial
cells with the endothelium. In addition, a model system allowing for elucidation
of these differences will aid in the the discovery of novel anti-metastasis targets.
The power of our model system is the ability to isolate a single stage within the
metastatic cascade: interactions between metastatic cells and the endothelium that
may precede intravastion / extravasation within vessels.
3.2.1 Experimental design
We have established an organotypic co-culture model system combining endothe-
lial cells with epithelial cells of varying grades of tumorigenicity, ranging from nor-
mal primary cells to highly metastatic cell populations. Figure 3-4 is a schematic
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Figure 3-4: Schematic overview of epithelial-endothelial co-culture model system experimental design. Endothelial cells
are added to a laminin-rich basement membrane matrix and undergo spontaneous tubulogenesis. Epithelial Cells are added
to the endothelial vessels and the cells are co-cultured for > 24hrs. The phenotypes are characterized using microscopy and
various molecular biology techniques. Differences between co-cultures with primary epithelial cells, tumorigenic non-
metastatic epithelial cells, and metastatic epithelial cells are assessed. (A) SEM micrographs illustrate the matrix fibers,
which form the scaffold for the three-dimensional structures. (B/C) Co-cultures with metastatic cells affect endothelial
vessels leading to vessel widening and lengthening. (C) Projections can be seen on the cell surface of endothelial cells
in metastatic co-cultures, (B) while the endothelial cell surface is smooth in co-cultures with primary epithelial cells. The
projections may provide anchorage points for metastatic cell attachment to the endothelium.
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overview of the co-culture model system experimental design. The model system
was established using primary human umbilical vein endothelium cells (HUVEC)
obtained from ATCC. To further validate observed phenotypes, selected cell pop-
ulations were also co-cultured with primary human dermal microvascular blood
and lymph endothelial cells (Section 3.5.1). These cells are true untransformed pri-
mary cell populations isolated from fresh human plasma of a single patient. An-
alyzing co-culture phenotypes with primary endothelial cell populations further
emphasizes the physiological relevance of the observed phenotypes.
To begin a co-culture, endothelial cells were plated in a laminin-rich basement
membrane matrix (1:1 PBS: Matrigel@) for 4-24hrs, wherein the cells spontaneously
formed vessel-like structures (Figure 3-4). Growth factor enriched Matrigel@ was
used for all experiments unless otherwise noted. Following completion of tubulo-
genesis, epithelial cells are added to the culture and the cells are incubated together
for 24hrs unless otherwise stated. Epithelial cells are labeled with carboxyfluores-
cein succinimidyl ester (CFSE) cell-impermeable dye to distinguish the two cell
populations. CFSE is a widely used tracer that is retained within cells for long
periods of time without leaching through the plasma membrane.
Following an incubation period, the cultures were analyzed with a variety of
microscopy and cell biology techniques. To summarize, light microscopy was used
to characterize overall morphology and phenotype, angiogenic parameters, and
the degree of epithelial-endothelial cell interaction. In this analysis, epithelial-
endothelial cell interaction is defined as physical alignment of the epithelial cells
on the vessel surface. Quantification of these parameters is described in great de-
tail in Section 3.4.3. Scanning electron microscopy (SEM) was used for closer ex-
amination of the culture phenotype and to detect evidence of metastatic invasion.
The model system was also used to assess molecular mediators of adhesion and
cell-cell interactions. The role of these pathways was probed using RNA interfer-
ence (RNAi), neutralizing antibodies, or pharmacological inhibitors. Finally, the
model system was used as a screening platform to test anti-angiogenic and anti-
tumorigenic small molecule inhibitors to assess the drug effects on disruption of
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EEC interactions. A detailed protocol of the co-culture study design can be found
in Appendix B.
Figure 3-4A is a high-magnification SEM micrograph that illustrates the laminin-
rich basement membrane matrix fibers in which the cells are embedded. The ma-
trix provides the scaffold on which the cells can establish a three-dimensional con-
formation. In co-culture, the metastatic MDA-MB-231 breast epithelial cells can be
seen aligning along the endothelial vessels (Figure 3-4C). The vessel structures in
co-culture appear visibly distinct compared to HUVEC monoculture (Figure 3-4B),
exhibiting visible widening, increased number of branches, and larger nodes. In-
terestingly, in high magnification micrographs of metastatic cell co-cultures, small
projections can be seen on the surface of the endothelium (Figure 3-4C), contrast-
ing the smooth appearance of the endothelial cells in co-culture with primary ep-
ithelial cells (Figure 3-4B) in which there is little interaction between cell types.
One can speculate as to how these projections form and the role they may play in
mediating interactions between cell types. On possibility is that these structures
form in response to soluble factors secreted by metastatic cells that are not present
in HUVEC monocultures or co-cultures with primary epithelial cells. The projec-
tions may serve a biomechanical function providing points of anchorage for the
metastatic cells to better adhere to the endothelial vessels. One could speculate
on the invasive advantage that inducing these structures in the endothelium may
provide the metastatic cells as they attach to the vessels. Figure 3-5 further illus-
trates differences in endothelial vessels in primary, tumorigenic non-metastatic,
and metastatic epithelial cell co-cultures.
3.2.2 Matrix
The selection of an appropriate matrix is a critical element for establishing 3D
model systems. There are a variety of natural and synthetic matrices such as
collagen, fibrin, Matrigel@, and hydrogels that have been used to engineer three-
dimensional model systems301 . We selected Matrigel@, a commercially available
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Figure 3-5: Endothelial cells appear distinct in co-cultures with epithelial cells
exhibiting increased tumorigenicity. SEM micrographs show low- and high-
magnification views of endothelial cells in co-culture with primary epithelial cells,
tumorigenic non-metastatic epithelial cells, and metastatic epithelial cells. En-
dothelial cell morphology appears distinct in each culture model. In a metastatic
cell co-culture platform the endothelium is significantly wider with small projec-
tions on the cell surface. Contrast this with the smooth narrow vessels seen in the
primary cell co-culture platform.
tumor-derived laminin-rich basement membrane matrix from mouse sarcoma tu-
mor cells as the appropriate basement membrane to establish the co-culture system
(Figure 3-6). Although, synthetic matrices are highly tunable allowing for manip-
ulation of various matrix properties such as stiffness, pore sizes, and proteoglycan
composition, Matrigel@ remains the best characterized extracellular matrix and is
well established in the use of mammosphere culturesis,2 97-299. Therefore in extend-
ing this work to include the endothelial cell compartment we decide to continue
with the same matrix. Furthermore, cells in vivo normally produce a laminin-rich
basement membrane, making Matrigel@ a suitable substitute for the naturally pro-
duced ECM. However, it should be noted that Matrigel@ is not a perfect repre-
sentation of the ECM because it is composed of a poorly characterized mixture
of ECM proteins17 ,1 8,2 99,300 . Furthermore, Matrigel@ often leads to batch-to-batch
variations in cellular phenotypes that commonly lead to inconsistencies between
experiments, potentially affecting the fidelity and reproducibility of the cultures.
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Figure 3-6: Laminin rich basement membrane matrix. SEM micrograph image
illustrating matrix fibers. Cells use this scaffold to adopt 3D morphologies that
mimic tissue structures in vivo.
The variabilities in batches of Matrigel@ may alter vessel structures, which may
in turn affect epithelial-endothelial interactions. However, this limitation can be
minimized by maintaining consistent lot numbers and by increasing the number
of experimental replicates. In future extensions of this work there is a possibility of
extending the model system into alternative matrices that are better characterized
to increase experimental reproducibility.
3.2.3 3D model system provide a more physiologically relevant
platform to study cancer
By recapitulating the cells native orientation in vivo, 3D cultures are a better repre-
sentation of a cells physiological responses, including (1) cell-cell and (2) cell-ECM
interactions and (3) communication with, and in response to, the external environ-
ment. In a 3D matrix, the metastatic breast epithelial cells organize into mammary
body structures, resulting in remarkably different cell-cell interactions than the
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traditional 2D planar cultures. Figure 3-7 illustrates the architectural differences
present between 2D and 3D monoculture systems. In 2D both non-malignant and
malignant breast epithelial cells adopt similar morphologies. However, in 3D the
architectural differences between 2D and 3D cultures becomes evident 299. Non-
malignant epithelial cells adopt an organized morphology with a distinct central
lumen, apical-basal polarity, cell-cell tight junctions, and an intact basement mem-
brane. In 3D cultures, malignant epithelial cells lose this organized phenotype
and adopt a disorganized and erratic morphology (Figure 3-7)17. Furthermore,
in addition to differences in cellular architecture, culturing cells in 3D leads to
changes in expression patterns of important oncogenic signaling pathways, such
as the P13K and ERK/MAPK pathways, that better correspond to expression lev-
els present in vivo16. Figure 3-7 illustrates the up-regulation of p-AKT(S473), p-
ERKi /2 (T202/Y204), and p-FAK(Y925) expression in MDA-MB-231 cells both in
2D (inset) and 3D platforms. There is significant activation of these oncogenic
pathways in the 3D culture that is not observed when the cells are plated in 2D.
The activation of these oncogenic pathways is likely due to the enhanced cell-cell
interactions that are present in 3D environments, but absent in 2D cultures.
Similarly, in epithelial-endothelial co-cultures, there are dramatic changes in
both cellular architecture and in expression of oncogenic pathways. As an illus-
trative example, Figure 3-8 provides representative images that highlight the ar-
chitectural and phenotypic differences present in 2D and 3D cultures. The upper
panels show metastatic breast cancer cells MDA-MD-231 monocultures in 2D and
3D platforms, while the lower panels illustrate MDA-MB-231 + Human Umbilical
Vein Endothelial Cell (HUVEC) co-cultures also in 2D and 3D platforms.
Three-dimensional organotypic culture systems combining several cell types
provide greater advantages compared to traditional systems. They can be used to
capture cell-cell interactions that do not exist in 2D culture platforms (Figure 3-8).
Instead of forming the expected mammary structures, in the 3D co-culture plat-
form the metastatic MDA-MB-231 breast cancer cells (EPI) interact directly with
the endothelium (ENDO), elongating and aligning along the endothelial vessels
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Figure 3-7: 3D model systems are physiologically relevant platforms for study-
ing cancer. (A) When seeded in a basement membrane matrix, breast epithelial
cells form mammospheres that significantly differ from the planar architecture
present in 2D. In traditional 2D cultures there are limited differences in morphol-
ogy between non-malignant and malignant breast epithelial cells. However, in
3D malignant cells adopt an architecture that is very different from the phenotype
of non-malignant cells. Primary epithelial cells form organized spheroid struc-
tures with characteristics resembling mammary acini in vivo. Contrast this pheno-
type with the disorganized mammosphere structures formed by malignant cells,
which lack a central lumen and organized morphology consistent with normal
cellular morphology. (B) The difference between 2D and 3D cultures also extends
to expression of oncogenic pathways. There is up-regulation of p-AKT (S473), p-
ERK1/2 (T202/Y204), and p-FAK (Y925) expression in 3D cultures compared to
2D cultures (inset). Cells were immunostained with the aformentioned antibodies
(Red) and counterstained with DAPI (Blue).
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Figure 3-8: 3D model systems capture cell-cell interactions in tumorigenesis.
Analogous to results seen with breast epithelial cell monocultures, our data high-
lights the advantages of 3D organotypic co-cultures to study epithelial-endothelial
(ENDO/EPI) cell-cell interactions. The 2D co-culture is characterized by a segrega-
tion phenotype where the epithelial cells sit upon a bed of endothelial cells (dashed
arrow) clustered in epithelial islands (circle). However, in 3D co-cultures there is a
high degree of interaction between the cell types (solid arrow). All cultures were
incubated for 24-hours followed by immunostaining with rhodamine phalloidin
(Red) and counterstaining with DAPI (Blue).
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(solid arrow). There are limited numbers of mammary spheroids formed in these
cultures indicating preferential interactions of the MDA-MB-231 cells with the en-
dothelium compared to other epithelial cells. Compare this phenotype with the
2D platform. In a 2D culture, the cells adopt no particular organizational struc-
ture. Furthermore, in contrast to the intimate interaction formed in 3D cultures, in
the 2D cultures we observe segregation of cell types, characterized by the forma-
tion of epithelial islands (circle) that sit atop a platform of endothelial cells (dashed
arrow) (Figure 3-8).
Three-dimensional co-cultures also reveal alterations in expression of impor-
tant signaling pathways. Similar to results seen in monocultures, in 3D co-cultures
there was notable up-regulation of oncogenic pathways. This up-regulation seemed
to be strongly associated with areas of interaction between epithelial cells and the
endothelium. Figure 3-9 illustrates immunostaining of MDA-MB-231 and HUVEC
co-cultures with p-AKT (S473), p-ERK1/2 (T202/Y204), and p-FAK (Y925). In ar-
eas of EEC interactions, there is enhanced FAK phosphorylation, suggesting that
the FAK-Integrin signaling axis is critical for epithelial-endothelial cell interactions
(Figure 3-9C, solid arrows). Compare this to phosphorylated FAK signaling in ar-
eas with minimal EEC interactions (Figure 3-9C, dotted arrows). In these areas,
there is lower expression of FAK signaling.
Upregulation of phosphorylated FAK in turn activates downstream targets of
the P13K and MAPK pathways (Figure 3-9). Similar to p-FAK expression, p-AKT
(S473) and p-ERK1/2 (T202/Y204) expression is also enhanced in areas of high
EEC interactions (Figure 3-9 A and B, solid arrows) compared with areas of mini-
mal interaction (Figure 3-9 A and B, dotted arrows). Surprisingly, AKT activation
seems to occur mostly in the endothelial cells (Figure 3-9A), while ERK activation
occurs predominantly in the tumor compartment (Figure 3-9B). The differential
activation of these pathways in the tumor and endothelial compartments may sug-
gest a possible therapeutic strategy to target the endothelial cell compartment with
a P13K inhibitor and the tumor compartment with a MAPK inhibitor.
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Figure 3-9: Activation of oncogenic pathways in co-culture model system. Co-
culture model systems with GFP labeled metastatic breast epithelial cells (green)
were immunostained with (A) p-AKT (S473), (B) p-ERK1 /2 (T202/Y204), and (C)
p-FAK (Y925) (Red) and counterstained with DAPI to identify nuclei. Activation
was observed in areas of epithelial-endothelial interactions (solid arrows) versus
areas with limited cell-cell interactions (dotted arrows). This data highlights the
unique features that can be captured in model systems, combining multiple cell
types that are not present when either cell type is cultured alone. A platform mod-
eling cell-cell interactions is particularly important for complex, multicellular dis-
ease pathways such as metastasis.
3.3 The effect of the endothelium on oncogenic phe-
notypes
There are multiple mechanisms by which cells interact in the co-culture system.
These mechanisms can be categorized as biomechanical, chemokine, and commu-
nication interactions. Each of these mechanisms may individually or collectively
enhance metastatic capacity of the cells. Indeed, previous work has established
that the endothelium increases the invasiveness of metastatic breast epithelial cells
by enhancing transmigration through an endothelial layer105 . To better understand
the complex dynamics that occur within the co-cultures, we attempted to decouple
these mechanisms. We first began by studying the role of chemokine signaling on
EEC interactions that may regulate tumorigenicity and invasiveness of metastatic
cells in co-culture. Specifically, we probed the effects of endothelial cell soluble
factors on cellular proliferation (Section 3.3.1) and migration (Section 3.3.2) of
MDA-MB-231 cells. The role of intercellular communication in mediating EEC
interactions is extensively discussed in Sections 4, 5, and 6.
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3.3.1 Endothelial cells increase metastatic cell proliferation
To assess cellular proliferation, we measured the expression of Ki67 in the MDA-
MB-231 cells in co-cultures versus monocultures. Ki67 is a nuclear protein that is
commonly used as a marker of cellular proliferation. It is present during the entire
cell cycle, but is absent in non-dividing cells. Figure 3-10 summarizes the results
from this experiment. GFP labeled MDA-MB-231 cells were co-cultured with un-
labeled endothelial tubes. The cultures were fixed and immunostained with Ki67
antibody 24hrs post co-culture. Compared to monoculture, in co-culture there is
an increase in Ki67 staining in MDA-MB-231 cells (Figure 3-10A). The increase
in Ki67 in co-cultured MDA-MB-231 cells was confirmed via flow cytometry. In
the flow cytometry experiments, GFP labeled MDA-MB-231 cells were added to
DiL-Ac-LDL labeled endothelial cells. After 24 hours, cultures were stained with
PECAM-1 antibody to identify endothelial cells. The dual-labeling protocol allows
for easy separation of the two cell populations. The details of this analysis are ex-
tensively described in Section 4.3.1. The pink outline highlights the MDA-MB-231
population.
Histogram measurements of the MDA-MB-231 population shows a shift of the
Ki67 peak in co-cultured endothelial cells signifying increased Ki67 expression
compared to cells in monoculture (separate). Interestingly, at the 24hr time point
there seem to be minimal changes in Ki67 expression in the endothelial cell popu-
lation. However, at later time points, endothelial cells show an increase in prolifer-
ation markers in co-cultured in comparison to monocultured cells. Therefore, it is
likely that 24 hours is too soon to observe the proliferative effect in the co-cultured
endothelial cells. Co-cultured epithelial cells have higher expression of Ki67 com-
pared to cells in monoculture. However, it is unclear as to what mechanisms lead
to this increase in cellular proliferation.
We hypothesized that soluble factors secreted by the endothelium may con-
tribute to the enhanced proliferation. To test our hypothesis, we performed a cell
viability assay using an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
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Figure 3-10: Co-cultured MDA-MB-231 cells show increased Ki67 expression.
(A) Immunostaining with a Ki67 antibody in GFP+ve MDA-MB-231 epithelial cell
and HUVEC endothelial cell co-culture shows enhancement of Ki67 expression in
co-cultured epithelial cells. (B) This phenotype is confirmed via flow cytometry.
In these studies, GFP+ve MDA-MB-231 cells are added to DiL-Ac-LDL labeled en-
dothelial cells. After 24hrs, the cultures are fixed and stained with PECAM-1 and
Ki67. PECAM-1 is used to stain the endothelial cells to allow for sufficient separa-
tion of the two populations. The MDA-MB-231 cells are gated (pink) and the Ki67
expression is measured. Co-cultured MDA-MB-231 cells have higher expression
of Ki67 than cells in separate monocultures. The increased Ki67 expression may be
a response to soluble factors released by the endothelium.
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2-(4-sulfophenyl)-2H-tetrazolium) reagent on MDA-MB-231 cells exposed to con-
ditioned media. This assay is described in detail in Section 4.4.1.
To summarize our protocol, conditioned media was collected after four days of
incubation with HUVEC endothelial cells as well as other tumor stromal cells in-
cluding mesenchymal stem cells (MSCs), fibroblasts, smooth muscle cells (SMCs),
and embryonic stem cells (ESCs). Although ESCs are not found in the tumor envi-
ronment, they may potentially provide a surrogate for poorly differentiated cells,
commonly found in the tumor microenvironment, such as cancer stem cells. Media
was collected from cells at 65-90% confluency to ensure viability and proliferative
activity of the stromal cells. MDA-MB-231 cells were incubated in non-conditioned
and conditioned media from each cell type. For both groups media optimized for
each cell type was used. For exact media preparation refer to materials and meth-
ods in (Appendix B). The study was performed in this manner to ensure that
stromal cells received the appropriate media in order to minimize cellular stress
that could potentially alter the composition of released soluble factors.
Three distinct treatment protocols were used in this study summarized in Fig-
ure 3-11. In the first protocol, labeled conditioning, the cells were pre-treated for 4
days in conditioned media and then incubated in non-conditioned control DMEM
for 36hrs, 60hrs, 84hrs, and 5days. This group was included to observe the long-
term effects of the secreted factors persisting after removal of the stimulus. In the
second treatment strategy, referred to as no pre-conditioning, the cells were added to
conditioned media without a 4 day pre-conditioning. This group allows for direct
probing of immediate proliferative responses of cells to stromal growth factors.
Similar to the conditioning, the cells were incubated for 36hrs, 60hrs, 84hrs, and
5days. In the final condition, the cells were pre-treated for 4 days and continued in
conditioned media for the aforementioned time points. This group was referred to
as conditioned media throughout, which allowed us to assess the effect of continued
exposure to the secreted factors, analogous to continued exposure in the tumor mi-
croenvironment. Each data point was normalized to the DMEM non-conditioned
control.
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Figure 3-11: Schematic overview of proliferation assay protocol. Three treatment
protocols were used to assess the role of soluble factors on proliferation of MDA-
MB-231 and MCF-7 cells.
Figure 3-12A shows images of the MDA-MB-231 cells in conditioned media±ve
groups, while Figure 3-12B-D summarizes the results of this analysis. Condi-
tioned media from HUVEC endothelial cells increased cellular proliferation in all
three treatment strategies. However, the proliferative response diminished after
continued exposure to conditioned media, illustrated by only a modest increase
in cellular proliferation in the conditioned media throughout treatment protocol
(Figure 3-12D). The decreased robustness of the response may be due to receptor
down-regulation secondary to continuous receptor stimulation. Changes in recep-
tor expression after continuous exposure to growth factors is commonly observed
in many growth factor signaling pathways30 2.
There was no statistically significant proliferative advantage conferred by con-
ditioned media from fibroblast, MSCs, or SMCs. Indeed, conditioned media from
these cell types actually inhibited growth of MDA-MB-231 cells. The only excep-
tion was the 60hr time point of the no pre-conditioning group (Figure 3-12C). At this
time point, conditioned media from fibroblast cells showed an increase in prolif-
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mesta3-12: Effects of secreted growth factors on proliferation of MDA-MB-
231 cells. (A) Bright field image showing MDA-MB-231 cells in conditioned+ve
and conditioned-ye from each cell type. The effects of secreted growth factors
isolated from HUVEC endothelial cells, mesenchymal stem cells, embryonic stem
cells, fibroblasts, and smooth muscle cells were measured using a commercially
available viability assay. The following three protocols were used: (B) conditioning:
metastatic cells are pre-conditioned for 4 days and then transferred to DMEM; (C)
no pre-conditioning: metastatic cells are not pre-conditioned and then transferred to
conditioned media; (D) conditioned media throughout: metastatic cells are incubatd
in conditioned media for 4 days and remain in conditioned media for the duration
of the study. Measurements were taken at 36hrs, 60hrs, 84hrs, and 5days. Con-
ditioned media collected from endothelial cells, and no other tumor stromal cells
increased proliferation of MDA-MB-231 breast epithelial cells.
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eration, the opposite effect from what was observed in every other measurement.
However, this effect was only transient. At 84 hours there was no difference be-
tween conditioned±ve groups and even a reversal of the phenotype to an inhibi-
tion of cellular proliferation was observed by 5 days. The reversal of the phenotype
may again be due to down-regulation of growth factor receptors on the surface of
the cells after continued stimulation.
Interestingly, the only other cell type that increased proliferation of the MDA-
MB-231 cells were embryonic stem cells. ESCs create a growth factor rich envi-
ronment that is needed in development of tumors. The metastatic cells robustly
responded to this stimulus. It is interesting to speculate if there are any similarities
in the composition of growth factors secreted by ESCs and cancer stem cells. Can-
cer stem cells have been shown to enhance tumorigenic qualities of cancer cells.
It should be noted that there were some inherent toxicities associated with
growing the MDA-MB-231 cells in stromal cell media. For example, non-conditioned
media from some groups resulted in either increased or decreased proliferation
compared to the DMEM control. MDA-MB-231 cells are generally grown in DMEM.
However, each group was compared to a matched control, keeping the media con-
stant, eliminating this consideration from analysis. It should also be noted that
the stromal cells used here are normal cells, not tumor stromal cells. It is well
established that stromal cells in tumors are transformed 274 ; therefore the growth
factors secreted by these cells are likely to be different from the growth factors se-
creted by normal cells. Nevertheless, secreted factors from endothelial cells did
indeed enhance proliferation of MDA-MB-231 cells, while secreted factors from
other cell types did not have a similar effect, thus highlighting the unique nature
of epithelial-endothelial interactions.
In order to understand if the observed effects on cellular proliferation were
unique to metastatic breast epithelial cells, we performed a similar study with
MCF-7 breast epithelial cell lines. This data is summarized in Figure 3-13. The
MCF-7 cell line is a tumorigenic non-metastatic breast epithelial cell line that is
estrogen receptor positive, progesterone receptor positive, and HER2/neu nega-
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Figure 3-13: Effects of secreted growth factors on proliferation of MCF7. (A)
Bright field image showing MCF7 cells in conditioned+ve and conditioned-ye
from each cell type. The effects of secreted growth factors isolated from HUVEC
endothelial cells, mesenchymal stem cells, embryonic stem cells, fibroblasts, and
smooth muscle cells were measured using a commercially available viability assay.
The following three protocols were used: (B) conditioning: tumorigenic cells are
pre-conditioned for 4 days and then transferred to DMEM; (C) no pre-conditioning:
tumorigenic cells are not pre-conditioned and then transferred to conditioned me-
dia; (D) conditioned media throughout: tumnorigenic cells are conditioned for 4 days
and remain in conditioned media for the duration of the study. Measurements
were taken at 36hrs, 6Ohrs, 84hrs, and 5days. In contrast to results with MDA-
MB-231 cells, soluble factors from endothelial cells suppress growth of MCF7 cells.
These results suggest that tumorigenic cells respond differently to soluble factors
secreted by endothelial cells than metastatic cells of the same tissue type.
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tive. These cells offer an ideal comparison to the highly invasive, triple negative
MDA-MB-231 cells, enabling examination of responses of metastatic cells and non-
metastatic cells to soluble factors released by stromal cells.
Surprisingly, in contrast to results with MDA-MB-231 cells, conditioned media
from the HUVEC endothelial cells inhibited growth of MCF7 cells, an effect that
persisted for up to seven days of continued exposure to soluble factors (Figure 3-
13D). This effect even continued once growth factor had been removed for up to
five days (Figure 3-13B). Conditioned media from mesenchymal stem cells initially
increased proliferation of MCF-7 cells for the first 60hrs of exposure (Figure 3-13C).
However, following this time period, this phenotype reversed dramatically to an
inhibitory phenotype (Figure 3-13B,C), which persisted for several days. Only af-
ter 9 days of exposure was there a slight change in phenotype to a pro-proliferative
state (Figure 3-13D). As described before, the altered response of cells from an anti-
proliferative to a pro-proliferative state after continuous stimulation is likely due
to transient changes in receptor expression.
Fibroblast and SMCs had only a minimal inhibitory effects on proliferation of
MCF-7 cells (Figure 3-13C). However, when exposed to growth factors derived
from fibroblast cells, the inhibitory effect was slightly reversed after several days
of exposure to the conditioned media (Figure 3-13D). Unlike the MDA-MB-231
cells, proliferation of the MCF-7 cells was not affected by secreted factors from
embryonic stem cells (Figure 3-13A).
The results of this study are complex due to variability of receptor expression,
leading to changes in stimulus response. This data also highlights that a singu-
lar time point measurement cannot completely capture the effects of the stromal
environment on tumor growth. Furthermore, cell-cell interaction dynamics are
complex with varying and hard to to predict responses that are difficult to cap-
ture with such simple experimental methods. However, in spite of these weak-
nesses, two trends were clear. The first was that growth factors secreted by the
endothelial cells enhanced proliferation of metastatic cells while inhibiting growth
of tumorigenic cells. In addition, tumorigenic cells did not show any proliferative
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response to conditioned media from ESCs while metastatic cells showed a very
robust response. These results highlight that metastatic cells respond differently
to the endothelium than the non-metastatic cells. These differences may not be
limited to the endothelium as suggested by differential responses of the tumori-
genic and metastatic cell lines to soluble factors secreted by ESCs. Presumably, a
cell's ability to respond to and interact with the endothelium in a certain manner
may strongly indicate which cells will be able to continue to successfully progress
through the multiple of steps of the metastatic cascade.
3.3.2 Endothelial cells increase metastatic cell migration
It has been clearly outlined in the literature that endothelial cells can directly stim-
ulate transformation of metastatic cells105 . Furthermore, in the co-culture model
system, we observed preferential interaction and alignment of metastatic cells along
the endothelial tubes that support these findings. We hypothesized that these ob-
servations may in part be due to the ability of metastatic cells to respond to secreted
factors released by endothelial cells that enable the metastatic cells to specifically
home to endothelial vessels. Presumably, the metastatic cells may be following a
concentration gradient of growth factors secreted by endothelial cells. Migration
can be described in 3 distinct stages: (1) morphological polarization plus mem-
brane extension and formation of cell-substratum attachments, (2) internal con-
traction, and (3) rear release. Dynamic interactions with the membrane leads to
formation of protrusions that, in response to a gradient of soluble factors, leads to
directed growth of actin filaments and cytoskeletal structures.
Cells require polarization in order to migrate. Cellular polarization can be
achieved directly via concentration gradients or indirectly via spatial/temporal
stimulus gradients due to non-uniformities in receptor-ligand binding. The conse-
quence of polarization is extension of active membrane processes primarily at the
cell front, giving cell locomotion a persistent random walk characteristic. In order
to determine if soluble factors secreted by endothelial cells increase the migratory
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Figure 3-14: Endothelial cells increase migration of metastatic cells. (A)
Schematic of Boyden chamber study design. Metastatic cells are seeded in the
top chamber in matrix, while endothelial cells are plated on a layer of fibronectin
in the bottom chamber. Metastatic cells can be seen migrating through the mem-
brane pore. (B) Image of HUVEC monolayer on the bottom of each well. (C) Rep-
resentative images of migrated cells through growth factor enriched and growth
factor reduced matrix in HUVECtve groups. (D) Quantification of the number of
migrated cells. In both growth factor reduced and growth factor enriched matrix
groups, the presence of endothelial cells enhanced cellular migration.
and invasive capacity of MDA-MB-231 metastatic breast epithelial cells, a Boyden
chamber assay was performed.
The study was designed as depicted in Figure 3-14A. MDA-MB-231 cells were
plated in the top chamber coated with growth factor reduced (GFR) or growth
factor enriched (GFE) Matrigel@ in order to eliminate confounding results from
growth factors within the matrix. In the bottom chamber endothelial cells were
seeded in complete endothelial cell basal media on a fibronectin coating and incu-
bated overnight until a monolayer was formed. An image of the endothelial cells
is given in Figure 3-14B. An 8 pim pore size transwell membrane was used that
157
A. EPI+ B.
ENDO 150 1(-) HUVEC
-Q*(+) HUVEC
0U
100 *
50
=WW zl~
0 MCF-10A MCF-7 MDA-MB-231
'i
Figure 3-15: Endothelial cells increase migration of breast epithelial cells. The
presence of endothelial cells enhance migration of fibrocystic MCF-10A, tumori-
genic non-metastatic MCF-7, and metastatic MDA-MB-231 cells. (A) Representa-
tive images of migrated cells and (B) graph of quantification results illustrate the
enhanced migration of cells due to the presence of the endothelium.
allowed cells to freely migrate from the top of the membrane to the bottom. Fig-
ure 3-14A provides an illustration of cells migrating through the pores. The cells
were allowed to migrate for 6 days prior to quantification. The results of this anal-
ysis is given in Figure 3-14C and D. Addition of endothelial cells led to an increase
of 82.837±31.360% and 66.736t14.973% in the number of migrated cells in GFR
and GFE groups, respectively. Subsequently, this analysis was extended to include
MCF-10A and MCF-7 breast epithelial cells. MCF-10A is a non-tumorigenic cell
line isolated from a fibrocystic nodule. All three cell lines exhibit increased mi-
gration in the presence of endothelial cells (Figure 3-15). Presumably endothelial
cells secrete growth factors that increase epithelial cell migration with the greatest
enhancement seen in the metastatic cell population.
This data is further supported by a matrix invasion assay performed with MDA-
MB-231 cells, which confirms that growth factors secreted by the endothelial cells
are responsible for the increased invasive potential. To establish this assay a criss-
cross pattern of matrix was deposited in each well as shown in Figure 3-16A.
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Figure 3-16: Growth factors secreted from HUVEC endothelial cells increase
migration of MDA-MB-231 in a matrix invasion assay. (A) Illustration of criss-
crossed pattern of matrix enriched with conditioned media from HUVEC endothe-
lial cells and mouse ESCs. (B/C) MDA-MB-231 cells were stained with phallodin
and counterstained with DAPI. (C) MDA-MB-231 cell can be seen migrating to-
ward the growth factor enriched matrix. (D) Scoring examples used in quantifying
the matrix invasion assay. (E) Graph summarizing results of the matrix invasion
assay. Conditioned media increases migration of metastatic cells.
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Figure 3-17: Metastatic cells align along the matrix. MDA-MB-231 cells can be
seen aligning along the matrix analogous to alignment along endothelial vessels.
MDA-MB-231 cells were added to the wells and invasion into the matrix was quan-
tified. The matrix was supplemented with concentrated growth factors from con-
ditioned media collected from HUVEC endothelial cells and mouse ESCs (mESCs).
MDA-MB-231 cells migrating into the matrix were captured in Figure 3-16B and
C. MDA-MB-231 cells were stained with phalloidin to identify actin filaments and
counterstained with DAPI (Figure 3-16B and C). Only a fraction of the population
seems to be pre-disposed to migration as highlighted by positive phalloidin stain-
ing of F-Actin fibers (Figure 3-16B). A cell can been seen with migrational polarity
in the direction of the growth factor enriched matrix (Figure 3-16C).
The invasion assay was quantified as outlined in Figure 3-16D. There was an
increase in migration for Matrigel@ enriched with conditioned media from HU-
VEC endothelial cells and mESCs. This data correlates with previous observations
showing an increase in cellular proliferation of MDA-MB-231 cells when exposed
to conditioned media from these cell types (Figure 3-12).
Interestingly, analogous to the phenotype obtained in the co-culture model sys-
tem, the metastatic cells can be seen aligning and elongating along the growth
factor enriched matrix lattice as shown in Figure 3-17. The ability to re-create this
phenotype suggests that both chemical and biomechanical forces are necessary for
EEC interactions. Similar to techniques used for tissue patterning, when presented
with a structure approximating the physical properties of a endothelial tubes, the
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MDA-MB-231 cells adopt the elongated morphology seen in the co-culture model
(Figure 3-17). Potentially, artificial recreations of this phenotype may offer addi-
tional insight into the critical elements underlying the EEC interactions. For ex-
ample, the matrix could be seeded with a single growth factor, or a combination
of growth factors to probe which soluble factors are responsible for attracting the
metastatic cells. Alternatively, physical properties of the matrix (e.g. stiffness) can
also be altered in order to investigate the biomechanics of EEC interactions.
3.4 Expansion of the co-culture model system to a panel
of breast epithelial cells
Our studies and others have demonstrated that endothelial cells alter the biology
of metastatic breast epithelial cells resulting in increased cellular proliferation and
migration. The response of the metastatic cells to soluble factors secreted by the
endothelium may in part dictate the observed EEC phenotype seen in co-culture,
which in turn may provide insight into invasive mechanisms in vivo. We next
turned our attention to elucidation of biomechanical and physical cell-cell interac-
tions that may further enhance our understanding of EEC interactions in metasta-
sis.
The model system was expanded to include a panel of breast epithelial cells of
varying grades of tumorigenicity ranging from normal to highly metastatic. These
cells types offer a basis of comparison necessary to determine features unique to
metastatic cells.
3.4.1 Breast cancer
In the US, breast carcinoma is the most prevalent cancer in women1 0 17. The mam-
mary gland is an intricate network of ductal structures lined by epithelium 17. it
is composed of a double-layer of epithelium; an inner sheet of polarized lumi-
nal epithelial cells surrounded by an outer layer of myoepithelial cells. Crosstalk
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between the cell types are important for maintenance of mammary gland home-
ostasis and normal and carcinogenic physiologies.
The most common forms of breast cancer arise from carcinogenesis of the lumi-
nal epithelial cells. In breast tissue, as with many tissue types, the in vivo 3D archi-
tecture is critical to the maintenance of normal physiological processes 17,3 3 and 3D
mammary recapitulation has also been shown to highlight tumorigenic changes
and responses to experimental intervention that could not be gleaned from 2D cul-
tures alone16 -18' 303.
Like metastasis in other tissues, breast cancer metastasis involves a variety
of physical and biochemical changes to both the metastasizing cells and the sur-
rounding environment. Breast cancer metastasis occurs primarily through lym-
phatic endothelium, however, metastasis can also occur through vascular endothe-
lium. The primary sites of breast cancer metastasis are lung, liver, and bone. The
tumor biology underlying the development of primary breast cancer is relatively
well understood making it an ideal platform to study subsequent stages along the
metastatic cascade.
3.4.2 Co-culture model with breast epithelial cell lines of varying
grades of tumorigenicity
The HUVEC endothelial co-culture model system was expanded to include a panel
of breast epithelial cells lines ranging from normal primary epithelial cells to highly
metastatic cell lines. Representative images of 2D and 3D monocultures and co-
cultures for each of the cell types can be seen in Figure 3-18. The cell lines included
in the panel are given below: Human Mammary Epithelial Cells (HMEC), a pri-
mary breast epithelial cell line, MCF-10A, a non-tumorigenic, fibrocystic cell line,
MCF7 and SKBR3, tumorigenic/non-metastatic breast epithelial cell lines, MDA-
MB-468, tumorigenic, low metastatic breast epithelial cell line, MDA-MB-231, tu-
morigenic, highly metastatic breast epithelial cell line, and 4T1 highly metastatic
breast epithelial cell line of mouse origin engineered to mimic human metastatic
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Figure 3-18: Representative 2D and 3D monoculture and co-culture images for a panel of breast epithelial cells. HUVEC
endothelial cell co-cultures with breast epithelial cells of varying grades of tumorigenicity. Epithelial cells are labeled with
CFSE prior to addition to unstained endothelial tubes. Samples are fixed after 24 hour co-culture and counterstained with
phallodin and DAPI. Three-dimensional co-cultures reveal striking differences between EEC interaction phenotypes that
correspond to tumorigenicity of the cell types.
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breast cancer. As in previous studies, the epithelial cells are labeled with CFSE and
therefore appear green in the images.
Similar to the phenotype observed with MDA-MB-231 cells, in 3D monocul-
tures the breast epithelial cells adopt a characteristic mammosphere structure anal-
ogous to mammary acini in vivo. This phenotype dramatically differs from the
2D conformation. Further, in 2D co-cultures the breast epithelial cells segregate
from the endothelium, revealing few difference between normal and metastatic
cells. However, this phenotype is dramatically altered in 3D, showing striking
differences between the cell types. Similar to the phenotype observed with the
MDA-MB-231 cells, the other metastatic cells lines preferentially interact with the
endothelium, aligning and incorporating within the vessel structure. In contrast
to this phenotype, co-cultures with primary and tumorigenic epithelial cell lines
exhibit low to moderate interaction with the endothelium, respectively. Through-
out this analysis primary cells are highlighted in pink, tumorigenic cells are high-
lighted in green, and metastatic cells are highlighted in purple.
A kinetics study examining the co-cultures over a 24hr period further high-
lights these differences (Figure 3-19). Epithelial-endothelial co-cultures with MCF-
10A, MCF-7, MDA-MB-231, and 4T1 were imaged at 0min, 5min, 15min, 30min,
2hr, 6hr, 12hr, 16hr, 20hr, and 24hr time points. At early time points the cells can be
seen just after seeding into the matrix. As time progresses, the phenotypes begin to
diverge. Co-cultures with metastatic epithelial cells show a high degree of interac-
tion between the cell types exhibiting intact robust vasculature for the entire 24hr
time period. In contrast, in the MCF-10A and MCF-7 co-cultures, the endothelial
tubes begin to regress, exhibiting more fragile and thinner branches. There is also
limited interaction between the non-metastatic cells and the endothelium.
These observations are confirmed via time lapse imaging of MDA-MB-231 co-
cultures. Time lapse imaging captured the dynamic and rapidly changing nature
of the model system phenotype over a 12 hour period. Metastatic cells are ob-
served actively integrating within the vessels, as well as directly remodeling ves-
sel structures (i.e. fusing neighboring branches into a larger single branch). This
164
0 min 5 min 15 min 30 min
6 hr 12 hr 16 hr 20 hr 24 hr 6 hr 12 hr 16 hr 20 hr 24 hr
0 min 5 min 15 min 30 min 2 hr 0 min 5 min 15 min 30 min 2 hr
6hr 12hr 16hr 20hr 24hr 6hr 12hr 16hr 20hr 24hr
o 0
Figure 3-19: Kinetics of formation of co-culture phenotypes. HUVEC endothelial
co-cultures with MCF-10A, MCF-7, MDA-MB-231, and 4T1 cells were monitored
over a 24hr period.
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remodeling contributes to the wide and robust vessel structures observed in these
co-cultures.
SEM micrographs show high magnification views of the co-culture model sys-
tem with primary (Figure 3-20A, pink), tumorigenic (Figure 3-20B, green), and
metastatic (Figure 3-20C, purple) breast epithelial cell lines. Epithelial cells are
indicated with the abbreviation EPI and endothelial cells are indicated with the
abbreviation ENDO. A dotted line is used to outline the endothelium. On the left
of each panel are mammosphere images taken in monocultures and on the right
are co-culture images. The SEM micrographs show clear differences in EEC inter-
action phenotypes in primary, tumorigenic, and metastatic cell co-cultures.
Primary epithelial cell lines (Figure 3-20A) preferentially interact with other
epithelial cells, exhibiting minimal interactions with the endothelium. At points
of interaction the cells can be seen sitting discretely on the endothelial cell tubes.
There are clear boundaries between the cell types with no evidence of intravasation
into the endothelial tube lumen. Co-cultures with tumorigenic cell lines exhibit
similar phenotypes as the primary cells (Figure 3-20B). The tumorigenic cell lines
are commonly seen forming large tumor spheroids near the vasculature, however,
with limited interaction with the endothelium. In co-cultures with metastatic ep-
ithelial cells, this phenotype is dramatically altered (Figure 3-20C). Here the cells
align along the vessel, elongate, and potentially invade the endothelium. There
are no clear boundaries between the cell types due to incorporation of metastatic
epithelial cells within the vessel structures. The dramatic alteration in phenotype
seen in metastatic cell co-cultures may suggest that this specific mechanism of in-
teraction with the endothelium may be unique to metastatic cells. Indeed a cell
must potentially be able to interact with the endothelium in a similar manner as
captured in these images before it can progress along the metastatic cascade, suc-
cessfully intravasating into and extravasating from the vasculature.
To capture invasion of the metastatic cells into the co-cultured endothelial ves-
sels, the co-cultures were cryosectioned. Cryosectioning of vessel structures show
a clear lumenal structure (Figure 3-21A). Epithelial cells can be seen surround-
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Figure 3-20: SEM images of epithelial-endothelial co-cultures. SEM micrographs show EEC interaction phenotypes in
HUVEC endothelial co-cultures with (A) primary, (B) tumorigenic non-metastatic, and (C) metastatic cells lines. Epithelial
cells are indicated by EPI and endothelial cells are given by the abbreviation ENDO. Vessel structures are outlined with dot-
ted lines. Monoculture and co-culture images for each class of cells are given on the left and right of each panel, respectively.
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ing the endothelial tubes. Figure 3-21B shows an epithelial cell penetrating the
endothelial cell layers, passing through intercellular junctions to enter into the en-
dothelial lumen. The ability of this model system to potentially capture elements of
intravasation expands its utility as a mechanism for not only examining EEC inter-
actions preceeding intravasation/extravasation, but also the actual process itself.
This finding highlights the utility of this model system and emphasizes the ability
of simplistic artificial systems to capture elements of complex cellular interactions.
3.4.3 Quantification of epithelial-endothelial co-culture model sys-
tem
The above descriptions have only qualitatively described differences been endothe-
lial cell co-cultures with primary, tumorigenic, and metastatic cell lines. However,
to fully understand the differences in phenotypes, we have developed an algo-
rithm for quantifying the different co-culture phenotypes. Figure 3-22 shows rep-
resentative examples of bright field images used to quantify the co-culture model
system. The breast epithelial cells were labeled green, while the endothelial cells
were left unlabeled. Again, these images highlight the dramatic differences be-
tween primary, tumorigenic, and metastatic co-culture phenotypes.
There were two main classes of quantification parameters analyzed, angiogenic
parameters and interaction parameters. Angiogenic parameters focus on changes
in the endothelium, while interaction parameters attempt to quantify EEC interac-
tions. Figure 3-23 is a schematic illustration of the quantified parameters, showing
both a cartoon representation and an example of an actual image used for quan-
tification. The angiogenic parameters quantified were vessel length, vessel width,
and nodal area. These are parameters commonly quantified in endothelial cell
tubulogenesis studies. However, since we were also interested in quantifying the
degree of interaction between the two cell types we developed two novel quantifi-
cation parameters, namely an epithelial-endothelial dissociation index (EEDI) and
an elongation index (El).
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Figure 3-21: Cryosectioning of co-culture model with metastatic epithelial cells.
(A) Cryosectioning of vessel structures in co-culture show an open vessel lumen.
The vessel is surrounding by metastatic cells (green). (B) Metastatic cells can be
seen penetrating the endothelial cell boundary. Endothelial cells are labeled with
DiL-Ac-LDL (red) and metastatic cells are labeled with CFSE (green). The cultures
are fixed and counterstained with DAPI.
169
. .. ..... . . ... ..... ... .............. ... 
0
E
0
U
U.
Figure 3-22: Bright field images of co-culture model systems with primary, tu-
morigenic, and metastatic cells. Angiogenic and interaction parameters were
quantified using bright field images. Primary cells, tumorigenic non-metastatic
cells, and metastatic cells are outlined in pink, green, and purple, respectively.
For each cell line analyzed approximately -300-400 4x images were taken over
2-3 independent experimental setups with a minimum of 4 replicates each. The
images were taken across the entire well capturing the diversity of phenotypes
present in the co-culture system. Thousands of vessel structures were analyzed for
each epithelial cell line in co-culture. Strict metrics were developed and applied
to maintain consistency of the analysis over several cell lines and experiments.
The rules applied in this analysis are summarized below; however, for a more
detailed description of the methods used in quantifying the co-cultures refer to
Appendix B.
Quantification of angiogenic parameters The following rules were applied for
quantification of angiogenic parameters:
1. Vessel structures were identified as a network of endothelial tubes in bright
field images
2. Vessel length was measured from the outer edge of one node to the outer
edge of an adjacent node
3. A node is defined as an intersection of two branches. A node attached to less
than two branches is not quantified. A node is approximated as a circular
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Figure 3-23: Example of quantification parameters. Images demonstrating how
the quantification of angiogenic and interaction parameters were performed. The
angiogenic parameters quantified were length, width, and nodal area and the in-
teraction parameters quantified are EEDI and the elongation index.
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region and the nodal area is defined as the area of the circle.
4. Vessel width measures the short-axis of the vessel structure. Given that the
vessels are very heterogenous structures with varying widths, three width
measurements are taken for each branch and then averaged to obtain an av-
erage width.
Quantification results from the angiogenic parameter are summarized in Figure 3-
24. Vessel length (Figure 3-24A), vessel width (Figure 3-24B), and nodal area
(Figure 3-24C) results have been normalized to quantification results for endothe-
lial cell monocultures (black bar). Epithelial-endothelial co-cultures with normal
cells (pink bars) showed no enhancement of angiogenic parameters. Moreover, co-
cultures showed regression of the endothelial tubes as given by a decrease in vessel
width (p<0.0001) and nodal area (p<0.0001). This data suggest that the primary
epithelial cells are not able to support the vasculature and may be even enhance
endothelial cell death. Angiogenesis is regulated by a dynamic balance of pro-
and anti-angiogenic factors. These cell types may create a more anti-angiogenic
environment. This phenotype contrasts quantification results with both tumori-
genic (green) and metastatic (purple) cell lines. There is increased vessel width
and nodal area in tumorigenic co-cultures compared to HUVEC only control and
primary epithelial cell co-culture model systems. The increase in these parame-
ters highlights both the ability of the tumorigenic cells to support the vasculature
and the resulting vessel widening and enlargement of the nodes due to increased
EEC interactions. As expected quantification results with the metastatic cell lines
show the greatest enhancement of angiogenic parameters with statistically signif-
icant increases in vessel length (p<0.001), vessel width (p<0.001), and nodal area
(p<0.001) compared to both HUVEC endothelium alone and primary epithelial
cell co-cultures.
Quantification of interaction parameters Not surprisingly, both tumorigenic and
metastatic cells supported the vasculature to a greater extent then the primary ep-
ithelial cells, likely as a result of secretion of pro-angiogenic factors. However, the
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Figure 3-24: Summary of results of quantification of angiogenic parameters.
Quantification of (A) vessel length, (B) vessel width, and (C) nodal radius area
show that metastatic cells increase angiogenic parameters. Primary cells are in-
dicated with pink, tumorigenic non-metastatic cells are indicated with green, and
metastatic cells are indicated in purple. Results are normalized to HUVEC mono-
culture cells (black bar graph). Cell lines of non-human origin are indicated with
stripped bars.
most interesting differences between these two cell types was found when charac-
terizing EEC interaction phenotypes. The epithelial-endothelial dissociation index
provides a measure of the degree of interaction between the cell types by indi-
rectly quantifying the percentage of the cell population physically interacting with
the endothelium and the percentage of the cells not in physical contact with the
endothelial cell tubes.
The following assumptions were made and rules were applied to quantify the
epithelial-endothelial dissociation index:
1. An epithelial cell physically on the endothelial tube is considered an inter-
acting cell, or as being "on" the vessel, while an epithelial cell not in physical
contact with the endothelium is considered "off" the vessel.
2. Fluorescence intensity was assumed to be an estimate of cell number so that
a higher intensity implies a greater number of cells.
3. The vessels are outlined as illustrated in (Figure 3-23D). The fluorescence
intensity is measured within the outlined region. This measured value repre-
sents the fluorescence intensity on the vessel and is a measure of the number
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of interacting cells.
4. Total fluorescence is an approximate measure of the total number of epithelial
cells present in the image. Total fluorescence is equal to the fluorescence "on"
plus the fluorescence "off" the vessel.
The epithelial-endothelial dissociation index (EEDI) is defined by the following
expression:
EEDI = Fluorescencetotai - Fluorescenceo,,
Flourescencetotai
where Fluorescencetotal is a measure of the total number of epithelial cells and
Fluorescenceo, is a measure of the number of epithelial cells on the vessel.
Figure 3-25A summarizes quantification results for the EEDI parameter. This
metric provides a measure of the percentage of cells not interacting with the en-
dothelium. Therefore, cells with a high EEDI index have little interaction (i.e. pri-
mary epithelial cells), while cells with a low EEDI index exhibit a high degree of
interaction with the endothelium (i.e. metastatic cells). The EEDI score for all cells
lines was normalized to HMEC, the primary epithelial cell line, which serves as
the control in this analysis.
As discussed previously, primary cells show minimal interaction with the en-
dothelium. MCF-10A show a higher degree of interaction than the true primary
cells (i.e. HMECs). This difference in phenotype highlights that although a cell
type might not be tumorigenic it does not necessarily behave exactly as a normal
cell might. The highly metastatic MDA-MB-231 cells showed the highest degree
of interaction with the endothelium, which was statistically significant compared
to both primary (p<0.0001) and tumorigenic cell lines (p<0.0001). The moder-
ately metastatic cell line, MDA-MB-468, showed slightly less interaction with the
endothelium compared to the highly metastatic MDA-MB-231 cells, suggesting
that increased interaction with the endothelium may correlate with increased in-
vasive capacity. Surprisingly the 4T1 showed less interaction with the endothelium
than the MDA-MB-468 cells despite being highly metastatic (Figure 3-25A, purple
stripped bar). However, this may be due to species-to-species differences that may
174
A.
X
1.0
0.5 r- 1
e**
0i
C.
S2.5
*03t
3.0 1.5
0 i100 "0
U L R - r
D.
4
C
.0
3
21
1
*-, r d
U ] - .
1 r 2 R
Figure 3-25: Summary of quantification results of interaction parameters. (A)
Quantification results of the EEDI. Metastatic cells exhibit increased interaction
with the endothelium compared to other cell types. (B) Elongation ratio on the
vessel, (C) elongation ratio off the vessel, and (D) elongation index are presented.
Metastatic cells undergo a large deformation when in contact with the endothe-
lium as indicated by the elongation index >>1. Primary cells, tumorigenic non-
metastatic cells, and metastatic cells are indicated by pink, green, and purple, re-
spectively. Cell lines of non-human origin are indicated with stripped bars.
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affect the cells' ability to interact. Therefore the human and non-human cell lines
cannot be directly compared. Nevertheless, these results support a trend indicat-
ing that metastatic cells lines greatly interact with the endothelium. Furthermore,
unlike the angiogenic parameters, the EEDI metric easily distinguishes the tumori-
genic and metastatic cell populations. Could measurement of the EEDI shed light
on to the invasive potential of a population of cells?
A second feature unique to metastatic cells is the ability of these cells to un-
dergo large deformations when in contact with the endothelium, resulting in dra-
matic changes in cellular morphology from rounded structures to flat fibroblast
like structures. Indeed, studies have shown that the adoption of a flat, spindle-like
fibroblasts morphology aids cells during metastatic invasion" 0 . The elongation in-
dex is used to quantify the deformation that occurs when the epithelial cells come
in contact with the endothelium.
The following assumptions and rules were used in calculating the elongation
index:
1. An epithelial cell physically on the endothelial tube is considered an inter-
acting cell or "on" the vessel, while an epithelial cell that is not in physical
contact with the endothelium the cell is considered "off" the vessel.
2. The long axis (length) to short axis (width) of cells "on" and "off" the vessel
were measured as depicted in Figure 3-23.
3. The elongation ratio (ER) for each cell is calculated by relating the long axis
to the short axis:
ER = longaxis
shortaxis
4. The final elongation index is determined using the following expression:
El EROn - ERoff
ERoff
5. ERoff is measure of the normal baseline cellular morphology prior to defor-
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mations resulting from interactions with the endothelium
The elongation index quantifies the change in shape of epithelial cells due to in-
teraction with the endothelium. When "off" the endothelium, the breast epithelial
cells appear rounded with no distinct cellular polarity. This result is supported by
the calculated elongation ratio of the endothelium approximately equaling 1 for
each of the cell lines (Figure 3-25C). When interacting with the vessel, normal and
tumorigenic cells maintain this morphology or actually become more rounded as
indicated by a negative El (Figure 3-25D). The cells may become more rounded
because these cell types likely organize into tumor spheroid structures when in
contact with the vessel as seen in the SEM micrographs (Figure 3-20). Unlike the
other cell types, metastatic cells undergo a significant deformation from rounded
to spindle shaped when in contact with the endothelium as indicated by an EI>1
compared to normal (p<0.001) and tumorigenic (p<0.001) (Figure 3-25D). This lin-
ear deformation may be required for successful intravisation and may be a unique
property of metastatic cells.
The observed cellular deformation results from dynamic remodeling of the
cytoskeleton that occurs when the two cell types interact. Alterations in cellu-
lar morphology is an energy intensive process requiring mobilization of signaling
pathways and cytoskeletal regulatory pathways. These alterations may potentially
lead to changes in cell biomechanical properties (i.e. stiffness) that may enable a
normally immobile and stiff cell to squeeze through tight endothelial cell-cell junc-
tions.
This observation introduces several interesting questions on the biological sig-
nificance of the El. What enables a cell to undergo these deformations? Do these
changes in cellular shape enhance the cells' ability to adhere to the endothelium or
intravasate into /extravasate from the vessel? Does elongation of the cells change
the biomechanical properties of metastatic cells to promote invasion?
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3.4.4 2-parameter metastatic index
Quantification of interaction phenotypes introduces two features unique to metastatic
cells, namely the EEDI and El. Metastatic cells lead to significant changes in the en-
dothelium. However, examining interaction phenotypes provides the best criteria
to distinguish between metastatic and non-metastatic phenotypes. The results of
the epithelial-endothelial co-culture quantification is summarized in Figure 3-26A.
Using the results from our quantification parameters, we derived a 2-parameter
metastatic index. The graph in Figure 3-26B correlates EEDI and El parameters
from each cell line. The EEDI is plotted on the x-axis and the El is plotted on the y-
axis. From these correlations emerge three regions that can be used to differentiate
normal, tumorigenic, and metastatic cell population (shaded regions). The elonga-
tion and interaction phenotype observed in vitro corresponds with observations of
metastatic cells within mouse lung endothelium in vivo.
The 2-parameter index may potentially provide a predictive model to identify
cells with a higher metastatic capacity from a population of tumorigenic cells. By
measuring the EEDI and El unique regions on the plot begin to emerge distin-
guishing normal, tumorigenic, and metastatic cells. Future studies can focus on
validating the use of the metastatic index using cells of unknown metastatic ca-
pacity.
3.5 Expansion of the co-culture model system
3.5.1 Co-culture model system with primary blood and lymph en-
dothelial cells
Metastatic breast cancer cells may invade the systemic circulation directly, haematoge-
nous dissemination, or indirectly through the lymphatic circulation. However,
once in the lymph nodes the cells must travel into the systemic circulation to ac-
cess the common organs of metastasis (e.g. bone, liver, brain, and lung) because
there are no direct lymphatic routes to these sites. Entering the systemic circu-
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Figure 3-26: 2-parameter metastatic index. (A) Summary of quantification results
of angiogenic and interaction parameters. (B) The 2-parameter index may be a
predictive model for identifying metastatic capacity based on the behaviors of cells
in co-culture.
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lation could occur directly through growing blood vessels feeding lymph node
metastases or indirectly through emptying of efferent lymphatic vessels into the
venous system. Lymph node metastasis is a negative prognostic factor for many
cancers, however, it's unclear if metastasis to other sites occurs as a result of lym-
phatic spread or if lymphatic dissemination occurs concurrently with haematoge-
nous dissemination.
In consideration for both the haematogenous and lymphatic routes of dissemi-
nation, the model system was expanded to evaluate interactions between metastatic
MDA-MB-231 cells with primary human microvascular blood endothelial cells and
primary lymph endothelial cells. Figure 3-27 illustrates co-culture phenotypes
with primary endothelial cells. Interactions between metastatic cels and primary
epithelial cells are analogous to observations with HUVEC endothelial. Cells can
be seen elongating and aligning along both blood and lymph endothelial vessels
(Figure 3-27B and C). Analogous to the in vivo phenotype, lymph endothelial cells
form less defined vessel structures with looser cell-cell junctions and disorganized
vessel structures (Figure 3-27A).
Quantification of these co-cultures further confirm observations with HUVEC
endothelial cells. Results are summarized in (Figure 3-28B). There is a significant
increase in nodal area (p<0.0001) (Figure 3-28B) and vessel width (p<0.0001) (Fig-
ure 3-28C) in metastatic cell co-culture compared to monocultures. Furthermore,
there is a high degree of interaction between the metastatic cells and the endothe-
lial cells that does not occur with other stromal cells (Figure 3-28D). Metastatic cell
co-cultures with SMCs show minimal interaction between the two cell types, pro-
viding additional evidence that metastatic cell interactions with the endothelium
are unique and distinct from interactions with other cell types commonly found in
the tumor stroma.
Metastatic epithelial cells show the highest degree of interaction with blood
endothelial cells when compared to lymph endothelium with no significant dif-
ference in interaction with HUVEC. It's unclear why this difference in phenotype
between the blood and lymph endothelium is present. It may be due to differential
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Figure 3-27: Co-culture model with primary epithelial cells. Co-cultures with
MDA-MB-231 cells established with primary blood and lymph endothelial cells.
(A) 10x bright field images show formation of the co-culture phenotype with pri-
mary endothelial cells that support observations with HUVECs. (B) 10x and (C)
40x fluorescence images of co-cultures. Endothelial cells are stained with LDL
(green), MDA-MB-231 cells are labeled with Calcein Red-Orange (red), and sam-
ples are counterstained with DAPI.
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Figure 3-28: Quantification of metastatic cell co-cultures with primary blood and
lymph endothelial cells. (A) Vessel length, (B) nodal area, (C) vessel width, and
(D) EEDI were quantified in co-cultures with primary blood and lymph endothe-
.al cells and compared to quantification results in HUVEC co-culture. Co-cultures
with SMCs were used as a negative control to identify if interactions with endothe-
lal cells were unique compared to other stromal cells.
secretion of soluble factors that attract metastatic cells to the endothelium. Alter-
natively, the differences may emerge due to differential expression of adhesion
molecules.
3.5.2 Expansion of co-culture model to other tumor types
Breast, colorectal, lung and prostate cancers represent the four most prevalent can-
cers. However, in less than 10% of breast and prostate cancer patients, 20% of
colorectal cancer patients, and 40% of lung cancer patients are distant metastases
found at diagnosis'. This finding presents a therapeutic opportunity and indicates
that for many cancer patients, interruption of the metastatic process at diagnosis
could result in improved clinical outcomes. Therefore, the co-culture model sys-
tem was expanded to several tumor types to determine if the observations found
in breast cancer extended to other tumor types.
We have successfully established co-cultures with epithelial cells of breast, lung,
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Figure 3-29: Schematic of the cancer types included in the co-culture model sys-
tem. The co-culture model was established with epithelial cells from a wide range
of tissue types to determine if the phenotypes observed with breast epithelial cells
were translatable to other tumor types.
ovarian, prostate, colon, and skin origin. These tissue types were selected because
they represent the majority of human cancers, which all have a high propensity for
metastatic invasion. Figure 3-29 illustrates the most commonly occurring cancers,
which we have included in our co-culture model.
Figure 3-30A summarizes quantification results from a panel of prostate cancer
cell lines derived from human and rat origin. Again in this data analysis primary,
tumorigenic, and metastatic epithelial cells are indicated with pink, green, and
purple bars, respectively. Similar to results obtained with breast epithelial cells,
the metastatic cells showed an increase in angiogenic parameters. Cell lines of
nonhuman origin are indicated with stripped bars. The increase in vessel length,
vessel width, and nodal area correlates with the metastatic behavior of the cells.
These results are further supported when examining the interaction indices. The
metastatic prostate cancer cell lines have low EEDI values indicating a high level
of interaction with the endothelium. Similarly, the metastatic cells showed a high
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Figure 3-30: Schematic of the cancer types included in the co-culture model system. Quantification results from (A)
prostate cancer epithelial cell lines and (B) epithelial cells from other tissue types. Primary, tumorigenic non-metastatic
epithelial cells are indicated with pink, green, and purple bars, respectively. Cell lines of non-human origin are indicated
with stripped bars. Quantification results in other tissue types are similar to results observed with breast epithelial cells.
elongation index, indicating large deformations when in contact with the endothe-
lial tubes. However, these observations are seen consistently in the prostate cancer
cells derived from human origin. Similar to results seen in 4T1 cells, the prostate
cancer cells of nonhuman origin exhibited erratic interaction phenotypes with the
human endothelium that may be due to species-species incompatibilities.
Interestingly, the prostate cancer cell lines caused very dramatic increases in
vessel width and nodal area. These cells have distinct morphologies in co-culture
characterized by a high degree of interaction, aligning, and elongating along ves-
sel structures, similar to metastatic co-cultures with breast epithelial cells. Further-
more, these cell lines also exhibit unique features in co-culture. The prostate cancer
cells can be seen completely encapsulating vessel structures. Metastatic cell lines
derived from lung cancer, ovarian cancer, and melanoma further confirm these
quantification results, emphasizing the physiological significance of these obser-
vations (Figure 3-30B).
3.6 Disruption of co-culture phenotype
The previous sections describe our characterization of the co-culture model sys-
tem. Through this analysis novel metrics of measuring cell-cell interactions were
introduced, highlighting unique methods for studying interaction phenotypes be-
tween metastatic cells and the endothelium. However, these findings do not pro-
vide evidence on how this model system can be used used to directly probe path-
ways responsible for these cell-cell interactions.
As a proof of concept, we investigated the role of the FAK-integrin signaling
axis in mediating EEC interactions between metastatic cells and the endothelium.
Integrins are important for cell-ECM interactions and have been implicated in en-
dothelial cell transmigration1 08 . Integrins act through FAK, which in turn activate
cellular signaling pathways. As illustrated in Figure 3-31A, attachment to the en-
dothelium is a critical step in metastatic cell dissemination likely involving ad-
hesion mechanisms utilizing integrins. We hypothesized that metastatic cells use
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Figure 3-31: Co-culture model can be used to examine molecular mediators of
EEC interaction phenotypes. (A) Adhesion to the endothelium is a critical precur-
sor to metastatic dissemination. (B) The role of the FAK-integrin signaling axis in
mediating the metastatic co-culture phenotype was probed at three points along
the pathway.
integrins to bind to endothelial vessels, which in turns activates FAK and other
downstream signaling pathways. To test this hypothesis, we probed this mech-
anism by independently targeting each point along the pathway as illustrated in
Figure 3-31B, beginning first with integrins.
3-1 integrins have been implicated in metastatic phenotypes in breast cancer
cells 2 98 ,3 04 . Furthermore, there is increased expression of 0-1 integrins in metastatic
MDA-MB-231 cells compare to MCF-7 cells in both a 2D and 3D platform (Figure 3-
32A). Furthermore, areas of interaction between the cells types show a punctate
staining signature pattern (Figure 3-32B).
To test the role of 3-1 integrins in EEC phenotypes, 0-1 integrins were knocked
down in MDA-MB-231 cells using siRNA prior to addition of these cells to co-
cultures. siRNA knockdown of 4-1 integrins completely disrupted the interaction
phenotype, typically observed in metastatic cell co-cultures (Figure 3-33A). The
breast epithelial cells (green) are scattered throughout the image with few cells
aligning along the vessels as is seen in control cultures (Figure 3-33A). However,
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Figure 3-32: 3-1 integrins are implicated in cancer metastasis. (A) Immunostain-
ing with -1 integrin antibody (Red) showed increased expression of the protein
in metastatic cells. (B) Areas of EEC interaction show a punctate #-1 signature in
co-cultures with GFP-labeled metastatic breast cancer cells (green). Cultures were
counterstained with DAPI (blue).
interestingly, knockdown of the 0-1 did not indiscriminately reduce cell-cell adhe-
sion. Surprisingly, there were no significant differences observed in monoculture
between control and /-1 siRNA groups. KD of /-1 integrins seemed to dispropor-
tionally affect epithelial-endothelial adhesion, rather than cell-cell adhesion in gen-
eral. The EEDI was calculated to quantify the change in the EEC interaction pheno-
type due to knockdown of /-1 integrins. The EEDI shows that knockdown of /-1
integrins resulted in an 8.6 + 1.225 (p<0.001) fold change in epithelial-endothelial
interactions compared to control (Figure 3-33C).
These results were confirmed using a 4-1 integrin blocking antibody. 4-1 in-
tegrins are important for both endothelial vessel formation (Figure 3-34A) and
interactions between the two cell types (Figure 3-34B). Treatment of endothelial
cells with a blocking antibody reduced the ability of the endothelial cells to form
vessel structures. Therefore, pre-treatment of the endothelial cells with blocking
antibody completely disrupted the metastatic cell co-culture phenotype due to im-
proper vessel formation (Figure 3-34B, top panel). Pre-treatment of breast epithe-
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Figure 3-33: SiRNA knockdown of 3-1 integrins led to disruption of the co-
culture phenotype. (A) SiRNA knockdown of 0-1 integrins disrupted the ability
of metastatic cells to interact with the endothelium. (B) Western blots show knock-
down results. (C) Calculation of EEDI metric quantified the increased dissociation
resulting from inhibition of /-1 integrins.
188
C* p-Integrin
p-FAK(Y925) [ om m
...
D.
S10
8
6
4
- Control siRNA P1 siRNA
DAPI
.... ...... . .................... .....  ............... . ... I . ........... ..... ... . .................. . .. . .... ...........
lial cells with blocking antibody produced similar results as seen with RNAi. The
metastatic cells were unable to effectively migrate toward or adhere to the endothe-
lial tubes (Figure 3-34B, middle row) . Pre-treatment of both cell types with block-
ing antibody again led to disruption of the co-culture phenotype (Figure 3-34B,
bottom row).
Focal adhesion kinases lie downstream of /-1 integrins in FAK /-1 integrin
pathway. Therefore, we next probed the pathway at the level of FAK phospho-
rylation. FAK is a critical regulator of cell-cell adhesion. It regulates a variety of
cellular functions including cell spreading, migration, and proliferation. FAK can
be phosphorylated at several different sites, each implicated in regulating separate
downstream pathways (Figure 3-35A).
SiRNA knockdown of FAK showed similar results as knockdown of 3-1 inte-
grins except the effects were slightly more muted (Figure 3-35D). The result of this
analysis is summarized in Figure 3-35. There was a 3.42 ± 0.162 fold increase in
metastatic cell dissociation from the endothelium following knockdown of FAK.
FAK signaling is activated in areas of high EEC interactions (Figure 3-35B). There-
fore, it follows that inhibition of FAK expression resulted in loss of the ordered
phenotype typically seen in metastatic cell co-cultures. Loss of FAK results in er-
ratic co-cultures, characterized by reduced interaction between the two cell types.
Quantification of the EEDI confirmed the increased dissociation resulting from loss
of FAK (Figure 3-35D). Furthermore, FAK knockdown resulted in decreased phos-
phorylation of several FAK targets including pAKT and pERK, as well as other
molecules within these pathways (Figure 3-35E). The effects of FAK knockdown on
the EEC interaction phenotype were much less dramatic than loss of /-1 integrins.
/-1 integrins are upstream of FAK and may mediate cell-cell adhesion through
FAK independent mechanisms. Therefore, it may be a more effective strategy to
target the most upstream regulators of a pathway.
Since FAK plays varied roles in cellular physiology, it's likely that inhibition of
FAK may reduce EEC interactions through several mechanisms. However, the two
primary ways are likely through a reduction in the ability of metastatic cells to ad-
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Figure 3-34: Inhibiting 3-1 integrins with a neutralizing antibody disrupts the
metastatic co-culture phenotype. 3-1 integrins are important for (A) endothelial
vessel formation and (B) adhesion between metastatic cells and the endothelium
in co-culture. These interactions can be blocked with a neutralizing antibody.
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Figure 3-35: FAK knockdown disrupts the co-culture phenotype. (A) FAK can be
phosphorylated at several sites, affecting signaling to several important regulator
pathways. (B) FAK phosphorylation is increased in areas of high EEC interactions
(C) that can be disrupted by siRNA knockdown of FAK. (D) Quantification re-
sults show an increase in EEDI after FAK knockdown consistent with the observed
decline in epithelial-endothelial interactions. (E) Knockdown of FAK decreases
signaling in several downstream pathways.
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Figure 3-36: FAK KD decreases migration of metastatic breast cancer cells.
Knockdown of FAK expression leads to defects in cell migration. (A) Images and
(B) quantification results showing a decline in cell migration. The decrease in mi-
gration likely contributes to the disrupted EEC interaction phenotype seen in co-
culture.
here to the endothelium or defects in the ability of the metastatic cells to effectively
migrate toward the endothelial tubes. To distinguish these contributions, we ex-
amined the effect of FAK inhibition on migration. Figure 3-36 shows the result of a
Boyden chamber invasion assay examining migration of metastatic cells after FAK
knockdown. Loss of FAK seems to affect both the ability of the cells to adhere to
one another, as well as the migratory capability of the metastatic cells. FAK knock-
down inhibited the ability of these cells to migrate towards the endothelial cells.
Loss of FAK expression leads to migrational defects which may in part explain the
disrupted EEC interaction phenotype.
Recruitment of angiogenic vessels by tumor spheroids is a P13K dependent
pathway. Recruitment of vessel structures was captured over 100 minutes. The
vessel structures do not form randomly, but instead are directly recruited by the
tumor spheroids. This experimental design differs from the traditional co-culture
setup because endothelial cells are added to pre-existing tumor spheroids, there-
fore instead of capturing EEC interaction phenotypes, this experiment captures
angiogenesis. Increasing concentrations of the P13K inhibitor, LY294002, disrupted
formation of endothelial vessel structures (Figure 3-37B) leading to an increased
expression of apoptotic markers (Figure 3-37C).
Ours results illustrate that RNAi inhibition of FAK and f-i integrins can dis-
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Figure 3-37: P13K pathway is critical for endothelial cell biology. (A) Recruit-
ment of angiogenic vessels by tumor spheroids is dependent on P13K. Vessel re-
cruitment assay shows recruitment of endothelial vessels by tumor spheroids. (B)
Endothelial vessels can be disrupted by the P13K inhibitor LY294002. (C) Treat-
ment with the PI3Ki led to a decrease pAKT expression and an increase in apop-
totic markers (e.g. caspase-9 and pARP). Interestingly, there was also inhibition of
p-FAK after treatment with PI3Ki. This may be due to a feedback loop.
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rupt the co-culture phenotype. However, can small molecule inhibitors of their
downstream targets also disrupt EEC interactions? Using small molecule inhibitors
to disrupt interactions between metastatic cells and the endothelium expands the
utility of the model system into a tool for screening therapeutics.
To test this hypothesis, we used commercially available inhibitors of the P13K
and MAPK pathways. These pathways were targeted for two primary reasons.
The first is because they are downstream of the integrin-FAK signaling axis and
enable testing of targets further downstream of these pathways. The second is due
to differential activation of the AKT and ERK signaling pathways in the endothelial
and tumor compartment, respectively.
A dose titration was performed using the P13K inhibitor, LY294002, and the
mitogen activated protein kinase (MAPK) inhibitor, PD98059, in the MDA-MB-
231 cells to determine the dose of drug that inhibited signal but did not lead to
toxicity (Figure 3-38A). Once appropriate drug doses were determined, the effects
of the drugs on proliferation and migration of the MDA-MB-231 cells was tested
using both free drug and a hybrid nanoparticle conjugated with both inhibitors
(Figure 3-38B,C). Inhibition of these pathways lead to defects in both proliferation
and migration of the MDA-MB-231 cells, suggesting that the combination of these
inhibitors would be an effective strategy for targeting EEC interactions.
Treatment of co-cultures with a combination of these inhibitors disrupted the
co-culture phenotype similarly to results obtained with RNAi of FAK and 3-1
integrins. Furthermore, drug treatment increased the susceptibility of the cul-
tured cells to doxorubicin treatment (Figure 3-39A,B). Combination of the three in-
hibitors resulted in complete disruption of the EEC phenotype. Fragmented vessel
structures are seen after drug treatment. There is minimal interaction between the
cell types. In fact, there is very little cellularity after drug treatment indicative of
cell death in response to treatment. These results are further confirmed by examin-
ing apoptosis markers. There is an increase of PARP signaling following treatment,
further supporting the decreased cellularity present in the representative images
(Figure 3-39C). Lastly, quantification of the EEDI showed increased dissociation
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Figure 3-38: Inhibiting the P13K and MAPK pathways affects migration and pro-
liferation of MDA-MB-231 cells. (A) Dose titration was performed to determine
appropriate drug concentrations. Combination of PI3Ki and MAPKi leads to de-
fects in (B) proliferation and (C) migration of MDA-MB-231 cells. These defects
likely both contribute to reduced EEC interactions.
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Figure 3-39: Combination of PI3Ki and MAPKi reduce EEC interaction phen-
toypes. (A) Images and (B) quantification of co-cultures following treatment with
a combination of inhibitors targeting the P13K and MAPK pathways. (C) Drug
treatment results in increased apoptosis markers.
characteristic of the decreased cell-cell interaction observed after knockdown of
FAK and 3-1 integrins. Nevertheless, inhibition of P13K and MAPK pathways was
not as potent as inhibition of FAK or 0-1 integrins. These results further support
the conclusion that targeting mediators further downstream in the pathways may
be less effective in disrupting EEC interactions. To probe this observation, we next
targeted an upstream regulator of P13K and MAPK that could be inhibited with
drug.
Similarly to the FAK integrin signaling axis, EGFR also acts through the P13K
and MAPK pathways (Figure 3-40A). Abberations in EGFR signaling have been
strongly linked to cancer of the breast. Furthermore, there are several commer-
cially available inhibitors to target this receptor. Therefore, we tested the effects of
EGFRi on the metastatic co-culture phenotype. Similar to previous results, treat-
ment with EGFRi led to defects in cellular proliferation (Figure 3-40F), migration
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Figure 3-40: Inhibition of EGFR signaling disrupts the co-culture phenotype. (A) EGFR pathways acts through P13K and
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(Figure 3-40D), and disruption of the EEC interaction phenotypes (Figure 3-40G).
Future work may investigate further the role of the EGFR pathway in EEC interac-
tion phenotypes.
3.6.1 Conclusion of drug studies
We demonstrated that FAK and /-1 integrin signaling are important mediators
of the observed phenotypes. Inhibiting FAK--1 signaling disrupted the architec-
ture, reducing the ability of the MDA-MB-231 cells to migrate and adhere to pre-
formed vessels. Furthermore, treatment with small molecule inhibitors of phos-
phatidylinositol 3 kinase, LY294002 1.6uM, and mitogen activated protein kinase
(MAPK), PD98059 20uM, also perturbed this architecture, indicating that these
signaling pathways play a key role in controlling the observed phenotype. Fur-
thermore, the inhibition of the P13K and MAPK pathways destroyed the tumor
vasculature and inhibited progression and invasion of the MDA-MB-231 by 86%
(p<0.001) while enhancing the cells susceptibility to the cytotoxic agent doxoru-
bicin. We also showed that inhibitors of EGFR signaling can also disrupt EEC
interactions, further emphasizing the utility of the model. Our studies show that
a three-dimensional co-culture system provides a powerful in vitro model system
to study the mechanisms underlying tumor metastasis and is a powerful tool to
screen combination therapies.
3.7 Summary of co-culture model system data
This chapter outlines the development of a co-culture model system to study unique
interaction phenotypes between epithelial cells and the endothelium. Understand-
ing these interactions may provide insight into mechanisms underlying cancer
metastasis, which could in turn offer new therapeutic strategies for the treatment of
cancer. The data demonstrates that soluble factors released by endothelial cells en-
hance the proliferation and invasion of metastatic cells that presumably enable the
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cells to effectively home to the endothelium (Figure 3-41A). Once in contact with
the endothelium, the cells undergo cytoskeletal deformation, flattening, and elon-
gation along the vessel (Figure 3-41B and C). Surprisingly, the co-culture model
system could even capture intravasation of the epithelial cells into the endothe-
lial tubes. Confocal images show that the epithelial cells begin to intravasate into
the endothelial lumens (Figure 3-41D), finally appearing completely within the en-
dothelial cell lumen (Figure 3-41E). Furthermore, the data demonstrates that these
interaction phenotypes could be targeted by disrupting pathways implicated in
cell-cell adhesion. This suggests that the model system may provide a platform
to screen pharmacological therapies targeting both the tumor and the endothelial
compartments.
This data furthers understanding of the biomechanical and chemokine signal-
ing mechanisms critical to defining EEC interaction phenotypes. However, it does
not address the role of intercellular communication in EEC interactions. The fol-
lowing chapters discuss the identification of a novel form of intercellular commu-
nication that enables direct communication between tumor cells and the endothe-
lium. Communication through thin cytoskeletal projections that connect the two
cell types may underly potential mechanisms of pathological angiogenesis.
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Figure 3-41: Overview schematic of steps captured by the co-culture model. CFSE (green) labeled metastatic breast ep-
ithelial cells are added to the matrix containing DiL-Ac-LDL (red) labeled endothelial tubes. The figure depicts the distinct
stages captured in the co-culture model.
Chapter 4
NanoChannel-mediated
communication between metastatic
breast cancer cells and the
endothelium
4.1 Introduction
Uncovering molecular mechanisms underlying metastasis is the final-frontier in
cancer biology 7-9. Currently, therapeutic options for advanced invasive disease
are limited, resulting in dismal 5-year survival rates8 . Cancer metastasis is diffi-
cult to study due to dynamic and reciprocal system-wide interactions that define
the advanced stages of cancer20 . Metastasis is a complex process with many dis-
crete stages: development of the primary tumor, progression to invasive disease,
intravasation, transport and survival in the systemic circulation, extravasation at
distant sites, colonization of secondary tumor sites, and induction of neovascula-
ture by the micrometastatic colony7' 8 . While there has been much research on the
seed (metastatic tumor cells) and the soil (colonized host tissue) hypothesis, lim-
ited knowledge exists on the interaction between metastatic cells and vascular en-
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dothelial cells, which leads to attachment and extravasation. Metastatic cell inter-
actions with the endothelium is a pre-requisite for the development of metastatic
disease and presents a key point of therapeutic intervention 102 10 ' 106
Intercellular communication between cancer cells and the endothelium is a
key element in metastasis 28 7. For example, early studies implicated traditional
chemokine signaling (e.g. secreted soluble factors) in mediating the retraction of
endothelial cells and the subsequent attachment and transmigration of tumor cells
through the endothelial monolayers105 . More recent studies indicate that physical
interactions between cells can also mediate intercellular communication promot-
ing cancer progression. For example, heterocellular gap junctional intercellular
communication was reported to be involved in breast cancer diapedeses through
the endothelium30 . Similarly, intercellular membrane exchange was recently im-
plicated in cell-to-cell p-glycoprotein transfer resulting in multidrug resistance in
breast cancer cells 209 . Taken together these results suggest that better understand-
ing of tumor-endothelial intercellular communication can offer attractive thera-
peutic opportunities in the management of metastatic cancer142 209 287 305' 306
An emerging mechanism of intercellular communication is through the forma-
tion of physical nanoscale structures. Recently, a novel form of cellular commu-
nication was discovered wherein direct transfer of intercellular contents occurs
through thin, nanotubular projections called tunneling nanotubes (TNTs)2 . Since
the initial observation of TNTs in rat pheochromocytoma cells (PC12)2, TNT and
TNT-like structure have been observed in prokaryotic 174 and diverse eukaryotic
cell types, such as neuronal, immune, and epithelial cells 2,3,1 1 7 ,1 75 . TNTs form con-
tinuous connections between cells, serving as a conduit for dynamic cell-cell ex-
change of contents over hundreds of microns of physical separation117 193 . These
structures mediate the transfer of a diverse array of cellular contents, including or-
ganelles, proteins, and pathogens1 1 7,1 7 6,1 7 8 ,193. TNTs may serve important roles in
disease pathology, highlighting the motivation to understand their physical prop-
erties and biological characteristics 178,193,195 . For example, in a recent study the
formation of tunneling nanotubes (TNTs) was shown to mediate bacterial com-
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munication resulting in the transfer of non-hereditary resistance. Similar struc-
tures have been shown to facilitate HIV-1 transmission between T cells178, traf-
fic organelles2 , and enable the spread of calcium-mediated signal between con-
nected cells1 80. TNTs have been implicated in cancer promoting mechanisms in
breast cancer cells and malignant plueral mesothelioma 203,209; however, the role of
physical intercellular communication between tumor cells and endothelium dur-
ing metastasis is yet underexplored. Transport of intercellular cargo through TNT
or TNT-like structures may mediate pathological transformation of tumor stromal
cells that is commonly seen in cancer20 ,203.
In this chapter, I describe a novel form of intercellular communication between
metastatic cells and the endothelium. Formation of nanoscale tubular structures,
or nanoChannels (nCs), mediates early intercellular communication between tumor
epithelial cells and the endothelium in vitro and in vivo. The ability to form such
nanoChannels correlates with metastatic potential of the tumor cells and enables
direct trafficking of both synthetic materials (chemicals and nanoparticles) and
bioorganic macromolecules (proteins and miRNAs).
These structures were examined in a 3D in vitro co-culture model system cap-
turing molecular and physical interactions between metastatic cells and the en-
dothelium. NanoChannel (nC) connections are structurally unique compared to
other TNT projections in both composition and transported cargo. We make the
functional distinction between nCs and TNTs because nCs contain actin and tubu-
lin cytoskeletal components, while only a fraction of the TNTs described have both.
Furthermore, nCs seem to indiscriminately transport small molecules, and parti-
cles, including proteins, small fluorescent dyes, organelles, nanoparticles, and cy-
toplasmic RNAs through active and passive mechanisms. As one specific example,
we show that miR-132, which is implicated in pathological angiogenesis 129 , can
translocate from tumor cells to the endothelial cells through the nanoChannels, re-
sulting in decreased p12ORasGAP and activation of AKT in the recipient endothe-
lial cells. Furthermore, in the endothelium, nanoChannel-mediated communica-
tion resulted in the upregulation of markers of pathological angiogenesis, such
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as CD137 and CD2763 17 . The increase in these pathological angiogenesis markers
could be reduced by pharmacological inhibition of nanoChannel formation. We re-
fer to this phenomenon as metastatic parasitism which describes the transformation
of a normal endothelial cell into a pathological phenotype induced by intercellular
communication received from metastatic cancer cells through nanoChannels. Tar-
geting the formation of these nanoChannels and the resulting metastatic parasitism
may potentially emerge as a new therapeutic opportunity in the management of
metastatic cancer.
4.2 NanoChannels form visible connections between
metastatic cells and the endothelium
4.2.1 Experimental Design
To study nanoChannel-mediated communication between metastatic cells and the
endothelium, we utilized our previously described 3D co-culture model system
(Chapter 3). The engineered 3D co-culture model creates an ecosystem that closely
mimics tumor pathophysiology, where endothelial tubulogenesis was enabled on
a laminin-rich basement membrane tumor-derived matrix prior to the addition of
tumor cells. In contrast to the characteristic tumor spheroids (mammospheres)
that are formed in 3D monocultures 16 (Figure 4-1), the metastatic MDA-MB-231
breast cancer cells preferentially interacted with the endothelium (ENDO), align-
ing on and incorporating into the vascular network (Figure 4-1, solid arrow). This
phenotype differs from that present in 2D cultures, where there is limited interac-
tion between epithelial cells (EPI) and the endothelium. Instead, in 2D co-cultures
the epithelial cells segregate into epithelial islands (Figure 4-1, circle), which sit
upon a layer of endothelium (Figure 4-1, dotted arrow). This phenotype had been
previously described in a lung epithelial-endothelial 2D co-culture model 47 .
The co-culture phenotype was validated using scanning electron microscopy
(SEM) (Figure 4-2A1,A2). Interestingly, inspection of the model system using SEM
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Figure 4-1: Three-dimensional co-cultures provide a physiologically relevant
platform to study interactions between metastatic cancer cells and the endoth-
lium. Epifluorescence imaging of 2D and 3D monocultures and co-cultures of
metastatic cancer cells (EPI) and the endothelium (ENDO). CFSE (green) loaded
MDA-MB-231 tumor cells were incubated with pre-formed HUVEC endothelial
tubes in a 3D matrigel@ matrix followed by immunostaining with rhodamine phal-
loidin and counterstaining with DAPI. In the 3D platform, the metastatic breast
cancer cells interact directly with the endothelium, elongating and aligning along
the endothelial vessels (solid arrow). This phenotype contrasts with the mammo-
spheres observed in traditional 3D monotypic cultures. In 2D co-cultures, there is
segregation of cell types where epithelial cells cluster together in epithelial islands
(circle) atop a bed of endothelial cells (dashed arrows).
revealed nanoscale tethers connecting the tumor and endothelial cells (Figure 4-
2B). The change in phenotype from round to elongated in co-culture was consistent
with observations in previous studies of tumor cells adopting elongated, spindle-
shaped morphologies as a consequence of interaction and migration through en-
dothelial layers105 . Interestingly, long filopodial extensions were also observed in
these cells, reminiscent of nanoscale membrane projections seen in our system105 .
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Figure 4-2: SEM images of co-cultures model reveal intimate interactions be-
tween metastatic cells and the endothelium. (Al/A2) Metastatic breast epithe-
lial cells MDA-MB-231 (EPI) align along endothelial tubes (ENDO). Metastatic
cells preferentially interact with the endothelium compared to normal and tumori-
genic, non-metastatic cell lines. (A2) Higher magnification view of the intimate
interactions between the cell types. (B) NanoChannels (nCs) form connections be-
tween metastatic breast epithelial cells and endothelial tubes (arrow). NanoChan-
nel structures project from the surface of the metastatic epithelial cell to the surface
of the endothelium. Inset shows lower magnification view.
4.2.2 Characterization of nanoChannel structures
In an attempt to better understand the unique properties of nanoChannel projec-
tions, the physical dimensions, the kinetics of formation and the composition of
nanoChannel structures were characterized. Whenever possible, attempts were
made to provide quantitative, as well as qualitative descriptions of the structures.
From the results of this quantification emerged a definition of what structures
are considered nanoChannels, providing clear distinctions from other cytoskele-
tal projections, such as lamellipodia and filopodia.
4.2.2.1 NanoChannels contain actin and tubulin cytoskeletal proteins
To understand the physical properties of nanoChannels, the cytoskeletal compo-
sitions of the structures were determined. Immunocytochemistry staining with
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Figure 4-3: NanoChannels contain both actin and tubulin cytoskeletal compo-
nents. Unlike TNTs, which are typically formed from actin fibers2'3 , the nanostruc-
tures observed in this study included both F-actin and a/3-tubulin cytoskeletal
components. (A) Representative epifluorescence images reveal F-Actin and ai/fl-
tubulin cytoskeletal components within nC structures. Co-cultures were stained
with oa/0-tubulin antibody (green) and phalloidin (purple) and counterstained
with DAPI (nuclear) + WGA (plasma membrane) (blue). Endothelial cells were
labeled with DiL-Ac-LDL (red). (B) Immunocytochemistry revealed the presence
of myosin V (green) within the nCs. The presence of myosin V motor proteins
suggests a possible active transport mechanism in intercellular transfer of cargo
within nCs. Samples were counterstained with phalloidin (red) and DAPI (blue).
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ao/-tubulin and phalloidin identified tubulin and actin cytoskeletal components,
respectively, within the nanoChannel structures (Figure 4-3A). This was a unique
finding because previous observations of similar structures (i.e. TNTs) in other
cell types describe these projections as containing only F-actin cytoskeletal com-
ponents2 3 . However, examination of TNT structures in macrophages did identify
tubulin cytoskeletal components in larger TNTs (> 0.7pm), suggesting that the in-
corporation of tubulin cytoskeletal components may alter the physical properties
of the structures176 . Additionally, immunocytochemistry with a myosin V antibody
revealed a punctate expression signature within the nanostructures, suggesting an
active transport system may exist within nCs (Figure 4-3B). The myosin family is a
group of actin motor proteins that function in many diverse and important cellular
properties. Specifically, myosin V has been implicated in transport of RNAs, mem-
brane trafficking, and establishing cellular polarity308 . Identification of myosin V
motor proteins holds interesting prospects for the possibility of an active transport
based mechanisms within nCs.
4.2.2.2 Measurement of physical dimensions of nanoChannels
Experimental design To better understand the physical properties of nanoChan-
nels and to clearly distinguish nanoChannels from other projections, the dimen-
sions of these structures were quantified in the MDA-MB-231 cell line. This quan-
tification was performed on greater than 300 cells from a minimum of 5-6 culture
replicates for 2D and 3D cultures in both monoculture (culture with only epithelial
cells) and co-culture (culture with epithelial cells and HUVEC endothelial cells)
formats. Quantification of length (long axis) and width (short axis) of nanoChan-
nel structures was determined using either fluorescence microscopy or SEM. Struc-
tures were grouped into the following categories:
1. nCs from 2D monocultures imaged with SEM
2. nCs from 3D monocultures imaged with SEM
3. nCs from 2D monocultures imaged with Fluorescence Microscopy
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4. Other projections (non-nC) from 2D monocultures imaged with SEM
5. nCs from 2D co-cultures imaged with SEM
6. nCs from 3D co-cultures imaged with SEM
7. nCs from 2D co-cultures imaged with Fluorescence Microscopy
8. Other projections (non-nC) from 2D co-cultures imaged with SEM
Figure 4-4 shows representative illustrations of nanoChannels versus other pro-
jections. In our quantification schema, the category of other projections, in general,
includes lamellipodia and filopodia, the most common cellular projections 88. Fig-
ure 4-4 A and B compare the structures of filopodia, lamellipodia, and nanoChan-
nel projections. Filopodia contain parallel actin bundles while lamellipodia and
nCs are composed of both actin and tubulin cytoskeletal components. Lamellipo-
dia are typically wide and flat containing a meshwork of actin at the leading edge
supported by a zone of microtubules and function primarily for migration 8 . In
contrast, filopodia are much smaller projections (similar in size to nCs), function-
ing primarily for environmental sensing. Although filopodia and lamellipodia are
structurally distinct, for the purposes of this quantification, they are grouped to-
gether in the category "other projections".
The following constraints were applied when classifying these structures:
1. The structure must extend from one cell (donor) and physically come in con-
tact with another cell (recipient) (Figure 4-5A). Incomplete or broken projec-
tions were not considered to be nanoChannels (Figure 4-5D). Small hair-like
structures (Figure 4-5B) were also not considered to be nanoChannels and
were instead considered to be filopodia and fell into the category of other
projections (non-nC). The only exception to these rules was quantification per-
formed at time points < 6hrs or quantification performed after pharmacolog-
ical inhibition of nCs. NanoChannel formation was found to peak approxi-
mately 5-6hrs after plating of cells. At early time points (i.e. before mature
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Figure 4-4: Schematic of nCs versus other cytoskeletal projections. (A) Filopo-
dia are composed of parallel actin bundles, while lamellipodia contain a mesh-
work of actin filaments supported by a zone of microtubules. (B) nCs are struc-
turally unique. They are approximately the same physical dimensions as filopodia
but contain both actin and tubulin cytoskeletal components. (C) Images illustrat-
ing other projections versus nC structures. NanoChannels are thinner structures,
while many of the other projections quantified in the culture are typically much
wider. (C4-6) nCs are very structurally diverse, ranging from linear projections to
structures with large curvatures.
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Figure 4-5: Rules for defining nC structures. (A) Schematic illustration of nC
growth. A structure must extend from a donor cell, an epithelial cell, to a recipient
cell, typically an endothelial cell, in order to be considered an nC. SEM images
show examples of (B) small protrusions, (C) nascent nCs, or (D) broken nCs.
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nanoChannels are formed) or after pharmacological inhibition of nCs, filopo-
dia (Figure 4-5B), disrupted (broken) nCs (Figure 4-5D), and nascent nCs
(Figure 4-5C) appear indistinguishable. In these limited circumstances, small
hair-like projections were also included as potential nCs or disrupted nCs for
the purpose of quantifying nC structure formation kinetics (Section 4.2.2.4)
or nC formation disruption by pharmacological inhibitors (cytoskeletal poly-
merization inhibitors) (Section 4.4), respectively. Except for the above men-
tioned circumstances, quantification was performed 24hrs post culture, and
only intact nC structures were considered. Any deviations from the descrip-
tions above are noted on a case-by-case basis.
2. The length (long axis) of the nC projection was measured from the point of
origin to the point of termination (Figure 4-6).
3. Due to size variabilities in length of nC projections, three width (short axis)
measurements were taken at distinct positions along the length of the nC
structure. The three width measurements were used to obtain an average
width (Figure 4-6).
4. The length of non-linear nC structures were quantified by summing the lengths
of shorter linear segments (Figure 4-6).
5. NanoChannel structures were classified as intercellular connections, approx-
imately < 1 pIm in width.
NanoChannel structures have unique physical characteristics The nanostruc-
tures observed in our model system have unique physical dimensions. These pro-
jections are thinner (short axis: 0.31LO.Olpm)(p < 0.0001) and longer (long axis:
36.58±2.07pum) (p < 0.0001) than other cytoskeletal projections such as lamellipo-
dia and filopodia (short axis: 4.99+0.23pm; long axis: 12.9011.79[m) that primar-
ily function in cellular migration and chemotactic sensing (Figure 4-7A). These
averages were obtained by measuring nC structures present in MDA-MB-231 and
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Length Width
Non-Linear nC
Figure 4-6: Demonstration of nanoChannel length and width measurements.
This schematic provides an illustration of how length (long axis) and width (short
axis) measurements were performed. The long axis (length) of the structures were
considered from the point of origin (donor cell) to the point of termination (re-
cipient cell). Due to size variabilities along the length of the structures, measure-
ments of the short axis were taken at three distinct positions along the length of
the structure and then averaged together to obtain an average width measurement.
Non-linear nC structures were quantified by summing the lengths of shorter linear
segments.
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HUVEC epithelial-endothelial co-cultures. To determine if nCs structures were
unique to the 3D culture format nCs measurements from both 2D and 3D cultures
were compared (Figure 4-7B). There were no statistical differences between the
widths of nCs in either culture format. However on average, the length of nCs
in 3D co-cultures is slightly shorter than the average length of structures in 2D.
This reflects the close proximity of the cell types in 3D epithelial-endothelial co-
cultures. In contrast to the intimate interactions formed in 3D cultures, in the 2D
cultures we observe segregation of cells types (Figure 4-1). Because the cells are
spatially separated (farther away) in 2D, on average, nCs are slightly longer in
these cultures. However, in all other comparisons (e.g. composition, cargo trans-
ported) nC structures in 2D and 3D cultures are similar. Therefore, we concluded
that this difference likely arises as an artifact of the culture and that the structures
in 2D and 3D cultures are identical in composition and function.
We also assessed which imaging modality, SEM or fluorescence microscopy,
would allow for more precise identification of nC projections (Figure 4-7B). There
are strengths and limitations to both techniques. For example, correlative mi-
croscopy (i.e. the ability to determine relationships between structure and func-
tion) is significantly more straight forward using fluorescence microscopy than
with traditional electron microscopy (EM). Furthermore, EM suffers from com-
plex sample preparation requirements that are both cumbersome and mechani-
cally stressful on the samples, often disrupting delicate structures. On the other
hand, EM allows for powerful resolving capacity that could never be achieved
with fluorescence microscopy.
We performed a side-by-side comparison of the projection length and width
quantification measurements using SEM and fluorescence microscopy. As hypoth-
esized, thinner structures could be observed using SEM, yielding an average width
of 0.3 2 +0.0 2 btm compared to 1.53+0.13pum (p < 0.0001) for 2D co-culture samples
imaged with fluorescence microscopy. Interestingly, nCs imaged with fluorescence
microscopy were also slightly longer (60.15±6.24pIm) than nCs in analogous cul-
tures imaged with SEM (42.46±3.26pam) (p < 0.0001). There is a degree of error
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Figure 4-7: Physical dimensions of nanoChannel projections. (A) Length and
width of nanoChannels (nCs) and larger cytoskeletal projections, such as lamel-
lipodia and filopodia were quantified using SEM. NanoChannels have unique
physical properties. They are much thinner and longer then other cytoskeletal
projections found in co-cultures (p < 0.0001). (B) Length and width of cytoskeletal
projections in 2D versus 3D cultures. nCs have the same width dimension in both
2D and 3D. However, nCs are slightly longer in 2D likely due to the spatial sepa-
ration of the cells. SEM captures smaller projections that are not easily visible with
fluorescence microscopy.
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associated with length scale measurements made on SEM micrographs due to fore-
shortening effects. Efforts were made to minimize this error; however, since our
measurements were conducted on biological samples for the purposes of distin-
guishing nCs from different classes of cellular projections and because we were
dealing with relatively large length scales, greater error was tolerated. However,
this error may explain the differences between length measurements made using
fluorescence microscopy versus SEM. An additional explanation may be that due
to the mechanical stress of SEM sample preparation the larger projections may
have broken. Nevertheless, projections larger than 200pm can be observed in SEM
micrographs (Figure 4-8).
Identification of a characteristic length A characteristic size descriptor, de-
fined as the width:length ratio of the projections, can be used to distinguish nCs
(0.0134t0.001) from other cytoskeletal projections (1.254+0.140) (p < 0.0001). Plot-
ting the characteristic size of the structures against width shows a visible difference
between nCs and other projections. (Figure 4-9B). On a plot of width versus length
(Figure 4-9A), nCs cluster distinctly from other projections (n > 300). Defining ap-
propriate lengths scales may provide insight into future work examining transport
dynamics within nC structures.
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Figure 4-8: nC structures can span hundreds of microns of distance.
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Figure 4-9: NanoChannel characteristic size descriptor (A) Length and width di-
mensions of nCs and other projections were plotted, demonstrating unique length
scales of nCs. (B) A characteristic length scale was defined by taking a ratio of the
width:length of the projections. This parameter was plotted against width. nCs
tightly cluster at W/L ratio less than 0.3036.
Comparison of nCs in co-cultures versus monocultures In order to assess whether
nC structures were unique to co-culture model systems, we compared nC projec-
tions in MDA-MB-231 epithelial-epithelial cultures with MDA-MB-231 and HU-
VEC co-cultures. We assessed the physical characteristics of the projections, as
well as the percentage of the population expressing nCs and the average number
of nCs per cell. There were no measurable differences in the physical dimensions
of nCs in co-culture and monoculture (Figure 4-10A, Table 4.1), indicating that the
same structures are present in both culture platforms. Interestingly, the presence
of endothelial cells induced increased expression of nC structures. In both the 2D
and 3D platforms, a higher percentage of the metastatic epithelial cells were nC+ve
compared to the same cells in monoculture. In 2D and 3D co-cultures, 56.10+3.90%
and 69.93t5.91% of the breast epithelial cells, respectively, were nC+ve compared
to 24.15±1.64% and 32.98±1.45% of cells in 2D and 3D monocultures, respectively
(Figure 4-10B). In addition, the average number of nCs expressed by cells in co-
culture were also higher (Figure 4-10C,D). There was a 1.5 fold (p < 0.001) and
1.8 fold (p < 0.0001) increase in nCs per cell in 2D and 3D co-cultures compared
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EPI-EPI
2D 3D FL
Width (pm) 0.31 ±0.02 0.29±0.02 1.05±0.05
Length (pm) 31.55±5.67 45.62±4.29 6.75±0.41
EPI-ENDO
2D 3D FL Other
Width (um) 0.32±0.02 0.29±0.022 1.53±0.13 4.99±0.23
Length (pm) 42.46±3.26 30.69±2.43 60.15±6.24 12.90±1.79
Table 4.1: Summary of nanoChannel projection length and width measure-
ments.
to analogous monocultures, respectively (Figure 4-10C). This difference in nCs per
cell is further emphasized when averaging in the nC-ve cells (Figure 4-10D). In-
cluding nC-ve cells, there is a 3.5 (p < 0.0001) and 4.2 (p < 0.0001) fold increase
in nCs per cell in 2D and 3D co-cultures compared to monoculture, respectively.
Taken together, this data indicates that the presence of endothelial cells induces nC
formation in metastatic breast epithelial cells, increasing both the number of cells
expressing nCs and the number of nC structures per cell. Surprisingly, the percent-
age of nC+ve cells was also dependent on the culture format. There is a 37% and
25% increase in percentage of nC+ve in 3D platforms compared to 2D in mono-
culture and co-culture formats, respectively. This difference further highlights that
adopting a 3D conformation in culture leads to significant biological differences
that are otherwise lost in cells cultured on 2D substrates.
4.2.2.3 Speculation on the unique arrangement of cytoskeletal fibers within
nanoChannels
The unique physical properties of these structures may provide insight into why
tubulin cytoskeletal components are incorporated within nC structures. Figure 4-
11B provides a schematic of idealized cytoskeletal arrangements within nCs. Ex-
tending the arguments made by Atilgan et al. in describing filopodial projections,
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Figure 4-10: Comparison of nanoChannel structures in monoculture versus co-
culture. (A) Length and width measurements of nCs in monoculture and co-
culture. The physical dimensions of the structures are the same in both mono and
co-culture indicating that the structures in both culture platforms are the same.
(B) Percentage of nC+ve cells in monoculture versus co-culture. (C/D) Average
number of nCs per cell excluding nC-ve cells (C) and including nC-ve cells (D).
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it is possible to estimate the theoretical number of actin cytoskeletal bundles re-
quired to achieve the length scales observed in nanoChannels0 9 (Figure 4-7). This
model incorporates properties of cell membrane elasticity and fluctuation dynam-
ics with actin polymerization kinetics to describe protrusion speed of filopodia as
a function of the number of filaments in a bundle0 9 . In this model, the authors
describe that one filament alone is not sufficient to cause a protrusion longer then
several hundred nanometers even though the chemical energy derived from poly-
merization can lead to protrusion; a filopodia will not form without sufficient stiff-
ness to create a projection3 09 . They define the buckling force of a filopodia to be
fb 7I2pkbTpestnc
A = 12 I, where 1p is filopodia persistence length, 1 is actual filopodia length, I
is a dimensionless quantity for bundle stiffness, kb is the Boltzmann constant, and
T is temperature1 01 3 09 . Using this model, a nanoChannel with an average length of
approximately 50pm would require > 410 actin filament bundles, creating a pro-
jection with a minimum diameter 1.5[pm, 5x greater than the average measured nC
diameter. This model would predict that nC projections should buckle at lengths
on the order of several microns3 09 . However, our studies have shown that nCs
in nature are significantly longer (several hundred microns). We hypothesize that
these descriptions fail to define structural characteristics of nCs because they do
not account for actin-tubulin interactions (Figure 4-11A). NanoChannels seem to
be formed from an actin core supported by a punctate -Tubulin signature (Fig-
ure 4-11C). Microtubules are roughly two orders of magnitude more rigid than
microfilament bundles. The presence of microtubules may be critical in providing
the structural support required to achieve the length scales observed in nC struc-
tures (Figure 4-7).
Figure 4-11B illustrates the possible arrangement of cytoskeletal fibers within
nCs. Two extremes are possible: a hollow cylinder with cytoskeletal fibers ar-
ranged along the periphery of the channel or a solid pipe with cytoskeletal fibers
packed at a high density throughout the structures. The reality likely exists some-
where in between these two extremes.
The cytoskeletal arrangement within nC structures may play a critical role in
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Figure 4-11: Cytoskeletal arrangement inside nCs. (A) Unlike filopodial cellu-
lar projections, nanoChannels are composed of both actin and tubulin cytoskeletal
fibers. Filopodia contain parallel actin fibers and few microtubules. Interactions
between actin and tubulin may be critical in achieving the unique length scales
seen in nCs. Models used to describe mechanical properties of filopodia are not
appropriate to use in describing nCs. These models may fail to define structural
characteristics of nCs because they do not consider actin tubulin interactions. Mi-
crotubules are roughly two orders of magnitude more rigid than microfilament
bundles. The presence of microtubules may be critical in providing the struc-
tural support required to achieve the length scales observed in nC structures. (B)
Schematic of idealized cytoskeletal arrangement inside nCs represents the two ex-
tremes: hollow cylinder and solid pipe. The reality may likely exist somewhere in
between. (C) 3D cross-section of an nC projection with labeled a/-Tubulin and
F-Actin cytoskeletal proteins. nCs seem to be formed from an actin core supported
by a punctate -tubulin signature. Tubulin may provide structural support as the
nC elongates, potentially serving as a protein cap for the elongating actin filaments
(solid arrow).
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the transport mechanisms that dominate within nanoChannels. A more hollow
configuration may indicate that diffusive mechanisms dominate. In contrast, a
more dense configuration might suggest an active transport mechanism. A high
density of cytoskeletal fibers may inhibit passive diffusion (within the time scales
of interest) of large molecules due to spatial constraints. Actin motor proteins (i.e.
myosins) and microtubule motor proteins (i.e. kinesins and dyneins) may predom-
inate in a diffusion limited context.
4.2.2.4 Kinetics of formation of nanoChannel structures
We next examined the kinetics of nanoChannel formation over a 24 hour time pe-
riod (Figure 4-12). Cultures were fixed at the indicated time points and visualized
using SEM (Figure 4-12A).The length of nC structures (Figure 4-12B) and the av-
erage number of nCs were quantified at each time point (Figure 4-13A). At 1.0hr
after addition of MDA-MB-231 cells to the culture, the epithelial cells appeared
rounded with a smooth surface. However, within 1.5hrs, visible projections were
seen forming from MDA-MB-231 cells with directional polarity (arrow, Figure 4-
12A). NanoChannels were found to arise from the surface in closest proximity to
the endothelial vessel, while limited projections were observed on the opposing
side (arrowhead), suggesting that nanoChannel formation is a highly directed and
non-stochastic process. At 2.Ohrs, the structures continue to lengthen toward the
endothelium to form complete nCs (arrow). By 3.Ohrs intact projections were ob-
served but did not appear to be fused with the endothelial membrane, indicating
non-functionality (solid arrow). An epithelial cell can be seen invading the en-
dothelial structure (dotted arrow). By 5.Ohrs intact projections were present, which
persisted over 24hrs. At 24hrs the structures appear to be fused with the membrane
correlating with functional studies examining intercellular transport through nCs
(Section 4.3). The growth of nanoChannel structures was measured over time sup-
porting these qualitative observations (Figure 4-12B). Elongation of nCs occurs
slowly until approximately 2hrs, at which point structures quickly elongate until
approximately 16hrs when nC growth plateaus (Figure 4-12B).
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Figure 4-12: Kinetics of formation of nC structures over 24hrs. (A) SEM micrographs show representative nC structures
at a selected subset of time points (0.5hr, 1.5hr, 2.Ohrs, 3.Ohrs, 5.Ohrs, and 24hrs). NanoChannel formation appears to be a
directed process with structures forming with directional polarity toward endothelial cells. (B) Growth of nC projections
was quantified over time. Lengthening of nC structures begins slowly, followed by a burst of nC growth from 2-16hrs with
a plateau of length after 16hrs. These results correlate with studies examining intercellular transport through nC structures
over time.
Next, the average number of nC structures per cell was quantified over time
(Figure 4-13A). NanoChannels were classified into two groups nascent nCs or
complete nCs. Nascent nCs refer to the small hair-like projections that can be
seen forming from cells at early time points (Figure 4-5C), while complete nCs
extend from donor epithelial cells to the recipient cells without disruption (Fig-
ure 4-5A,D). The average number of complete (green) and nascent (pink) nCs was
quantified over a 24hr period (Figure 4-13A). Total projections (black) represents
the sum of nascent nCs and complete nCs at each individual time point. At early
time points the majority of projections are nascent nCs with very few complete
nCs present. This phenotype reverses at later time points. Interestingly, the num-
ber of projections is greatest at low time points. This data suggests that at very
early time points metastatic breast epithelial cells form several small projections
on their surface. At slightly later times, a fraction of these projections, maybe in
response to a soluble factors released by endothelial cells, go on to form complete
nC structures. Nascent nCs may have receptors that respond to factors secreted by
neighboring cells. The nascent nCs that efficiently respond to nanoChannel growth
signals go on to form complete nCs, while the remaining nCs regress, possibly due
to an inability to sense the appropriate growth signal. The number of complete nC
structures peaks at approximately 5hrs and declines quickly by 6hrs and remains
fairly constant until 24hrs. The number of complete nCs is likely proportional to
nC growth signals released by neighboring cells. The sudden decline in nCs struc-
tures between 5 and 6 hours is likely due to equilibration of nC projections with the
concentration of nC growth signals. The number of projections present at 5hrs may
not be maintained by the level of nC growth signals released at 6hrs. Figure 4-13C
illustrates the proposed mechanism of growth of nCs over time.
To further understand how nCs form over time, we quantified the percentage
of nC+ve cells (Figure 4-14B). We assessed the percentage of cells with nascent
nCs, complete nCs, and both nascent and complete nCs (Figure 4-14B). At early
time points, almost 100% of the cells were nC+Ve. However, the percentage of the
population declined slightly by 24hrs. As illustrated in Figures 4-13A and 4-14B,
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Figure 4-13: Quantification of nascent versus mature nCs over time. (A)
NanoChannel projections were quantified over time. NanoChannels were quan-
tified as complete nCs (green) or nascent nCs (pink). Total projections (black) is
the sum of complete nCs and nascent nCs. At early time points the majority of
projections are nascent nCs, while at later time points mature nCs dominate. (B)
The percentage of nascent nC+ve cells, complete nC+ve cells, and both nascent
and complete nC+ve cells was quantified over time. (C) Schematic illustration of
nC growth over time. At early time points, small projections emerge on the cell
surface. A fraction of these nascent nCs go on to form complete nCs, while the
remaining nCs regress. At 5hrs, the number of complete nCs peaks, quickly de-
clining by 6hrs and staying fairly constant up to 24hrs.
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Figure 4-14: Percentage of nC+ve cells over time. (A) The nC+ve population was further subdivided into cells with
epithelial-epithelial connections (EPI-EPI) (grey), epithelial-endothelial connections (EPI-ENDO) (maroon), and both con-
nections (light blue). A majority of metastatic cells form connections with the endothelium. (B) Average number of nCs per
cell were quantified and classified according to the type of nC projection (mature vs. nascent) and the recipient (EPI, ENDO,
or Both). Cells which form EPI-ENDO connections also express a higher number of nC structures per cell.
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at early time points most of the nC+ve cells have nascent nC projections, while at
later times the nC+ve cells express exclusively mature nCs. From approximately 2-
5hrs, nC structures transition from nascent to mature projections with the majority
of cells expressing both complete and nascent nCs.
We further stratified the quantification into epithelial-epithelial connections (EPI-
EPI) (grey), epithelial-endothelial connections (EPI-ENDO) (maroon), and both
connections (light blue). In Graph 4-14A, nC+ve cells were grouped by both the
type of nCs formed (nascent vs complete) and by the recipient cells (endothelial,
epithelial, or both epithelial and endothelial cells). A majority of nCs structures
formed are toward the endothelium with very few cells forming connections with
other epithelial cells (Figure 4-13A). In addition, at each time point cells that form
connections with the endothelium exhibit a higher number of both nascent and
complete nCs per cell than the same cell type forming connections with other ep-
ithelial cells (Figure 4-13B). Taken together these data show that the endothelium
may be producing a signal that induces formation of nC structures.
4.2.3 NanoChannels preferentially form between metastatic cells
and the endothelium
From our analysis of nC structures in MDA-MB-231, we were able to characterize
the cytoskeletal composition, physical dimensions, and kinetics of formation of
nC structures. However, to investigate the correlation between the ability to form
nanoChannels and metastasis, we co-cultured epithelial cells of increasing tumor
grades with the endothelial networks. Developing these model systems allowed
for analysis of nC structures in other epithelial cell lines.
NanoChannels were analyzed in co-cultures of primary human mammary ep-
ithelial cells (HMEC), tumorigenic non-metastatic breast epithelial cell lines (SkBr3,
MCF-7), or metastatic epithelial cell lines (MDA-MB-468, MDA-MB-231, and MDA-
MB-435). Again, the nCs quantified were grouped into three types of connections:
epithelial-epithelial (EPI-EPI) connections, epithelial-endothelial (EPI-ENDO) con-
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Figure 4-15: NanoChannel structures in primary, tumorigenic, and metastatic
cells (A) SEM images show nanoChannels formed by primary breast epithe-
lial cells (HMEC), tumorigenic breast epithelial cell lines (SkBr3, MCF-7), and
metastatic breast epithelial cell lines (MDA-MB-468, MDA-MB-435). (B) Graphs
show the percentage of nC+ve cells and (C) average number of nCs per cell quan-
tified in each culture. (D) Average number of nCs per cell including nC-ve cells. (E)
Maximum and mean number of nCs (per cell) for each analyzed epithelial cell line.
Averages are indicated by the black band on each bar. (F) nC structures formed by
different cell lines have similar length scales. Quantification was performed on
>300 cells of each cell type.
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nections, or both connections (Figure 4-15A). Over 70% of the metastatic cell pop-
ulations were nC+ve, which was 1.73±0.12 fold (p<0.01) greater than the percent-
age of nC+ve cells in the case of normal epithelial cells (Figure 4-15B). Metastatic
cells preferentially formed EPI-ENDO to EPI-EPI connections, at a ratio of ap-
proximately 2:1 (p<0.01). Compared to normal epithelial cells, tumorigenic non-
metastatic populations contained 1.34±0.10 fold (p<0.05) higher percentage of nC+ve
cells. However, contrary to the phenotype observed in the metastatic cell lines,
these connections were primarily EPI-EPI type, with similar levels of EPI-ENDO
connections in tumorigenic cell lines compared to normal (Figure 4-15B). We next
quantified the number of nanoChannels formed per cell. Interestingly, the metastatic
cells which formed nC connections with the endothelium expressed 1.59±0.18
times (p<0.05) the number of nanostructures per cell than the same cell type form-
ing EPI-EPI connections (Figure 4-15C). Furthermore, compared to the normal
breast epithelial cells, both tumorigenic and metastatic populations formed more
EPI-EPI nC connections per cell; however, only the metastatic cells expressed higher
EPI-ENDO nC connections (Figure 4-15C). The average number of nCs per cell in-
cluding nC-ve cells is given in Figure 4-15D. Taken together these data suggest that
a higher percentage of metastatic cells are nC+ve, and metastatic cells preferen-
tially form connections with the endothelium compared to normal (p<0.001) and
tumorigenic cell lines (p<0.0001), which preferentially form monotypic intercellu-
lar connections. Indeed, the ability of a cell to form nCs may provide important
insight into its metastatic potential. Figure 4-15E graphs the maximum and mean
number of nCs (per cell) observed for each analyzed epithelial cell line. In accor-
dance with the previous data, cells with ten or more nCs were commonly found in
the metastatic cells lines.
To confirm that the structures analyzed in each of the co-cultures are similar, we
quantified the physical dimensions of nC projections in MDA-MB-468 co-cultures
(Figure 4-15F). There is no statistical difference between the length and width of
nC structures formed by MDA-MB-231 and MDA-MB-468 cells when in co-culture,
confirming that nCs formed by different cell lines have similar length scales. There-
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fore, this data provides confidence that the same structures are being analyzed in
each of these model systems.
4.3 Communication of intercellular contents occurs through
nanoChannels
The aforementioned data highlights important characteristics of nC structures.
Formation of nanoChannel structures occurs in a regulated fashion with a high
degree of correlation with a metastatic phenotype. Furthermore, nanoChannels
formed by metastatic cells are induced by endothelial cells. Normal breast epithe-
lial cells preferentially form monotypic nC connections (EPI-EPI), while metastatic
cells predominately form epithelial-endothelial (EPI-ENDO) nC connections. For-
mation of nanoChannels requires polymerization of the actin-tubulin cytoskele-
ton and is therefore likely a high energy process. To understand why cells have
evolved the ability to form nC structures, we sought to investigate their biological
function, specifically the role of nCs in intercellular communication.
4.3.1 Experimental Design
We first assessed the ability of nanoChannel structures to transport cytoplasmic
contents. To perform these studies MDA-MB-231 cells were loaded with carboxyflu-
orescein succinimidyl ester (CFSE) cell-impermeable dye prior to their addition to
DiL-Ac-LDL labeled endothelial cells tubes. CFSE is a small, fluorescently labeled,
non-membrane permeabilizing, cytoplasmic dye that can be used as a non-specific
maker of cytoplasmic contents. CFSE was chosen as an appropriate reagent to use
in these experiments due to its minimal cytotoxicity and its inability to cross the
plasma membrane once it has been internalized by cells. CFSE is formed from
carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) after the removal of
acetate groups by intercellular esterases. CFDA-SE is highly cell permeable due
to the presence of acetate groups, while CFSE is highly membrane impermeable.
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CFSE can be retained in cells through many cell division, making it an excellent
marker for non-specific intercellular contents.
Figure 4-17 provides a general overview of the experimental design used to
evaluate nC-mediated intercellular transfer. Epithelial cells were pre-treated with
cytoskeletal inhibitors for 24hrs to disrupt formation of nanoChannel structures
prior to loading with fluorescently labeled synthetic materials (CFSE, quantum
dots) or labeling of endogenous cytoplasmic contents (GFP). Co-cultures were in-
cubated for 24hrs after which nC-mediated intercellular transfer was analyzed via
FACS. Endothelial cells were isolated, the percentage of cells receiving intercellular
contents was quantified, and the effects of drug treatment were determined. These
methods were used to evaluate changes with drug inhibition and phenotypic dif-
ferences in endothelial cells receiving intercellular communication verses endothe-
lial cells receiving no intercellular communication. Specifically, the adoption of a
pathological phenotype due to intercellular transport received via nanoChannels
was assessed.
Flow cytometry was used as the primary method for quantifying intercellu-
lar transport through nC structures. Optimization of the flow cytometry protocol
required determination of the appropriate concentration of CFSE to load in the ep-
ithelial cells and the development of a robust mechanism for identifying each of
the cell populations.
The first requirement was optimization of the concentration of CFSE to load
into the epithelial cells. Endothelial cells naturally autofluoresce producing an aut-
ofluorescent background. As a result, it was critical to choose a concentration of
CFSE that would allow for an optimal signal to noise ratio. In order to determine
this concentration, we performed a dose titration of CFSE to assess the minimum
concentration required to achieve a concentration-independent measure of inter-
cellular transport.
Figure 4-16 illustrates the results of this dose titration. The percentage of in-
tercellular transfer in the recipient population was quantified as illustrated in Fig-
ure 4-16A. At low concentrations of CFSE only a small percentage of the recipient
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labeled with Dil-Ac-LDL and PECAM-1.
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cell population receives intercellular transfer (Figure 4-16B). The percentage of re-
cipient cells increases with CFSE concentration until approximately 2pM. In the
range of 5-9pM the percentage of cells receiving intercellular contents is constant,
indicating that this range is appropriate to achieve a concentration-independent
measure of intercellular transfer (Figure 4-16B).
The second requirement was to optimize the staining protocols used to dif-
ferentiate each of the cell types. HUVEC endothelial cells were stained with VE-
cadherin (pink), two concentrations of PECAM-1, PECAM-1 low (blue) and PECAM-
1 high (grey), and Tie-2 (green) (Figure 4-16C). Immunostaining with PECAM-1
offered the best separation of the stained population from unstained cells (black).
However, MDA-MB-231 breast epithelial cells express low levels of PECAM-1 (pink)
(Figure 4-16E). Therefore, in order to achieve complete separation of the popula-
tions, HUVEC endothelial cells were also stained with DiL-Ac-LDL. Staining with
DiL-Ac-LDL was beneficial for two primary reasons. First, DiL-Ac-LDL staining
could be done on live cells allowing for staining of endothelial cells prior to co-
culturing. Staining the endothelial cells independently of epithelial cells better
ensured specificity of the staining. Second, MDA-MB-231 cells (pink) did not stain
positive for DiL-Ac-LDL even when directly incubated with the dye due to the ab-
sence of LDL receptors on the surface of breast epithelial cells (Figure 4-16D). Dual
labeling with DiL-Ac-LDL and PECAM-1 provided optimal separation of two cell
populations. Figure 4-16D illustrates the double stained endothelial cell popula-
tion (blue) providing significant separation from MDA-MB-231 cells in co-culture
(grey).
4.3.2 NanoChannels provide continuous conduits for intercellu-
lar transfer
To analyze the role of nanoChannels in intercellular communication, cross-sections
of MDA-MB-231 (EPI) and endothelial (ENDO) cell co-cultures were analyzed
using transmission electron microscopy (TEM). In Figure 4-18A a nanoChannel
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(white arrow) is seen connecting an epithelial cell to and endothelial cell. TEM
micrograph shows intercellular connectivity between the cell types. Intercellu-
lar connectivity further differentiates nanoChannels from other cellular projec-
tions. NanoChannels are open conduits of communication between two cells.
Protrusions with similar physical dimensions but closed ends are referred to as
cytonemes or filopodial bridges (Figure 4-18B).
To examine transfer of intercellular contents through nanoChannels and corre-
late the kinetics of nanoChannel formation with acquisition of functionality, MDA-
MB-231 cells were loaded with CFSE and then added to DiL-Ac-LDL labeled en-
dothelial cell tubes (Figure 4-18C). The co-cultures were counterstained with phal-
loidin and wheat germ agglutinin (WGA) to label the actin cytoskeleton and plasma
membrane boundaries, respectively. De-convolved volume rendering provided a
3D view of the co-cultures (Figure 4-18C), revealing trafficking of CFSE via nanoChan-
nels formed between the cancer cells and endothelial cells in both 2D (Figure 4-
18B1-B3) and 3D (Figure 4-18B4-B7) settings. nC projections can be seen penetrat-
ing neighboring endothelial cells (white arrow) (Figure 4-18B1,2). Figure 4-18B2 is
a 3D reconstruction of Figure 4-18B1. The nanoChannel burrows through the en-
dothelial cell boundaries, entering the cytoplasmic compartment of a neighboring
endothelial cell. The nanoChannel can be seen depositing CFSE into the endothe-
lial cell cytoplasmic compartment (yellow arrow heads) (Figure 4-18B3).
In a 3D co-culture, a metastatic epithelial cell can be seen invading within the
lumen of the endothelial tube (dotted white arrow) (Figure 4-18B4,5). A nanoChan-
nel projection can be seen extending to the surrounding endothelial cells (Figure 4-
18B7), depositing intercellular contents (yellow arrow heads). These data con-
firm that nanoChannels are able to transfer intercellular contents from metastatic
breast epithelial cells to the endothelium. To provide insight into the frequency of
nanoChannel-mediated intercellular communication, we next sought to quantify
the percentage of the endothelial cell population receiving intercellular transfer
through nCs.
Endothelial cells were dual-labeled with DiL-Ac-LDL and PECAM-1 antibody,
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Figure 4-18: NanoChannels provide intercellular connectivity between cells. (A)
TEM micrograph shows intercellular connectivity between an MDA-MB-231 ep-
ithelial cell (EPI) and a HUVEC endothelial cell (ENDO). (B) Cytonemes versus
nanoChannels. (C) Confocal microscopy images capture nanoChannel-mediated
transfer of cytoplasmic contents. CFSE loaded MDA-MB-231 (EPI) cells (green)
were co-cultured with HUVEC endothelium (ENDO). Transfer of the CFSE dye
was observed after 24-hr co-culture through nCs (solid white arrow). CFSE dye can
be seen within the DiL-Ac-LDL (red) labeled HUVEC cells (yellow arrowheads).
Metastatic breast epithelial cells can be seen invading endothelial vessels (white
dashed arrow).
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Figure 4-19: Quantification of transport of intercellular contents through
nanoChannels. (A) Schematic and (B) graph summarize flow cytometry results
examining intercellular transfer of CFSE from metastatic cells into the endothe-
lium through nCs. Dual cultures control for endocytosis/exocytosis-mediated in-
tercellular transfer. Separate cultures control for background autofluorescence of
endothelial cells. (C) Images illustrate bottom chamber of 0.4[m and 3pm dual
chamber assay. Both pore sizes allow for transport of extracellular vesicles. (D)
The percent intercellular transfer in both chambers was equivalent to background,
illustrating that extracellular vesicles are not mediating the observed intercellular
transfer in co-culture.
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and the percentage of CFSE+ve endothelial cells was measured using flow cytome-
try (Figure 4-19A). The cells were grown in three different configurations, separate,
dual, and co-cultures (Figure 4-19A). In separate cultures the cells are grown in two
separate wells and then combined together during sample collection and run on
the flow cytometer. Separate cultures were used to control for background autoflu-
orescence of the endothelial cells because at no time do they come into contact with
the CFSE labeled MDA-MB-231 cells. As a control for potential endocytic/exocytic
mechanisms of intercellular transfer, the two cell types were grown in separate
compartments in Boyden chambers (dual cultures) that allow for media contact
but do not allow for physical contact between the cells. Expression of CFSE in the
dual-labeled endothelial cells is compared across the three culture types. Figure 4-
19B is a graph summarizing the percentage of the endothelial cell population re-
ceiving intercellular communication. In co-cultures, 43.30±2.35% (p<0.0001) of the
endothelial cell population was found to be CFSE+ve, compared to 14.09±0.69%
and 15.47±1.46% in the separate cultures and dual cultures, respectively.
To ensure that the dual chambers were an appropriate control for endocytotic-
exocytotic mechanisms both 0.4im and 3pum pores-size Boyden chambers were
used. Extracellular vesicles may aggregate making it difficult to fit through smaller
pore sizes. In order to determine if 0.4pm dual chambers allowed for sufficient
diffusion of extracellular vesicles, such as exosomes, a comparison of percent in-
tercellular transfer was performed with both 0.4pum and 3pum dual chambers. Fig-
ure 4-19C shows a representative image of the bottom well of a Boyden chamber
assay. Endothelial cells are DiL-Ac-LDL labeled and MDA-MB-231 cells are loaded
with CFSE. Endothelial cells are grown in the lower chamber while MDA-MB-231
cells are seeded in the upper chamber.
Both pore sizes allow for the exchange of extracellular vesicles. In the 3.0Qm
pore chambers, migrated cells and extracellular vesicles can be seen in the bottom
chamber. However, these migrated vesicles do not lead to transfer of CFSE com-
pared to background autofluorescence measured in endothelial cells grown in sep-
arate chambers. These results confirm that the observed transfer is not occurring
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through endocytotic or exocytotic mechanisms. The background autofluorescence
values observed in 0.4pim and 3.0pim pore chambers are equivalent. Both pore sizes
exhibited similar results, demonstrating that exososomes can cross the pores and
that this mode of communication is not the source of the observed intercellular
communication.
4.3.3 Kinetics of nanoChannel-mediated intercellular transfer
The analysis of nanoChannel growth kinetics in Section 4.2.2.4 examined forma-
tion of nanoChannel projections over a 24-hour period. However, a full under-
standing of nC kinetics requires correlating both form and function. To better un-
derstand nC dynamics, we next sought to correlate nanoChannel development
with acquisition of functionality (Figure 4-20). This analysis was performed by as-
sessing intercellular transport through nanoChannels at multiple time points rang-
ing from Ohrs to 96hrs. Data was collected at thirty minute intervals for the first
hour, at hour intervals from 1-2hrs, two hour intervals from 2-12hrs, four hour in-
tervals from 12-24hr, and at twenty-four hour intervals from 24-96hrs. At each time
point, percent of the endothelial cell population receiving intercellular transfer was
plotted with time (Figure 4-20B).
Temporal quantification of CFSE transfer directly correlated with the kinetics
of nanoChannel formation (Figure 4-20B). Intercellular transfer begins approxi-
mately 4hrs after initiation of co-cultures, coinciding with initial formation of in-
tact nC projections around 3-5hrs (Figure 4-12). Transfer of intercellular contents
occurs primarily between 4-20hrs and remains fairly stable until 72hrs (Figure 4-
20B).
These results provide insight into initiation of nanoChannel-mediated intercel-
lular communication. However, a critical question that remains unanswered is
whether nC transport occurs through active transport, passive transport, or com-
bination of both mechanisms. In addition, another confounding factor in transport
dynamics through nCs is the cytoskeletal arrangement within nC structures. As
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previously described in Section 4.2.2.3, the cytoskeletal arrangement within nCs
may dictate which transport mechanisms dominate: a hollow configuration may
indicate that diffusive mechanisms dominate, while a solid configuration might
suggest an active transport mechanism. To address these questions required mod-
eling of CFSE transport.
CFSE is a small molecule that is foreign to the cellular environment and there-
fore with almost complete certainty is transported through a diffusion based mech-
anism. Therefore, we were able to compare a theoretical diffusion model based on
physical properties of CFSE with the experimental data of CFSE transport in order
to get a first order approximation of transport dynamics within nCs.
To begin this analysis, we derived a concentration versus time plot from our
experimental data (Figure 4-20E). This graph was derived by correlating fluores-
cence intensity with concentration over a 24-hr period. The following assumptions
were made to derive the concentration curve:
1. Concentration of intercellular CFSE is directly proportional to fluorescence
intensity.
2. The intercellular concentration of CFSE is equivalent to the initial concentra-
tion of CFDA-SE in which the cells are incubated.
3. Intercellular CFSE is not significantly degraded over the time scales of inter-
est.
4. There is negligible change in CFSE concentration in the MDA-MB-231 cells
in separate cultures over time. Therefore, the initial concentration is equal to
to the final concentration.
5. The intercellular concentration of CFSE in MDA-MB-231 is >> than the con-
centration of CFSE transferred to the endothelium. Therefore, MDA-MB-231
cells act as an infinite source of CFSE.
With these assumptions, at each time point we estimated the average concentration
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of CFSE in the HUVEC populations isolated from both separate cultures and co-
cultures. Utilizing the expression
X ConcentrationSeparateMDA
MedianFl.HUV EC MedianFl.-mDA
where X represents the average CFSE concentration of the HUVEC population,
ConcerntrationSeparateMDA represents the initial intercellular concentration of CFSE
inside the MDA-MB-231 cells in separate cultures, and MedianF-SepaateMDA and
MedianFl-HUVEC represent the median intensity value of the MDAseparate and HU-
VEC peaks, respectively, the average CFSE concentration within HUVEC cells was
calculated at each time point (Figure 4-20A).
Figure 4-20C shows the percent difference in intercellular CFSE concentration
between MDA-MB-231 cells in co-culture compared to separate cultures at each
time point (pink bars). There was < 10% difference between intercellular CFSE
concentration in MDA-MB-231 cells isolated from separate and co-culture groups
validating the assumption that the MDA-MB-231 cells act as an infinite source of
CFSE and that the intercellular CFSE concentration in the MDA-MB-231 cells is
not changed as a result of transfer. The black region denotes the range of percent
difference between the cultures over time. With this validation we were able to
obtain a relationship between CFSE concentration versus time in the co-cultured
HUVEC cells. The results are given by the graphs Figure 4-20E. The data was
corrected to account for background autofluorescence and experimental variability
by subtracting the separate curve (black curve, Figure 4-20D) from the co-culture
(pink curve, Figure 4-20D) curve producing the final relationship illustrated in
Figure 4-20E. This concentration curve derived from experimental data could then
be compared to a theoretical model of diffusion.
4.3.3.1 CFSE diffusion model
Fick's laws provide a general mathematic description of diffusive transport dy-
namics. The second law of diffusion describes the change in concentration over
242
LengthB. 6
3 0
20 
10.
0 20 40 60 80 100
Time (hrs)
D o 400 
- Separate Co-Culture
S300
200
100'a
Time (hrs)
30
20
10
S 0
TransferI4030
20
10
a-
Co-
'I
'a
Recipient Donor
Concentration
A. ENDO
PECAM-1
Recipient Donor
Intensity
earn L Median FL
HUVEC SEP MDA SEP
Separate
IU 15 2UJ
Time (hrs)
E.
150
S100
50
0sS 5 10 15 20 25
1 Time (hrs)
Recipient Donor
Concentration
Co-Culture
10
5
0
-5
0 5 T0 15 20 25
Time (hrs)
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time and is given by the following expression,
ac
+ V - (CV - DVC) = R(C),
where C is the concentration scalar field in Molar units, t is time in units of seconds,
D is diffusion constant in units of m 2/s, V- is the velocity vector field in units of m/s,
and R is a generation/consumption term (scalar field) of the molecule of interest
in units of Molar/s. Fick's second law will be used as the basis of modeling CFSE
transport through nanoChannels.
Diffusion through a nanoChannel can be modeled as one-dimensional axial
transport as illustrated in Figure 4-21A. In constructing this model, we made the
following assumptions:
1. MDA-MB-231 cells act as the singular CFSE source so at t = 0, X = 0, C = Co
2. NanoChannel walls are impermeable so CFSE can not diffuse radial or cir-
cumferentially, and can only travel in the axial direction. Therefore, diffusion
through the nanoChannel can be considered as one-dimensional axial trans-
port.
3. Crecipient <<C0 , therefore MDA-MB-231 cells can be modeled as an infinite
source, and MDA-MB-231 cell concentration change with time is negligible.
4. At time zero, CFSE is only in the intercellular compartment of MDA-MB-231
cells, and not in nanoChannels or endothelial cells, so that t =0, X > 0, C = 0.
5. At infinite lengths the CFSE concentration is zero, so that t > 0, x = oc, C = 0.
6. CFSE is not consumed or generated in nanoChannels therefore the genera-
tion term (R) is zero.
7. There are no convective forces presents making the V' equal to zero.
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Molecule Diffusion Coefficients
Small Molecule in water 1000-1500pm 2 /s
Carboxyflourescein in water 487±22pm2 /s
Carboxyflourescein in cytoplasm 1624m 2 /s
Small Protein in water 100im2 /S
Protein in cytoplasm 101Pm 2 /S
miRNA in water lOpM2 /S
miRNA in cytoplasm lOpm 2/S
Table 4.2: Diffusion coefficients for different classes of molecules~ 6.
8. NanoChannels are presumably filled with cytoplasmic contents which are
composed of 80% water. At low velocities, water, and therefore cytoplasm,
can be considered incompressible flow.
9. CFSE can freely diffuse from MDA-MB-231 to HUVEC endothelium as un-
bound free molecules.
Applying these assumptions in the limited case of one-dimensional diffusion with
a singular source into the more common form of Fick's second law,
Oc _ 2C
Ot DOx 2 '
where C is the concentration in molar units, t is time in seconds, D is diffusion
constant in units of pm 2/sec, and x is length in units of pm gives the final expression:
C = Co(1 - erf )
2 Dt
where C0 is the initial CFSE concentration loaded in the MDA-MB-231 cells.
Figure 4-21 presents the results of this analysis compared to theoretical data.
Estimation of diffusion constants were taken from the literature and presented in
Table 4.2. CFSE was considered to be analogous to a carboxyfluorescein molecule
in cytoplasm. NanoChannel length was used as the value of x and diffusion was
modeled over a 24hr period. Graph 4-21B is a plot of predicted CFSE concentration
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versus length at varying times. An average nanoChannel length of 31um given in
Table 4.1 was used to generate this graph. At early times, CFSE has only diffused
a small fraction of the length of nanoChannels. At approximately 5hrs, similar to
the behavior of the experimental data, the CFSE molecules have traveled down the
entire length of the nanoChannel and have begun to diffuse into the endothelium.
To probe the dynamics of CFSE diffusion, we next varied the input param-
eters of this model. In all plots experimental data is given by the black curve.
Figure 4-21C and D plot changes in diffusion dynamics of CFSE with changing
nanoChannel length. Setting the diffusion constant at D=0.005pmru 2 /sec, we varied
nanoChannel length over the range of nCs. Intuitively, and supported by the theo-
retical results given in Figure 4-21C and D, CFSE diffuses to the endothelium more
quickly through shorter nCs. Figure 4-21D is a blow up of Figure 4-21C, focusing
only on the longer nCs. The experimental data (black curve, Figure 4-21C,D) of
CFSE transfer represents a statistical average over a population of structures, with
a range of length scales. However, two trends emerge from the plots. The first
trend shows that theoretical data predicting diffusion through longer nanoChannel
structures better correlates with experimental data. This observation is supported
by length scale measurements given in Figure 4-7 which show that the majority of
nCs tend to be long. The second trend is that the diffusion constants used to fit
this data are several orders of magnitude smaller than the values given in the lit-
erature. This trend is further highlighted in Figure 4-21E, which probes the affects
of varying diffusion constants on transport. Figure 4-21E presents results of diffu-
sion constant varied over a constant nanoChannel length. Increasing the diffusion
constant, enhanced the speed of diffusion and also increased the maximum con-
centration achieved in the endothelium by 24hrs. The apparent diffusion constant
that best fits the experimental data is much smaller than values predicted in the lit-
erature. This could imply that CFSE does not freely diffuse or that diffusion is im-
peded within the nanoChannel. The reasons for this impediment may be linked to
the cytoskeletal composition of the nC. This analysis suggests that nanoChannels
may have a more solid configuration, characterized by densely packed cytoskeletal
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proteins that impedes free diffusion.
A densely packed configuration of cytoskeletal proteins within nanoChannels
is further supported when comparing experimental and theoretical CFSE concen-
trations at 24hrs. At early time points, the gray curve given in Figure 4-21E closely
models experimental data. However, at later time points the graph significantly
overshoots the maximum CFSE concentration measured experimentally. The ex-
perimental data plateaus at a concentration of 127nM while the theoretical plot
predicts a concentration of 679nM. The vast difference between these two values
likely arises due to an incorrect assumption made when creating this model. We
initially assumed that CFSE was able to freely diffuse through nanoChannels, how-
ever this may not be the case. Instead diffusion through nanoChannels may be
more analogous to diffusion through a porous medium. An effective diffusion co-
efficient describes the actual diffusive transport accounting for restrictions placed
on free diffusion.
An effective diffusion coefficient is given by the following expression:
De = DEt6I
T
where D is the free diffusion coefficient in units of m2/s, et is the porosity, 8 is the
constrictivity, and r represents the tortuosity. Porosity is the measure of empty
space in a material given by the fraction of the volume of voids over total volume.
Figure 4-21G illustrates a cross-section of a nanoChannel with a dense cytoskeletal
network. There is limited void space in this type of structure making free diffusion
very difficult due to a low porosity. Constrictivity accounts for spatial constraints
affecting diffusion and is calculated by taking a ratio of the diameter of a diffusing
particle to the pore diameter. Tortuosity is a measure of curve being tortuous. Con-
strictivity likely has a negligible effect due to the small particle diameter of CFSE.
However, tortuosity and porosity may significantly contribute to the low effective
diffusion coefficient compared to theoretical diffusions coefficients initially used
for this analysis. For example nanoChannels adopt a varied, often curved, config-
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Figure 4-21: Modeling diffusive transport through nanoChannels (A) Diffusion
through nanoChannels can be modeled as one dimensional axial transport. (B)
CFSE concentration versus length plot in endothelial cells. Intuitively, increasing
nanoChannel length increases time required for CFSE to diffuse through the entire
length of the projection. (C/D) Examines concentration of CFSE in endothelial cells
versus time with changing nanoChannel length or (E) diffusion constant. (F) Con-
centration versus time over the range of possible diffusion constants determined
by fitting the experimental data over the entire range of nanoChannel length. (G)
Based on results of the diffusion model, it can be concluded that nanoChannels
are likely solid structures with limited empty space. The lack of void space sig-
nificantly retards diffusion possibly implying the existence of an active transport
mechanism within nCs.
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uration that results in a high tortuosity. A combination of low porosity and high
tortuosity may contribute significantly to restricted diffusion within nanoChan-
nels. Finally, Graph 4-21F fits the model for the two extremes of nC length scales
to find the possible range of diffusion constants. The effective diffusion constant
may lie within the range from 0.00004pm 2/s - 0.08pm 2/s. How can we explain this
large deviation from theoretical values of CFSE diffusion coefficients in water?
First diffusion coefficients in the cytoplasm are typically one order of magni-
tude lower than diffusion coefficients due to macromolecular crowding caused by
steric restrictions and weak intermolecular interactions6 . CFSE is a small molecule
with an atomic radius of approximately 9.4A so steric constraints are unlikely. A
second contributor to this large deviation results from the large inaccuracy of the
assumption that CFSE freely diffuses when transported through nCs. Due to a
succinimidyl group, CFSE covalently couples to intercellular molecules. There-
fore, bound CFSE does not have the same transport dynamics of free CFSE. For
example, if CFSE were covalently bond to a protein the diffusion coefficient would
be two-orders of magnitude less than free CFSE. However, the effective diffusion
coefficient is 4 to 7 orders of magnitude smaller than would be predicted by trans-
port of bound CFSE. Therefore, covalent bonding of CFSE to intercellular proteins
can not completely account for the dramatic difference in theoretical vs effective
diffusion coefficients.
Other limitations not accounted for by the model is that CFSE may be degrad-
ing in the endothelium. However, this is highly unlikely to occur within the time
scales of interest. In addition, fluorescence intensity may not be directly correlated
with concentration, leading to errors in determining a concentration versus time
plot from experimental data. Also, experimental data represents a statistical aver-
age of a diverse population of nCs, while the ideal model is narrowly constrained
considering only a single projection at a time. Therefore it is unlikely to be a com-
plete representation of diffusion through nCs. To address this limitation, transport
through a single nC must be studied. Lastly, the model does not include the ki-
netics of cytoskeletal rearrangement required for nC projection formation. A more
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robust model would integrate transport membranes with cytoskeletal dynamics.
4.3.4 Transport of synthetic materials and bioorganic macromolecules
through nanoChannels
NanoChannels are a complex mode of intercellular communication with unique
properties. In order to understand the physiological role of nanoChannels, we
sought to understand the range of intercellular contents that could be transported
through these structures. NanoChannels facilitated the trafficking of nanostruc-
tures (quantum dots) (Figure 4-22), intercellular proteins (GFP) (Figure 4-23), cyto-
plasmic organelles (lysosomes) (Figure 4-24), and miRNAs. MicroRNA transport
will be discussed in Chapter 5.
The ability of nCs to transport quantom dots (Qdots), GFP, and lysosomes holds
interesting implications on the physiological roles of these structures and also in-
troduces a mechanism to exploit these structures for therapeutic benefit. Analo-
gous to studies done with CFSE, the MDA-MB-231 cells were loaded with either
Qdots or GFP (through transfection) prior to incubation with DiL-LDL labeled en-
dothelial cells (red). In Figure 4-22A and Figure 4-23, transported intercellular
contents are indicated with yellow arrows in 3D reconstructions of de-convolved
fluorescence images. Figure 4-22A and Figure 4-23 reveal fluorescent cargo within
the endothelial cell bodies. Figure 4-22 schematic (A) and graph (B) quantify in-
tercellular transport of Qdots which supports imaging data.
Transport of GFP highlights that active proteins can be transported through
nC structures. Transport of proteins may temporarily alter the downstream ex-
pression of recipient cells, acting as a mechanism of acquired drug resistance or
pathological angiogenesis. The ability of metastatic cells to transfer biomolecules
that may transform recipient cells holds implications on how tumors manipulate
the surrounding cell population to promote tumorigenesis. Furthermore, Qdot
transfer holds interesting implications on how nanoChannel-mediated communi-
cation can be capitalized on for novel therapeutic strategies. One possibility is that
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Figure 4-22: Intercellular transport of Qdots through nCs. (A) 3D volume re-
construction illustrating quantum dot nanoparticles in DiL-Ac-LDL labeled en-
dothelial cells. Yellow arrowheads indicate endothelial cells containing transferred
nanoparticles. (B/C) Intercellular transfer of Q-dots was confirmed via flow cy-
tometry. In co-cultures, 48.10t7.200% of the endothelial cell population was posi-
tive for quantum dots compared to 9.570±0.4300% in separate cultures (p<0.05).
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Figure 4-23: Intercellular transport of GFP through nCs. nCs provide a mecha-
nism of transfer of soluble cytoplasmic proteins. GFP is detected within endothe-
lial cells (indicated with yellow arrow heads).
nanoparticles can be uptaken by the cancer cells and transferred to other malig-
nant cells as well as the surrounding stroma. There may be therapeutic strategies
that can take advantage of this novel form of intercellular communication, espe-
cially capitalizing on the propensity of metastatic cells to form connections with
the endothelium.
NanoChannels are also a conduit for organelle transfer. Figure 4-24 summa-
rizes the results from studies examining organelle transport through nCs. These
studies were performed by co-culturing two populations of MDA-MB-231 cells
(Figure 4-24A). Half of the population was stained with a fluorescent cell mem-
brane dye (CMD+ve), while the other half of the population was stained with a
fluorescent dye that labels lysosomes (CMD-ve). The two cell populations were
co-cultured for 24hrs and the prescence of fluorescently labelled lysosomes was
determined in each population (Figure 4-24B and C). As expected, in separate cul-
tures, the CMD+ve population was negative for fluorescently labelled lysosomes
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Figure 4-24: Organelle transfer through nanoChannels. (A) Schematic illustrat-
ing experimental design used to detect intercellular transfer of lysosomes through
nC structures. MDA-MB-231 cells were fluorescently labeled with LysoTracker
Red and then co-cultured with MDA-MB-231 cells labeled with a green cell mem-
brane dye (CMD) at a 1:1 ratio. (B/C) Fluorescently labeled lysosomes were
tracked using flow cytometry. The presence of fluorescently labeled lysosomes
were assessed in CMD+ve and CMD-ve cells. In co-culture, 53.867±7.451% of the
CMD+ve cells were positive for fluorescently labeled lysosomes (p<0.0001), com-
pared to 2.613±0.478% of the CMD+ve cells in the separate cultures. The detection
of labeled lysosomes in CMD+ve cells is likely due to the natural autofluorescence
background of endothelial cells.
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with only 2.613±0.478% of the population detected as positive (likely secondary
to the natural autofluorescence of endothelial cells). In contrast, a high percent-
age of (53.867±7.451%) the cell population in co-cultures was positive for stained
lysosomes. Furthermore, the increase of labelled organelles in these cells was mir-
rored by a cognate decrease in lysosomes in the CMD-ve group. This dcrease is
likely due to transfer of lysosomes from the CMD-ve cells in co-culture and to the
CMD+ve cells. Recall that this group represents the half of the co-culture popula-
tion originally labelled with a fluorescent lysosomal dye. Although not explicitly
demonstrated nanoChannels are likely the mechanism by which transport of lyso-
somes occurs in this model system.
NanoChannel-mediated communication appears to be universally conserved
mechanism of intercellular communication. Stromal cells are also able to form
nC structures by which intercellular contents can be communicated. Figure 4-
25A illustrates nanoChannels or nanoChannel-like structures formed between en-
dothelial cells. A projection formed by an endothelial cell (Figure 4-25A3) can be
seen bypassing two breast epithelial cells (white arrows, Figure 4-25A2) to instead
form a connection with a distant endothelial cell (yellow dotted arrow, Figure 4-
25A2). Since a full characterization was not done on these structures, it is un-
clear if these projections are nanoChannels or another related structure. Regard-
less of their identify, these structures too function in intercellular communication.
When loaded with CFSE, the HUVEC endothelial cells were able to transfer inter-
cellular contents to metastatic MDA-MB-231 breast epithelial cells. However, the
percentage of the population receiving this reverse transfer was lower than com-
munication from metastatic epithelial cells to the endothelium (Figure 4-25B/C).
This may be the result of endothelial cells preferentially forming connections with
other endothelial cells, possibly in response to the same growth factors that drive
metastatic cells to preferentially form nanoChannel connections with the endothe-
lium.
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Figure 4-25: Reverse transfer through nanoChannel like structures. (A) SEM mi-
crographs show connections formed between two endothelial cells. (B) Schematic
and (C) graph of intercellular transfer from endothelial cells to metastatic breast
epithelial cells. Only a small percentage of the epithelial cell population received
intercellular communication from the endothelium.
255
100 EPI CC 100 ENDO
80 .480
60 Sep 19.8 r-) 6 0O
40 40
20 20
1F I 3 51 7 1 3 5 7
101 103 105 107 101 103 105 101_
CFSE CFSE
..... . .. ......... ........
4.4 Disruption of nanoChannels using cytoskeletal poly-
merization inhibitors
NanoChannel-mediated communication allows for the transport of a diverse ar-
ray of intercellular contents, including small molecules, cytoplasmic proteins, or-
ganelles, and synthetic materials. To further validate the role of nanoChannels
in intercellular communication, we hypothesized that pharmacological inhibitors
that blocked polymerization of a / -Tubulin and F-Actin cytoskeletal proteins would
disrupt nanoChannel structures. To validate this hypothesis, we tested effects of
the a/3-Tubulin cytoskeletal inhibitor, docetaxel, and the F-actin cytoskeletal in-
hibitors, latrunculin A and cytochalasin D, on nanoChannel formation by MDA-
MB-231 cells. Graphs 4-26 A, B, and C illustrate results from dose titrations with
latrunculin A, docetaxel, and cytochalasin D, respectively, examining the effects
of these drugs on intercellular transport. The drugs were tested in MDA-MB-231
monoculture, where half of the MDA-MB-231 cell population was labeled with
CFSE and the other half was unlabeled. The metastatic epithelial cells were pre-
treated with inhibitors for 24 hours prior to adding the cells to the culture as out-
lined in Figure 4-17. The percent of the cells receiving intercellular transfer was
quantified and plotted. The data was normalized to control.
At low concentrations all the cytoskeletal inhibitors decreased intercellular trans-
fer. Interestingly, at high concentrations the percent of intercellular concentration
actually increased in some of the drug groups. It's unclear why this increase oc-
curred, however, there are two likely factors responsible for this trend. The first is
that nanoChannel projections are increased due to stress. High concentrations of
drug may induce physiological stresses that result in projection formation which
in turn leads to increased intercellular transfer. Similar cytoskeletal projections
were found to increase in response to stress conditions. The second possibility is
that high concentrations of drug destabilize the cytoskeletal membrane so much
that the membrane actually disrupts. In this case CFSE would be able to freely
diffuse from the cell to the recipient cell population independent of the presence
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Figure 4-26: Optimization of pharmacological inhibition of nanoChannel struc-
tures. Dose titrations with cytoskeletal polymerization inhibitors (A) latrunculin
A, (B) docetaxel, and (C) cytochalasin D were performed in a MDA-MB-231 mono-
culture system. (D) Combination of the c/-Tubulin and F-Actin polymerization
inhibitors resulted in decreased intercellular communication compared to each
drug alone.
of nanoChannel projections.
The most effective concentration of each drug was selected and a combination
of a//3-Tubulin and F-Actin polymerization inhibitors were tested. Combinations
of the inhibitors achieved slightly greater inhibition compared to either drug alone
Graphs 4-26D.
These optimization studies next enabled testing of the cytoskeletal polymer-
ization inhibitors in an epithelial-endothelial co-culture format. From the thera-
peutic perspective of metastatic cancer, it is much more advantageous to disrupt
epithelial-endothelial cell-cell communication. Therefore, we tested the optimized
combinations in the co-culture platform. The data is summarized in Figure 4-27
and Figure 4-28.
MDA-MB-231 cells were pre-treated for 24 hours with a combination of doc-
etaxel (500pM) with latrunculin A (30nM) or cytochalasin D (50nM), before ad-
dition to the endothelial vessels as described in Figure 4-17. Combination of the
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Figure 4-27: Combination of a/6-Tubulin and F-Actin polymerization inhibitors
disrupt nanoChannel-mediated communication between metastatic breast ep-
ithelial cells and the endothelium. (A) NanoChannels are visibly disrupted after
exposure to cytoskeletal polymerization inhibitors. (B/C) Drug combinations with
small molecule inhibitors of F-actin (latrunculin A and cytochalasin D) and micro-
tubules (docetaxel) were used to disrupt nC structures leading to a decrease in
intercellular communication (p<0.0001)
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Figure 4-28: Quantification of nanoChannel disruption by cytoskeletal polymer-
ization inhibitors. Drug combinations with small molecule inhibitors of cytoskele-
tal components F-actin (latrunculin A and cytochalasin D) and microtubules (doc-
etaxel) were used to disrupt nC structures leading to (A) a decrease in percentage
of EPI-ENDO nC+ve cells (p<0.0001), and (B) reduction in the number of nC struc-
tures per cell. (C-F) Drug treatment prevented the formation of nCs (p<0.01) (C)
and also affected lengthening of the structures (p<0.0001). High power field (hpf)
cytoskeletal inhibitors disrupted nanoChannel structures as shown in Figure 4-
27A. This data supported decreased intercellular transfer quantified using flow
cytometry. Figure 4-27 B and C show a schematic and graph summarizing the per-
cent of the HUVEC population receiving intercellular transfer at each concentra-
tion. As shown in Figure 4-27C, there was a significant reduction in nanoChannel-
mediated communication following drug treatment. Physical disruption of nanoChan-
nel structures (Figure 4-27A) corresponded to a decrease in nC functional activity.
Intercellular transfer of CFSE decreased by 42.0±2.8% (p<0.0001) and 56.6±0.4%
(p<0.0001) following pre-treatment of metastatic cells with combination of doc-
etaxel (500pM) with latrunculin A (30nM) or cytochalasin D (50nM), respectively.
Furthermore, drug treatment inhibited the total number of nC structures (Figure 4-
28C), as well as, the length of immature nanoChannels (Figure 4-28F). However,
there was no effect on the length of mature (tethered) nanoChannels (Figure 4-
28E). Taken together these data suggest that drug treatment prevents both initi-
ation and lengthening of nCs but once intact structures are formed they are not
disrupted by drug. Additionally, heterotypic epithelial-endothelial nCs were more
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Figure 4-29: Heterotypic versus homotypic nC structures. (A/B) Inhibiting
actin tubulin cytoskeletal has a greater effect on nanoChannels formed in het-
erotypic EPI-EPI co-cultures (MDA-MB-231/HMEC) and heterotypic EPI-ENDO
co-cultures (MDA-MB-231/HUVEC) than homotypic EPI-EPI co-cultures (MDA-
MB-231/MDA-MB-231). (C) This difference may highlight differences in mecha-
nisms of formation of heterotypic vs. homotypic nCs.
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Figure 4-30: Treatment with low-dose F-Actin and tubulin polymerization in-
hibitors does not affect cell viability. (A-C) Graphs show concentration effect
curve for docetaxel, latrunculin A, and cytochalasin D in MDA-MB-231. (D-E) Vi-
ability studies using combination of F-actin and tubulin polymerization inhibitors
showed no effect on cell proliferation at (D) 24h and (E) 48hrs.
sensitive to the combination of actin-tubulin cytoskeletal inhibitors as evident by
reduction in the number of nanoChannel+ve cells by <60% (p<0.0001) (Figure 4-
28A), as well as, a decrease in the average number of EPI-ENDO nanoChannels
formed per cell, compared to homotypic EPI-EPI nanoChannels (Figure 4-28B).
The differential drug effects may arise from distinct mechanisms of formation of
EPI-EPI and EPI-ENDO connections. EPI-ENDO nanoChannels likely form only
through de novo protrusions mediated by actin-tubulin cytoskeletal machinery, while
EPI-EPI connections may be the result of de novo projections, as well as, remnants
of incomplete cytokinesis. Inhibition of cytoskeletal projections in heterotypic cul-
ture is more effective at reducing nanoChannel communication as shown in Fig-
ure 4-29. This result further emphasizes that nCs in homotypic versus heterotypic
cultures likely resulting from different mechanisms.
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4.4.1 Cytoskeletal polymerization inhibitors do not affect cellular
proliferation, cellular migration, or induce apoptosis
To confirm that inhibition of intercellular communication was due specifically to
disruption of nanoChannels rather than non-specific drug effects, we studied the
effects of these inhibitors on cellular proliferation, cellular migration, and apopto-
sis at drug concentrations found to effectively inhibit nanoChannel formation. If
drug inhibition significantly disrupted cellular physiology, the decline in intercel-
lular transfer could potentially be a consequence to cellular death or an inability
of cells to migrate and interact with the endothelium. These outcomes would be
independent of nanoChannel formation and would not validate the role of nCs in
intercellular transport. Figure 4-30, Figure 4-31, Figure 4-32 provide the results
of studies examining changes in proliferation, migration, and cell viability, respec-
tively, in response to drug treatment.
Graphs 4-30 A, B, and C show the results of dose titrations with docetaxel, la-
trunculin A, and cytochalasin D, respectively, on cellular proliferation. Cell viabil-
ity was measured using an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) assay. The MTS assay is a colorimetric method
for assessing cell viability. The MTS tetrazolium reagent is reduced by NADPH or
NADH to produce a colored formazan product. NADPH and NADH are produced
by dehydrogensase enzymes present in metabolically active cells. The quantity of
colored formazan product can be measured using absorption spectroscopy and is
directly proportional to the number of living cells in the culture.
NanoChannel formation is inhibited at low drug concentrations with minimal
effects on cellular viability. There were no changes in cell viability for each of the
drug concentrations utilized in the aforementioned studies (i.e. 500pM docetaxel,
30nM latrunculin A, and 50nM cytochalasin D). These conclusions are highlighted
by dose-titration plots which show no change in cell viability at the concentrations
used to inhibit nanoChannels (Graphs 4-30 A, B, and C). Furthermore, even drug
combinations had no effect on the percentage of viable cells. Graphs 4-30 D and E
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Figure 4-31: Treatment with low-dose F-actin and tubulin polymerization in-
hibitors does not affect cellular migration or invasion. (A) Images and (B) results
from migration assay. Drug treatment did not affect cellular migration or invasion
as assessed using a Boyden chamber assay. (A) Images were taken of migrated
cells that have crossed the membrane toward the bottom chamber. (B) To test in-
vasion, basement membrane was added to the Boyden Chambers, in contrast to
migration studies, which are performed without basement membrane matrix. (C)
Schematic illustration of Boyden Chambers. Cells can migrate from the top to the
bottom chambers through membrane pores.
summarize results from viability studies at 24 and 48 hrs, respectively, performed
at the drug concentrations used to inhibit nanoChannels using single inhibitors as
well as drug combinations.
Similar results were observed when assessing drug effects on cellular migration
or invasion. Figure 4-31 show the results from Boyden chamber migration studies.
Figure 4-31C is a schematic representation of the Boyden Chamber studies. The
Boyden chambers are similar to the dual chambers described previously. How-
ever, in these studies, 8pm pore size chambers were used that enabled the cells to
freely migrate from the top to the bottom chamber. The images in Figure 4-31A
show the migrated cells that have crossed the membrane pores. Both migration
and invasion assays were conducted. The migration assays were performed over
three days without addition of a basement membrane matrix to the Boyden cham-
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ber. In contrast, the invasion assays were performed over six days with basement
membrane added. The migration assay measures the inherent ability of cells to
move, while the invasion assay assesses both migration and invasion. The inva-
sion assays are performed with matrix added to the wells, as a result, in order for
cells to move from the top to bottom chambers, the cells must be able to proteolyt-
ically breakdown the matrix. This requirement provides a surrogate measure of
invasive capacity.
Drug treatment at the concentrations of interest did not affect cellular migration
or invasion (Figure 4-31B). This is an important result because the ability of cells
to interact with the endothelium in 3D cultures requires preserved migratory and
invasive properties. Furthermore, formation of nC structures seems to be strongly
correlated with intact EEC interactions. Consequently, nC structure formation is
linked to invasive and migratory capacities. Drug treatment does not affect these
properties, further emphasizing that the pharmacological inhibition of intercellu-
lar communication is nanoChannel specific.
Finally, the effect of drug treatment on apoptosis was assessed using an an-
nexin V assay. Annexin V binds to phosphatidylserine residues on the surface of
cells that are present during cellular apoptosis. Figure 4-32 summarizes the results
of this analysis. Figure 4-32A shows representative images of annexin V staining.
Fluorescence was quantified over several images and summarized in Figure 4-32B.
The results of this analysis show that drug treatment did not induce apoptosis in
the cells 24 hours post drug treatment. The results of the proliferation, migration,
and viability studies further emphasize that drug treatment specifically inhibited
nanoChannel formation and that the observed decrease in intercellular communi-
cation was due to nC inhibition and not non-specific drug effects.
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Figure 4-32: Treatment with low-dose F-actin and tubulin polymerization in-
hibitors does not induce apoptosis. (A) Images and (B) quantification of Annexin
V staining used to assess induction of apoptosis by the inhibitors. The combination
of F-actin and tubulin polymerization inhibitors did not induce apoptosis follow-
ing 24 hours of drug exposure. The data was collected 24 hours after drug was
removed.
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Figure 4-33: Exocytosis inhibitors do not affect intercellular transfer through
nCs. Pre-treatment of MDA-MB-231 cells with verapamil and nilotinib had no ef-
fect on intercellular communication. These drugs target multidrug resistant trans-
porters that are known to expel small molecules (such as CFSE or drugs) from the
cells. The limited effect of these drugs further support that that observed intercel-
lular transfer is likely not do to endocytosis-exocytosis mechanisms.
4.4.2 Pharmacological inhibition of potential endocytosis/exocy-
totic mechanism
Dual chambers were introduced into the study design as a mechanism to exclude
endocytotic and exocytotic mechanisms of intercellular communication. However,
to directly probe these mechanisms we also utilized pharmacological inhibitors of
these mechanisms. Verapamil and nilotinib were selected because these drugs are
inhibitors of efflux transporters. Multidrug resistance (MDR) is a common char-
acteristic seen in many cancer tumor types. MDR is caused by efflux of drugs by
ATP-binding cassette transporters, the most common being P-glycoprotein. Ver-
apamil is a voltage dependent calcium channel blocker that was found to inhibit
efflux pumps such as P-glycoprotein3 1 0 . Nilotinib is a tyrosine kinase inhibitor also
found to inhibit multidrug resistance transporters 1 . Cancer cells express high
levels of multidrug resistant pumps 312 , therefore we postulated that CFSE may be
pumped out of the cells using these transporters, resulting in the observed inter-
cellular transfer. In order to exclude exocytotic mechanisms, we performed dose
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Figure 4-34: Intercellular transfer in normal, tumorigenic, and metastatic cells
lines. Normal mammary epithelial cells (HMEC) and tumorigenic cells (MCF-7)
transport intercellular contents significantly less than metastatic cells. This result
correlates with quantification results showing fewer projections with the endothe-
lium in primary and tumorigenic cell lines compared to metastatic cells.
titrations with each of the two inhibitors prior to co-culture. There were minimal
effects on percent intercellular transfer with verapamil and no effect with nilotinib.
These results are analogous to results seen with dual chambers (Figure 4-33).
4.5 Comparison of nC-mediated communication in pri-
mary, tumorigenic, and metastatic cell lines
We have shown the ability of metastatic breast epithelial cells to form nC connec-
tions with the endothelium. Metastatic cells preferentially form nC connections
with endothelial cells compared to other epithelial cells. However, does this phe-
notype correspond to functional activity of the nCs? To address this question, we
examined the ability of normal and tumorigenic breast epithelial cells, HMEC and
MCF-7, respectively, to transfer intercellular contents through nanoChannels. The
results of this analysis are given in Figure 4-34 and Figure 4-35.
All the cell types show intercellular transfer in co-culture cells compared to
control dual chambers (Figure 4-34). Primary epithelial cells transfer intercellu-
lar contents to 12.39±1.079% of the endothelial cell population. Compare that to
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Figure 4-35: Inhibiting cytoskeletal protein polymerization does not reduce in-
tercellular transport in normal and tumorigenic, non-metastatic epithelial cells.
(A) Percent intercellular transfer in endothelial cells following pretreatment of
breast epithelial cells with cytoskeletal inhibitors. Normal and tumorigenic cell
lines show no inhibition of intercellular transfer with drug, implying that this
communication may be due to alternative mechanisms. (B) Percent intercellular
transfer normalized to control.
16.34t2.1% and 39.374±2.496% transfer of intercellular contents by tumorigenic
and metastatic cells, respectively. There is an enhanced ability of metastatic cells
to transfer intercellular contents to endothelial cells compared to primary and tu-
morigenic cells (Figure 4-34). The results of this analysis correlates with previously
described quantification of nC structures showing an increase in both percentage
of nC expressing cells and number of nC structures per cell in metastatic cell lines
compared to normal and tumorigenic non-metastatic cells (Figure 4-15).
We assessed the ability of cytoskeletal polymerization inhibitors cytochalasin
D and docetaxel to inhibit intercellular transfer in the primary and tumorigenic
cell lines (Figure 4-35). Interestingly, these inhibitors were not able to inhibit in-
tercellular transfer in the primary epithelial cell co-cultures and only resulted in
minimal inhibition in the tumorigenic cells. This data suggest that the intercellular
transfer observed in endothelial cell co-cultures with primary and tumorigenic ep-
ithelial cells may not be nanoChannel mediated. An alternative hypothesis is that
nanoChannel structures in these cell populations may not be composed of both
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tubulin and actin cytoskeletal proteins therefore are not susceptible to inhibition
with these inhibitors.
4.6 NanoChannel-mediated communication occurs in
co-cultures with primary human dermal microvas-
cular blood and lymph endothelial cells
We next examined nanoChannels formed by MDA-MB-231 cells in co-culture with
primary human dermal microvascular blood and lymph endothelial cells. These
cells represent matched pairs isolated from human plasma. The ability for MDA-
MB-231 cells to form nC connections with true primary epithelial cells further high-
lights the clinical relevance of the observed phenotype and supports the notion
that nCs may play a role in metastatic progression.
Figure 4-36 illustrates epithelial-endothelial cell co-cultures with the primary
epithelial cells. Figure 4-36A shows scanning electron micrographs of monocul-
tures and co-cultures with primary endothelial cells. Co-culture images capture
interactions between MDA-MB-231 cells and primary human blood and lymph
endothelial vessels. Similar to phenotypes with HUVEC endothelial cells, the
presence of metastatic epithelial cells increases endothelial angiogenic parameters
leading to widening and lengthening of vessel structures. Furthermore, like HU-
VEC co-cultures, there is a high degree of epithelial-endothelial cell interactions.
The MDA-MB-231 cells were observed preferentially interacting with the endothe-
lium, elongating along the vessel structures (solid white arrows). In contrast to
the blood endothelium, the primary lymph cells formed disorganized vessel struc-
tures with less cell-cell adhesion compared to vascular endothelial vessels, cor-
relating with physiological differences between lymphatic and vascular endothe-
lium. NanoChannels form between metastatic cells and both types of primary
human endothelial cells (dashed white arrows).
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Figure 4-36: Metastatic breast cancer cells form nanoChannel connections with primary human blood and lymph en-
dothelial vessels. (A) SEM images capture interactions between MDA-MB-231 cells and primary human blood and lymph
endothelial vessels. Similar to phenotypes observed in 3D co-cultures with HIUVEC vessels, MDA-MB-231 cells were ob-
served elongating along the primary endothelial vessel structures (white arrows). There is significant vessel widening
in vascular and lymphatic endothelial vessel co-cultures compared to monoculture. The lymph endothelial cells formed
disorganized vessel structures with less cell-cell adhesion compared to vascular endothelial vessels, correlating with physi-
ological difference between vascular and lymphatic endothelium. In agreement with previous results, nanoChannel struc-
tures formed between metastatic cells and primary endothelial cells (dotted white arrows). (B) As previously described,
MDA-MB-231 cells preferentially formed nanoChannel structures with primary blood endothelial cells and primary lymph
endothelial cells at a ratio of 1.503±0.266 and 3.525±0.690 (p<0.0001) compared to other epithelial cells, respectively. Sta-
tistical analysis performed using a 2-way ANOVA (n>300). (C) There is also an increase in nC structures formed per cell in
EPI-ENDO interactions compared to EPI-EPI interactions, 2.695±0.560 (p<0.0001) and 4.057t0.783 (p<0.0001), respectively.
Statistical analysis was performed using a 2-way ANOVA (n>300).
...........
MDA-MB-231 cells preferentially formed nC structures with primary blood en-
dothelial cells and primary lymph endothelial cells at a ratio of 1.503+0.266 and
3.525±0.690 (p<0.0001) compared to other epithelial cells, respectively. This data
directly correlates with trends observed in HUVEC co-cultures (Figure 4-36B).
Furthermore, there was also an increase in nC structures formed per cell in EPI-
ENDO interactions compared to EPI-EPI interactions, 2.695±0.560 (p<0.0001) and
4.057±0.783 (p<0.0001), respectively (Figure 4-36C).
nC-mediated intercellular transfer also occurred between metastatic cells and
primary endothelial cells (yellow arrowheads) (Figure 4-37). Fluorescence imag-
ing show CFSE within the endothelial cell compartment (yellow arrow heads, Fig-
ure 4-37A). These results were quantified using flow cytometry. The percentage of
CFSE+ve cells in dual-labeled endothelial cell populations was determined (Fig-
ure 4-37B and C). MDA-MB-231 cells were also co-cultured with smooth muscle
cells to demonstrate that the nC-mediated communication is specific to endothelial
cells and does not occur with other stromal cells. Vascular endothelial cells were
identified with immunostaining for PECAM-1 /DiL-Ac-LDL, Thrombomodulin/DiL-
Ac-LDL, or PECAM-1/Thrombomodulin. Lymph endothelial cells were identi-
fied with immunostaining for PECAM-1/DiL-Ac-LDL, LYVE-1/DiL-Ac-LDL, or
PECAM-1/LYVE-1. Graph 4-37C shows percentage of CFSE+ve endothelial cells
averaged over three studies. In both primary blood and primary lymph endothe-
lial co-cultures there was significant intercellular transfer compared to control.
However, in co-cultures with smooth muscle cells there was no transfer of CFSE
between cell types. These data further highlight that nC-mediated communication
may underly important interactions between metastatic cells and the endothelium
which are unique from interactions with other stromal cells.
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Figure 4-37: NanoChannels transfer intercellular cargo to primary endothelial cells. (A) nC-mediated intercellular trans-
fer occurs between metastatic cells and primary endothelial cells through nanoChannel structures (yellow arrow heads).
(B) Intercellular transfer was quantified using flow cytometry to determine the percentage of CFSE+ve cells in dual-labeled
endothelial cell populations. Vascular endothelial cells were identified with immunostaining for PECAM-1/DiL-Ac-LDL,
Thrombomodulin/DiL-Ac-LDL, or PECAM-1/Thrombomodulin. Lymph endothelial cells were identified with immunos-
taining for PECAM-1/DiL-Ac-LDL, LYVE-1/DiL-Ac-LDL, or PECAM-1/LYVE-1. (C) Percentage of CFSE+ve endothelial
cells were averaged over three studies. Removing background signal, 17.76%±1.099% of the primary endothelial cell pop-
ulation and 12.29%±2.075% of the primary lymph endothelial cell population were CFSE+ve. Statistical analysis was per-
formed using a 2-way ANOVA and Bonferroni post-test.
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4.7 Conclusion
In summary, this chapter describes a novel form of heterotypic intercellular com-
munication between cancer cells and the host endothelium, wherein tumor cells
can transfer intercellular contents through nanoscale projections directly into neigh-
boring endothelial cells. NanoChannel connections can transport a diverse array of
intercellular contents, including small molecules, cytoplasmic proteins, organelles,
and synthetic nanoparticles. NanoChannels have unique length scales and cy-
toskeletal composition that differentiates these structures from other cytoskeletal
projections.
Interestingly, metastatic cells form more nC structures than primary and tu-
morigenic cells. Furthermore these connections preferentially form with the en-
dothelium. nC-mediated communication can be inhibited by cytoskeletal poly-
merization inhibitors at concentrations that do not affect cellular proliferation, cel-
lular migration, or induce apoptosis.
NanoChannel communication exhibits interesting properties which may en-
hance metastatic progression. In order to better understand nC-mediated com-
munication, we next sought to explore transport of genetic materials through these
structures. Intercellular communication of genetic material offers a powerful mech-
anism by which nC-mediated communication by metastatic cells can produce phys-
iological changes in the endothelium that promote cancer progression.
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Chapter 5
NanoChannel-mediated
communication is a mechanism for
miRNA transport
Multiple studies have highlighted the role of microRNAs as signaling regulators
in tumor progression and angiogenesis313 . For example, targeting miR-10b and
miR-196b leads to significant defects in angiogenesis-mediated tumor growth.
Additionally, miR-10b is highly expressed in metastatic breast cancer cells and pos-
itively regulates cell migration and invasion 315 . Similarly, miR-132 was reported to
be highly expressed in the endothelium of human tumors and hemangiomas but
was undetectable in normal endothelium102 .
Intercellular communication of cytoplasmic RNAs has been recently identi-
fied as a powerful mechanism of cell-cell communication. These studies have
focused on the role of carrier-mediated signaling (e.g. exosomes, ectosomes) in
mediating tumor-endothelial interplay through the trafficking of microRNAs dur-
ing metastatic progression1 35 . For example, microRNAs packaged in microvesicles
were transferred from tumor to endothelial cells and have been shown to prime the
latter for morphological changes14 2. Furthermore, microRNAs have been shown
to directly regulate endothelial cell recruitment in metastasis. MiR-126 has been
identified as a negative regulator of endothelial cell recruitment, acting through
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the IGFBP2/IGF1/IGF1R and GAS6/MERTK signaling pathways 28 7. Endogenous
suppression of miR-126, present in many cancers, enhances recruitment of the en-
dothelium, while overexpression of miR-126 has been shown to inhibit endothe-
lial cell recruitment 2 7. To further emphasize the reciprocal interactions between
metastatic cells and the endothelium, miR-126 activity can be directly regulated
by the endothelium287. Interestingly, the use of antagomirs, engineered oligonu-
cleotides, led to microRNA silencing in an in vivo context 30 6 .
Transport of microRNAs through nanoChannels presents a novel mechanism of
RNA-mediated intercellular communication. Unlike previously described mecha-
nisms of genetic intercellular communication135 , communication of miRNA through
nCs offers a highly specific and controlled mechanism by which a tumor cell can
regulate stromal populations in a profound and persistent manner. Unlike ex-
osomal transfer of microRNAs, miRNA transport through nanoChannels would
be highly specific and localized, enabling a metastatic cell to directly alter neigh-
boring cells. This mode of communication combines the advantage of specificity
offered by the direct modes of cell-cell communication that require physical con-
tact, with the versatility, diversity of cargo, and the long-range effects offered by
indirect forms of cell-cell communication. Communication through nCs may po-
tentially be a mechanism utilized by tumor cells to transform stromal populations.
It is commonly know that the stroma of a tumor is genetically altered 274 . How-
ever, the mechanism underlying these transformations are largely unknown. Of
particular interest in cancer progression and metastasis is how tumor cells initiate
the angiogenic switch and the conversion of normal endothelium to pathological
endothelium. It has long been established that the endothelium of tumor is trans-
formed1 22 . However, the mechanisms by which this transformation occurs have
yet to be established 2 .
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5.1 NanoChannels are a mechanism for physical inter-
cellular translocation of miRNAs
Our previous data revealed that in addition to CFSE, nanoChannels facilitated the
trafficking of nanostructures (Figure 4-22), proteins (GFP) (Figure 4-23), and even
organelles (lysosomes) (Figure 4-24); therefore, we rationalized that maximal am-
plification of signaling could potentially be created through the transfer of mi-
croRNAs. We investigated whether nanoChannels can act as a physical bridge
for microRNA-mediated intercellular communication by assessing nanoChannel-
mediated transport of miR-132. MicroRNA 132 was chosen as a proof of concept
because it has been implicated in pathological angiogenesis as a regulator of the
angiogenic switch129 . MicroRNA 132 functions through p120RasGAP to induce
neovascularization 29 . Its expression was found to be high in embryonic stem cell
models and also in the endothelium of tumors and hemangiomas129 . In contrast,
expression of miR-132 in normal healthy endothelium was found to be low. MiR-
132 acts by inhibiting p120RasGAP, which increases RAS activity, inducing angio-
genesis129. P120RasGAP is expressed in normal but not tumor endothelium. Lastly,
inhibition of miR-132 with an a-mir resulted in restoration of p120RasGAP expres-
sion. This leads to inhibition of angiogenesis and a decrease in tumor burden in an
orthotopic metastatic breast cancer model 129.
Figure 5-1 is an overview of microRNA transfer studies. MicroRNAs are trans-
fected into the MDA-MB-231 cells followed by treatment with cytoskeletal inhibitors.
The metastatic breast epithelial cells are then added to the pre-formed endothelial
tubes and co-cultured for 36hrs. Following co-culture, the endothelial cells are
isolated from the matrix for subsequent analysis. The percentage of miRNA+ve
cells, effects of pharmacological inhibition of nCs, and the functional activity of
the microRNAs are then determined.
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Transport of microRNA was initially analyzed using confocal fluorescence mi-
croscopy. Control microRNA and miR-132 are labeled with Cy3. Control mi-
croRNA and miR-132 were transfected in the MDA-MB-231 cells. The Cy3-labeled
microRNAs were detected within the nanoChannels, 36hrs post co-culture incu-
bation. Figure 5-2 provides representative images of nanoChannel-mediated mi-
croRNA transport in both a 2D and 3D co-culture format. After co-culturing LDL
(green) labeled endothelial cells with MDA-MB-231 cells containing Cy3-labeled
miRNAs, the co-cultures were counterstained with phalloidin (purple) and DAPI
+ WGA (blue). The images show microRNAs within nanoChannel structures trav-
eling toward an endothelial cell (white arrows). MicroRNAs within the cytoplasm
of endothelial cells are indicated with yellow arrow heads. Transport of microR-
NAs through nCs does not appear to be regulated. NanoChannels allow for the
transport of a control miRNA and miR-132.
MicroRNA transfer was quantified using flow cytometry in a similar manner as
CFSE transfer. Figures 5-3A and B show schematic and graph of flow cytometry
results, respectively. Co-cultures with untransfected MDA-MB-231 cells, MDA-
MB-231 cells transfected with miR-132, and control miRNA were analyzed. Again,
LDL and PECAM-1 dual-labeled endothelial cells were isolated and the percentage
of endothelial cells expressing fluorescently labeled microRNAs were quantified.
Figure 5-3B shows the percent of the endothelial cell population receiving intercel-
lular transfer averaged over several studies.
Trafficking of miRNAs was observed in both the miR-132 (p<0.01) and control
miRNA (p<0.05) groups at 36hrs as indicated by a shift in the co-culuture curve
(pink) compared to background fluorescence seen in the duals (green) (Figure 5-
3A). There was 9.66±1.01% and 23.98±2.60% of the endothelial cell population
receiving intercellular transfer in the control miRNA dual and co-culture groups,
respectively. Similarly, 8.82+0.53% and 21.18±1.93% of the endothelial cell pop-
ulation receiving intercellular transfer in the miR-132 dual and co-culture groups,
respectively. Compare this to percent seen in the untransfected groups, 7.49±1.04%
and 6.85±0.93% in the dual and co-culture groups, respectively. As expected, no
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Control miRNA
Figure 5-2: NanoChannels are a mechanism for physical translocation of miR-
NAs. Confocal images showing nanoChannel (nC)-mediated transfer of control
miRNA and miR-132 from MDA-MB-231 cells (EPI) to endothelial cells (ENDO).
LDL (green) labeled endothelial cells were co-cultured with Cy3-labeled miRNA
transfected MDA-MB-231. Co-cultures were counterstained with phalloidin (pur-
ple) and DAPI + WGA (blue). nCs (white arrows) are conduits for direct cell-to-cell
transfer of miRNAs to endothelial cells (yellow arrow heads). 3D reconstructions
show miRNAs within the nC structures.
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miRNA-132
shift was seen in co-cultured samples in the untransfected groups. There is no sta-
tistical difference between measurements made in dual cultures from the control
miRNA and miR-132 groups and co-cultures from the untransfected groups. These
results emphasize that there is no intercellular transfer observed in dual cultures
secondary to an endocytotic/exocytotic mode of intercellular communication.
To confirm that miRNA transfer was occurring through nanoChannels and not
an alternative mechanism, pharmacological disruption of the nC projects with cy-
toskeletal polymerization inhibitors was performed. Similarly to the studies per-
formed with CFSE, a combination of low dose a / -Tubulin and F-Actin polymer-
ization inhibitors were used to disrupt miRNA transfer through nC structures. The
results of inhibition of nC-meditated intercellular transfer after pre-treatment with
docetaxel (500pM) combined with latrunculin A (30nM) or cytochalasin D (50nM)
are given in Figure 5-3. The horizontal black lines in Figure 5-3A indicates the per-
cent of intercellular transfer in co-culture groups after drug treatment. Figure 5-3B
shows that intercellular transport of miRNAs reverted to baseline (dual groups)
after treatment with a combination of tubulin and actin inhibitors, validating the
role of nanoChannels in miRNA trafficking. Compare this to no change in the
untransfected group.
5.1.1 Kinetics of miRNA transfer
Interestingly, trafficking of miRNAs occurred less frequently and more slowly than
diffusion-mediated transport of CFSE. Figure 5-3B shows percent intercellular trans-
fer for the untransfected, control miRNA (24hrs), control miRNA (36hrs), and miR-
132 (36hrs) experimental groups. A lower percentage of the endothelial cell pop-
ulation received intercellular transfer of miRNAs compared to CFSE transfer. In
studies examining CFSE transfer, 43.30t2.35% (p<0.0001) of the endothelial cell
population was found to be CFSE+ve, compared to 15.47+1.46% in the dual cul-
tures. Correcting for background by removing the percent intercellular transfer
observed in the duals, approximately 30% of the endothelial cell population re-
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Figure 5-3: NanoChannel-mediated miRNA transport confirmed with flow cy-
tometry. (A) Schema and (B) graph show quantification of nC-mediated mi-
croRNA transfer using flow cytometry. In co-culture (dual cultures were in-
cluded as controls), endothelial cell populations were isolated and percentage of
miRNA+ve cells were determined. Pharmacological disruption of nC structures
inhibited miRNA transfer.
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Figure 5-4: Revist of CFSE transport over time.
ceived intercellular transfer of cytoplasmic contents, while approximately 15% of
the endothelial cell population received transported miRNAs. Furthermore, there
was a significant increase in miRNA transfer at 36hrs compared to the observed
transfer at 24hrs. This contrast the results seen with CFSE transfer where intercel-
lular transfer of CFSE remained fairly constant after 24hrs (Figure 5-4). The dif-
ference in transport kinetics in miRNA trafficking may indicate that an alternative
mechanism may be involved in miRNA transport through nC structures. For ex-
ample, there may be regulatory mechanism underlying miRNA transport through
nCs. However, it is not likely specific to any particular miRNA sequence since
transport dynamics of the control and miR-132 groups are similar. Alternatively,
the difference in kinetics of intercellular transport may be due to detection limi-
tations of the Cy3-labeled miRNAs. Possibly a higher concentration of miRNAs
is required in order to achieve a signal-to-noise ratio allowing for sufficient and
reproducible detection. However, this hypothesis is not likely because microRNA
signal could be detected at 24hrs over baseline. Therefore, assuming that these
alternative mechanisms are not occurring, the difference observed between CFSE
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and miRNA transport may point to an active transport mechanism for trafficking
of miRNAs via motor proteins, such as myosin V. Indeed, transport of RNA by
motor proteins has been reported in other systems.
Using a similar approach as adapted to study the kinetics of CFSE transfer, we
developed a model of nC-mediated miRNA transport. Again, we used fluores-
cence intensity as a surrogate measure of concentration. The MDA-MB-231 cells
were transfected with a known concentration of 50pM of labeled oligonucleotide.
Using the relationship given by:
X ConcentrationSeparateMDA
MedianFl-HUVEC MedianFl-MDA
where CocentrationSeparateMDA is the initial intercellular concentration of miRNA
inside the MDA-MB-231 cells in separate cultures, X is the average miRNA con-
centration of the HUVEC population, and MedianFlSep.rateMDA and MedianFlHUVEC
are the median intensity values of the MDAseparate and HUVEC peaks, respec-
tively; we estimate that at 36hrs, the final concentration of miRNA is approxi-
mately 30pm.
Figure 5-5A predicts miRNA transport kinetics through nCs. Similar to CFSE
transfer, we predict diffusion of miRNAs will begin at approximately 5hrs after
intact nanoChannels are formed and continue for 36hrs, reaching a concentration
of 30pm in the endothelial cells. We then compared this prediction to plots gener-
ated using the previously derived model from Fick's second law that yielded the
following expression (Figure 5-5B,C):
C = Co(1 - erf x
2 vDt
where C0 is the initial miRNA concentration loaded in MDA-MB-231 cells in M
units, t is time in s, D is diffusion constant in units of M2 /s, and x is length in
units of m. Table 4.2 provides diffusion coefficients for miRNA in water and cyto-
plasm. However, from the previous analysis we determined that in nanoChannels
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Figure 5-5: Kinetics of miRNA transport through nCs. (A) Predicted concen-
tration versus time plot of miRNA diffusive transport through nCs. (B/C) The
predicted curve was compared to a theoretical diffusion model. (B) Plot of concen-
tration versus time and (C) length comparing the theoretical model to the predicted
data.
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the effective diffusion coefficient is given by the expression,
De = DEt6
T
where et is the porosity, 5 is the constrictivity, and -r represents the tortuosity, and
may be 4 to 7 orders of magnitude smaller than diffusion coefficients determined
in free space. The effective diffusion coefficient may be decreased due to com-
plex geometry and spatial constraints present within nCs. Furthermore, the size
of fluorescently conjugated miRNA molecules is significantly bigger than CFSE
molecules. Recall that constrictivity may further limit diffusive transport of miR-
NAs through nCs. Constrictivity, accounts for spatial constraints due to particle
size.
Figures 5-5B and C illustrate the results of this analysis, plotting concentra-
tion versus time and length, respectively. There is a significant difference in trans-
port dynamics in free diffusion of miRNAs in water (purple line) and cytoplasm
(gray line) compared to diffusion of miRNAs through nanoChannels (blue and
pink lines). These results clearly show that in the time scales of interest, diffu-
sion alone cannot achieve the expected concentration of miRNAs in the endothe-
lial cells. Even when accounting for an appropriate effective diffusion coefficient,
diffusion alone cannot achieve the concentration of microRNAs measured within
endothelial cells. This discrepancy highlights the possibility that an additional
mechanism may be involved in miRNA transport through nCs.
Molecular motor proteins are responsible for the transport of a diverse array of
cellular cargo including proteins, lipids, organelles, and miRNAs. They function
in a wide array of critical cellular processes such as cell division, signal transduc-
tion, and embryonic development 316 . There are three classes of cytoskeletal motor
proteins: myosin, an actin-based motor, and dynein and kinesin, two microtubule
motors3 1 6 (Figure 5-6). All motor proteins are composed of a dimer of two heavy
chains with an ATP catalytic domain that enables their function. They each have
diverse functions, however, with several similarities. The majority of kinesin mo-
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Figure 5-6: Molecular motor proteins are responsible for transport of diverse
cargo. There are three classes of motor proteins: myosin, an actin-based motor,
and dynein and kinesin, two microtubule motors.
tors are unidirectional walking toward the positive end of the microtubule, typi-
cally toward the periphery of the cell. This transport is referred to as anterograde
transport 316 . In contrast, dynein motors move toward the negative end of the mi-
crotubule in a retrograde fashion 316. Microtubule motor proteins maintain their
interaction with tubulin through electrostatic force between the positively charged
head of the motor protein and the negatively charged carboxyl groups on tubulin.
The myosin family of molecular motors hold diverse functions ranging from mus-
cle movement to organelle transport316. Myosin V is a unique member of this fam-
ily that has been recently implicated in miRNA transport308. Kinesin and myosin
V are both processive motors, meaning they are able to continuously move down
the cytoskeletal protein without dissociating317.
In this analysis we will use myosin V to model active transport through nanoChan-
nels. However, any of these motors may be implicated since nanoChannels con-
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tain both actin and tubulin cytoskeletal components. Myosin V mediated trans-
port along actin filaments is considered bi-directional due to the network of cross-
linked actin fibers. Furthermore, studies have also shown that microtubule motors
also exhibit bi-direction transport. Using the mathematical description derived by
Smith et a1318 , we modeled combined diffusion and active transport through nCs.
This model makes the following assumptions:
1. One-dimensional motion
2. A particle is considered a motor protein bound to an miRNA molecule
3. Particles move at a steady velocity
4. Binding and detachment from filaments can be modeled with first-order rate
kinetics
5. Transport is bi-directional
6. Motion occurs directly following binding
7. Maximum loading of motor proteins
8. Starting concentration in the endothelium of labeled miRNA is zero
The result of this analysis yields a facilitation factor given by the expression:
L (
F= (1+ Of),2 10f f of f
where F is the flux facilitation over free diffusion, L is nanoChannel length in units
of m, 'off is the mean path free length in units of m, l, is the mean path length
on a filament in units of m. icr and loff can be determined from the following
relationships, v/k' and (')I, respectively, where v is the motor speed of particles
on the filaments in units of m/s, D is the diffusion coefficient in units of M 2 /8,
and k and k' are the attachment and detachment rates to filaments of one polarity,
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respectively, with units of 1/s. This relationship can be used to scale the diffusion-
only transport to predict the combined contribution of both diffusion and active
transport.
Figure 5-7 illustrates the results of this analysis. Figure 5-7A models the trans-
port of miRNAs with increasing motor protein speed ranging from 40nm/s - 400nm/s.
As the motor protein speed increases, there is significant enhancement of miRNA
transport speed. It is clear that in order for the concentration of miRNA to reach
the predicted value in the endothelium, an active transport mechanism is required.
Due to the complex geometry of nanoChannels, diffusion is severely impeded (Fig-
ure 5-7B, blue). It's only when an active transport mechanism is included (Fig-
ure 5-7B, pink) does the model more closely resemble experimental results. The
summed contribution of both active and passive transport is given by the solid
black line. Compare this curve to the predicted transport curve (dashed line).
Active transport dominates in the context of severely limited diffusion. There
are some unique aspects of the transport dynamics predicted with this analysis.
First, there is a longer lag in transport than with diffusion-only transport. This
might result from the requirement of both an intact nC structure as well as an
intact cytoskeletal transport chain.
Interestingly, miRNAs are transported to less endothelial cells than CFSE. This
may be due to a variety of reasons. First, miRNA transport may be regulated com-
pared to non-specific intercellular contents such as CFSE. An additional considera-
tion is the timescale of the experiment. If miRNA transport kinetics are dependent
on an active transport mechanism it may require more time to achieve intercellular
transport of a larger percent of the endothelial cell population. There is a signifi-
cant time delay in transport observed in the active transport models. This can be
rationalized by the requirement of both an intact nC structure, as well as an in-
tact cytoskeletal transport chain. It's possible that nCs are formed between cells
but that no miRNAs are transported due to a lack of an intact cytoskeletal trans-
port network. This is especially true for longer nanoChannels. Figure 5-5C shows
transport in longer nanoChannels. It requires significantly more time to achieve
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Figure 5-7: Modeling active transport. An active transport mechanism may be re-
sponsible for the transport of miRNAs through nCs. (A) Graph plotting increased
concentration versus time with increasing motor protein speed. (B) Transport ki-
netics through nanoChannels combining contributions from both active and pas-
sive transport mechanisms. (C) Only with an active transport mechanisms within
nanoChannels can the theoretical model match the concentration of miRNAs in
endothelial cells measured experimentally.
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Figure 5-8: Proposed active transport mechanism of miRNAs. MiRNAs may be
transported down nanoChannels using motor proteins.
detectable levels of miRNA for longer nanoChannel structures. Figure 5-5C shows
that it take up to 96hours hours for miRNAs to travel down longer nanoChannels.
Possibly, we could detect transport of miRNAs to a higher percentage of the en-
dothelial cell population at longer time points. In nanoChannels, it may be that
at early time points, diffusion dominates. However, at longer times, active trans-
port begins to dominate through nCs, providing significant additive benefits com-
pared to diffusion alone. Figure 5-8 illustrates active transport of miRNAs through
nanoChannels.
5.1.2 Transport of miRNAs are confirmed using PCR
Using a fluorescently tagged miRNA oligonucleotide, we have demonstrated that
nanoChannels are a mechanism of microRNA transport. We next sought to quan-
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tify the transferred oligonucleotide sequence via PCR. Quantification of the miRNA
sequence using PCR was used to further confirm the presence of oligonucleotide.
This confirmation is important because it excludes the possibility that the flow cy-
tometry and imaging studies are detecting a dissociated fluorescent tag instead of
the oligonucleotide sequence of interest.
We began by determining the appropriate endogenous control to use in quanti-
fying transport of miR-132. Figure 5-9 shows Ct values for ubiquitously expressed
endogenous controls in endothelial cells. It was critical to choose an endogenous
control that was not regulated by the epithelial-endothelial interactions that occur
in co-culture. There was no difference in expression of RNU44 and hsa-mir-16-1
in dual and monoculture conditions, however, there was a significant difference in
RNU48 expression in the two culture formats. These results indicate that RNU48
expression may be regulated by soluble factors secreted by epithelial cells, and
therefore is not an appropriate endogenous control to use. Either RNU44 or hsa-
mir-16-1 would be appropriate to use in our studies. We eventually concluded that
RNU44 was the best candidate.
Figure 5-10 shows the results of the PCR analysis. MDA-MB-231 cells were
transfected with miR-132 and a-miR-132 oligonucleotides prior to addition to en-
dothelial cell vessels. After 36 hours, the LDL and PECAM-1 dual labeled en-
dothelial cell populations were isolated and sorted into miRNA+ve and miRNA-
ve groups. The expression of miR-132 in these groups was compared to HUVEC
monoculture controls.
Metastatic cells increase expression of miR-132 through two mechanisms: sol-
uble factors acting through the VEGFR pathway 129 and direct nC-mediated trans-
port of microRNAs. nC-mediated transport of miR-132 and a-miR-132 led to a 5x
increase (solid red) (p<0.0001) and 26x decrease in miR-132 expression (p<0.0001)
compared to miRNA-ve samples, solid blue bar and striped blue bar, respectively.
This corresponds to an increase of 544.1+52.79% (p<0.0001) and decrease of 3262+943%
(p<0.01) in copies miR-132 oligonucleotides, for the miR-132 and a-miR-132 groups,
respectively. This data further strengthens the previous results, demonstrating the
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Figure 5-9: Selecting an endogenous control. The endogenous control used to
analyze expression of miR-132 was selected based on minimal differences in ex-
pression in monoculture versus co-culture. Ideally, expression of the endogenous
control in the endothelium will not be changed by the presence of metastatic cells.
role of nCs in miRNA transport. These results indicate that actual oligonucleotide
was transferred. As expected, miR-132 groups showed an increase in miR-132 ex-
pression, while a-miR-132 showed a decrease.
In previous studies, microRNA-132 expression has been shown to be regulated
in a VEGFR dependent manner129 . Consistent with the findings implicating MDA-
MB-231 conditioned media-induced activation of the VEGFR pathway, miR-132
expression is up-regulated from baseline in dual cultures. Compare the miR-132
expression in HUVEC monoculture control (gray bar) and dual (solid green bar).
This data suggests that the miR-132 pathway is activated by soluble factors re-
leased by MDA-MB-231 cells. This activation was inhibited by a-miR-132 oligonu-
cleotide (striped green bar) (p<0.0001).
Direct transfection of miR-132 (black) and a-miR-132 (light blue) in endothelial
cells act as positive and negative controls, respectively. Fold change in these stud-
ies was determined compared to endothelial cell transfection with control miRNA
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Figure 5-10: PCR of miR-132 confirms transport of miRNAs via nCs. Schema
shows experimental design for RT-PCR detection of miR-132 in endothelial cells
under different experimental conditions. MDA-MB-231 cells transfected with miR-
132 and a-miR-132 were co-cultured with endothelial tubes. FACS isolated en-
dothelial cell populations were analyzed for expression of miR-132. MiR-132+ve
cell populations (solid red) show 5x increase compared to miR-132-ve populations
(solid blue)(p<0.0001), while a-miR-132+ve cells (striped red) show 26x decrease
in miR-132 expression (p<0.0001) compared to a-miR-132-ve cells (striped blue).
Direct transfection of miR-132 (black) and a-miR-132 (light blue) in endothelial
cells act as positive and negative controls, respectively. Upregulation of miR-132
from baseline was observed in dual culture due to VEGFR pathway activation
(solid green) which could be inhibited with a-miR-132 (striped green). Fold change
was determined compared to endothelial cell transfection with control miRNA
(gray).
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(gray). As expected, miR-132 expression was similar in the miRNA-ve cell popu-
lations from both miR-132-ve and a-miR-132-ve co-culture group. This is not sur-
prising because this population represents the cells that did not receive intercellu-
lar oligonucleotides. Surprisingly, however, the miR-132 expression in miRNA-ve
cell population was 446.5t55.65% (p<0.01) and 685.0±146.8% (p<0.001) higher in
the miR-132 and a-miR-132 groups, respectively, than levels of miR-132 expres-
sion in dual chambers. These results suggest that additional mechanisms may be
regulating miR-132 expression in co-cultures. One possibility is that physical con-
tact between the metastatic cells and the endothelial vessels increases expression
of miR-132 through nC transport of intercellular contents, but not the fluorescently
labeled microRNA. Studies examining transport of CFSE suggests that intercellu-
lar communication through nanoChannels occurs more frequently then is captured
with fluorescently labeled microRNAs. Presumably, there may be other intercellu-
lar contents that are transported through nCs that affect miR-132 expression other
than the assayed oligonucleotide.
5.2 Transported miRNAs have functional activity
To confirm that the transported microRNAs were physiologically active, endothe-
lial cells receiving intercellular transfer were isolated from co-cultures, and the
downstream targets of miR-132 were assayed via flow cytommetry. Recent work
has shown that miR-132 leads to increased Ras activation through down regulation
of p120RasGAP 129. Endothelial cells receiving nC-mediated transport of miR-132
showed a decrease in expression of p120RasGAP and an increase in pAKT (S473)
(Figure 5-11). The reverse was observed when using a-miR-132 oligonucleotide
(Figure 5-11A). These finding correlate with miR-132 inhibition of p120RasGAP
and subsequent activation of the Ras pathway leading to up-regulation of pAKT.
These results were confirmed via PCR (Figure 5-11B). Figure 5-12 shows p120RasGAP
and pAKT (S473) expression in both the MDA-MB-231 and HUVEC cell popula-
tions. The miR-132 group is indicated in black, the control group in gray, and the
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Figure 5-11: NanoChannels transport physiologically active miRNA oligonu-
cleotides. (A) FACS analysis shows nC-mediated transfer of miRNAs leads to
changes in p120RasGAP and pAkt (S473) expression downstream in endothe-
lial cell populations isolated from co-cultures. Bar graphs show decreased
p120RasGAP expression in the miR-132+ve cell populations and increased expres-
sion in the a-miR-132+ve cell populations, while further downstream miR-132 pos-
itively regulated pAKT expression. Data shown is mean ±SEM. (B) Expression of
p120RasGAP was confirmed via PCR.
a-miR-132 group in light blue. Expression patterns in both the MDA-MB-231 and
HUVEC cells are analogous, the only difference being slightly lower expression of
miR-132 in the epithelial cells compared to the endothelial cell population. This
data implies that the microRNAs transfected into the MDA-MB-231s are being ex-
pressed, resulting in changes in downstream pathways measured by p120RasGAP
and pAKT (S473). This data would suggest that the microRNAs once transfected
into the cells are released into the cytoplasm of the MDA-MB-231s, where they
can exert cellular activity. Contrast this to transport of the microRNAs if they
remained in the transfected lipid vesicles. In this situation, expression of miR-
132 oligonucleotide in MDA-MB-231 population would likely not mirror what is
seen in the HUVEC endothelial cell population because the microRNAs would be
trapped within the transfected lipid vesicles. Therefore, these microRNAs would
be unable to exert effects on cellular expression. Taking all this data together sug-
gests that physiologically active microRNAs are transported through nanoChan-
nels and transport of these oligonucleotides can be inhibited using cytoskeletal
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Figure 5-12: P120RasGAP and pAKT expression in MDA-MB-231 and HUVEC
endothelial cells. The expression of p120RasGAP and pAKT in MDA-MB-231 cells
mirrored expression patterns in HUVEC endothelial cells, suggesting that microR-
NAs are physiologically active within the metastatic cells. This data would suggest
that the microRNAs once transfected into the cells are released into the cytoplasm
of the MDA-MB-231 cells, where they can exert cellular activity. (A) Schema and
(B) graph examining expression in MDA-MB-231 and HUVEC cells.
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small molecule inhibitors.
Finally, in order to confirm that changes in p120RasGAP expression was oc-
curring due to transport of miR132 through nanoChannels and not the result of
VEGFR receptor activation by soluble factors secreted from MDA-MB-231 cells, we
analyzed p120RasGAP expression in co-culture after inhibition of the VEGFR path-
way. The schematic and graph (Figure 5-13A,B) show expression of p120RasGAP
in HUVEC control sub-populations, dual populations, and co-culture populations
both with and without VEGFR inhibitor. As previously described, the HUVEC
monocultures are indicated with purple bars, the dual populations are indicated
with light green bars, and co-culture populations are indicated with pink bars.
Figure 5-13A and B show no change in p120RasGAP expression in dual groups
compared to co-culture populations. Furthermore, when treated with a VEGFR
inhibitor, no change in p120RasGAP expression in either dual or co-culture popu-
lation. Together this data supports previous studies concluding that p120RasGAP
regulation is due to nanoChannel mediated transport of microRNAs and not through
transfer of soluble factors from the MDA-MB-231 to the endothelial cell popula-
tion, in turn activating the VEGFR pathway.
The vessel structures were also quantified to ensure that treatment with VEGFR
inhibitors did not affect endothelial tube morphology which may indirectly alter
p120RasGAP expression through an nC independent pathway. It was important to
ensure that the cells were physiologically viable and that the inhibitors were only
affecting the VEGFR receptor pathway leaving other functions in the endothelial
cells untouched. As described in Chapter 3, the nodal area, vessel length, and ves-
sel width were quantified after exposure to O.1 p M and 1pM of the VEGFR inhibitor,
vatalinib.
The results of this analysis is given in Figure 5-13C, which highlights that there
are no significant changes in any of the angiogenic parameters after drug treat-
ment. Therefore, we can conclude that the physical form of the vessel structures
are not altered by drug treatment, despite significant inhibition of VEGFR phos-
phorylation at 6 hours.
297
A. 
-VEGFRi +VEGFRi B.
101 103 105 10
o 0
1.5-
1.0.
0~5
0.0 1L
EDual ECo-Culture
-VEGFRi +VEGFRi
I j C.
1.5 .5I
- Z I
z 00CControl 0.1PiM 1.OPM
.~1.5~So "11.0
0.5
Control 0.1sM 1
D.
1.5-
S1.0.
1110.5 __
0.01 11i
.RM Control O.1sM 1.0sM Control 0.lisM 1.0pM2hr 6hr
Figure 5-13: Inhibiting VEGFR signaling does not alter measured p120RasGAP expression in endothelial cells. (A) FACS
data examining p120RasGAP expression following inhibition with vatalinib. (B) The VEGFRi did not alter p120RasGAP ex-
pression in dual versus co-cultures, indicating that the increase in p120RasGAP seen in miR-132 studies is due to miRNA
transfer and not through a VEGFR mechanism. (C) Low dose inhibition of VEGFR signaling does not alter normal en-
dothelial cell morphology in co-cultures. (D) The concentrations of drug used in these studies inhibited VEGFR signaling
as measured by detection of VEGFR phosphorylation via western blot.
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5.3 Conclusion
Transport of the microRNAs through nanoChannels is a unique mode of intercel-
lular communication because nCs enable directed and specific transport of inter-
cellular materials via a highly controlled mechanism allowing one population to
transform neighboring cell populations in a very potent and long term manner. In
contrast to similar forms of cell-cell communication, for example exosomes, this
mechanism of miRNA transfer demonstrates functional activity of this communi-
cation in the secondary cell population. Much of the work done examining exo-
somal transfer of RNAs demonstrate very little functional activity of transported
RNAs. Instead these studies emphasize the role of the released nucleotides as
biomarkers of disease as opposed to mediators of disease. Much insight can be
gained from understanding the mechanisms that underlie miRNA transport and
cancer pathogenesis, as well as downstream effects of this form of communica-
tion. If indeed microRNA transport through nanoChannels is mediating a trans-
formation of endothelial cell populations, this offers a unique and underexplored
opportunity to target both tumor angiogenesis as well as metastatic progression.
The ability of nC structures to transport microRNAs offers a potent mecha-
nism by which metastatic cells can utilize nanoChannels in order to promote can-
cer pathogenesis. What is unique about transport of microRNAs is that unlike
transport of proteins or other small molecules, a microRNA can exert its effect for
long durations of time, and since one microRNA regulates many pathways, the
effects of a transported microRNA can be quite pronounced, unlike the singular
effect, for example, of the transport of one particular protein.
299
Chapter 6
NanoChannel-mediated
communication occurs in vivo and
may present a novel mechanism for
pathological angiogenesis
6.1 Introduction
The pioneering work of Juda Folkman established the intimate connection be-
tween cancer progression and angiogenesis. His work and the work of others have
demonstrated that tumor growth is strongly regulated by the 'angiogenic switch.'
Tumors will cease to grow unless they can successfully recruit vessels to provide
the blood flow necessary to meet the metabolic demands of a quickly growing
tumor. Not only are tumors able to recruit endothelium, but it has been estab-
lished that the endothelium in a tumor is genetically altered compared to normal
endothelium"'. However, there is no definitive mechanism explaining how this
transformation occurs.
We have previously described a model system that characterizes the unique in-
teractions between metastatic cells and the endothelium. Using this model system,
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we elucidated a novel form of communication through thin cytoskeletal projec-
tions called nanoChannels. NanoChannels can transport a variety of contents in-
cluding small molecules, soluble proteins, organelles, and most interestingly miR-
NAs.
In our continued characterization of nCs, we sought to understand if nanoChannel-
mediated communication leads to physiological changes in the endothelium con-
sistent with pathological angiogenesis. We also sought to demonstrate the occur-
rence of nC-mediated transport in an in vivo context.
6.2 Evidence of in vivo nanoChannel-mediated com-
munication
We hypothesized that metastatic cells transfer intercellular cargo to endothelial
cells in vivo, and that disruption of these structures reduces metastatic lesions by
preventing endothelial-epithelial cell interactions that are important for intravasa-
tion and extravasation.
To determine the role of nanoChannel mediated cellular transfer in vivo, we
injected CFSE loaded MDA-MB-231 cells intravenously in CD1 nude mice. The
animals were then sacrificed at 18, 24, 48, and 72hrs. Lung and liver tissue was
isolated from each mouse and the presence of injected metastatic cancer cells was
determined using H&E staining (Figure 6-1). At the time points of interest, there
was very little evidence of invasion of the MDA-MB-231 cells in the liver tissue,
therefore, only representative images from H&E stained lung samples are given in
Figure 6-1. Metastatic MDA-MB-231 cells can been seen in the lung tissue at 18hrs.
At early time points, predominantly single cells are observed in the lung tissue.
Within the vessel structures, cancer cells are evident identified by their large cell
bodies, multiple nuclei, and alignment along the side of the endothelial cell vessel.
By 24hrs small groups of metastatic cells can be seen within the mouse endothelial
vessels. By 48hrs and 72hrs there is evidence of micrometastases forming within
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Figure 6-1: H&E images isolated from mouse experimental lung metasta-
sis model. Metastatic MDA-MB-231 cells can be seen within the mouse lung
parenchyma at 18hr, 24hr, 48hr, and 72hr. The MDA cells are highlighted with
a dashed black outline. At 18 hours single cells can be seen within the lung tissue,
by 24hrs small groups of cells are isolated, at 48 and 72 hr there is evidence of small
micrometastases forming.
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the tissue. Hemorrhage can be seen within the lung tissue at late time points,
which is evidence of microemboli formation.
Once the presence of the metastatic cells within the lung tissue was confirmed,
evidence of in vivo intercellular communication was examined. To begin this anal-
ysis, lung tissue was stained with VWF, CD34, and CD31 markers used to identify
the endothelial cells. Confocal images of the mouse lung tissue isolated at the
time points given above were used to identify nanoChannel-mediated communi-
cation. Figure 6-2 provides representative confocal images of immunostained lung
tissues. In these images, MDA-MB-231 cells are seen in green and the endothelial
cell vessels are highlighted in red and marked with dashed outlines. NanoChannel
projections can be seen forming as early as 18 hrs. The nanoChannels are outlined
with a solid white line and yellow arrows show evidence of transport. By 24hrs,
the metastatic breast epithelial cells can be seen leaving and extravasating outside
the endothelial vessels into the lung parenchyma. By 48 hrs small micrometaste-
ses are being formed. Cells can been seen in clumps along the vessel, potentially
within a thrombus, or also beginning to invade the surrounding lung parenchyma.
At this time point, there is evidence of several nanoChannel projections showing a
significant amount of transfer in the neighboring endothelial cell populations. By
72hrs, frank micrometasteses were found within the lung parenchyma. The en-
dothelial vessels are indicated with dashed white lines and the micrometasteses
are outlined with dashed yellow lines. SEM images illustrate nCs in vivo (Figure 6-
3, which under close inspection appear identical to projections detected in vitro
(Figure 6-4).
Evidence of intercellular transfer identified in the confocal images was fur-
ther validated by isolating lung endothelial cells and quantifying the percentage
of CFSE+ve cells using FACS. Figure 6-5 summarizes the results of this analysis.
Endothelial cells were isolated using magnetic CD31 beads and the percentage
of CFSE+ve cells were measured 48hrs post injection. Not surprisingly only a
small, but significant, percentage of the endothelial cell population was CFSE+ve.
This gave increased confidence that the observed intercellular transfer was likely
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Figure 6-2: Nanochannel (nC)-mediated transfer of intercellular contents in an in
vivo metastatic breast cancer model. MDA-MB-231 cells were loaded with CFSE
(green) and injected into the tail vein of CD1 nude mice. The mice were sacri-
ficed at the indicated time points and the lungs were removed, fixed, and stained.
Endothelial cells (red) were triple-stained with vWF, CD34, and PECAM-1 (white
dashed outline). 3D confocal reconstructions demonstrate nCs penetrating the en-
dothelial cells and transferring CFSE dye (white solid outline). Examples of inter-
cellular transfer are indicated with yellow arrowheads. MDA-MB-231 cells can be
seen migrating out of the endothelial vessels 24hrs post-injection. Micrometastases
began to form by 72hrs (yellow dashed outline).
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Figure 6-3: In vivo nanoChannel projections captured with SEM micrographs.
The figure shows a metastatic breast epithelial cell, highlighted in yellow, extend-
ing an nC projection to the endothelium, highlighted in purple. The endothelium
is identified due to the presence of red blood cells in the endothelial cell lumen.
Metastatic breast epithelial cells are loaded with gold nanoparticles in order to
identify these cells in the tissue.
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Figure 6-4: High magnification view of nanoChannels in vitro. High magni-
fication SEM micrographs show nanoChannels extending from metastatic breast
epithelial cells to the endothelium in in vitro cultures. These nanoChannels look
similar to structures observed in vivo, which further confirms that the structures
observed in the in vitro model system are similar to the structures that are formed
in vivo.
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Figure 6-5: In vivo intercellular transfer was reduced after pre-treatment with cy-
toskeletal polymerization inhibitors. Endothelial cells were isolated from mouse
lungs 48hrs post-injection and the level of transfer was quantified using FACS.
Intercellular transfer was reduced by 43% (p<0.001).
nanoChannel-mediated.
To definitely confirm that nCs were involved in the observed transport in vivo,
the MDA-MB-231 cells were pre-treated with cytoskeletal polymerization inhibitors
prior to systemic injection within the mouse. Small molecule pharmacological in-
hibition of nanoChannels with 500pM Docetaxel combined with either 30nM La-
trunclin A or 50nM Cytoklasin D significantly decreased the intercellular trans-
fer of CFSE in vivo (Figure 6-5), suggesting that indeed this observed intercellular
transfer is of nanoChannel origin. Interestingly, low metronomic dose of taxanes
have been reported to be clinically effective 315 , which could potentially arise from
the disruption of nanoChannel-mediated intercellular communication.
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6.3 Communication through nanoChannels leads to in-
crease in pathological angiogenesis both in vitro
and in vivo
Tumor endothelium is physiologically distinct from endothelium found in healthy
tissue exhibiting both genotypic and phenotypic alterations. We next evaluated
if nanoChannel-mediated intercellular communication can modify a normal en-
dothelial cell by examining changes in expression of pathological angiogenic mark-
ers. We evaluated expression of two of the most ubiquitously expressed patho-
logical angiogenesis markers CD137 and CD276 7 . CD137 and CD276 have been
shown to be upregulated in tumor endothelium as well as in other states of patho-
logical angiogenesis, for example, in chronic inflammation0 7 . We analyzed expres-
sion of CD137 and CD276 in endothelial intercellular transfer+ve and intercellular
transfer-ve cell populations. Figure 6-6 summarizes the results of this analysis.
Interestingly, we observed an overexpression of CD137 and CD276 in endothelial
cells in vivo that were positive for physical intercellular communication. The up-
regulation of tumor endothelial markers CD137 and CD276 becomes very promi-
nent when analyzing intercellular+ve versus intercellular-ve population (Figure 6-
6).
We then tested if the upregulation of pathological angiogenic markers can be
inhibited with cytoskeletal polymerization inhibitors (Figure 6-7). Indeed pre-
treatment of MDA-MB-231 cells with 500pM docetaxel combined with either 30nM
latrunculin A or 50nM cytochalasin D decreased both the percentage of cells ex-
pressing CD137 and CD276 and the number of CD137 and CD276 receptors on
the cell surface as measured by a decrease in median fluorescence. Taken together
these results reaffirm that the observed increase in expression of pathological an-
giogenesis markers is secondary to communication through nC projections.
An upregulation of pathological angiogenesis markers in endothelial cells re-
ceiving communication from the metastatic MDA-MB-231 cells was also observed
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Figure 6-6: NanoChannel-mediated communication leads to increase in patho-
logical angiogenic markers in human endothelial cells in vivo. Analogous to
in vitro results, segregation of cells receiving nC-mediated intercellular transfer
shows significantly higher expression of pathological angiogenic markers in inter-
cellular transfer+ve cells.
in vitro (Figure 6-8). This upregulation, similarly to what was seen with the in vivo
cells, could be disrupted using cytoskeletal inhibitors. Figure 6-8 highlights the
results of this analysis. HUVEC endothelial control cells in monoculture are indi-
cated in purple, HUVEC cells isolated from dual cultures are indicated in green,
and HUVEC cells isolated from co-cultures are indicated in pink. The cytochalasin
D and docetaxel drug treatment group is represented by the gray curve and latrun-
culin A and docetaxel are indicated in black. The graph shows that in co-culture
the percentage of CD137+ve and CD276+ve endothelial cells was greater then in
dual groups. Furthermore, the number of CD137+ve and CD276+ve cells were
decreased by drug treatment.
Similarly to results observed in vivo, the upregulation of pathological angiogen-
esis markers become much more pronounced when comparing intercellular trans-
fer+ve and intercellular transfer-ve cell populations. Given that the percentage of
the endothelial cells receiving transport is much smaller than the negative intercel-
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through pharmacological inhibition of nCs. FACS analysis of in vivo samples
illustrate expression of pathological angiogenic markers CD137 and CD276 in the
isolated endothelial cells, which was decreased with pharmacological inhibition of
nC projections.
lular population, its easy to underestimate the change in expression of these mark-
ers when analyzing whole endothelial cell populations. However, by segregating
the two endothelial cell populations into plus and minus transport, the signal-to-
noise ratio is improved and the dramatic effects of this form of communication can
fully be appreciated.
Upregulation of these markers may potentially enhance metastatic invasion.
For example, recent studies have reported that activation of CD137 can increase
endothelial cell surface expression of adhesion molecules such as intercellular ad-
hesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-
selectin, which play a critical role in invasion 319. Similarly, expression of CD276
(B7-H3), a cell surface transmembrane glycoprotein, was related to migration and
invasion in melanoma and ductal and lobular breast cancer 320a 21.
Figure 6-9 is a schematic overview postulating how nanoChannel-mediated
communication fits into the metastatic cascades. The metastatic cascade starts with
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Figure 6-8: NanoChannel-mediated communication leads to increase in patho-
logical angiogenic markers in human endothelial cells in vitro, which can be
inhibited with pharmacological inhibition of nC projections. (A) Tumor en-
dothelial markers CD137 and CD276 are upregulated in co-cultures, presumably
through nC-mediated intercellular transport. This upregulation of pathological
angiogenesis markers can be disrupted using combination of F-actin and tubulin
polymerization inhibitors. (B) Segregation of intercellular transfer+/-ve cell pop-
ulations show significantly higher expression of pathological angiogenic markers
in intercellular transfer+ve cells.
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formation of the primary tumor and invasion into the surrounding tissue. This is
followed by elongation of the breast epithelial cells along the vessels and formation
of the nanoChannel structure. The nanoChannel structures transport intercellular
contents into the endothelium which may aid in metastatic progression.
There are two ways that nanoChannel-mediated communication may enhance
metastatic cell invasion. The first mechanism is through long-term transformation
of the endothelium into a pathological phenotype. The second mechanism requires
quick induction of transient changes in the endothelial cells that in real-time en-
hance metastatic invasive potential. One example of this is nC-mediated endothe-
lial cell retraction. There is evidence to suggest that nanoChannels may function
in endothelial cell retraction through cdc42 108',322 . Previous work has shown that
cdc42 expression in metastatic breast epithelial cells can lead to endothelial cell
retraction through a /-1 integrin pathway". Cdc42 has also been implicated in
formation and extension of nanoChannel structures 322. Its interesting to contem-
plate how expression of cdc42 in the breast epithelial cell population can lead to
a change in a second population (i.e. the endothelial cells). One potential mech-
anism of how these two elements can be connected is through communication of
intercellular contents through nanoChannels. For example, cdc42 might be an im-
portant mediator of nanoChannel formation. When cdc42 is overexpressed, more
nanoChannels are formed, leading to increased intercellular transport. The inter-
cellular contents might include miRNAs, proteins, etc. that lead to changes in the
endothelial cell biology which result in endothelial cell retraction and promote the
transmigration of the metastatic breast cancer cells across the endothelial cell bar-
rier. Understanding alternative consequences to nanoChannel mediated commu-
nication in cancer is the next step in the project and I will discuss some potential
ideas in Chapter 7.
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Figure 6-9: Schematic illustration of potential role of nCs in metastatic progression.
6.4 Conclusion
In summary, we describe a novel form of heterotypic intercellular communication
between cancer cells and the host endothelium, where tumor cells can physically
hijack and transform normal endothelial cells to a pathological angiogenesis phe-
notype. We define this process as metastatic parasitism. NanoChannel-mediated
transfer of microRNAs may emerge as a new signaling mechanism in metasta-
sis, which may function to prime the endothelium to facilitate transmigration of
tumor cells and/or recruitment of vasculature to growing metastases. Indeed, elu-
cidation of microRNAs transported through the nanoChannels presents a power-
ful opportunity to both explain mechanisms underlying pathological angiogenesis
and for the development of metastasis-specific therapeutics. Interestingly, the abil-
ity to disrupt nanoChannels with sub-lethal doses of F-actin and tubulin inhibitors
posits whether the clinical benefits of metronomic dosing315 could arise from the
disruption of this intercellular communication. Further mechanistic understand-
ing of the nCs can offer the potential for novel strategies for the management of in-
vasive disease, which are currently associated with dismal 5-year survival rates8 .
Important questions underlying mechanisms of nC formation, endogenous mi-
croRNA transport, and downstream changes in the endothelial cell populations
remain to be addressed. However, the exploration of nanoChannels in the spread
of invasive cancer introduces new insight into mechanisms exploited by cancer
cells to facilitate cancer progression by directly manipulating the surrounding cell
populations to promote pathogenesis.
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Chapter 7
Future Directions
7.1 Summary of Work
Disease can be classified into two paradigms: diseases that can be cured and those
which are managed. Modern medicine is well adept in treating localized disease
- disease with one singular cause, affecting one singular organ system, and with
one singular treatment, typically resulting in a cure. Infectious diseases are classic
examples of the localized disease paradigm. These diseases are commonly treated
with a single or combination of drug therapies that target well-defined biologi-
cal mechanisms. In contrast, modern medicine is not well adept at treating non-
localized, multi-system diseases. Systemic diseases are not one single disease, but
instead a constellation of diseases, typically having multiple etiologies, and unfor-
tunately due to their complexity, limited therapies. This results in diseases that
cannot be cured, falling into the category of chronic disease and managed care.
Examples of non-localized diseases include autoimmune disorders, chronic heart
failure, and cancer metastasis.
Great strides have been made in the war against cancer that have led to sig-
nificant improvements on 5-year survival rates for many cancers, transforming
cancer from a death sentence to a chronic disease. However, the final-frontier in
cancer, metastatic invasion, continues to present formidable obstacles that must be
traversed to achieve further improvements on cancer treatment outcomes. Metas-
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tasis is difficult to treat because like cancer at the primary site, metastatic disease
is not one singular disease, but instead a constellation of several diseases, that are
as numerous as the diversity of tumor types. Metastatic cancer is a systemic dis-
ease that leads to physiological disruptions of a wide range of cellular processes.
Therefore, identifying and targeting the dominant pathways that control cancer
progression remains a great challenge.
Mechanisms of cancer metastasis occur deep in the body, regulated by systemic
interactions with the tissue microenvironment. Furthermore, the possible paths
traversed by each invasive cell may potentially be as numerous as the signaling
pathways that regulate cellular proliferation or metabolism. In order to advance
knowledge of mechanisms underlying cancer metastasis, the fields of science and
engineering must develop new cell-based and imaging tools that allow for isola-
tion of discrete mechanisms involved in the metastatic cascade.
Cancer metastasis can be broadly divided into three distinct stages: develop-
ment and invasion of the primary tumor, interactions with the endothelium, and
seeding of the secondary tumor site. These stages offer three separate opportu-
nities for therapeutic intervention. Currently the majority of existing drug ther-
apies are targeted toward the growth of the primary tumor, therefore targeting
the later two stages of metastasis presents several untapped therapeutic oppor-
tunities. However, elucidation of mechanisms underlying metastatic colonization
remain fledgling, making this stage less desirable as a therapeutic target. Further-
more, tissue colonization is dependent on the biology of the primary tumor, as well
as the biology of the new microenvironment making colonization a very complex
systems biology problem. Lastly, drug therapies inhibiting metastatic colonization
would target the late stages of metastasis. Arguably, greater therapeutic benefits
could be achieved by targeting molecular events early in disease progression.
In contrast to the limited opportunities to target metastatic colonization, the
current state of technology is ripe for making significant advances in our under-
standing of mechanisms regulating interactions between metastatic cells and the
endothelium. Targeting this stage of the metastatic cascade may enable develop-
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Figure 7-1: Summary of work. (A) An epithelial-endothelial co-culture system
captures interactions between metastatic cells and the endothelium. (B) This model
system enabled discovery of nanoChannel connections. These structures function
in intercellular communication between metastatic cells and the endothelium.
ment of cancer therapies targeted toward early stages of metastasis.
Interactions with the endothelium occur during two distinct pathological events:
intravasation/extravastion and the recruitment of angiogenic vessels by the pri-
mary tumor and the newly formed metastases. To this end, we have described
the engineering of a three-dimensional, cell-based, co-culture model system used
to study population and single cell interactions between metastatic epithelial cells
and the endothelium. The primary motivation in developing this system is cen-
tered on the critical role the endothelium serves in cancer progression.
Our engineered 3D epithelial-endothelial co-culture system allows for the study
of novel interaction phenotypes between epithelial cells and the endothelium (Fig-
ure 7-1). We have demonstrated that this model system enables identification of
molecular pathways that regulate these interactions and also provides a platform
for probing these pathways using commonly available molecular biology tech-
niques such as RNAi and small molecule pharmacological inhibitors. In the future,
the model system may prove to be a valuable tool in screening potential therapeu-
tics that not only target the tumor and angiogenic compartments individually, but
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also target the intersection of these two compartments, a feature that has emerged
to be a critical aspect of cancer progression. However, the most powerful aspect
of the model is the window it offers into the typically occult process of metasta-
sis. The ability to directly observe interactions between two cell types that phys-
iologically should never come into direct contact offers witness to the formation
of a symbiotic relationship that may provide powerful clues into the connection
between aberrant cell-cell relationships and cancer metastasis. The power of ob-
servation, unlike other techniques used in science, introduces an opportunity to
discover phenomenon without a priori knowledge of a phenomenon. It provides
the purest form of inquisition guided not by previous knowledge or assumptions,
but instead by direct observations.
Our observations of these cell-cell interactions enabled the identification of
novel cytoskeletal projections extending between the metastatic cells and the en-
dothelium. These projections, coined nanoChannels, seem to primarily function in
intercellular communication (Figure 7-1). However, they may also be involved in
other yet to be explored mechanisms of cell-cell interactions. Communication of
intercellular contents through these channels is a powerful mode of cellular com-
munication that I would argue is distinct from other forms of cell-cell communica-
tion.
Unlike other forms of intercellular communication, nanoChannel projections
allow for a level of tunability and specificity that cannot be achieved with simi-
lar forms of intercellular communication. For example, membrane vesicles trans-
port similar cargo as nanoChannels, such as cytoplasmic RNAs. However, un-
like membrane vesicles which are released from a cell to be taken up by a neigh-
boring cell in a non-specific and seemingly random manner, communication via
nanoChannels allows a singe cell to communicate directly with another single
cell in a highly regulated and defined fashion. The ability to communicate with
surrounding cells with specificity, combined with the wide array of transported
biomolecules through nCs, highlights the unique nature of this communication. It
also introduces many interesting questions regarding the function of nanoChan-
318
nels in cancer. What is the role of nCs in normal cellular physiology? How can
this mode of communication be exploited by tumor cells in order to enhance can-
cer spread? For example, our data has shown that intercellular transfer through
nanoChannels leads to the development of a pathological phenotype in the en-
dothelium. However, could this form of communication serve other roles in metastatic
invasion? For example, could nC-mediated communication enhance endothelial
cell retraction to promote transendothelial cell migration? Presumably, a metastatic
cell could arrest within a vessel and then rapidly, and specifically transport in-
tercellular contents that alter the biomechanics of the endothelium in a manner
that enhances the ability of metastatic cells to intravasate or extravasate. Alter-
natively, contents transported through nCs could transform the endothelium to
not only enhance the metastatic potential of that particular cell, but potentially
also make the endothelium more permissive for colonization by future metastatic
cells. Lastly, nanoChannels may also function in primary tumor biology. We have
demonstrated that nCs can promote cancer progression by quieting surrounding
healthy cells. Communication of intercellular contents from tumor cells through
nanoChannels leads to a decrease in cellular proliferation of normal breast epithe-
lial cells. Just as pathogens enhance the spread of disease by monopolizing re-
sources in order to outcompete normal cells, tumor cells can directly manipulate
their surrounding environment to enhance survival.
The introduction of nanoChannels as a novel route of intercellular communica-
tion incites a wide array of questions and also presents therapeutic opportunities
to target early and late stages of metastatic progression. However, to fully un-
derstand the importance of this mode of communication, future research on the
subject is critical. Of particular importance is understanding the downstream con-
sequences of nC-transport both in the primary tumor and in metastasis. How are
these structures formed? Would inhibition of these structures lead to improved
therapeutic outcomes? What drives these structures to form with high specificity
with the endothelium? In the following section, I identify the critical questions
regarding expansion of this body of work to address the role of nanoChannels in
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metastasis and address possible therapeutic strategies for disrupting these projec-
tions.
7.2 Downstream consequence of nanoChannel trans-
port
Transport of cytoplasmic contents through nanoChannels may have profound con-
sequences in the primary tumor and in metastatic progression. Transfer of miR-
NAs through these structures presents a mechanism for long-term transforma-
tion of recipient cell types. Unlike other biological macromolecules, such as pro-
teins with a limited half-life, transport of miRNAs leads to lasting and persistent
changes. A single miRNA can target multiple mRNAs affecting several cellular
pathways.
Although other forms of intercellular communication can transport miRNAs,
such as exosomes, these mechanisms may not be capable of actively regulating
metastasis at the level of tumor-endothelial interactions in the same manner as
nCs. Membrane vesicles are non-specifically released by cells and the direction of
transport is not directly controlled. For example, tumor cells that arrest within a
capillary may release extracellular vesicles. However, what determines the ability
of this mechanism to promote cancer is the probability that these vesicle will be
uptaken by the endothelial cells. This probability in turn is dependent on the local
concentration of vesicles near the cell of interest. It's unlikely that a high local
concentration of exosomes can be achieved by metastatic cells within the blood
stream. Exosomes randomly released by the cells are more likely to diffuse into
the blood stream than be uptaken by surrounding endothelial cells.
Consider this analogy: transfer of genetic material via exosomes is analogous to
insemination in plants while transfer of genetic material through nanoChannels is
analogous to insemination in mammals. Take dandelions in a field. Dandelions are
constantly releasing pollen, however in a strong wind, the majority of the pollen
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released does not fall at the base of the plant, but instead is carried great distances.
Exosomes in this analogy are like dandelion seeds. Contrast this to how insemi-
nation occurs in mammals. NanoChannels form direct connections between cells
that can withstand the shear stress of blood flow. Formation of direct cell-cell con-
nections greatly enhances the likelihood that intercellular contents will actually be
transported into the specific cell of interest. Not only do nanoChannels allow for
transport of potent regulatory biomolecules, but they also enhance the ability of
cells to tightly regulate dispersion of these biomolecules that cannot be achieved
through other modes of intercellular communication.
Given these unique characteristics of nanoChannels, what are the potential
downstream consequences of this communication and how can these consequences
be tested? NanoChannels likely serve dual functions in metastasis, broadly char-
acterized into direct and indirect metastasis priming mechanisms. A direct mecha-
nism is one that increases the metastatic potential of the communicating cell, while
indirect mechanisms prime for subsequent metastatic invasions. An example of
a direct mechanism is nC communication enhancing transendothelial migration.
Previous studies have demonstrated that tumor cells can change the biomechani-
cal properties of the endothelium, leading to increased transendothelial migration.
In other studies, metastatic cells have been shown to promote endothelial cell re-
traction through /-1 integrins and cdc42. However, the mechanisms by which
these phenomena occur have not been elucidated, introducing interesting consid-
erations regarding the possible role nCs may play in creating this pro-metastatic
phenotype. The forefront question is how does expression of proteins by metastatic
cells, promote biomechanical changes in the endothelium? Our studies have shown that
0-1 integrins are important for endothelial-epithelial cell-cell interactions. In ad-
dition, cdc42 is an actin cytoskeletal regulatory protein that has been implicated
in formation of tunneling nanotubes, which are cytoskeletal projections with sim-
ilar properties as nanoChannels. Therefore, it may be the case that expression of
/-1 integrins and cdc42 is correlated with formation of nanoChannel projections
and also that the cytoplasmic contents transported through these structures cause
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changes in the biomechanical properties of endothelial cells.
NanoChannels indirectly contribute to metastatic invasion through transfor-
mation of the endothelium. Our work has shown that nanoChannels promote
development of a pathological phenotype by endothelial cells. These pathologi-
cal vessels, in turn, feed the growing metastatic lesion promoting development of
frank metastases. Furthermore, pathological vessels are physically distorted char-
acterized by irregular, leaky vessel structures. Those leaky vessels may make it
easier for tumor cells to escape the endothelium and enter surrounding tissues.
Lastly, transformation of the endothelium primes formation of future metastases
by creating a pre-metastatic niche. Tumor endothelial cells have been linked to
creation of a pre-metastatic niche through secretion of soluble factors, particularly
pro-inflammatory signals. These signals recruit other tumor stromal cells, such as
macrophages, that promote growth of metastatic lesions.
Investigating these hypotheses involves identifying phenotypic and genetic
changes in the endothelium that occur as a result of communication through nanoChan-
nels. Studies examining changes in cellular biomechanical properties would shed
tremendous insight into the role nCs play in directly enhancing invasion by pro-
moting transendothelial cell migration. Furthermore, examination of changes in
cytoskeletal regulatory proteins may provide insight into endothelial cell retrac-
tion. An analysis of which specific microRNAs are transported may elucidate
mechanisms explaining the origin of these changes in the endothelium. Stud-
ies have shown the endothelium of tumors is genetically transformed274 . Poten-
tially secondary to mutations caused by this miRNA transport. Other transported
biomolecules may also be implicated in this transformation. Examining alterations
in cytokine secretion may also shed light into the pro-metastatic role of nanoChan-
nels, which may function through the formation of a pre-metastatic niche or via
promotion of angiogenesis.
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Figure 7-2: Mechanism of formation of nC structures. There are several possi-
ble mechanisms by which nanoChannels form, de novo protrusion formation, rem-
nants of incomplete cytokinesis, and extensions of cell-cell adhesions.
7.3 Mechanism of formation of nC structures
NanoChannels introduce a new mechanism by which cellular transformation oc-
curs called metastatic parasitism. The unique nature of this mode of communication
potentially highlights these structures as druggable targets in cancer. However,
development of nC specific therapeutics requires an understanding of how nCs
are formed. NanoChannel formation is complex involving biological pathways
regulating cytokine sensing, cytoskeletal rearrangement, and membrane fusion.
There are several possible mechanisms by which nanoChannels form. The first
mechanism is de novo protrusion formation (Figure 7-2). This requires initiation
and extension of a nanoChannel structure by one cell that eventually contacts a
neighboring cell. De novo protrusion formation is likely the mechanism underly-
ing formation of heterotypic nC-mediated communication. NanoChannels struc-
tures may also be remnants of incomplete cellular cytokinesis resulting from cell
division. Alternatively, nanoChannels may form from tight cell-cell adhesion con-
nections that remain intact as cells move further and further apart. In metasta-
sis, the relevant function of nanoChannels is in heterotypic cell-cell interactions.
Therefore, the most significant therapeutic opportunity lies in impeding de novo
protrusion formation.
The steps of de novo protrusion formation can be divided into five stages with
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distinct mechanisms: dynamic motions in the membrane, response to external nC
promoting stimulus, initiation and extension of a projection, and fusion with the
secondary cell membrane. These steps are summarized in (Figure 7-3). Insight
into the initial steps of nC protrusion formation may be gained by examining for-
mation of other cytoskeletal projections such as filopodia or tunneling nanotubes.
The initial steps of nC protrusion formation likely occur due to dynamic Brown-
ian motions in the membrane that generate small projections. These motions are
an inherent property of the membrane and are also likely the first step in initia-
tion of similar cytoskeletal projections, such as filopodia. These small projections
may contain cytokine receptors. Detection of an nC growth stimulus by these re-
ceptors may stimulate initiation and extension of these projections. Extension of
the growing projection probably occur in response to chemotactic gradients of nC
promoting factors secreted in high concentrations by endothelial cells.
Cytoskeletal regulatory proteins such as M-Sec, RalA, and the exocyst, have
been implicated in the formation of similar cytoskeletal projections 32 3 . M-Sec is ho-
mologous to the Sec6 subunit of the exocyst 323. M-Sec and RalA have been found
to co-localize with the exocyst complex 322 . This protein complex regulates F-Actin
remodeling required for protrusion formation. Formation of nanoChannel connec-
tions likely involves similar cytoskeletal regulatory molecules and therefore may
be targeted with drugs inhibiting cytoskeletal regulatory proteins. For example,
preliminary data shows that treatment of MDA-MB-231 cells with an aurora kinase
inhibitor (Tozasertib) and a TNFao inhibitor (Pomalidomide) decreased intercellu-
lar transfer through nanoChannels (Figure 7-4). The aurora kinases are known reg-
ulators of the actin cytoskeleton 32 4 , while TNFoz has been implicated in regulation
of the exocyst complex325 . Interestingly, activation of Fas ligand caspase signaling
has been implicated in TNT formation by regulating Rho GTPase signaling326. This
data suggests that screening for small molecules inhibitors of cytoskeletal regula-
tors may yield drugs that effectively disrupt communication through nanoChan-
nels.
The final step in nanoChannel formation involves fusion with the endothelial
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Figure 7-3: Formation of de novo nanoChannel protrusions. NanoChannel for-
mation is theorized to involve five distinct steps. Brownian membrane fluctuations
lead to formation of small protrusions that in response to soluble factors result in
initiation and extension of nC projections toward the stimulus. The final step in-
volves fusion with the endothelial cell membrane.
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Figure 7-4: Inhibitors of aurora kinase and TNFa decrease intercellular transfer
through nanoChannels. Aurora kinase inhibitor (Tozasertib) and a TNFa inhibitor
(Pomalidomide) decreased intercellular transfer through nanoChannels.
cell membrane. Cytonemes or filopodial bridges are unfused closed-end tubular
projections that may be precursors of nanoChannels. Fusion of the nanoChannel
projections may occur through a clathrin-mediated pathway. A dose titration with
chlorpromazine, a clathrin-mediated endocytosis inhibitor, resulted in a dramatic
reduction in intercellular communication that correlated with increasing drug con-
centration (Figure 7-5). In this experiment, the endothelial cells were treated with
the endocytosis inhibitor chlorpromazine prior to seeding in the matrix. Dual
chamber studies and pharmacological inhibition of exocytosis in the MDA-MB-
231 cells show minimal effects on percent intercellular transfer. Furthermore, in
both the 0.4 pm and 3pm pore studies, extracellular vesicles can be seen in con-
tact with the endothelial cells. These vesicles, however, are not endocytosed by
the cells and do not result in a change in intercellular communication, excluding
the involvement of an endocytotic/exocytotic mechanism as the source of the ob-
served intercellular communication. Therefore, decline in intercellular transfer af-
ter treatment of endothelial cells with chlorpromazine likely results from defects in
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Figure 7-5: Clathrin mediated endocytosis inhibitor prevents nanoChannel fu-
sion with the endothelial membrane. Increasing concentrations of chlorpro-
mazine leads to a dose-dependent inhibition of intercellular transport through nCs
by preventing membrane fusion.
nanoChannel fusion with the endothelial cell membrane (Figure 7-5). Fusion of ex-
tracellular vesicles such as exosomes have also been shown to involve the clathrin
pathway327 . These results suggest possible overlaps regarding how nanoChannels
and exosomes are formed.
7.3.1 Therapeutic implications: Targeting exosomes and membrane
projections
Biogenesis of exosomes is a complex process and an active area of investigation.
Reports on the roles of molecules involved in exosome formation vary in different
cellular model systems, suggesting that exosome biogenesis may involve unique
mechanisms in different cell types328 . Exosome formation is signaled by ubiquiti-
nation of the cytosolic tails of receptors destined for degradation, which results in
the formation of intralumenal vesicles (ILVs) through coordinated interactions of
protein complexes collectively referred to as ESCRT (endosomal sorting complex
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required for transport)328 . ESCRT is believed to function in targeting the receptor
to the intraluminal vesicle, playing critical roles in insuring appropriate protein
composition of exosomes135 ,328 . However, it's unclear of the exact role of ESCRT in
all cell types or if other molecules may perform similar functions328. Annexins and
RAB GTPases (RAB11, RAB27, and RAB35) proteins are involved in trafficking
and secretion of exosomes13' 163 ,328 . The specific role of each RAB proteins in the
formation of exosomes is unknown, further complicated by the possibility of cell
type-to-cell type variability in function328 . In the final steps (fusion with the plasma
membrane and release into the extracellular environment) SNARE proteins are be-
lieved to play critical functions, however, the exact composition of this complex is
unknown328 .
Exosomes commonly contain proteins involved in signal transduction such as
protein kinases and G proteins. Heat shock proteins HSP70 and HSP90 are also
commonly found within exosomes along with the Tetraspanins family of trans-
membrane proteins, such as CD9, CD63, CD81, and CD82163 . The exact function of
the tetraspanins is unknown but they are believed to be involved in large protein
networks 163 . Exosomes have a specific lipid composition composed of cholesterol,
ceramide and spingolipids, which may function in proper exosome release. For
example ceramide is involved in exosome release and inhibition of ceramide syn-
thesis reduces exosome production13 .
There are potential mechanistic overlaps between formation of nC structures
and release of exosomes that present therapeutic opportunities for simultaneous
dual targeting of both mechanisms. For example, each of these structures is regu-
lated by cytoskeletal proteins. Future work may involve elucidating cytoskeletal
regulators that function in both modes of communication. Another possibility is
examining mechanisms that regulate the nature of the cargo transported by each
of these modes because there are many functional overlaps that exist such as the
ability of these structures to transport nucleic acids. However, the most similari-
ties are probably found when considering how these structures fuse with the sec-
ondary membrane. Due to similarities in dimension, exosomes and nanoChannels
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are likely indistinguishable to recipient cells. From the perspective of the recip-
ient cell, the radius of a nanoChannel is much much smaller than the radius of
the cell, therefore, an approaching nanoChannel likely appears similar to an ap-
proaching exosome. When these two structures interact with the recipient cell,
it's likely that the cells respond similarly to both. Given our preliminary results,
this shared mechanism involves clathrin-mediated endocytosis. However it's also
possible that other mechanisms are involved, such as phagocytic mechanisms or
membrane fusion.
7.4 Conclusion
Much of the work examining transport of miRNAs have focused on exosomes as
the primary carriers. However, exosomes, like other extracellular vesicles, are ran-
domly released into the microenvironment. This introduces questions about the
efficiency of transport of miRNAs within extracellular vesicles and if transport of
these molecules through other encapsulated structures, such as membrane bridges,
offer additional specificity. There are many functional, and perhaps mechanistic,
overlaps between intercellular communication through membrane bridges and ex-
tracellular vesicles. This introduces the question of what advantage does having
both of these mechanisms provide cells. Potentially, exosomal mediated transport
function more in long-range, low-specificity communication, while communica-
tion through membrane bridges better enables short-range, high-specificity com-
munication.
Furthermore, these models likely have overlapping mechanisms of formation.
Therefore, one potential therapeutic strategy may be to simultaneously target both
membrane bridges and extracellular vesicles. In addition, each of these mecha-
nisms exhibit both pro- and anti-tumorgienic properties. Could a viable therapeu-
tic strategy be to induce intercellular communication through these mechanisms
that are protective against tumor growth? Furthermore, can these mechanisms be
explored for the delivery of anti-tumorigenic therapies, similar to strategies being
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pursued for delivery of siRNAs 329. To answer these questions and others requires
a better understanding of the function of these structures. How are formed? What
regulates the intercellular cargo they carry? What stimuli leads to secretion of ex-
osomes versus formation of membrane bridges? What are the functional overlaps
between these two modes of communication? How are they different? Are there
mechanistic overlaps that will provide an opportunity for therapeutic interven-
tion?
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Appendix A
Matlab Code
% 2 PARAMETER INDEX
% -Analysis of Normal, Tumorgenic and Metastatic cell lines
% -Epithelial-Endothelial Disassociation Index (EEDI)
% -Elongation Index (EI)
% Last modified: yamicia Jun 20, 2013 16:25:00
9 clear;clc;close all;
10
if exist ('yami-data.mat' )
load ( yami-data .mat');
else
lines = {'HMEC','MCF10A','MCF7
'M4T1 '};
Cols = {'A', 'B', 'C', 'D', 'E', 'F
% Normal (2), Tumorogenic (2),
% analyzed for the 2 parameter
', 'SKBR3', 'MDA-MB-231', 'MDA-MB-468',...
', 'vG ', 'H ', 1'I 1', ' ' ;
and Metastatic (3)
index
cell lines being
for i = 1:length(lines)
inter. (lines{i}) = xlsread('YamiData.xlsx','EEDI',...
[cols{i},'2:',cols{i},'1000'1);
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11
12
13
14
15
16
17
18
19
20
21
22
.. ... .. . ... ...  ........................................  .............
23 elongation.(lines{i}) = xlsread('YamiData.xlsx', 'EI',...
24 [cols{i},'2:',cols{i},'1000']);
25 end
26
27 save ('yami-data.mat');
28 end
29
30 for i = 1:length(lines)
31 if(length(elongation.(lines{i})) >= length(inter.(lines{i})))
32 elong.(lines{i}) = convert2elong(elongation.(lines{i}),...
33 inter.(lines{i}));
34 else
35 elong.(lines{i}) = elongation.(lines{i});
inter.(lines{i}) = convert2elong(inter.(lines{i}),...
37 elongation.(lines{i}));
38 end
39 end
40
41 % Average and Standard Deviation for both EEDI and EI across all seven cell
42 % lines.
43 for i = 1:length(lines)
44 avg-inter.(lines{i}) = mean(inter.(lines{i}));
45 std-inter.(lines{i}) = std(inter.(lines{i}));
4 avg-elong.(lines{i}) = mean(elong.(lines{i}));
47 std-elong.(lines{i}) = std(elong.(lines{i}));
48 end
49
so % Normal Lines
51 avg-inter.norm = mean( [avg-inter.HMECavg-inter.MCF10A]);
52 avg-elong.norm = mean([avg-elong.HMEC,avg-elong.MCF10A]);
53 std-inter.norm = rms([std-inter.HMEC,std-inter.MCF10A]);
54 std-elong.norm = rms([std-elong.HMEC,std-elong.MCF10A]);
55 % Tumorgenic Lines
56 avg-inter.tumr = mean( [avg-inter.MCF7,avg-inter.SKBR3]);
57 avg-elong.tumr = mean([avg-elong.MCF7,avg-elong.SKBR3]);
58 std-inter.tumr = rms([std-inter.MCF7,std-inter.SKBR3]);
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std-elong.tumr = rms([std-elong.MCF7,std-elong.SKBR3]);
% Metastatic Lines
avg-inter.meta = mean([avg-inter.MDAMB_231,avg-inter.MDA-MB_468,
avg-inter.MAT1]);
avg-elong.meta = mean( [avg-elong.MDAJMB_231,avg-elong.MDAJMB_468,
avg-elong.M_4Tl]);
std-inter.meta = rms([std-inter.MDAJMB_231,std-inter.MDAMB_468,...
std-inter._MAT1]);
std-elong.meta = rms([std-elong.MDAJMB_231,std-elong.MDAMB_468,...
std-elong.M-4Tl]);
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70 lines = [lines {'norm'} {'tumr'} {'meta'}];
71
72
% Plotting
t = 0:0.01: 2 *pi;
xlswrite('Yami-Data.csv',lines, 'ellipse.
xlswrite('YamiData.csv',lines, 'ellipse.
for i = 1:length(fieldnames(avg-elong))
x{i} = [std-inter. (lines{i})*cos(t)
y{i} = [std-elong.(lines{i})*sin(t)
end
.x 'Al')
.y', 'Al')
+ avg-inter. (lines{i})] ';
+ avg-elong. (lines{i})] ';
save export-data.mat x y lines;
xlswrite('YamiData.csv',x{i}, 'ellipse-x', [cols{i},
xlswrite('YamiData.csv',y{i}, 'ellipse-y', [cols{i},
figure (1);
clr = [0 0 255; 0 127 0; 255 0 0; 0 191 191; 191 0
0 0 0]/255;
clr2 = [0 0 255; 0 127 127;0 255 0]/255;
hold on;
for i = 1:length(fieldnames(avg-elong))
h = plot(x{i},y{i});
if i<=7
'2:',cols{i},
'2:',cols{i},
'1000']);
'1000']);
191; 191 191 0;...
set (h, 'Color',clr(i,:), 'LineWidth',1);
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.............................. . ..... -- - . ............... . ... .. ... - - - ----- . ....
else
set (h, 'Color',clr2 (i-7,:),'LineWidth',2.5);
end
95
96
97
98
99
100
101
102
103
');xlabel('Interaction'); ...
MCF7', 'SKBR3', 'MDA-MB-231',...
Tumorgenic', 'Metastatic');
1 function elong = convert2elong(elongation,offr)
2
3 lower = floor(length(elongation)/length(offr));
4 numup = mod(length(elongation),length(offr));
5 if numup ~=O
6 upper = lower+l;
7 else
8 upper = lower;
9 end
.o num = upper;
elong =
C = 1;
for i =
for
zeros(size(offr));
1:length(offr)
j = 1:num
elong(i) = elong(i) + elongation(c);
c = c+1;
end
elong(i) = elong(i)/num;
if i >= numup
num = lower;
end
end
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end
title('Elongation vs. Interaction
ylabel('Elongation');
axis([O 1 -1 7]);
grid on; legend('HMEC', 'MCF10A','
'MDA-MB-468','4T1','Normal','
.............. -  .  .......... .. ....... .. .... ......... - "I'll, 11 - . ......... -- - - --- - -- - -,- --- :
i % CFSE Transfer Kinetics
2 % Calculates kinetics transfer through nanotubes, at various diffusion
3 % rates.
4 %
5 % Last modified: vamicia Jun 25, 2013 13:20:00
6%
7
8 clear;clc;close all;
x = 0:0.01:177; % um
t = 0:1/60:96; % hour
% D = 10; % um^2/sec
% D = 100; % um^2/sec
D = 0.001; % um^2/sec
v = 0.350; % speed in
k = 0.05;
k_1 = 0.5;
L = 72;
L-on = v/k-l;
L-off = (D/2*k)^(1/2);
C = zeros(size(x));
Cend = zeros (size(t));
CO = 50000; %nM
% Time-evolving graph,
for i = 1:length(t)
-- protein in cytoplasm; miRNA in cytoplasm
-- small protein in water; miRNA in water
small molecule in water
um/sec
indicating transfer of CFSE in time
C = CO*erfc(x/(2*sqrt(D*t(i)*3600)));%*(L/2*L-off)*(l+ (L-on/L-off));
Cend(i) = C(end);
figure (1);
plot (x, C);
grid on;
title(['time = ',num2str(round(t(i))),' out of ',num2str(t(end)),' hours']);
axis([min(x) max(x) 0 CO]);
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22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
.. ................... .  .. ........ . ...... ....  ...................  ...  ....... , _ _ - .
37 xlabel('Distance [\mum] ');ylabel('Concentration [nM] ');
38 drawnow;
39 end
40
41 % Concentration in Epithelial cell over time.
42 figure(2)
43 plot(t,Cend);
44 grid on;
45 title('Concentration vs. Time')
46 axis([min(t) max(t) 0 C0]);
47 xlabel('Concentration [nM] ');ylabel('Time [hrs] ');
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Appendix B
Materials and Methods
B.1 Cell Culture
HUVEC cells (ATCC) were cultured on 0.1% gelatin in EBM-2 (Lonza) supple-
mented with bullet kit (Lonza) and 0.1% antibiotic/antimycotic (A/A) (Life Tech-
nologies). Human primary Blood and Lymph endothelial cells, collected from
plasma, were cultured on collagen (1:60) in MCDB 131 supplemented with 5%
MVGS (Life Technologies), 1% L-alanyl-L-glutamine (Life Technologies), and 1%
A/A. MDA-MB-231 (ATCC), MDA-MB-435 (ATCC), MCF-7 (ATCC), 4306, 4412,
LLC, and B16 cells were cultured in DMEM supplemented with 10% FBS and 1%
A/A. MDA-MB-468 cells were cultured in DMEM supplemented with 5% FBS
and 1% A/A. SKBR3 (ATCC) were cultured in McCoys 5A (Life Technologies)
supplemented with 15% FBS and 1% A/A. SKOV3 and HT29 cells were cultured
in McCoys 5A supplemented with 10% FBS and 1% A/A. PC3, PC3M, PC3LN4,
AT2.1, AT3.1, AT6.1, and 4T1 cells were cultured in RPMI supplemented with 10%
FBS and 1% A/A. HMEC (Life Technologies) and MCF10a cells were cultured in
MEBM (Lonza) supplemented with MEGM bullet kit (Lonza) and 1% A/A.
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B.2 MicroRNA Labeling & Transfection
The Cy-3 labeled control miRNA was purchased from Life Technologies. miRNA-
132 (Life Technologies) and a-miRNA-132 (Life Technologies) were labeled using
Label IT miRNA Labeling Kit (Mirus) according to manufacturers protocol. Cells
were transfected with Control microRNA (Life Technologies), miRNA-132 (Life
Technologies), and a-miRNA-132 (Life Technologies). The microRNAs were trans-
fected with siPORT NeoFX transfection reagent (Life Technologies) at a concen-
tration of 50nM and 1x Opti-MEM I (Life Technologies). All transfections were
completed according to manufacturers protocols for 24 hours.
B.3 Pharmacological Inhibition
Cells were incubated with a combination of cytoskeletal pharmacological inhibitors
Latrunculin A (Sigma) or, Cytochalasin D (Sigma), and Docetaxal (Sigma) in com-
plete media for 24hrs post 6-18hrs of serum deprivation.
B.4 Co-Culture Protocol
1. Appropriately coat well with Matrigel@ is diluted with COLD sterile PBS -
50% Matrigel@; 50% PBS for 3D samples or gelatin for 2D samples
2. After 30 minutes of incubation at 37 C, for 2D samples, remove gelatin before
adding endothelial cells, and the cells are ready to plate for 3D samples
3. Incubate endothelial cells with DiL-Ac-LDL reagent (1:100) (Life Technolo-
gies) in complete media for 1hr
4. Plate the endothelial cells in their respective media, and incubate the HU-
VEC and primary human dermal microvascular blood endothelial cells for
4-6 hours, or the primary human dermal microvascular lymph endothelial
cells for 24 hours
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5. Load epithelial cells with GFP, CellTrace CFSE (Life Technologies), Qtracker
(Life Technologies), LysoTracker (Live Technologies), or MicroRNAs (Life
Technologies) according to manufacturers specifications
6. Add stained epithelial cells to preformed vessels in their respective media,
and incubate for 24-96 hours before further analysis
Matrigel per well:
1. 12 well - 400iL
2. 24 well 250pL
3. 12 well Dual chamber - 400pL bottom chamber, 118pL top chamber
Total Volume of Media per well:
1. 12 well - 2ml total volume
2. 24 well 1ml total volume
3. 12 well Dual chamber - 1.5mL bottom chamber, 0.5mL top chamber
Cells to add per well:
1. 2D: MDA-MDA/MDA-HUVEC add 150,000 cells/well (Of each type: Total
number of cells = 300,000) in a 12 well plate
2. MDA-MDA/MDA-HUVEC add 75,000 cells/well (Of each type: Total Num-
ber of cells = 150,000) in a 24 well plate
3. 3D: MDA-MDA add 200,000 cells/well (Of each type: Total number of cells
= 400,000) in a 12 well plate
4. MDA-HUVEC add 200,000 cells/well (Of each type: Total number of cells
400,000) in a 12 well plate
5. MDA-BLOOD add 275,000 cells/well (Of each type: Total number of cells =
550,000) in a 12 well plate
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6. MDA-LYMPH add 275,000 cells/well (Of each type: Total number of cells =
550,000) in a 12 well plate
7. MDA-MDA add 200,000 cells/well (Of each type: Total number of cells =
400,000) in a 24 well plate
8. MDA-HUVEC add 100,000 cells/well (Of each type: Total number of cells =
200,000) in a 24 well plate
B.5 Flow Cytommetry Sample Collection and Analy-
sis
1. Incubate samples in trypsin EDTA (10x) (Sigma) for 20min at 37'C. Collect
the samples, and incubate the remaining samples in the well again in trypsin
EDTA (10x) (Sigma) for 20 minutes at 37'C.
2. Collect the remaining samples, and centrifuge for 15 minutes at 450rcf
3. Remove supernatant, and fix the diffuse pellet in 1mL of 4% Para-formaldehyde
(PFA) for 20 minutes
4. Centrifuge samples after fixation for 15 minutes at 450rcf, and resuspend in
100iL staining buffer (0.1% Sodium Azide (Sigma), 5% FBS, 1% BSA (Sigma)
in PBS)
5. Stain samples with one or more of the following antibodies: Rb pAB to CD31
(abcam, ab28364), Purified Mouse Anti-Human CD141 (BD Bioscience, 559780),
Monoclonal Anti-human LYVE-1-APC (R&D Systems, FAB20892A), CD137
(abcam, ab3169), CD276 (abcam, ab89133), p120RasGAP (Santa Cruz Biotech-
nology, sc-63), or pAKT (Cell Signaling, 4051s).
6. Once samples are analyzed, use Cflow Plus (or Flowjo) software to plot dou-
ble+ve endothelial cells, and check for the presence of CFSE, Qtracker, Lyso-
Tracker, or miRNAs.
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B.6 In Vivo Studies
1. Drug treat MDA-MB-231 cells
2. Stain cells with CFSE per manufacturer's protocols
3. Inject cells into CD1 Nude Mice through tail vein injection
4. Sacrifice mice at 18hrs, 24hrs, 48hrs, or 72hrs.
5. Harvest lungs, and store or add magnetic CD31 beads for endothelial cell
isolation
6. Stain samples with CD 137 or CD 276, and sort using a BD FACS Aria IIu
SORP
B.7 Immunocytochemistry (ICC) Protocol
1. Remove about half the volume of excess media (siphon out using vacuum
if it is a 2D sample or use Kim wipes to remove excess media by capillary
action if it is a 3D sample)
2. Add 4% PFA (diluted in PBS) to the samples, and incubate at room tempera-
ture for 15 minutes.
3. Remove PFA, and wash once for 5 min in PBS.
4. Add 1mg/ml NaBH 4 (dissolved in PBS) to the samples, and incubate at room
temperature for 10 min.
5. Remove NaBH 4, and wash once in PBS for 5 min.
6. Add buffer A (0.1% Tween + 0.1% Triton in PBS) and incubate at room tem-
perature for 10 minutes.
7. Remove buffer A, and wash twice in PBS for 5 minutes each.
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8. Add buffer B (1% BSA + 0.5% Sodium Azide (g/ml) in PBS) and incubate at
room temperature for 1 hour.
9. Remove buffer B, and wash twice in PBS for 5 minutes each.
10. Add 200pL primary antibody (per well in a 24 well plate) (diluted in buffer
B) and incubate overnight at 4'C, or at room temperature for 3 hours.
11. Remove primary antibody, and wash thrice in PBS for 5 minutes each.
12. Add secondary antibody (diluted in buffer B) and incubate at room temper-
ature for 1 hour.
13. Remove secondary antibody, and wash thrice in PBS for 5 minutes each.
14. Add 200piL phalloidin to each well (1:100 dilution in PBS i.e. 1pL in 100PL
PBS), and incubate at room temperature for one hour.
15. Remove phalloidin, and wash twice with PBS, for 5 min each.
16. Counterstain with DAPI (1:10000 in PBS i.e. 1[pL in 10mL PBS) for 3 minutes
at room temperature.
17. Remove DAPI and wash thrice in PBS for 5 minutes each.
18. Mount the coverslips with a drop of antifade onto slides.
Cells were stained with on or more of the following: rhodamine phalloidin
(Life Technologies, R415), Alexa-fluor 647 phalloidin (Life Technologies, A22287),
a/,3 Tubulin antibody (Cell Signaling, 2148s), Myosin (Life Technologies, 3402S),
Wheat Germ Agglutinin (WGA)-CF405S conjugate (Biotium, 29027-1), Alexa Fluor
647 Conjugate WGA (Life Technologies, W32466).
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B.8 Immunohistochemistry (IHC) Protocol
B.8.1 Deparaffinization
1. Place the slides on a slide rack in the staining vials.
2. Wash slides with 100% Xylene 2x3 minutes
3. Wash slides with 1:1 100% Xylene: 100% EtOH for 3 minutes
4. Wash slides with 100% EtOH 2x3 minutes
5. Wash slides with 95% EtOH for 3 minutes diluted in distilled water
6. Wash slides with 70% EtOH for 3 minutes
7. Wash slides with 50% EtOH for 3 minutes
8. Wash slides with running cold tap water to rinse sections. Keep slides in
running water to prevent sections from drying out until antigen retrieval can
be performed
B.8.2 Quench Aldehydes with NaBH 4
1. Wash slides in FRESH NaBH 4 . Dissolve 1 mg/mL NaBH 4 in TBS. While the
solution is still fizzing, submerge the slides. *Note* Take NaBH 4 from bottom
of bottle. Fill bottle with Argon and store in dessicator until needed.
2. Wash 3 times for 10 minutes each
B.8.3 Antigen Retrieval
1. Make Sodium Citrate Buffer (10 mM sodium citrate, 0.05% Tween 20, pH
6.0): 2.94 g Tri-sodium citrate (dihydrate), 1 L distilled water, Mix to dissolve.
Adjust pH to 6.0 with IN HCl, add 0.5 mL Tween 20 and mix. Store at 4'C
until needed.
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2. Put slides in glass plate holders and fill with citrate buffer until samples are
submerged
3. Heat the buffer to 100'C for 30 minutes in the fume hood. Let slides cool
for 20 minutes at room temperature, otherwise the samples will come off the
slides!
B.8.4 Antibody Staining
Day 1:
1. Make I0x TBS Recipe: 24g Tris Base, 88g NaCl, 900 mL dH20, Adjust pH to
7.6 with 12N HCl, bring final volume to IL with distilled water
2. Wash slides 2x5minutes in TBS plus 0.025% Triton X-100 with gentle agitation
3. Block slides with 10% FBS and 1% BSA in Ix TBS for 2 hours at room temper-
ature
4. Drain slides for a few seconds (do not rinse) and wipe around the sections
with tissue paper
5. Apply primary antibodies (1:50 Rabbit anti-human CD31, 1:300 Von Wille-
brand Factor) in 1x TBS with 1% BSA. Incubate overnight at 4C
Day 2:
1. Rinse slides 2x5 minutes in TBS plus 0.025% Triton X-100 with gentle agita-
tion
2. Apply secondary antibody (Alexa Fluor 568 anti-rabbit) at 1:1000 dilution in
TBS plus 1% BSA for one hour at room temperature.
3. Wash slides 3 times for 5 minutes in TBS plus 0.025% Triton X-100
4. Incubate slides for 10 minutes in 1:100,000 DAPI diluted in TBS
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5. Wash slides 2 times for 5 minutes in 1x HBSS
6. Incubate slides 10 minutes in 1:200 Alexa Fluor 647 Conjugate WGA diluted
in HBSS
7. Wash slides 2 times for 5 minutes in 1x HBSS
8. Check slides under microscope to verify staining!
9. Apply cover slip over sample with mounting medium. Let dry for a few days
at room temperature covered from light.
B.9 Scanning Electron Microscopy (SEM)
B.9.1 Sample Preparation Protocol
1. Make 2X Sodium cacodylate buffer: 0.2 M sodium cacodylate, 4% gluteralde-
hyde, 3% PFA, 10% Sucrose
2. Make 2X osmium tetroxide in aqueous buffer: 2% osmium tetroxide in diH20
3. Mix both 2X sodium cacodylate buffer and 2X osmium tetroxide right before
use to get final working buffer.
4. Fix sample for 2 hours in SEM fixative, and change fixative at least 2-3 times,
or when it turns dark brown-black.
5. Wash once for 5 minutes with sodium cacodylate solution.
6. Successively incubate at room temperature in the following ethanol solu-
tions: 50%, 70%, 85%, 90%, 95%, and 100% for 5-10 minutes each.
7. Wash with 100% ethanol for 10 minutes again.
8. Store in 100% ethanol until ready. Sample can be kept in ethanol overnight
if plate is sealed with Para film. If kept overnight, replace with fresh ethanol
prior to critical point drying.
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9. Bring to facility for critical point drying (Autosamdri 815 critical point dryer)
and sputter coating (Cressington 208HR sputter coating with Au or Pt/Pd).
B.9.2 SEM Quantification
1. Imaging was done on a Jeol 5600LV SEM, Zeiss EVO SEM, or Zeiss FESEM
Ultra55 microscope.
2. For each image count: total number of cancer cells, cancer cells with nCs,
cancer cells without nCs, total number of nCs, total number of epi-epi nCs,
epi-endo nCs, number of cells forming epi-epi nCs, epi-endo nCs, and num-
ber of cells positive for both epi-epi and epi-endo nCs.
3. Measure the length and width of the nCs using the CarlZeiss TIF annotation
editor. Measure the width at 3 different positions across the length of the nCs
and calculate the average width.
B.10 Cell Viability
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) Assays: MDA-MB-231 cells were plated in a 96 well plate, and
drug treated for 24 hours. MTS reagent (Life Technologies) was added to the sam-
ple and the plate was analyzed using a BioTek Epoch Microplate Spectrophotome-
ter. Drug treated MDA-MB-231 cells were treated with Alexa Fluor 488 Annexin V
(Life Technologies), incubated with endothelial cells, and imaged after 24hrs. The
fluorescence of each image was measured and compared between the treatment
groups.
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B.11 PCR
B.11.1 Primer Design
p12ORasGAP and GAPDH primers (IDT) were designed using mRNA reference
sequences from NCBI database and Life Technologies OligoPerfect Designer soft-
ware. Primer specificity was analyzed using NCBI PrimerBLAST. Primer self-
dimerization and hetero-dimerization were analyzed using IDT OligoAnalyzer per
iQ SYBR Green Supermix (Biorad) PCR assay experimental conditions. GAPDH
Forward: 5 AGTCAGCCGCATCTTCTTTT 3 GAPDH Reverse: 5 GAGGTCAAT-
GAAGGGGTCAT 3 p12ORasGAP Forward: 5 TAACAGCATTGGGGACATCA 3
p12ORasGAP Reverse: 5 TTGCCATCCACTGTGTCATT 3 SYBR Green PCR Assay:
Co-cultured cells were sorted using BD FACS Aria IIu SORP. After total RNA ex-
traction and quantification, cDNA was created using iScriptTM cDNA Synthesis
Kit (Bio-Rad) per manufacturers protocol. Real-time PCR was performed on MyiQ
Real time PCR Detection System (Bio-Rad) using iQ SYBR Green Supermix (Bio-
Rad) per manufacturers protocol for p12ORasGAP and GAPDH primers.
B.11.2 miRNA PCR Assay
Co-cultured cells were sorted using BD FACS Aria IIu SORP. miRNAs were ex-
tracted from mono-cultured and sorted cells using the mirVana miRNA isolation
kit (Life Technologies) per the manufacturers protocol, and quantified using the
Take3 Micro-Volume plate (BioTek). cDNA was created using the Taqman miRNA
Reverse Transcription kit (Life Technologies) per manufacturers protocol for RNU44
and hsa-mir-132 Reverse Transcription primers. PCR was performed using Taq-
man Universal PCR Master Mix II, no UNG (Life Technologies) and Taqman Small
RNA Assay (Life Technologies) for RNU44 and hsa-mir-132 on MyiQ Real-Time
PCR Detection System (BioRad).
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B.12 Transmission Electron Microscopy
Cells were fixed in 2.5% gluteraldehyde, 3% paraformaldehyde with 5% sucrose
in 0.1M sodium cacodylate buffer (pH 7.4), pelletted, and post fixed in 1% Os04
in veronal-acetate buffer. The cell pellet was stained in block overnight with 0.5%
uranyl acetate in veronal-acetate buffer (pH 6.0), then dehydrated and embedded
in Embed-812 resin. Sections were cut on a Reichert Ultracut E microtome with a
Diatome diamond knife at a thickness of 50 nm, stained with uranyl acetate, and
lead citrate. The sections were examined using an FEI Tecnai spirit at 80KV and
photographed with an AMT CCD camera.
B.13 Imaging
Fluorescence imaging was performed on a Nikon Eclipse Ti camera (Nikon Instru-
ments) with NIS Elements Imaging Software (3.10) using Plan Apo 40X/0.95 air
(oo/0.11-0.23, WD 0.25-0.17) DIC, Plan Apo 20X/0.75 air objective lenses (Nikon).
The system has the capacity to do Z-stack images that can be processed using de-
convolution software to generate 3D reconstruction images. Confocal fluorescence
imaging was done on a PerkinElmer Ultraview Spinning Disk Confocal Micro-
scope with Velocity acquisition software and Hammamatsu ORCA-ER CCD cam-
era using Plan Apo 100X/1.4 oil DIC (oc/0.17) and Plan Apo 63X/1.4 oil DIC
(oo/0.17) objective lenses (Zeiss). Contrast and brightness parameter adjustments
were applied across the whole image or equally across all the comparison groups
when necessary.
B.14 Quantification
Fluorescent Imaging: Used NIS Elements Software: Quantification of angiogenic
parameters and endothelial-epithelial cell interaction was conducted using images
taken at 4x magnification. For each frame, one brightfield and one FITC image was
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captured for quantification.
B.14.1 Angiogenic Parameters
1. Nodes were first identified A node is classified as the intersection of 2 or
more vessel structures.
2. The area of all nodes in the image were measured using either the circular
or ellipse measurement tool for the circular nodes or the semi-axis measure-
ment, respectively.
3. Tube lengths were measured as a vessel between the circumferences of two
nodes.
4. If only part of the tube is captured in an image, the length of the tube is
measured between the circumference of the node of origin and the end of the
tube as seen in the image. Tubes shorter than 10 0 pm in length that extend
outside the image are not quantified as they will be covered in a different
image.
5. The widths of the tubes were measured by taking three measurements along
each vessel, making sure the measurements captured the heterogeneity in
size.
B.14.2 Interaction Index
1. Using the brightfield image, a Region of Interest (ROI) is drawn, enclosing
the network (all nodes and vessels). When drawing an ROI around the net-
work, any cells that were in contact with the network, or laying directly on
the network, are included in the ROI. If a cell was found adjacent to the ROI,
but not in direct contact with the node or vessel it was excluded from the
ROI.
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2. Using the ROI feature, 3 small rectangular ROIs were drawn in regions with
no cells.
3. All 4 ROIs were copied to the respective FITC image and the background
fluorescence was removed by subtracting the maximum fluorescent intensity
of the three rectangular ROIs from the total intensity of the image.
4. The sum intensity of the ROI enclosing the network is noted as the intensity
of the cells that are ON the networks. Fluorescence intensity was assumed to
be an estimate of cell number as the average intensity of each cell is assumed
to be the same.
B.14.3 Elongation
1. Images of fixed and stained cells (rhodamine phalloidin, CFSE and DAPI) in
co-culture were captured at a higher magnification (20x and 40x) to measure
individual cells.
2. 300 cells on the vessels and 100 cells off the vessels were measured using the
semi-axis feature.
3. The ratio of major axis to minor axis of the on cells was compared to the
average major/minor axis ratio of the off cells.
B.14.4 Drug Study Quantification
B.14.4.1 Fluorescent Imaging
Fluorescent imaging was performed on a Nikon eclipse Ti camera using NIS Ele-
ments Imaging Software (3.10) using 20X objective lens to capture a minimum of
300 cells from 5 replicate co-culture samples for each group (Control, Lat-A+Doce
and Cyto-D+Doce). Lengths of the complete and broken nCs were measured using
the same software.
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B.14.4.2 SEM
SEM imaging was done using Zeiss FESEM Ultra55 microscope for 3D co-cultured
cells (n=104) and using Nikon eclipse Ti camera using NIS Elements Imaging Soft-
ware (3.10) for the Fluorescence nanoChannels (n=63) and other projections (n=72)
to capture nanoChannels. Length and width of the nanoChannels was measured
using the CarlZeiss TIF annotation editor. Width was measured at 3 different po-
sitions across the length of the nanoChannels and average width was calculated
for the comparison of length and width of the groups. Quantification imaging was
done using Zeiss FESEM Ultra55 microscope in the magnification range 1.75KX
to 2.25KX to capture minimum 300 cells from 6 replicate co-culture samples for
each cell line. For each image the total number of cancer cells, number of can-
cer cells with nanoChannels, number of cancer cells without nanoChannels, total
number of nanoChannels, number of epi-epi nanoChannels, number of epi-endo
nanoChannels, number of cells forming epi-epi nanoChannels, number of cells
forming epi-endo nanoChannels and number of cells positive for both epi-epi and
epi-endo nanoChannels were counted. Average number of total nanoChannels,
epi-epi nanoChannels and epi-endo nanoChannels per cell were calculated.
B.15 Migration
3 drug treatment groups were plated to examine migration, invasion, and intrava-
sation:
1. Control
2. Lat A/Doce
3. Cyto D/Doce
B.15.1 Protocol
1. Plate 300,000 HUVEC cells into the bottom well of a 24 well plate
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2. Next, plate matrigel@ diluted 1:4 in cold PBS in the top chambers for invasion
and intravasation.
3. In the top chambers of the wells examining intravasation, plate 100,000 HU-
VEC cells for 24 hours prior to plating the MDA-MB-231 cells.
4. Once the HUVECs have formed a monolayer beneath the matrigel, add 300,000
of the MDA-MB-231 cells to the top chamber of each well. (3 replicates per
condition).
5. After 48-72 hours of incubation, fix the cells in the top chamber with 4% PFA.
6. Once fixed, use a Q-tip to clean out all contents from the inside of the cham-
ber, and place the top chambers in DAPI for 5 minutes to stain the cells that
have migrated to the bottom of the chamber.
7. Image each chamber, at 4x magnification, taking 26-27 images per well (this
should be enough to cover the entire chamber), making sure to focus on the
underside of the chambe, where the migrated cells lay.
B.16 Endothelial Cell Isolation
B.16.1 Bead Preparation
1. Prepare beads the day before isolation: Sheep anti rat beads (Invitrogen #110.35)
with Rat anti mouse CD31 (Pharmigen #55337 0.5mg/mL).
2. Wash Beads beadwash: PBS+ antibiotic/antimycotic (1:100) + 0.1% BSA(1.66mL/500mL)
(Sigma A9576-50ml).
3. Place on rotator overnight at 4'C (or 1 hour at room temperature).
4. Prepare Collagenase: Type I (Worthington #4197) 0.2g% in DPBS +Ca/Mg,
mix at 37'C for 1 hour and then filter (0.22 micron).
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5. Coat 4 plates with gelatin (0.1%) for 30 minutes at 37'C.
6. Harvest tissue into 25 mLs of DMEM+ pen/strep (1%) and keep on ice.
7. Pour off media into waste and rinse tissue in tube 2X with DPBS.
8. Pour tissue into sterile dish with a little of the DPBS (Tip: if extra blood clots,
cut lungs in half and rinse again, also press on lung to expel any blood).
9. Dissect off all extra tissue (Tip: tissue to be removed appears lighter in color),
then transfer to clean dish.
10. Remove all extra liquid and mince tissue with scissors until the consistency
of pate or garlic (Tip: wipe off scissors before mincing step. There will be
small chunks and this ok, take approx 1 minute.)
11. Add 10 mLs of collagenase to plate, mix with 5 mL pipet and transfer to new
50 ml tube; wash the plate with another 10 mLs and pool. (Tip: If more than
4 hearts use 25 mL of collagenase) Parafilm cap in place.
12. Place in hybridization oven at 37'C for 30 minutes with slow revolution or on
rocker. (Tip: After 30 minutes check, if clumps dont appear to be feathered
incubate another 5 minutes but no longer).
B.16.2 Endothelial Separation
1. Pipet tissue and collagenase up and down 15 times with 20 or 30 mL syringe
and 14 G cannula (Tip: do not create extra bubbles).
2. Drip over cell strainer into BD tube (Tip: drip slowly to prevent liquid block).
3. Rinse tube and filter with DPBS into BD tube.
4. Spin at 800 rpm for 8 minutes (Tip: no faster as high speed spin damages
cells).
5. Place tube in magnet, wait 1-2 minutes, remove liquid with 1mL pipet.
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6. Add 850mL fresh beadwash, mix and transfer to sterile tube and place in
magnet.
7. Repeat 5 times, the last time resuspend pellet in 100pL in sterile eppendorf
tube. These can be stored up to 2 weeks at 4'C. (Tip: if you leave beads in
magnet too long they become difficult to resuspend).
8. Remove supernatant from tissue pellet with pipet (not vacuum) as much as
easily removable. Gently resuspend in remaining volume.
9. Add 2 mLs bead wash to pellet, resuspend using 5ml pipet and transfer
to polystyrene tube (Falcon 2058, 12X75 sterile snap caps). (Tip: DO NOT
transfer any white clumps so use 5ml pipet horizontally and watch carefully,
dumping any clumps back into the original tube.)
10. Rinse original tube with lmL beadwash and pool, again watching carefully
for any clumps of tissue.
11. Add beads: (Tip: fine line between enough and too many beads).
12. Cap and parafilm tube and place on rotator for 15 minutes at room tempera-
ture.
13. Put tube into magnet (Tip: remove parafilm and cap first) leave for 2 minutes.
14. Do not remove the tube from magnet. Remove supernatant and save in ster-
ile tube (just in case) (Tip: keep pipet to front of tube away from the beads).
15. Pull tube out of magnet and add 3 mLs of bead wash, vigorously mix 4-5
times with 5 mL pipet (Tip: do not cause foaming of BSA).
16. Return to magnet, and wait for 2 minutes. Remove media with vacuum and
add 3 mLs fresh bead wash and mix vigorously (outside of magnet).
17. Return to magnet and repeat 6-8 times, waiting 2 minutes between or alter-
nating tubes so that the magnet has time to work.
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18. Let sit in magnet for 1 minute.
19. Once endothelial cells are separated, resuspend cells for FACS analysis
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